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1A. SUMMARY 
Protein synthesis is one of the costliest processes in the cell. Therefore, the 
initiation of translation is a tightly regulated process. One major control mechanism 
targets the activity or formation of the so-called eIF4F (eukaryotic initiation factor 
4F) complex bound to the 5’ cap structure of an mRNA. This heterotrimeric complex, 
consisting of the RNA helicase eIF4A, the cap-binding protein eIF4E and the scaffold 
subunit eIF4G, is ultimately required for the recruitment of the 43S PIC (pre-initiation 
complex) to the mRNA, leading to subsequent scanning and initiation. The formation 
of the eIF4F complex is under the control of a group of inhibitory proteins known as 
eIF4E-binding proteins (4E-BPs), which bind to eIF4E and prevent its interaction 
with eIF4G. 4E-BPs comprise a group of functionally distinct proteins and include 
global translational repressors such as the three human proteins 4E-BP1-3, or large, 
multidomain proteins that likely act on an mRNA-specific level. Alternatively, the 
assembly of the eIF4F complex can be prevented by the eIF4E-homologous protein 
(4EHP or eIF4E2), which competes with eIF4E in binding to the 5’cap structure of an 
mRNA. Compared to the global repression by 4E-BPs, the later mechanism only acts 
on a message specific level. 
Comprehensive molecular insight into eIF4E- and 4EHP-complexes involved 
in the regulation of translation initiation was lacking. My doctoral work provides a 
fundamental structural and mechanistic understanding of the formation of these 
regulatory complexes. In my initial studies, I characterized the binding of various 4E-
BPs to eIF4E and provided the first structural insights into an extended eIF4E-binding 
mode of different 4E-BPs. The structures revealed a conserved mode of interaction 
with eIF4E, despite the lack of sequence conservation. Additionally, in a collaborative 
project, I observed that the eIF4E-binding mode characteristic of 4E-BP complexes is 
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also present in eIF4E-eIF4G complexes, expanding the knowledge on the mechanism 
of translation initiation and its regulation. 
Another part of my doctoral studies focused on 4E-BPs very specific functions 
and architecture. Specifically, I investigated the binding mode of an invertebrate-
specific 4E-BP called Mextli. My studies unveiled an unexpected variation and 
evolutionary plasticity in the eIF4E-binding mode of Mextli homologs across species, 
which confer distinct functional properties to the respective eIF4E-complexes.  
I also studied 4EHP, the second member of the eIF4E protein family, and its 
specific interaction partners, the Grb10-interacting GYF domain-containing (GIGYF) 
proteins 1 and 2, and obtained the first crystal structures of theses 4EHP-specific 
binding partners bound to 4EHP. The molecular details of the 4EHP-GIGYF 
translational repressor complex explain why GIGYF proteins bind to 4EHP and not to 
eIF4E. Overall, my doctoral studies revealed new insights on eIF4E-related 
complexes and their diverse roles in posttranscriptional gene regulation. 
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1B. ZUSAMMENFASSUNG 
Die Synthese von Proteinen zählt zu den kostspieligsten Prozessen der Zelle. 
Daher unterliegt die Translation von mRNAs einer strikten Kontrolle, insbesondere 
deren Initiation. An dessen Regulierung ist der sogenannte eIF4F- (eukaryotischer 
Initiationsfaktor 4F) Komplex beteiligt. Dieser heterotrimere Komplex besteht aus 
eIF4E, welches direkt an die 5’-Kappe der mRNA bindet, der RNA-Helikase eIF4A 
sowie eIF4G, welches das Gerüst des Komplexes bildet. Letztlich rekrutiert der 
eIF4F-Komplex den 43S PIC (pre-initiation complex; zu deutsch 
Präinitiationskomplex) an die mRNA und ermöglicht somit die Suche nach einem 
Startcodon, was zum Beginn der eigentlichen Proteinsynthese führt. Die Bildung des 
eIF4F-Komplexes wird durch eine Gruppe inhibitorischer Proteine reguliert, welche 
als eIF4E-bindende Proteine (4E-BPs) zusammengefasst werden, da sie an eIF4E 
binden und dadurch die Interaktion zwischen eIF4E und eIF4G verhindern. 4E-BPs 
umfassen eine funktionell diverse Gruppe von Proteinen, zu welcher sowohl generelle 
Translationsregulatoren wie z.B. die menschlichen Proteine 4E-BP1, 2 und 3 zählen, 
als auch komplexere Proteine, welche sehr spezifisch agieren und nur bestimmte 
mRNAs kontrollieren. Auch das eIF4E-homologe Protein (4EHP oder eIF4E2) kann 
die Formierung des eIF4F-Komplexes an der mRNA unterbinden, da es mit eIF4E um 
die Bindung an der 5’-Kappe der mRNA konkurriert. Im Gegensatz zu 4E-BPs, 
welche hauptsächlich an der generellen Inhibierung der Translation in der Zelle 
beteiligt sind, reguliert 4EHP ausschließlich die Expression spezifischer mRNAs. 
eIF4E- und 4EHP-Komplexe spielen in der Kontrolle der Translations-
initiation eine wichtige Rolle, allerdings fehlte bisher ein umfassender molekularer 
Einblick in diese Proteinkomplexe. Meine Doktorarbeit erbrachte daher ein 
grundlegendes strukturelles und mechanistisches Verständnis über diese 
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regulatorischen Komplexe. Zu Beginn meiner Studien charakterisierte ich die 
Interaktion verschiedener 4E-BPs mit eIF4E und konnte Kristallstrukturen dieser 
4E-BPs in Komplex mit eIF4E bestimmen, welche einen erweiterten Bindungsmodus 
aufzeigten. Die Kristallstrukturen zeigten, dass die verschiedenen 4E-BPs trotz 
deutlich unterschiedlicher Proteinsequenzen dennoch auf sehr ähnliche Weise an 
eIF4E binden. Zudem konnte ich in einem weiteren, kollaborativen Projekt aufzeigen, 
dass dieser Bindungsmodus für eIF4E auch von eIF4G genutzt wird, was unser 
mechanistisches Verständnis über die Initiation und Regulation der Translation 
erweitert. 
Ein weiterer Teil meiner Doktorarbeit beschäftigte sich mit 4E-BPs und 
eIF4E-Proteinen, welche sehr spezifische Funktionen erfüllen. Im Einzelnen 
untersuchte ich ein 4E-BP namens Mextli, das ausschließlich in Invertebraten 
vorkommt. Meine Arbeit zeigte eine evolutionäre Plastizität zwischen homologen 
Mextli Proteinen verschiedener Spezies bezüglich ihrer Bindung mit eIF4E auf. Diese 
Unterschiede im Bindungsmodus wirken sich zudem auf die Funktionsweise des 
jeweiligen eIF4E-Komplexes aus. 
Schließlich untersuchte ich mit 4EHP ein weiteres eIF4E-Protein und dessen 
spezifische Interaktionspartner, die GIGYF-Proteine (Grb10-interagierende GYF 
Proteine) 1 und 2. Dabei konnte ich die erste Kristallstruktur dieser 4EHP-
spezifischen Bindungspartner in Komplex mit 4EHP bestimmen. Die molekularen 
Details des 4EHP-GIGYF Komplexes erklären, warum GIGYF-Proteine an 4EHP 
und nicht an eIF4E binden. Insgesamt erbrachte meine Doktorarbeit neue Einblicke in 
eIF4E-umfassende Proteinkomplexe und deren Funktionen in der 
posttranskriptionellen Regulation der Genexpression. 
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2. INTRODUCTION 
The flow of information from the genome in the nucleus to a protein in the 
cytoplasm requires a messenger molecule. This messenger RNA (mRNA) is the main 
player of a series of complex processes, starting with its biogenesis, export to and 
localization in the cytoplasm, translation and regulation, until its final decay (Moore, 
2005).  
mRNAs are transcribed from the genomic DNA in the nucleus. To produce a 
mature mRNA, the RNA transcript is processed in a series of reactions involving 5’-
end capping, splicing, 3’-end cleavage and polyadenylation. The mature mRNAs 
assemble with proteins into messenger ribonucleoprotein (mRNP) complexes and are 
exported into the cytoplasm where their encoded information is used by ribosomes for 
protein synthesis before they are ultimately degraded (Moore, 2005). 
However, this description is only a simplistic outline of the life cycle of an 
mRNA, which can be subjected to a variety of elaborate, posttranscriptional control 
mechanisms. One major node of regulation concerns the translation of mRNAs, as 
protein production entails high costs for the cell (Buttgereit and Brand, 1995; Kafri et 
al., 2016). mRNA translation can be divided into four phases: initiation, elongation, 
termination and ribosome recycling. Regulation of this process is mainly 
accomplished at the initiation phase and provides the quickest response in the gene 
regulation pathway, allowing for rapid changes of cellular factors (Sonenberg and 
Hinnebusch, 2009). Moreover, the tight control of translation is critical for 
developmental processes, cell differentiation and synaptic plasticity (Buffington et al., 
2014; Sonenberg and Hinnebusch, 2009). Accordingly, the dysregulation of almost all 
initiation factors and regulators towards higher translational output is linked to a vast 
number of human cancers (Ruggero, 2013). Therefore, a lot of effort is being made to 
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comprehensively study translation initiation from a structural, functional, genetic and 
biological perspective to efficiently target the translation machinery in malignancies 
caused by an abnormally elevated protein synthesis (Bhat et al., 2015; Buffington et 
al., 2014; Pelletier et al., 2015). 
 
2.1 Eukaryotic translation of mRNAs 
The translation of mRNAs describes the process of protein synthesis by 
decoding the mRNA molecule. Translation takes place in all living cells and is carried 
out on ribosomes. However, the process is not fully conserved, and eukaryotic mRNA 
translation differs in some fundamental aspects from the mechanism in prokaryotes. 
Those differences concern for example the ribosomal composition, the factors that are 
involved in each of the phases of translation, but also the genomic organization and 
nature of the mRNA molecule itself.  
In contrast to eukaryotic cells, prokaryotes do not have a nucleus and their 
genome is located in the cytoplasm. As such, prokaryotic transcription and translation 
occur simultaneously and can take place as a linked process. This so-called 
transcription-translation coupling is mediated by the pioneering ribosome proceeding 
on the nascent transcript synthesized by the RNA-polymerase. Concomitant 
translation promotes the rate of transcription by preventing pausing, backtracking and 
early termination (Kohler et al., 2017; Landick et al., 1985; Proshkin et al., 2010). 
Prokaryotic mRNAs also differ from its eukaryotic counterparts also in 
structure and organization. In bacteria, mRNAs are mostly polycistronic, meaning that 
one transcript is coding for two or more proteins (Kozak, 1983). Additionally, 
bacterial mRNAs do not contain a cap structure at the 5’ end, and unlike eukaryotes, 
3’ end polyadenylation leads to short poly(A)-tails that promote mRNA degradation 
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(Bandyra and Luisi, 2013; Regnier and Hajnsdorf, 2013; Sarkar, 1997; Steege, 2000). 
The distinct 5’ ends of bacterial and eukaryotic mRNAs imply that the initiation step 
of translation differs significantly in the two systems.  
Prokaryotic start codon recognition is mediated by a direct recruitment of the 
30S small ribosomal subunit to the initiation region of the mRNA. This is achieved by 
base-pairing between an upstream Shine-Dalgarno (SD) sequence of the mRNA and 
an anti-SD sequence in the 16S rRNA. In eukaryotes, recruitment of the small 
ribosomal subunit usually requires the 5’cap structure and multiple translation 
initiation factors (eIFs) and involves an elaborated series of events. Therefore, also 
the mechanisms that control translation are different between prokaryotes and 
eukaryotes (Duval et al., 2015; Gualerzi and Pon, 2015). Since the work described in 
this thesis focuses on eukaryotic translation factors, only the eukaryotic process and 
mechanism will be explained in the following sections. 
 
2.1.1 Translation initiation 
The initiation phase of translation describes the positioning of a translation-
competent ribosome on the start codon of the mRNA. In eukaryotes, the mechanism 
of canonical translation initiation requires the assembly of a multitude of eukaryotic 
initiation factors (eIFs) at the 5’cap structure (a methylated guanine nucleotide with a 
5’-5’ triphosphate linkage to the following nucleotide; m7GpppN, where N is any 
nucleotide) of an mRNA (Figure 1). This multifactorial assembly is initiated by the 
heterotrimeric eIF4F complex, which comprises the cap-binding protein eIF4E, the 
DEAD-box RNA helicase eIF4A and the scaffolding protein eIF4G (Jackson et al., 
2010). eIF4G not only mediates the interactions to eIF4A and eIF4E, but also causes 
the circularization of the mRNA molecule by additionally binding to the poly(A)-
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binding protein (PABP) associated with the 3’ poly(A)-tail of the mRNA. Further, 
eIF4G also recruits the 43S preinitiation complex (43S PIC) to the mRNA via 
interactions with subunits of the eIF3 complex (Jackson et al., 2010; Wells et al., 
1998). 
The 43S PIC comprises the initiator methionyl-tRNA (Met-tRNAMeti)- 
containing ternary complex (eIF2-GTP/ Met-tRNAMeti; TC), the 40S small ribosomal 
subunit and additional eIFs (eIF1, eIF1A, eIF3 and eIF5; Figure 1). Recruitment of 
the 43S PIC by the eIF4F complex results in the formation of the 48S particle, which 
scans the 5’ untranslated region (5’UTR) of the mRNA in search for an AUG start 
codon. Scanning of highly structured 5’UTRs requires the ATP-dependent helicase 
activity of eIF4A to unwind secondary structures (Svitkin et al., 2001). The AUG 
triplet, usually located in an optimal context called the Kozak sequence (a purine base 
at -3 and +4 positions relative to the A in the AUG codon), is recognized by the 48S 
PIC as a result of base-pairing with the Met-tRNAMeti [Figure 1; (Jackson et al., 2010; 
Kozak, 1991)]. Start codon recognition triggers conformational rearrangements of the 
48S PIC, including the displacement of eIF1 and eIF1A and the release of eIF2-GDP. 
The GTPase-activating protein eIF5 plays a crucial role in dissociating the eIF2 
heterotrimer (consisting of three subunits named α, β and γ), as it induces the GTP 
hydrolysis of the eIF2γ subunit (Maag et al., 2005; Unbehaun et al., 2004). 
Subsequently, eIF5B helps to dissociate the remaining eIFs and mediates the joining 
of the 60S large ribosomal subunit, before it catalyzes its own release from the 
assembled 80S ribosome by hydrolysis of bound GTP (Acker et al., 2006; Acker et 
al., 2009; Pestova et al., 2000). 
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Figure 1: Canonical cap-dependent translation initiation. 1) Cap-dependent translation is initiated by the 
formation of the eIF4F complex (consisting of the initiation factors 4A, 4E and 4G) at the 5’cap of an mRNA. 2) 
The ternary complex (TC) is another subcomplex important in the initiation of translation and contains the 
initiation factor 2 proteins (eIF2; consisting of α, β and γ subunits), the initiator methionyl-tRNA (Met-tRNAMeti) 
and guanosine triphosphate (GTP). 3) Formation of the 43S preinitiation complex (43S PIC) containing the TC 
and the 40S small ribosomal subunit with bound initiation factors eIF1, eIF1A, eIF3 and eIF5. eIF3 itself is also a 
large complex consisting of 13 subunits (named a-m). 4) Recruitment of the 43S PIC by interactions between 
eIF4G of the eIF4F complex and eIF3 leads to the formation of the 48S PIC. This complex scans the 5’ 
untranslated region (5’UTR) of the mRNA in search of an AUG start codon. 5) Start codon recognition upon base-
pairing of the Met-tRNAMeti with the AUG triplet triggers conformational changes in the 48S PIC, which results in 
a GTP-dependent release of several initiation factors and joining of the 60S large ribosomal subunit, forming the 
translationally competent 80S ribosome. The figure is adjusted from Bhat et al., 2015. 
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2.1.2 Elongation, Termination and Ribosome recycling 
Compared to the initiation step of translation, all subsequent steps are more 
akin between prokaryotes and eukaryotes. Specifically, the elongation phase, meaning 
the incorporation of amino acids into a growing polypeptide, is most similar, since the 
core architecture as well as the modus operandi of prokaryotic and eukaryotic 
ribosomes are well conserved (Buskirk and Green, 2017; Frank and Spahn, 2006).  
During the elongation cycle of translation, the tRNA with anticodon 
complementarity to the mRNA codon translocates between the A, P and E tRNA 
binding sites of the 80S ribosome (Steitz, 2008). In this process, aminoacyl-tRNAs 
bound in the A site are translocated into the P site after the peptidyl transferase 
reaction. This reaction links incoming amino acids to the growing peptide chain and 
occurs in the peptidyl transferase center of the large subunit of the ribosome [Figure 
2; (Buskirk and Green, 2017; Steitz, 2008)]. Deacylated tRNAs from the P site move 
into the E site of the ribosome before dissociation. The two elongation factors eEF1A 
and eEF2 facilitate tRNA selection and translocation, respectively [Figure 2; (Buskirk 
and Green, 2017; Steitz, 2008)]. 
The elongation cycle is repeated until a stop codon (UAA, UAG and UGA) is 
positioned in the ribosomal A site (Figure 2). The translation termination factor eRF1 
recognizes all of the three stop codons and is loaded into the A site. Together with 
eRF3, eRF1 promotes the deacylation of the peptidyl-tRNA on the P site in a GTP-
dependent manner, resulting in the release of the nascent peptide [Figure 2; (Eyler et 
al., 2013; Frolova et al., 1996)].  
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Moreover, eRF1 is also involved in the recycling of the ribosome after 
termination. In this case, eRF1 recruits the ABC-family ATPase ABCE1 to the A site 
of the ribosome. ABCE1 induces the dissociation of the ribosome into the 60S 
subunit, the tRNA- and the mRNA bound 40S subunit [Figure 2; (Pisarev et al., 2010; 
Pisareva et al., 2011; Shoemaker and Green, 2011)]. The free ribosomal subunits and 
tRNA can subsequently be used in a new translation cycle. 
 
	
Figure 2: Elongation, termination and recycling steps of translation. 1) Translating ribosome with 
eEF1A/GTP/aminoacyl-tRNA bound to the A site, the peptidyl-tRNA in the P site and the deacylated tRNA in the 
E site. 2) Peptidyl transferase reaction results in the translocation of the peptide chain onto the A site tRNA. 3,4) 
GTP-dependent translocation of tRNAs from the P site to the E site and from the A site to the P site by eEF2. 
Upon dissociation of eEF2/GDP the ribosome is ready for the next round of elongation (step 1). 5) A stop codon 
(e.g. UGA) in the A site is recognized by eRF1 and triggers termination. Together with eRF3, the nascent peptide 
is released in a GTP-dependent manner. 6) eRF1 remains bound to the A site (not shown) and is recognized by 
ABCE1, which mediates the dissociation of the ribosome upon ATP hydrolysis. The figure is modified from Steitz 
et al., 2008 and from Pisarev et al., 2010. 
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2.2 Regulation of translation initiation 
The control of translation has a central role in the regulation of gene 
expression at a post-transcriptional level. This type of regulation not only provides the 
possibility for the cell to quickly adapt to environmental changes, but it is also of 
crucial relevance in the cellular decision about the translational programs. As such, 
the regulation of translation has a major impact on cell growth, cell progression as 
well as on distinct developmental processes, as it ultimately controls the cellular 
proteome (Bhat et al., 2015; Hershey et al., 2012). The initiation process is the rate 
limiting and most regulated step of translation and can be modulated by many factors 
(Hershey et al., 2012; Morisaki et al., 2016; Wu et al., 2016). The regulatory 
mechanisms either impact on the activity of specific initiation factors, such as eIF2 
and the eIF4F complex, or on the mRNA itself through specific RNA-binding 
proteins (RBPs) or microRNAs [miRNAs; (Hershey et al., 2012; Jackson et al., 
2010)].  
 
2.2.1 Regulation of translation by miRNAs 
miRNAs are small non-coding RNAs of ~22 nucleotides (nt) in length derived 
from introns or exons of non-coding or coding transcripts (Kim et al., 2009). In 
essence, miRNAs are generated from precursor transcripts in multiple processing 
steps involving the RNAse III-type endonucleases Drosha and Dicer. The mature 
miRNAs form an RNA-induced silencing complex (RISC) together with Argonaute 
proteins (Ha and Kim, 2014). 
RISC complexes are recruited to specific target mRNAs via base-pairing 
between the ‘seed’ region of the miRNA, which are nt 2-7 at the 5’end of the miRNA, 
and a complementary sequence in the 3’UTR of the mRNA (Bartel, 2009; Huntzinger 
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and Izaurralde, 2011). Therefore translational regulation by miRNAs is sequence-
specific, but a single miRNA might control several mRNAs (Hershey et al., 2012). 
In animals, miRNA-mediated control of gene expression occurs through 
mRNA degradation and translational repression. The GW182 proteins 
(TNRC6A/GW182, TNRC6B and TNRC6C in humans) play an important role in this 
mechanism. They associate with Argonaute proteins (AGO1-4 in humans) and are 
essential components of miRISC complexes since they recruit downstream effectors 
to induce translational repression and mRNA degradation (Behm-Ansmant et al., 
2006a; Behm-Ansmant et al., 2006b; Chekulaeva et al., 2009; Eulalio et al., 2008). 
Degradation of miRNA-targets is accomplished through the direct recruitment of the 
CCR4-NOT complex by GW182 proteins, the major cytoplasmic deadenylase 
complex (reviewed in Jonas and Izaurralde, 2015). In contrast, much less is known 
about the mechanism of miRNA-mediated translational repression. Recent models are 
controversial but indicate that miRNAs affect the initiation step of the canonical cap-
dependent translation (Jonas and Izaurralde, 2015; Kuzuoğlu-Öztürk et al., 2016; 
Ricci et al., 2013). 
 
2.2.2 Phosphorylation of eIF2 
The initiation factor eIF2 consists of three subunits, named eIF2α, -β and –γ, 
and forms the TC with GTP and Met-tRNAMeti. The TC is an integral part of the 48S 
PIC required for the recognition of the start codon. Its GTPase activity is also 
necessary to trigger the structural rearrangement of the 40S ribosomal subunit that 
allows translation initiation [Figure 1; (Maag et al., 2005; Unbehaun et al., 2004)].   
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eIF2B is a guanine nucleotide exchange factor that replaces hydrolyzed GDP 
of eIF2 with GTP for another initiation cycle. The GTP-bound state of eIF2 has an 
increased affinity for the Met-tRNAMeti and can therefore be efficiently loaded to form 
a productive TC (Kapp and Lorsch, 2004). 
Phosphorylation of eIF2 restricts the availability of productive eIF2 during the 
initiation of translation. As a result of various stress stimuli like nutrient deprivation 
or oxidative stress, different eIF2α kinases (e.g. GCN2, PERK, PKR and HRI) 
phosphorylate a specific serine residue of the eIF2α subunit (Dever et al., 2007; 
Donnelly et al., 2013). In the phosphorylated state, the TC can still form, and the 
affinity for the guanine nucleotide exchange factor eIF2B is even increased 
(Krishnamoorthy et al., 2001; Rowlands et al., 1988). However, the tight interaction 
between eIF2B and phosphorylated eIF2α inhibits the nucleotide exchange on the 
eIF2γ subunit, whereby Met-tRNAMeti is also sequestered by this complex and 
removed from the translational pool (Krishnamoorthy et al., 2001; Rowlands et al., 
1988). Therefore, phosphorylation of eIF2α constitutes an auto-inhibitory mechanism 
that affects the translation of most mRNAs (Hinnebusch and Lorsch, 2012; Jackson et 
al., 2010). 
 
2.2.3 Regulation of translation by eIF4E-binding proteins 
The eIF4E-binding proteins (4E-BPs) inhibit translation by interfering with 
the formation of the eIF4F complex on the mRNA 5’cap structure. 4E-BPs bind to 
eIF4E and prevent the interaction with eIF4G, therefore blocking the subsequent 
assembly steps of the initiation complex [Figure 3; (Jackson et al., 2010)].  
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Figure 3: Regulation of translation by 4E-BPs. The assembly of the eIF4F complex (eIF4A, eIF4E and eIF4G, 
colored in blue) on the 5’cap structure of an mRNA is the initial step of the translation initiation process. Under 
stress conditions, 4E-BPs (magenta) interfere with the formation of the eIF4F complex by binding to eIF4E, an 
interaction that directly competes with eIF4G. Upon cellular stimuli that activate translation, the mTORC1 kinase 
complex phosphorylates 4E-BPs. As a result, hyperphosphorylated 4E-BPs cannot bind to eIF4E anymore and 
translation is activated. PABP binding to the poly(A)-tail is shown in gray and leads to the circularization of the 
mRNA through interactions with eIF4G. 
 
The competition between 4E-BPs and eIF4G for eIF4E-binding is based on a 
similar binding motif of the sequence YX4LΦ (where Y is tyrosine, X is any amino 
acid, L is leucine and Φ is a hydrophobic amino acid), which is termed the canonical 
eIF4E-binding motif [4E-BM; (Mader et al., 1995; Marcotrigiano et al., 1999)]. Since 
the canonical 4E-BM of 4E-BPs and eIF4G occupies the same binding site on eIF4E, 
described as the dorsal surface, the regulation of translation through 4E-BPs is based 
on a molecular mimicry to eIF4G, and the binding partner of eIF4E ultimately 
determines if cap-dependent translation is active or repressed [Figure 4; 
(Marcotrigiano et al., 1999)].  
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Figure 4: Structures of the canonical eIF4E-binding motifs of eIF4G and 4E-BP1 bound to eIF4E. The 
canonical 4E-BMs of eIF4G (green) and 4E-BP1 (magenta) bind to the dorsal surface of eIF4E (gray). The binding 
cavity for the 5’ mRNA cap is located at the ventral site of eIF4E and indicated by an asterisk. The lateral side of 
eIF4E shown in this figure becomes relevant in the ‘Results’ sections of my thesis. The structures were published 
by Marcotrigiano et al., 1999, and the atomic coordinates can be found under the pdb accession codes ‘1ejh’ 
(eIF4G complex) and ‘1ej4’ (4E-BP1 complex), respectively (http://www.rcsb.org). 
 
4E-BPs were initially identified as a group of small translational repressors 
that contain 3 members in mammals [4E-BP1, -2 and -3; (Bhat et al., 2015; Pause et 
al., 1994)]. Phosphorylation of 4E-BPs controls their repressive function by 
modulating the affinity for eIF4E. Hypophosphorylated 4E-BPs associate with eIF4E, 
but hyperphosphorylated 4E-BPs do not [Figure 3; (Gingras et al., 1999a; Gingras et 
al., 2001)]. 4E-BPs contain several phosphorylation sites that follow an hierarchical 
order of phosphorylation, and full phosphorylation is required to block the association 
with eIF4E (Gingras et al., 1999a; Gingras et al., 2001). A recent NMR study 
provided a structural explanation for the effect of the initial phosphorylation sites. 4E-
BPs are generally unfolded when they are not bound to eIF4E, yet this study shows 
that the intrinsically disordered 4E-BP2 undergoes a partial disorder-to-order 
transition upon phosphorylation at specific positions [Figure 5; (Bah et al., 2015; 
Lukhele et al., 2013)].   
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The fold of hypophosphorylated 4E-BP2 partially encloses its canonical 
eIF4E-binding motif and consequently reduces the affinity for eIF4E, however, the 
molecular consequences of the subsequent phosphorylation sites still remained 
unclear [Figure 5; (Bah et al., 2015)]. 
 
	
Figure 5: Schematic representation of the phosphorylation sites of 4E-BPs. The small translational repressors 
4E-BP1, 2 and 3 contain multiple phosphorylation sites dispersed along the protein. 4E-BP2 is shown in magenta. 
It is unfolded in the unbound and unphosphorylated state. On the left, the canonical 4E-BM of 4E-BP2 is indicated 
as a helix, but it only forms upon binding to eIF4E. Phosphorylation of 4E-BPs follows a hierarchical order, 
whereby the phosphorylation of the later sites (yellow circles) requires the phosphorylation of the initial sites 
(green circles). Based on Bah et al., 2015, 4E-BP2 undergoes a folding transition upon phosphorylation of the 
initial sites (green circles), which partially occludes the canonical 4E-BM. However, the role of the later sites 
remains unclear. Note that 4E-BPs contain additional phosphorylation sites that are not indicated in the scheme for 
clarity reasons. 
 
4E-BPs are one of the targets of the mechanistic target of rapamycin complex 
1 [mTORC1, Figure 3; (Burnett et al., 1998; von Manteuffel et al., 1996)]. mTORC1 
is a serine/threonine-specific protein kinase that acts as the downstream factor of the 
phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, which links nutrient 
availability and growth factors to protein synthesis (Dowling et al., 2010; Hsieh et al., 
2012). Importantly, the dysregulation of this signaling pathway is strongly related to 
some types of cancer and results in aberrant changes in the activity or amount of 
translation initiation factors or regulatory factors (Sonenberg and Hinnebusch, 2009). 
Overexpression of eIF4E is related to the tumorigenic transformation of cells, 
whereas the reduction of cellular eIF4E levels suppresses the oncogenic phenotype or 
provides resistance to tumorigenesis beforehand (Lazaris-Karatzas et al., 1990; 
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Rinker-Schaeffer et al., 1993; Ruggero et al., 2004; Truitt et al., 2015). Similarly, the 
total amount of 4E-BP1 and its phosphorylation status have implications in ovarian 
and breast cancer (Armengol et al., 2007). 4E-BP2 is an important factor for the 
regulation of protein synthesis in the brain tissue and controls the translation of 
mRNAs involved in learning, memory and behavior. As such, 4E-BP2 knock-out 
mice display a reduction in long-term memory and autistic phenotypes (Banko et al., 
2005). Misregulation of translation has also been related to some neuropsychiatric 
disorders, such as the autism spectrum disorders (ASDs) or specifically to the fragile 
X mental retardation (FMR) syndrome (Gkogkas et al., 2013; Napoli et al., 2008). 
Therefore, the activity of translation initiation factors needs to be tightly regulated to 
maintain cellular homeostasis. Correspondingly, much effort is being made to target 
the translation machinery in cancer cells to dampen their translational level and 
reduce tumor growth (Bhat et al., 2015; Pelletier et al., 2015). 
 
2.4 The broad class of eIF4E-binding proteins 
Eukaryotic cells express a plethora of low and high molecular weight proteins 
with different complexities that interact with eIF4E. The small, low molecular weight 
4E-BPs act as global translational repressors, i.e. the human 4E-BPs 1, 2 and 3, which 
have only one homolog in Drosophila melanogaster (Dm) called Thor. In contrast, 
the more complex, high molecular weight 4E-BPs link eIF4E to additional functions 
as they interact with different proteins to fulfill message-specific tasks [Figure 6; 
(Miron et al., 2003; Miron et al., 2001). 
 
2. Introduction   	
	 19	
	
Figure 6: The variety of eIF4E-interacting proteins. Schematic representation of selected eIF4E-binding 
proteins. The eIF4E-binding motif (4E-BM) is highlighted with a blue box in all proteins. Additional domains are 
indicated with a gray box in each protein and are labeled above the box. For 4E-BPs that do not exist in humans 
the species-specific occurrence is indicated. 
 
The Drosophila 4E-BP CUP controls translation during fly development 
One of the high molecular weight 4E-BPs is the Drosophila protein CUP. 
CUP is a germline-specific protein that represses the translation of the maternal 
mRNAs oskar and nanos during oogenesis and embryogenesis while the mRNAs are 
transported to and localized at the posterior pole of the oocyte. The specificity for 
those mRNAs is achieved by binding of CUP to the RBPs Bruno and Smaug, which 
recognize specific elements in the 3’UTR of oskar and nanos, respectively 
(Nakamura et al., 2004; Nelson et al., 2004; Wilhelm et al., 2003; Zappavigna et al., 
2004). Binding of CUP to eIF4E and to Bruno or Smaug is then required to repress 
translation. Additionally, CUP recruits the CCR4-NOT deadenylase complex to 
promote deadenylation of the target mRNA and to sustain translational repression 
(Igreja and Izaurralde, 2011). 
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The 4E-transporter protein is a paralog of Drosophila CUP 
In terms of protein organization, CUP is mainly defined by its 4E-T domain, 
which is based on the similarity to the 4E-transporter protein (4E-T). 4E-T is another 
4E-BP as it contains a canonical 4E-BM and, in contrast to CUP, is also present in 
vertebrates (Kamenska et al., 2014b). It was identified as a nucleocytoplasmic 
shuttling protein that transports eIF4E into the nucleus (Dostie et al., 2000). Although 
it has been shown that eIF4E is involved in the nuclear export of some mRNAs, no 
detailed nuclear function of eIF4E in complex with 4E-T is known (Culjkovic et al., 
2005; Dostie et al., 2000). In the cytoplasm, 4E-T localizes to P-bodies, distinct foci 
in which the mRNA is stored together with proteins that are involved in translational 
repression and mRNA decay (Andrei et al., 2005; Decker and Parker, 2012; Eulalio et 
al., 2007; Ferraiuolo et al., 2005). Due to its canonical 4E-BM 4E-T is able to inhibit 
cap-dependent translation and, moreover, it is known to interact with several decay 
factors (Ferraiuolo et al., 2005; Kamenska et al., 2014a; Nishimura et al., 2015; Ozgur 
et al., 2015). However, the functional implications of the multiple 4E-T interaction 
partners or a detailed cellular function of 4E-T in terms of specific mRNA targets is 
not fully understood. 
 
The invertebrate-specific 4E-BP Mextli promotes translation 
In sharp contrast to other 4E-BPs, Drosophila Mextli was found to promote 
translation instead of repressing it. Mextli proteins also bind to eIF4E via a canonical 
4E-BM and additionally exhibit a modular structure that allows further protein and 
RNA interactions [e.g. with subunits of the eIF3 complex and the DEAH-box 
DNA/RNA-helicase CG3225; (Hernandez et al., 2013)]. Therefore, parallels were 
drawn between Mextli and eIF4G in terms of function, and it was proposed that 
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Mextli forms alternative translation initiation complexes in specific cellular stages. 
Indeed, phenotypic analysis of mutant flies that show a strongly reduced expression of 
the Mextli protein indicated that Mextli plays a role in germ line stem cell 
maintenance and in early embryogenesis (Hernandez et al., 2013). Mextli orthologues 
can be found in several invertebrate species, e.g. in Caenorhabditis elegans (Ce), and 
more data from other organism could shed some light on the role of Mextli in 
translation. 
 
The CCR4-like protein Angel1 recruits eIF4E to specific subcellular compartments 
Several other factors have been reported to interact with eIF4E, many of 
which have not been shown to have a role in translation (Rhoads, 2009). The human 
protein Angel1 was identified in silico as a 4E-BP due to its canonical 4E-BM, and its 
interaction with eIF4E was validated in binding assays (Gosselin et al., 2013). 
Moreover, Angel1 provides an example that 4E-BPs might also control translation in 
specific cellular compartments as it localizes to the cytoplasmic perinuclear area, to 
the endoplasmic reticulum and to the Golgi (Gosselin et al., 2013). In addition to its 
canonical 4E-BM, Angel1 also harbors a CCR4-like endo/exonuclease phosphatase 
(EEP) domain that might fulfill a regulatory purpose. Due to the similarity between 
the Angel1 EEP domain and CNOT6, one of the two poly(A)-nucleases of the CCR4-
NOT complex, Angel1 might also act directly on the mRNA, even so no 
deadenylation activity could be shown so far (Gosselin et al., 2013; Tucker et al., 
2002). Therefore Angel1 might control the expression of a specific subset of mRNAs, 
but its molecular function is not yet understood.  
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Specific 4E-BPs in neuronal tissue 
In neurons, CYFIP1 and Neuroguidin bind eIF4E and control translation 
during synaptic maturation and neurogenesis, respectively, in an mRNA-specific 
manner and as part of a bigger complex (Jung et al., 2006; Napoli et al., 2008). 
 
4E-BPs in lower eukaryotes 
In unicellular eukaryotes, like Saccharomyces cerevisiae (Sc), the two 4E-BPs 
Caf20 (also called p20) and Eap1, have been identified. Both of them have been 
shown to compete with eIF4G for binding to eIF4E and inhibit translation (Altmann 
et al., 1997; Cosentino et al., 2000). In this context, the Sc proteins Caf20 and Eap1 
modulate the translation of different subsets of mRNAs (Cridge et al., 2010; Ibrahimo 
et al., 2006; Rendl et al., 2012). 
 
Viral proteins can capture host eIF4E for their own translational program 
Some viruses use specific proteins, called the viral protein genome-linked 
(VPg) factors, to hijack the host eIF4E protein in order to promote the translation of 
the viral proteome. However, the mode of binding to eIF4E is distinct for the VPgs 
compared to other 4E-BPs. The VPgs of plant potyviruses and human caliciviruses act 
as proteinaceous cap-substitutes that are covalently bound to the 5’end of the viral 
RNA (Murphy et al., 1996; Schaffer et al., 1980). VPgs bind to eIF4E without 
competing with eIF4G to recruit the host translation machinery to the viral RNA 
(Goodfellow et al., 2005; Leonard et al., 2000). Therefore, structural studies of the 
VPg-eIF4E interaction promise to reveal interesting and novel insights about the 
recruitment of eIF4E. 
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Overall, the diversity of proteins with the ability to bind to eIF4E allows the 
control of translation initiation in a diverse range of cellular and developmental 
processes. Furthermore, since many 4E-BPs are rather large proteins with additional 
domains and binding partners, they are able to couple the control of translation 
initiation with target specificity and other mechanisms that regulate gene expression 
post-transcriptionally (e.g. deadenylation, decapping, …). 
 
2.5 The eIF4E-binding mode of 4E-BPs 
eIF4G and 4E-BPs only have in common the presence of canonical 4E-BM. 
Apart from this motif, the eIF4E-interacting proteins including eIF4G and the various 
4E-BPs do not share any similarity. These proteins generally differ in size, domain 
organization and even on the sequence level in the regions flanking the canonical 4E-
BMs (see Figure 6). Remarkably, these flanking sequences diverge among 
orthologous proteins across the animal kingdom. Despite the sequence diversity, 
several studies indicated that additional binding elements in 4E-BPs and eIF4G also 
contribute to binding to eIF4E. These binding elements do not show an obvious 
similarity among 4E-BP or eIF4G proteins and are therefore termed as non-canonical 
eIF4E-binding motifs. Non-canonical 4E-BMs have been identified in the human 4E-
BP2, where a bipartite binding region is required for the interaction with eIF4E 
(Lukhele et al., 2013). A NMR study shows that the eIF4E-4E-BP2 complex is a 
dynamic assembly, in which 4E-BP2 exists as a heterogeneous ensemble within the 
bound state (Lukhele et al., 2013). Other biophysical studies on the interaction 
between eIF4E and 4E-BPs or eIF4G also suggested the presence of a second element 
on these proteins (their non-canonical 4E-BM), which contributes to the overall 
affinity of 4E-BPs and eIF4G for eIF4E (Paku et al., 2012; Umenaga et al., 2011).  
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Moreover, a detailed molecular insight into the interaction of a non-canonical 
4E-BM with eIF4E was provided by the crystal structure of the D. melanogaster 
protein CUP bound to eIF4E. CUP contains a conserved canonical 4E-BM, which 
binds to the dorsal surface of eIF4E in a similar way as eIF4G or 4E-BP1, forming a 
short α-helix (Kinkelin et al., 2012; Marcotrigiano et al., 1999). In the crystal 
structure, however, a second α-helix of the CUP peptide, the non-canonical 4E-BM, 
addresses a lateral, hydrophobic surface of eIF4E [Figure 7; (Kinkelin et al., 2012)].  
 
	
Figure 7: Structure of the eIF4E-binding region of CUP in complex with eIF4E. Dm CUP (red) binds to the 
dorsal surface of eIF4E (gray) with its canonical 4E-BM and to a lateral surface of eIF4E with its non-canonical 
4E-BM. The structure was published by Kinkelin et al., 2012, and can be found under the pdb accession code 
‘4axg’ (http://www.rcsb.org). 
 
Interestingly, the non-canonical 4E-BM of CUP is relevant for translational 
repression as it prevents decapping and complete degradation of CUP-regulated 
mRNAs (Igreja and Izaurralde, 2011). This data suggests that non-canonical 4E-BMs 
also play important roles for the function of 4E-BPs as translational repressors. 
At the beginning of my doctoral work our structural understanding of those 
additional binding motifs was only limited to CUP, which is a germline-specific 
protein in Drosophila and it does not exist in mammals. Because outside of the 
canonical 4E-BM the sequence of different eIF4E-binding partners is highly diverse, 
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the information from the structural model of the eIF4E-CUP complex could not be 
transferred to eIF4G or other 4E-BPs. Especially the molecular details about the 
interaction of 4E-BP1, 2 and 3 or eIF4G with eIF4E remained unclear and limited our 
understanding on the binding mode and of the functional relevance of non-canonical 
contacts in the control of translation. Nevertheless, theses studies pointed towards the 
existence of an extended and more complex binding mode of different 4E-BPs and 
eIF4G for eIF4E and were the starting point of my doctoral work. 
 
2.6 The 4E-homologous protein and its interaction partners 
Eukaryotic cells express two or more eIF4E proteins that share a conserved 
protein sequence, which constitutes the folded core of eIF4E (Joshi et al., 2005). The 
different eIF4E proteins are classified into three classes (class I, II and III) based on 
minor variations of the conserved protein sequence (Joshi et al., 2004; Joshi et al., 
2005). The binding capabilities, interaction partners, and the type of mRNA cap-
structure recognized by eIF4E proteins differ between the three classes (Rhoads, 
2009). According to theses properties, it is suggested that only one eIF4E (eIF4E1) in 
each organism is responsible for global translation, whereas the others (eIF4E2/3) 
perform more specific functions related to translation (Hernandez and Vazquez-
Pianzola, 2005). 
Caenorhabditis elegans (Ce) contains five eIF4E proteins termed initiation 
factor of elegans 1-5 (IFE1-5), which exhibit differences in binding specificity 
between monomethylguanosine (MMG; m7GTP) and trimethylguanosine (TMG; 
m32,2,7GTP) mRNA 5’caps. Whereas IFE-1, -2 and -5 can bind to MMG and TMG 
caps, IFE-3 and IFE-4 can only bind MMG caps (Keiper et al., 2000; Miyoshi et al., 
2002). The TMG cap is acquired by a process called trans-splicing in which the 
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5’UTR including the MMG cap (called ‘outron’) is replaced by a short spliced leader 
(SL) sequence that carries a TMG cap (Lasda and Blumenthal, 2011). The TMG cap 
can stimulate translation in nematodes, and since it is only recognized by some of the 
IFE proteins, it might be related to specific translation programs (Keiper et al., 2000; 
Lall et al., 2004; Wallace et al., 2010). 
Drosophila melanogaster contains eight eIF4E-related proteins (Dm eIF4E1-
8) that are differently expressed throughout the development of the fly (Hernandez et 
al., 2005; Hernandez et al., 1997). All of the Dm eIF4E proteins are able to bind to the 
5’ cap of mRNAs (usually MMG caps), and besides Dm eIF4E-6, which is C-
terminally truncated, and Dm eIF4E-8, all of them are able to bind eIF4G or 4E-BPs 
(Hernandez et al., 2005). Dm eIF4E-8, also called the 4E-homologous protein 
(4EHP), is classified as a class II eIF4E-family member, and it is the most diverse 
member among the Dm eIF4E proteins (Joshi et al., 2005). In Drosophila, 4EHP is 
expressed during early embryogenesis and is involved in the translational repression 
of the maternal mRNAs caudal and hunchback, to which it is recruited via 
interactions with the RBPs Bicoid and Brain tumor, respectively (Cho et al., 2006; 
Cho et al., 2005; Hernandez et al., 2005). 
Likewise, human cells also contain three eIF4E proteins (Hs eIF4E1-3), and 
each one is part of a different class (Joshi et al., 2005). Among them, Hs eIF4E1 is the 
major variant driving the canonical cap-dependent translation, whereas Hs eIF4E2 is 
the human homolog to Dm 4EHP and does not bind to eIF4G. Conversely, Hs eIF4E3 
does bind to eIF4G but not to 4E-BPs (Gingras et al., 1999b; Joshi et al., 2004; Joshi 
et al., 2005; Rom et al., 1998).   
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Similar to the Drosophila 4EHP, human 4EHP plays a role in the translational 
repression of specific mRNAs. Together with the Grb10-interacting protein 2 
(GIGYF2), 4EHP is recruited to mRNAs containing AU-rich elements (AREs) in 
their 3’UTR by the specific RNA-binding protein Tristetraprolin [TTP, Figure 8; (Fu 
et al., 2016; Morita et al., 2012; Tao and Gao, 2015)]. As TTP triggers repression and 
degradation of cytokine mRNAs, which usually contain AREs, the 4EHP-GIGYF 
translational repressor complex has been implicated in the regulation of cytokine 
expression during immune responses (Barreau et al., 2005; Fu et al., 2016). Because 
4EHP does not bind to eIF4G, it is proposed to interfere with translation initiation by 
competing with eIF4E1 for the mRNA cap-structure, ultimately preventing the 
assembly of the eIF4F complex [Figure 8; (Hernandez et al., 2005)]. A similar 
mechanism has been proposed in mice, in which the Zn-finger protein ZNF598 
recruits the 4EHP-GIGYF complex to yet unknown targets, but it plays an important 
role in the mouse embryonic development (Giovannone et al., 2009; Morita et al., 
2012).  
	
Figure 8: Translational repression by 4EHP. 4EHP (orange) competes with eIF4E (dark blue) for binding to the 
5’cap structure of an mRNA. Because 4EHP does not bind to eIF4G (light blue), it cannot recruit the 43S PIC to 
initiate translation. Together with GIGYF (red), 4EHP forms a translational repressor complex that is recruited to 
specific mRNAs by a RNA-binding protein X (purple). The protein X can be TTP, ZNF598 or a yet unknown 
factor. eIF4A as a part of the eIF4F complex is colored in light blue, PABP is colored in gray.  
2. Introduction   	
	 28	
In conclusion, the diverse functional roles of the eIF4E-family members are in 
part related to their binding specificity for mRNA 5’cap structures, but also by their 
distinct interacting partners. However, the high similarity between the eIF4E proteins 
in sequence and structure is in stark contrast to their binding specificity (Joshi et al., 
2005; Rosettani et al., 2007). For example, GIGYF proteins specifically bind to 4EHP 
but not to eIF4E1 in vivo, even though their characterized 4EHP-binding motif 
resembles the canonical 4E-BM of eIF4G or 4E-BPs [YXYX4LΦ vs. YX4LΦ for 
GIGYF and eIF4G/4E-BPs, respectively; (Morita et al., 2012)]. For that reason it is 
mechanistically not clear how eIF4G and GIGYF can discriminate between eIF4E and 
4EHP. Furthermore, even though Hs 4E-BP1 does not bind to 4EHP in vivo, it does 
bind in vitro but with a reduced affinity compared to eIF4E1 (Rom et al., 1998; 
Rosettani et al., 2007). This provides an indication that distinct molecular features 
might be involved in determining the binding specificity for eIF4E or 4EHP, a 
question that was addressed in my doctoral work and is discussed below. 
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3. AIMS & OBJECTIVES 
My doctoral work focused on two main aspects of translational regulation. In 
the first part of my work, I investigated different eIF4E-4E-BP complexes and the 
impact of their binding mode on the competition with eIF4G and the control of 
translational. The second part of my study aimed at the structural characterization of 
4EHP-related complexes involved in an alternative mechanism of translational 
repression. 
 
3.1 The contribution of non-conserved regions of 4E-BPs to eIF4E-binding and 
their impact on the function of 4E-BPs as translational repressors 
The class of 4E-BPs comprises functionally diverse proteins that share a 
conserved canonical eIF4E-binding motif of the sequence YX4LΦ (where Y is 
tyrosine, X is any amino acid, L is leucine and Φ is a hydrophobic amino acid) with 
eIF4G. Therefore, these proteins compete with eIF4G for binding to eIF4E and 
ultimately shut down translation.  
4E-BPs fulfill a critical function in the control of translation, either in a global 
manner or in a mRNA-specific context, however a detailed molecular understanding 
of the mechanism on how 4E-BPs compete with eIF4G and displace it from eIF4E 
remained elusive. Several studies focusing on the biophysical characterization of the 
eIF4E-4E-BP and eIF4E-eIF4G interactions indicated the presence of additional 
eIF4E-binding sequences, known as non-canonical eIF4E-binding motifs, in 4E-BPs 
and eIF4G (Lukhele et al., 2013; Paku et al., 2012; Umenaga et al., 2011). 
Additionally, the crystal structure of the Drosophila specific 4E-BP CUP bound to 
eIF4E revealed a second, lateral binding site on eIF4E (Kinkelin et al., 2012). 
Nonetheless, due to the sequence diversity among 4E-BPs, no common features could 
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be derived from the eIF4E-CUP complex and no detailed structural insight into other 
4E-BPs was available. 
For this reason, in the first part of my doctoral work I focused on obtaining a 
general understanding of the contribution and the molecular details of the interaction 
between non-canonical eIF4E-binding motifs from various 4E-BPs and eIF4E. My 
aim was to generate structural insight into different eIF4E-4E-BP complexes in order 
to deduce commonalities in their binding mode as well as a mechanistic explanation 
regarding the competition mechanism with eIF4G. 
Additionally, I also initiated and participated in a collaborative project that 
focused on the eIF4E-eIF4G interaction. This work aimed at obtaining molecular 
details of eIF4E-eIF4G complexes, which could help to understand the mechanism of 
translational regulation by 4E-BPs. 
Furthermore, I also investigated a highly specialized, invertebrate-specific 4E-
BP called Mextli because it was reported to initiate translation instead of repressing it 
(Hernandez et al., 2013). Therefore, the Mextli proteins promised to provide 
additional structural insights and functional understanding regarding eIF4E-
complexes that initiate translation.  
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3.2 The binding selectivity of eIF4E- and 4EHP-specific protein partners 
The final part of my doctoral work focused on an alternative mechanism of 
translational repression. In this mechanism, the key player is another eIF4E-protein, 
called 4EHP, rather than a 4E-BP. 4EHP does not bind to eIF4G, which is the reason 
why it acts as translational repressor, but it binds other proteins like GIGYF1/2. 
GIGYF1/2 bind specifically to 4EHP but not to eIF4E. 
The major objective of this study was to examine the binding specificity of 
GIGYF1/2, especially because molecular details about their interaction with 4EHP 
were limited. To address this question, I performed structural studies on the 4EHP-
GIGYF1/2 translational repressor complexes. This work provided novel insights on 
the selective binding of GIGYF proteins to 4EHP over eIF4E, and on how specific 
translational regulatory complexes might be maintained in vivo, in the presence of a 
plethora of 4E-BPs and eIF4E-like proteins. 
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4. RESULTS 
4.1 Non-canonical eIF4E-binding motifs are a common feature of different 4E-
BPs and are required for their function as translational repressors 
 
The work summarized in this section was published by Igreja et al., 2014 and 
Peter et al., 2015a, and the papers including detailed experimental data and methods 
are included in the Appendix. 
 
Binding studies on 4E-BP/eIF4E interactions 
To understand and compare the binding of different 4E-BPs to eIF4E, I 
focused on in vitro approaches that enabled working in minimal systems with purified 
components. For this purpose, I cloned the extended eIF4E-binding regions 
containing a canonical and a putative non-canonical 4E-BM (C+NC) of the Dm 
proteins CUP, Thor (homolog to human 4E-BP1-3 proteins), 4E-T and eIF4G for 
expression in E. coli BL21(DE3) cells. To define these regions, I made use of the 
crystal structure of the CUP-eIF4E complex, or published biophysical data regarding 
the human 4E-BP1, 4E-T and eIF4G proteins. This information could be transferred 
to the Dm proteins based on sequence comparisons [Figure 9; (Kubacka et al., 2013; 
Lukhele et al., 2013; Paku et al., 2012; Umenaga et al., 2011)]. To ensure the 
solubility and stability of the eIF4E-binding regions, which are predicted to be 
unstructured, I introduced the B1 domain of protein G (GB1) as a non-cleavable small 
globular domain at the C-termini of the constructs and purified the eIF4E-binding 
regions (C+NC), or fragments (C and ΔC) to homogeneity (Figure 9). 
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Figure 9: Schematic overview of different 4E-BPs from Drosophila melanogaster. (A) Schematic 
representation of Dm eIF4G, CUP, 4E-T and Thor. In gray are shown the PABP-binding region and the MIF4G, 
MA3 and W2 domains of eIF4G, and the 4E-T domain of CUP and 4E-T, which is based on the similarity to 
human 4E-T. In all proteins, the eIF4E-binding motif (4E-BM) is shown as a blue box. The numbers at the end of 
the protein schemes indicate their size in number of amino acids. (B) General construct design for the different 4E-
BPs. The constructs contain either the canonical motif and the non-canonical sequences (C+NC) or derived 
fragments (C or ΔC). A linker of approximately 15 to 29 amino acids (aa) connects the canonical and non-
canonical 4E-BMs. (C) Schematic representation of Dm CUP (red) bound to eIF4E (gray) based on the crystal 
structure (Kinkelin et al., 2012). The dorsal and lateral binding sites of eIF4E are indicated. Structure-based 
mutations disrupt the interaction at the lateral side of eIF4E (II-AA mut.). 
 
The purified peptides of the different 4E-BPs were used in isothermal titration 
calorimetry (ITC) measurements to obtain the binding constants and thermodynamic 
parameters of the interaction with eIF4E, as well as to derive the binding 
contributions of each binding motif. The ITC data showed that the C+NC peptides of 
CUP, Thor and 4E-T strongly bind to eIF4E and exhibit dissociation constants (KDs) 
in the low nanomolar range comparable to the affinity of a similar peptide of eIF4G. 
Furthermore, the canonical motifs of CUP, Thor and 4E-T showed a reduced binding 
affinity for eIF4E compared to their C+NC peptides. This indicates that similar to 
CUP, also Thor and 4E-T do contain non-canonical sequences, which contribute to 
the binding of eIF4E.   
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Moreover, fragments of the eIF4E-binding region, which either consisted of 
the canonical motif or the non-canonical sequences, also revealed variations in the 
binding to eIF4E between the different 4E-BPs. First, the affinity of the canonical 
motif for eIF4E differs by at least one order of magnitude among the proteins, 
suggesting different contributions of the non-canonical sequences for eIF4E-binding 
(affinity of the canonical motifs: 4E-T > CUP > Thor). Second, only the CUP 
fragment lacking the canonical motif (ΔC) could be measured by ITC, as no changes 
in enthalpy could be detected when titrating corresponding Thor and 4E-T ΔC 
fragments into an eIF4E-containing solution. This finding is consistent with the 
higher entropic penalty for the interaction between eIF4E and CUP compared to Thor 
and 4E-T. The entropic component of the binding thermodynamics is a measure for 
the number of states in a closed system and can be seen as the disorder of the overall 
system. In the case of CUP, the entropy change of the reaction indicates a lower 
degree of conformational freedom in the bound state, which is in agreement with the 
non-canonical sequences of CUP forming an α-helix in the crystal structure of the 
complex with eIF4E (Kinkelin et al., 2012). Therefore, it can be speculated that the 
contribution and the mode of binding of the non-canonical sequences varies among 
different 4E-BPs, especially since the sequence composition is very diverse between 
the proteins. 
Due to this diversity, I next tested if the non-canonical sequences of Thor and 
4E-T bind to the same lateral, hydrophobic binding pocket of eIF4E as CUP. To 
address this question, a structure-based mutant of eIF4E, in which two hydrophobic 
residues of the lateral binding pocket (two isoleucines) were mutated to alanine (II-
AA mutant), was used in ITC measurements to determine the binding affinities for the 
eIF4E-binding regions of eIF4G, CUP, Thor and 4E-T that comprise the canonical 
4. Results   	
	 35	
motif and the non-canonical sequences (Figure 9). In agreement with the different 
binding contributions of the canonical motifs, binding of all of the proteins was 
affected by these mutations but to a different extent. In summary, we can conclude 
from the ITC measurements that all of the different 4E-BPs that were tested contain 
non-canonical sequences, and that a common lateral, hydrophobic pocket of eIF4E is 
involved in the interaction with these motifs. Additionally, the high affinity of the 
eIF4G fragment already suggests additional binding sequences outside its canonical 
motif. 
To further investigate the relevance of the non-canonical interactions for the 
function of 4E-BPs as translational repressors, we performed competition assays in 
vitro using preassembled eIF4E-eIF4G complexes, in which eIF4E was either wild-
type or mutated at the lateral binding pocket (II-AA mutant). Those complexes were 
immobilized on Ni-NTA affinity resin via a hexahistidine-tag on eIF4E. The 
immobilized complexes were then challenged with constructs of different 4E-BPs, 
which compete with eIF4G for eIF4E-binding. These assays were carried out together 
with my colleague Cátia Igreja. We could show that 4E-BP peptides (CUP, Thor and 
4E-T) containing the canonical motif and the non-canonical sequences efficiently 
displace eIF4G from eIF4E. However, disrupting the non-canonical contacts either by 
deleting the non-canonical sequences of the competitor 4E-BP, or by mutating the 
lateral hydrophobic pocket of eIF4E, strongly reduced or abolished the ability of 4E-
BPs to displace eIF4G that is in complex with eIF4E.  
In agreement with the findings from the in vitro assays, in vivo studies 
confirmed the importance of the non-canonical sequences for the function of 4E-BPs 
as translational repressors, since mutations in the non-canonical motif abolished Thor- 
and CUP-mediated repression of the expression of a firefly luciferase reporter in 
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Drosophila cells (4E-T was excluded from the in vivo study because it causes mRNA 
degradation; the in vivo experiments were carried out by Cátia Igreja).  
 
Structural studies on 4E-BP-eIF4E interactions 
The functional importance of non-canonical sequences of different 4E-BPs is 
in stark contrast to the low sequence conservation outside their canonical motif. Due 
to this diversity among 4E-BPs, the structural insights from the Dm CUP-eIF4E 
complex could not be used to derive general principles for the non-canonical 
interactions. Therefore, in a continuation of the work with the Dm 4E-BPs Thor and 
4E-T, I used X-ray crystallography to obtain detailed molecular insights into the mode 
of binding of those 4E-BPs to eIF4E. To this end, I solved the crystal structures of the 
eIF4E-binding region of Dm Thor, its human homolog 4E-BP1 and Dm 4E-T bound 
to the respective eIF4E (Figure 10). 
	
Figure 10: Comparison of the structures of different 4E-BPs bound to eIF4E. The upper part of the figure 
shows the structural overview of Hs 4E-BP1 (magenta), Dm Thor (purple) and Dm 4E-T (green) bound to eIF4E 
(gray) in a cartoon representation. The lower part shows an alignment of the eIF4E molecules of the three 
structures, whereby only the human eIF4E is shown for clarity. The structural elements that are common between 
the three 4E-BPs are indicated in magenta. 
4. Results   	
	 37	
This comparative structural information revealed a common eIF4E-binding 
mode among distinct 4E-BPs. In the bound form, the eIF4E-binding region of Hs 4E-
BP1, Dm Thor and Dm 4E-T arrange similarly and share three common structural 
elements: (1) the canonical motif forming an α-helix at the conserved dorsal surface 
of eIF4E, (2) an elbow-loop C-terminal to the canonical α-helix that mediates a sharp 
turn for directing the (3) unfolded non-canonical sequences (NC loops) to engage the 
lateral surface of eIF4E (Figure 10). 
Besides the general arrangement, each of these three elements has specific 
molecular features. A comparative analysis of the canonical helices of Hs 4E-BP1, 
Dm Thor and Dm 4E-T revealed a conserved and important role of residues that flank 
the motif with long side chains containing a large aliphatic portion (mostly arginine or 
lysine residues). These residues are at the same position within the canonical motifs 
(position +2 and +9, whereby the tyrosine of YX4LΦ is 0), they extend the interaction 
surface with eIF4E by shielding hydrophobic patches with the aliphatic portion of 
their side chain and mediate charge-charge interactions with conserved residues on 
eIF4E. Accordingly, substitutions of those residues to alanine in Dm Thor impaired its 
ability to compete with eIF4G for binding to eIF4E in competition assays. Due to the 
consistent role and conservation of those residues among 4E-BPs, we suggested an 
extended canonical motif of the sequence YX[R/K]X2LΦX2[R/K]. 
In contrast to the canonical motif, the sequence composition of the subsequent 
C-terminal regions deviates between the different 4E-BPs. Nonetheless, I could derive 
a common structural principle regarding their arrangement, which involves the 
formation of similar elbow-loop structures that bend the 4E-BPs backbone towards 
the lateral surface of eIF4E. In general, the elbow-loops consist of a helical half-turn 
starting with a proline or glycine residue. Further the elbow loops are stabilized by a 
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network of intramolecular interactions and are tethered to the surface of eIF4E close 
to the lateral binding pocket by interactions with conserved residues of eIF4E. In 
addition, the structures of Dm Thor and Hs 4E-BP1 uncovered the location of two of 
the conserved phosphorylation sites (a serine and a threonine in both cases) placed 
within and after the elbow loop (Gingras et al., 1999a; Gingras et al., 2001; Miron et 
al., 2003). These two phosphorylation sites in Hs 4E-BP1-3 are the last to be modified 
in a phosphorylation cascade inhibiting the interaction with eIF4E (Gingras et al., 
1999a; Gingras et al., 2001). However, phosphorylation of these serine and threonine 
residues did not measurably impact the affinity of the eIF4E-binding region of Dm 
Thor for Dm eIF4E, as determined in ITC measurements with synthetic peptides of 
Dm Thor containing or not the phospho-modifications (wild-type peptide vs. pSpT 
peptide). Nevertheless, phosphorylation of these two residues had significant effects 
on a functional level. In competition assays in vitro, the pSpT peptide of Dm Thor 
was unable to replace eIF4G in preassembled eIF4E-eIF4G complexes compared to 
the wild-type peptide. This finding is supported by the effect of a phosphomimetic 
mutant of Dm Thor (the respective serine and threonine replaced by aspartates) in 
vivo, which, in contrast to wild-type Thor, does not repress the translation of a firefly 
luciferase reporter mRNA (the in vivo experiments were carried out by Cátia Igreja). 
These results indicate that phosphorylation at these two specific positions does not 
affect the interaction with eIF4E but destabilizes or hampers the formation of the 
elbow loop of Dm Thor or Hs 4E-BP1-3 upon binding to eIF4E, since the serine 
residue is involved in the intramolecular stabilization of the elbow loop. The potential 
hindrance introduced by the two strongly negative charged phosphates might be 
detrimental for 4E-BPs when another competing molecule like eIF4G is already 
bound to eIF4E. Moreover, the synergy of multiple phosphorylation sites on full 
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length Hs 4E-BP1-3 or Dm Thor might have additional regulatory effects, since the 
stepwise phosphorylation of Hs 4E-BP2 induces folding and increases its stability in 
the unbound state, but also strongly reduces its binding affinity for eIF4E (Bah et al., 
2015; Yanagiya et al., 2012). Dm 4E-T does not contain similar phosphorylation sites 
and it is not known how its interaction with eIF4E is regulated. 
Following the elbow-loop, Hs 4E-BP1, Dm Thor and Dm 4E-T approach the 
lateral side of eIF4E with their non-canonical motif, but all diverge in the path of their 
polypeptide chain and do not form a defined secondary structure like Dm CUP 
(Figure 10). Comparative analysis of the three eIF4E-complexes, however, shows that 
Hs 4E-BP1, Dm Thor and Dm 4E-T align again around the lateral hydrophobic pocket 
of eIF4E. This lateral binding site of eIF4E is conserved across species and lined by a 
phenylalanine (which is a tyrosine in Dm eIF4E) and two isoleucines in Hs eIF4E. In 
contrast to the lateral surface of eIF4E, the non-canonical motifs of 4E-BPs are highly 
variable at the sequence level. Nonetheless, the structural insight uncovered similar 
binding principles between Hs 4E-BP1, Dm Thor and Dm 4E-T. All of these proteins 
engage the lateral hydrophobic pocket of eIF4E with similar hydrophobic contacts, 
which involve either valine, leucine or isoleucine residues for Hs 4E-BP1 and Dm 
Thor, and bulky aromatic residues (phenylalanine and tryptophan) in the case of Dm 
4E-T. These interactions are associated with analogous main-chain contacts between 
eIF4E and the 4E-BP polypeptides, leading to an alignment of the 4E-BPs backbone 
along the lateral side of eIF4E. In conclusion, the sequence variability of the non-
canonical motifs of 4E-BPs is overcome on the structural level by similar interactions 
with the lateral hydrophobic pocket of eIF4E. Therefore it can be assumed that all 4E-
BPs, even those not yet studied at the structural level, generally bind to eIF4E in a 
bipartite manner and involve similar dorsal and lateral surfaces of eIF4E. 
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Targeting the eIF4E-eIF4G interaction in disease 
The overexpression of eIF4E is a hallmark of a variety of tumor cells and is 
linked to oncogenic transformation (Avdulov et al., 2004; De Benedetti and Graff, 
2004; Lazaris-Karatzas et al., 1990; Mamane et al., 2004). Since 4E-BPs are able to 
revert cellular transformation, the presented structural insights provide valuable 
information for alternative strategies to target eIF4E in malignancies (De Benedetti 
and Graff, 2004; Grzmil and Hemmings, 2012; Mamane et al., 2004). One possible 
strategy is the use of small molecule compounds that target protein-protein 
interactions. There are some inhibitors described to target the eIF4E-eIF4G 
interaction, e.g. a synthetic molecule called 4EGI-1 (eIF4E/eIF4G Interaction 
Inhibitor-1) that mimics the function of 4E-BP1, or the small molecules called 
4E1RCat/4E2RCat that are a dual inhibitor for the eIF4E-eIF4G and eIF4E-4E-BP 
interactions (Cencic et al., 2011; Moerke et al., 2007). 
Since such compounds have several drawbacks regarding efficiency, affinity 
or specificity, we made use of our structural knowledge to design a more potent, 
peptide-based 4E-BP mimic. For this purpose, we combined the canonical motif of 
Dm 4E-T, the elbow-loop of Dm Thor and the non-canonical motif of Dm CUP, 
which forms an α-helix (NC helix), to generate a 4E-BP chimera (Figure 11). The 
selection of the elements was based on the biophysical and structural studies 
described in the previous section, and only the connection between the Thor elbow-
loop and the CUP NC helix required the addition of a glycine residue as a spacer.  
4. Results   	
	 41	
	
Figure 11: Design of the 4E-BP chimera. Crystal structure of the 4E-BP chimera bound to eIF4E (gray). The 
elements of the 4E-BP chimera are shown in different colors for the parental proteins with Dm 4E-T in green, Dm 
Thor in purple and Dm CUP in red, whereby the glycine spacer is colored in black. 
 
The designed 4E-BP chimera was validated by ITC measurements, which 
revealed a low nanomolar affinity for Dm eIF4E that is in the same range as other 4E-
BPs. I also determined the crystal structure of the 4E-BP chimera in complex with Dm 
eIF4E, which showed that there were no deviations from the expected arrangement. 
Interestingly, the 4E-BP chimera displays significant functional improvements. In 
comparison to its parental proteins, the 4E-BP chimera was a more efficient 
competitor of the eIF4E-eIF4G interaction in vitro. Furthermore, in vivo it displayed a 
stronger translational repressor activity compared to Dm Thor (the competition assays 
in vitro were performed together with Ramona Weber, the in vivo experiments were 
carried out by Cátia Igreja). The improved function might result from advantages in 
the binding mode and also from the fact that, when compared to Dm Thor or Hs 4E-
BP1, it lacks the regulatory recognition sequences, so it cannot be regulated by 
phosphorylation. Moreover, even though the 4E-BP chimera is based on Dm proteins 
it efficiently disrupts the eIF4E-eIF4G interaction in human cells (the in vivo 
experiments were carried out by Lara Wohlbold). Therefore it presents a promising 
starting point for the future development of structure-based drug approaches. 
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Overall, these studies on 4E-BPs uncovered intrinsic molecular properties 
regarding the recognition of eIF4E by functionally distinct 4E-BPs. Moreover, the 
structural insights generated in theses studies can be used in therapeutic approaches 
targeting eIF4E that aim at reducing translation in cancer cells. The potential use of 
our research for therapeutic approaches is a topic that will be discussed below. 
 
  
4. Results   	
	 43	
4.2 eIF4G and 4E-BPs bind similarly to eIF4E 
 
The work summarized in this section was published by Grüner et al., 2016, and the 
paper including detailed experimental data and methods is included in the Appendix. 
 
The bipartite binding mechanism to two orthogonal surfaces of eIF4E is a 
prerequisite for 4E-BPs to act as competitors of eIF4G and consequently as 
translational repressors. However, a comparable structural insight into the mode of 
binding between eIF4G and eIF4E was lacking, even though previous studies also 
indicated the presence of a second eIF4E-binding site on the human eIF4G and 
auxiliary binding regions in yeast eIF4G (Gross et al., 2003; Umenaga et al., 2011). In 
a collaborative approach, we elucidated the eIF4E-binding mechanism of metazoan 
eIF4G. In this work, I initiated the project and further supported it with functional 
experiments and analysis, whereby my colleague Stefan Grüner did the major work 
and was responsible for the structure determination and the biophysical analysis. 
The findings of our work revealed that metazoan eIF4G (human and Dm) also 
addresses the lateral hydrophobic pocket of eIF4E in a similar way as 4E-BPs. This 
result was unexpected, since a NMR structure of the Sc eIF4E-eIF4G complex 
suggested that eIF4G does not bind to the lateral surface of eIF4E (Gross et al., 2003). 
In essence, the NMR structure of the Sc eIF4E-eIF4G complex showed that auxiliary 
sequences N- and C-terminal to the canonical motif of Sc eIF4G contribute to 
complex formation by forming a bracelet-like structure around the N-terminus of 
eIF4E (Gross et al., 2003). Such an arrangement would leave the lateral side of eIF4E 
open for non-canonical interactions with 4E-BPs, thus providing an anchoring point 
for the competition with eIF4G. However, our structural data about metazoan eIF4E-
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eIF4G complexes revises this idea of an exclusive 4E-BP binding site on eIF4E 
outside of the yeast system and extents the model of the 4E-BP competition 
mechanism to a complete molecular mimicry of 4E-BPs to eIF4G (Figure 12).  
 
	
Figure 12: Extended molecular mimicry between eIF4G and 4E-BPs for binding to eIF4E. Both eIF4G 
(green) and 4E-BP1 (magenta) contact the dorsal and lateral surfaces of eIF4E (gray). The mode of binding 
between both complexes is highly similar but decides upon activation or inhibition of mRNA translation. 
However, molecular differences in the binding mode enable 4E-BPs to efficiently displace eIF4G from eIF4E-
complexes. Phosphorylation of 4E-BPs by mTORC1 is required to regulate 4E-BPs. 
 
Despite the structural similarity with the eIF4E-binding region of eIF4G, 4E-
BPs are efficient competitors of the eIF4E-eIF4G interaction. In order to delineate the 
molecular details of their competitive advantage, we performed competition assays in 
vitro in which we tested several chimeric competitors for their ability to displace 
eIF4G from preassembled eIF4E-eIF4G complexes. Those chimeric competitors 
consisted of interchanged, defined elements between Dm Thor and Dm eIF4G, 
namely their canonical and non-canonical motifs, and the linker connecting both. 
These assays revealed that the linker and the non-canonical motif of Dm Thor confer 
a competitive advantage over eIF4G although the affinity of the different chimeric 
competitors was not significantly altered compared to Dm Thor or Dm eIF4G (the 
competition assays were done together with Ramona Weber, the ITC measurements 
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were performed by Stefan Grüner). Moreover, the competitive advantage of Dm Thor 
could partially be attributed to the rigidity of its linker, since an exchange of a double 
proline sequence in Dm Thor to the structural equivalents of Dm eIF4G (lysine and 
glutamine) impaired its ability to displace eIF4G from eIF4E compared to wild-type 
Dm Thor. In agreement with the important role of the linker and NC motifs of 4E-BPs 
for competition with eIF4G, further ITC analysis of Dm Thor revealed that 4E-BPs 
have a stronger requirement for the lateral side of eIF4E. Taken together, these results 
suggest a competition mechanism where 4E-BPs strongly rely on the lateral side of 
eIF4E to dissociate bound eIF4G and ultimately repress translation initiation 
(discussed below, see Figure 19).  
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4.3 Diverse eIF4E-binding modes among Mextli proteins confer distinct 
functional properties 
 
The work summarized in this section was published by Peter et al., 2015b, and the 
paper including detailed experimental data and methods is included in the Appendix. 
 
Mextli proteins are invertebrate-specific 4E-BPs that, in contrast to most other 
4E-BPs, exhibit a modular structure consisting of a MIF4G-like (middle domain of 
eukaryotic initiation factor 4G) domain and a KH- (hnRNP K homology-) domain 
(Figure 13). Besides the interaction with eIF4E mediated by a canonical motif, Mextli 
binds RNA and other protein factors involved in translation. The specific role of 
Mextli is thought to be the control of translation initiation in germline stem cells and 
during early embryogenesis in Drosophila (Hernandez et al., 2013). Indeed, Mextli is 
the only eIF4E-interacting protein currently known to activate translation besides 
eIF4G. In analogy to eIF4G, Mextli has been reported to interact with an 
uncharacterized DEAH-box DNA/RNA-helicase (encoded by CG3225) as well as 
with eIF3 subunits, leading to the recruitment of the 43S PIC to the bound mRNA 
[Figure 13; (Hernandez et al., 2013)]. Therefore, Mextli proteins might be involved in 
an alternative mechanism to initiate cap-dependent translation. 
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Figure 13: The modular architecture of Mextli proteins. (A) Schematic representation of Mextli. The MIF4G 
and KH domains are shown in gray, the 4E-binding motif (4E-BM) in blue. Reported interactions are indicated 
below the scheme. (B) Schematic comparison of the 4E-BMs of Ce and Dm Mextli. Besides the canonical and 
non-canonical motifs present in Ce (orange) and Dm (blue) Mextli, Dm Mextli contains C-terminal auxiliary 
regions (magenta). Secondary structure elements are indicated below the cartoons. 
 
To shed some light into this unusual pathway of translation, we analyzed the 
interaction of Dm and Caenorhabditis elegans (Ce) Mextli proteins with eIF4E from 
the respective species. Interestingly, Dm and Ce Mextli display differences in their 
eIF4E-binding region already at the sequence level. In both species, the eIF4E-
binding site of Mextli is located at the very C-terminus of the protein and consists of a 
canonical motif followed by a region of helical propensity and conserved hydrophobic 
residues, which could likely act as a non-canonical motif (α2). However, in fly Mextli 
the C-terminus extends even further and comprises another auxiliary helical region 
(α3) that is conserved in flies and some insects, but absent in worms like Ce (Figure 
13). This peculiarity between Mextli proteins on the sequence level also affects the 
binding to eIF4E in vivo and in vitro. Both Dm and Ce Mextli proteins respond to a 
lateral side mutant of their respective eIF4E (II-AA mutant in Dm, VI-AA mutant in 
Ce), which strongly reduces or abolishes the interaction in pull-down assays in vitro. 
However, fragments of Dm Mextli that consist of the canonical motif (C) and the non-
canonical sequences (NC), but contain or not the fly-specific auxiliary sequences 
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(including the helical region α3; fragments therefore described as C+NC+α3 or 
C+NC; Figure 13) were pulled down by eIF4E from cell lysates to a different extend. 
In particular, the lack of the auxiliary region of Dm Mextli resulted in a significantly 
reduced binding to eIF4E (the in vivo experiments were conducted by Cátia Igreja). 
This finding is in agreement with in vitro pull-down assays, in which a C+NC+α3 
fragment of Dm Mextli could partially bind to the II-AA mutant of eIF4E, whereas 
the C+NC fragment could not.  
For a quantitative assessment of the contribution of the auxiliary region of Dm 
Mextli for binding to eIF4E, I performed ITC measurements comparing the same 
fragments described above that contain or not the auxiliary sequences (C+NC+α3 vs. 
C+NC; Figure 13). The addition of the auxiliary region of Dm Mextli (C+NC+α3) 
increases the affinity for eIF4E around 10-fold and is associated with a significantly 
higher entropic penalty of the interaction compared to the C+NC fragment. This result 
indicates that the auxiliary region of Dm Mextli contributes to the interaction with 
eIF4E and is highly restrained in its flexibility in the bound state, likely undergoing 
folding upon binding. To also obtain insight into the unbound state of the eIF4E-
binding region of Dm Mextli, we performed nuclear magnetic resonance (NMR) 
measurements (NMR experiments and evaluation were performed together with 
Vincent Truffault). Therefore, I expressed the C+NC+α3 eIF4E-binding region of Dm 
Mextli in minimal medium supplemented with ammonium-15N chloride as the only 
nitrogen source. The purified 15N-labelled peptide was used for 1H-15N heteronuclear 
single quantum coherence (HSQC) experiments, which rely on the transfer of 
magnetization from proton to 15N nuclei and back. Thus, every bonded nitrogen-
proton pair of the protein (i.e. backbone amides and side chains with nitrogen-bound 
protons) yields a peak in the two-dimensional HSQC spectrum with a specific 
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assigned resonance. A broad dispersion of the peaks in the HSQC-spectrum indicates 
a well-folded protein since the residues of the protein are found in different chemical 
environments (solvent-exposed vs. globular fold). In contrast, a central cluster of 
peaks is a strong indicator of an unfolded state of a polypeptide, because most of the 
residues are similarly exposed to the solvent. This is the case for the C+NC+α3 
peptide of Dm Mextli in isolation, which confirms that, similar to other 4E-BPs, the 
eIF4E-binding region of Mextli is mainly unfolded in the unbound state (Lukhele et 
al., 2013; Tait et al., 2010). Upon addition of an excess of unlabeled eIF4E, the 
resonance dispersion of the Mextli peptide vastly increases and many peaks 
disappeared from the disordered region of the spectrum, reflecting a disorder-to-order 
transition upon binding. In conclusion, the NMR data of the unbound and bound state 
of the eIF4E-binding region of Dm Mextli supports the idea that the different entropic 
contribution of the two Mextli fragments observed in the ITC measurements is caused 
by additional folding of the auxiliary region of Dm Mextli. 
To obtain a detailed molecular insight into the differences in eIF4E-binding 
between the Mextli homologs from Dm and Ce, I determined the crystal structures of 
their eIF4E-binding regions bound to the respective eIF4E (Figure 14). Both, Dm and 
Ce Mextli contact eIF4E with canonical and non-canonical motifs, similarly to the 
4E-BPs described above. This classical bipartite mode of binding involves two 
orthogonal surfaces (dorsal and lateral) of eIF4E. At the dorsal surface of eIF4E, 
conserved interactions are established by the YX4LΦ consensus motif ubiquitously 
present in 4E-BPs and also in Mextli proteins. Interactions at the lateral surface of 
eIF4E are mainly mediated through hydrophobic contacts of Mextli and are 
structurally equivalent to the interactions of other 4E-BPs at this hydrophobic pocket 
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of eIF4E. Again this finding highlights a common structural principle for non-
canonical sequences of 4E-BPs despite the lack of conservation on the sequence level. 
 
	
Figure 14: Structures of eIF4E-Mextli complexes. (A) Structural overviews of Ce Mextli (orange) and Dm 
Mextli (cyan and magenta) bound to the species-related eIF4E (gray). (B) Schematic comparison of the Ce and Dm 
Mextli 4E-BM. Residues of the extended canonical motif are indicated in the consensus sequence and the positions 
+2 and +9 are highlighted, with the initial tyrosine (Y) is counted as 0. (C) Close-up view on the arrangement of 
Ce (top) and Dm (bottom) Mextli on the dorsal surface of eIF4E. The canonical helices of Mextli are colored in 
orange (Ce) or cyan (Dm) and the Dm Mextli auxiliary helix is colored in magenta. Residues at positions +2 and 
+9 of the extended canonical motif are shown as sticks. The figure is adapted from the book chapter of Hernandez 
et al., 2016 to which I contributed to and to which I provided the original figure. 
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The Mextli non-canonical motifs adopt an α-helical conformation (α2), a 
feature so far only described for CUP (Kinkelin et al., 2012). In the complex of Dm 
Mextli with eIF4E, the non-canonical helix is connected to the canonical motif by a 
well-ordered linker that forms the characteristic elbow loop structure of 4E-BPs. In 
contrast, the linker bridging both helices in Ce Mextli is rather flexible and adopts 
different conformations between the copies from the two independent crystal 
structures of the complex. The lacking coordination of the linker region of Ce Mextli 
might be compensated by the extension of the non-canonical helix compared to Dm, 
which contributes to the hydrophobic interaction with the lateral surface of eIF4E. 
Interestingly, Dm Mextli extends this classical bipartite binding mode in an 
exceptional manner. Following the non-canonical motif, the auxiliary sequences 
extend the interaction back to the dorsal surface of eIF4E, where Dm Mextli folds into 
a third, auxiliary α-helix (α3). The auxiliary helix is placed in close proximity and 
antiparallel to the canonical helix, and both form intramolecular contacts. This leads 
to an overall U-shaped arrangement of Dm Mextli on dorsal and lateral surfaces of 
eIF4E. Besides the three helical elements, also the linker regions of Dm Mextli 
contribute to the tight interaction with eIF4E and are well organized. For the 
coordination of the Dm Mextli linker regions, two highly conserved residues (an 
asparagine and a histidine) of eIF4E fulfill an important role. These residues are 
located at the edge between the dorsal and the lateral side of eIF4E and dually 
coordinate the linker region between the canonical and non-canonical helices (non-
canonical linker), and between the non-canonical and auxiliary helices (auxiliary 
linker). Mutations of those two residues to glutamate in Dm eIF4E (NH-EE mutation) 
abolished the interaction with Dm Mextli, but did not affect the interaction to other 
eIF4E-binding partners like eIF4G, CUP, Thor and 4E-T in immunoprecipitation 
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assays (IPs) from Dm S2 cells (the IPs were carried out by Cátia Igreja). This result 
confirms the importance of these two residues of eIF4E for the binding of Dm Mextli 
and illustrates the diversity of this binding mode in comparison to bipartite 4E-BPs. 
The plasticity in the eIF4E-binding mode among the Mextli orthologs can be 
attributed to a distinct structural feature in their canonical motifs. As suggested from 
the structural studies of bipartite 4E-BPs described above, residues with long aliphatic 
side chains usually flank the canonical helix and strongly contribute to the interaction 
with eIF4E. Due to the conserved position of those residues, we proposed an extended 
canonical 4E-BM of the sequence YX[R/K]X2LΦX2[R/K]. This extended canonical 
4E-BM is also present in Ce Mextli, which contains arginine residues on both 
positions (+2 and +9, whereby the tyrosine is counted as 0). In Dm Mextli, however, 
both positions are substituted by residues with shorter side chains (isoleucine at 
position +2, serine at position +9; Figure 14). For that reason, the auxiliary helix of 
Dm Mextli can be accommodated on the dorsal surface of eIF4E in proximity to the 
canonical helix. The surface that is contacted on eIF4E by the auxiliary helix of Dm 
Mextli is primarily overlapping with that covered by the long aliphatic side chains 
present in the eIF4E-complexes with bipartite 4E-BPs like the Ce Mextli. Moreover, 
the conserved interactions generally mediated by the long side chains of the R/K 
residues in bipartite 4E-BPs are replaced by equivalent contacts mediated by residues 
in the auxiliary sequences of Dm Mextli. Particularly, two aromatic residues establish 
these contacts, namely a phenylalanine shields the hydrophobic surface of eIF4E, and 
a tyrosine mediates hydrophobic and polar interactions with eIF4E and the canonical 
helix of Dm Mextli. In conclusion, the structural analysis of the Dm eIF4E-Mextli 
complex indicated that the presence of long side chains on positions +2 and +9 of the 
canonical motif would interfere with the arrangement of the auxiliary helix of 
4. Results   	
	 53	
Dm Mextli. As such, 4E-BPs containing the extended canonical 4E-BM cannot adopt 
a similar auxiliary arrangement, which seems to be unique to Dm Mextli. 
Furthermore, the presence of specific residues in the canonical motif can be used as 
an indication for a bipartite or non-bipartite 4E-BP. 
We also investigated the consequences of the tripartite binding mode of Dm 
Mextli on a functional level. For this purpose, we analyzed the behavior of bipartite 
and tripartite 4E-BPs in competition assays in vitro (the competition assays were 
performed with the help of Ramona Weber). From these assays, we could derive 
valuable insights into specific structure-function relations:  
First, a bipartite 4E-BP competes efficiently with eIF4G for eIF4E-binding. In 
contrast, the tripartite Dm Mextli C+NC+α3 fragment was a weak competitor of the 
eIF4E-eIF4G interaction.  
Second, the Dm eIF4E-Mextli complex is resistant to the competition by 
bipartite 4E-BPs. The stability of the Dm eIF4E-Mextli complexes in the presence of 
competitor proteins was assessed in competition assays with preassembled eIF4E-
Mextli complexes containing or lacking the auxiliary sequences. In the presence of 
different competitor proteins (eIF4G or the chimeric 4E-BP) only the Dm Mextli 
complex lacking the auxiliary sequences could be competed out. Hence, the auxiliary 
sequences of Dm Mextli confer stability and resistance to the eIF4E-Mextli complex 
against bipartite 4E-BP competitors.  
Third, the long aliphatic side chains at positions +2 and +9 of the extended 
canonical 4E-BM (YX[R/K]X2LΦX2[R/K]; Y is counted as 0) are an important 
feature of a bipartite 4E-BP. As stated before, substitution of these residues impairs 
the ability of 4E-BPs to compete with eIF4G. The functional significance of these 
residues can also be observed in the Mextli proteins. In Dm Mextli, these two 
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positions are substituted by smaller residues (isoleucine and serine) to accommodate 
the auxiliary helix. A Dm Mextli peptide lacking the auxiliary sequences competes 
poorly with other 4E-BPs or eIF4G for binding to eIF4E and, vice versa, is quickly 
displaced from eIF4E by other 4E-BPs. However, mutating positions +2 and +9 of the 
extended canonical motif of the Dm Mextli peptide that lacks the auxiliary sequences 
to arginine (IS-RR mutant) resulted in a bipartite Dm Mextli mutant with properties 
similar to other bipartite 4E-BPs. This bipartite Dm Mextli peptide carrying the IS-RR 
substitutions displaced eIF4G from preassembled eIF4E-eIF4G complexes as 
efficiently as Ce Mextli, which is a bipartite 4E-BP and already contains arginines at 
both positions. Further, the IS-RR mutant of Dm Mextli displayed an increased 
resistance to competition by other 4E-BPs when it was bound to eIF4E, but not to the 
some extent as the Dm Mextli peptide containing the auxiliary region. Therefore, the 
behavior of the bipartite Dm Mextli IS-RR mutant is clearly distinct from that 
mediated by the auxiliary sequences. The arginine substitutions do not provide similar 
properties to the eIF4E-complex but are the key features to turn a functionally 
impaired peptide of Dm Mextli that lacks the auxiliary sequences into a normal 
bipartite 4E-BP. These results underline the functional importance of the extended 
canonical motif for a bipartite 4E-BP. 
In summary, Dm Mextli is an interesting 4E-BP, not only because of its 
proposed function as a translational activator, but also in terms of its eIF4E-binding 
region. On a structural level, the novel tripartite eIF4E-binding mode of Dm Mextli 
underlines the relevance of the extended canonical motif. From a functional 
perspective, however, this binding mode implies a different regulatory mechanism to 
disassemble Dm eIF4E-Mextli complexes. 
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4.4 The eIF4E-homologous protein provides binding specificity to GIGYF 
through a surface that is not conserved in eIF4E 
 
The work summarized in this section is described in the manuscript by Peter et al., 
2017 and is accepted for publication in Genes	 &	 Development. The accepted 
manuscript including detailed experimental data and methods is included in the 
Appendix. 
 
The eIF4E-homologous protein (4EHP, or also eIF4E-2) is one of the three 
eIF4E proteins in vertebrates. However, compared to the major eIF4E protein in cells, 
eIF4E-1, 4EHP does not bind to eIF4G and therefore acts as a translational repressor 
(Morita et al., 2012). Instead 4EHP interacts with additional proteins involved in 
diverse cellular and developmental functions. Among those partners are the human 
Grb10-interacting GYF domain-contain (GIGYF) proteins 1 and 2. The 4EHP-
GIGYF repressive complex is recruited to specific mRNAs by additional interactions 
with certain RNA-binding proteins. Indeed, the Zn-finger protein ZNF598 has been 
shown to interact with GIGYF and is required for mouse embryonic development, 
whereas in the human context it has been shown that Tristetraprolin (TTP) recruits the 
4EHP-GIGYF complex to mRNAs containing AU-rich elements in their 3’-UTRs, 
which play a role in the inflammatory cytokine response (Fu et al., 2016; Giovannone 
et al., 2009; Morita et al., 2012; Tao and Gao, 2015). 
GIGYF proteins have been reported to specifically bind to 4EHP but not to 
eIF4E in vivo, despite the approximately 30% identity and 42% similarity between 
both human eIF4E proteins (Morita et al., 2012; Rosettani et al., 2007). To investigate 
whether GIGYF can also discriminate between eIF4E and 4EHP at a molecular level, 
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i.e. in the absence of a possible regulatory mechanism, we performed pull-down 
assays in vitro (the pull-down assays were performed with the support of Sigrun 
Helms). In these assays eIF4E or 4EHP were pulled down in the presence of a N-
terminal fragment of GIGYF1/2 containing the 4EHP-binding region, or the eIF4E-
binding region of 4E-BP1 (Figure 15). The GIGYF1/2 proteins were strongly pulled 
down by 4EHP, but only weakly by eIF4E, whereas 4E-BP1 bound similarly to both. 
These results indicate that GIGYF1/2 discriminates between eIF4E and 4EHP in 
vitro, whereas 4E-BP1 does not as previously reported (Rosettani et al., 2007).  
 
 
 
 
Figure 15: 4EHP-binding region of the human GIGYF proteins. (A) Schematic representation of the two 
human GIGYF proteins. GIGYF1 (purple) and GIGYF2 (blue) contain a GYF domain (gray) and a N-terminal 
4EHP-binding motif (black). (B) Close-up view on the 4EHP-BMs of GIGYF. Identified binding elements are 
shown with a blue box and refer to the canonical (C), non-canonical (NC) and auxiliary (A) binding sites. The 
canonical 4EHP-BM as well as predicted secondary structure elements are indicated below the corresponding 
regions. (C) Fragments of GIGYF that were used for in vitro binding studies with 4EHP. The relative change in 
affinity for 4EHP according to ITC measurements is indicated on the right. 
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The sequence and structural similarity between eIF4E and 4EHP suggests that 
4EHP also contains dorsal and lateral binding sites analogous to eIF4E. To address 
this question, 4EHP structure-based mutants were generated to disrupt interactions at 
the dorsal (W-A mutant) or lateral (IM-AA mutant) surfaces of 4EHP. Both mutations 
affected the interaction of 4EHP with endogenous GIGYF1/2 and abolished the 
interaction with overexpressed 4E-BP1 in pull-down assays from human cell lysates, 
showing that 4EHP indeed uses these two orthogonal surfaces to interact with its 
binding partners (the in vivo experiments were carried out by Lara Wohlbold). This 
result also shows that both the dorsal and the lateral binding surface are conserved 
within the eIF4E-protein family. 
The N-terminal 4EHP-binding region of Hs GIGYF1/2 is characterized by a 
canonical 4EHP-binding motif (YXYX4LΦ; canonical 4EHP-BM), which is similar to 
the canonical 4E-BM [Figure 15; (Morita et al., 2012)]. Moreover, GIGYF1/2 
proteins contain additional binding elements C-terminal to their canonical 4EHP-BM 
to address the lateral surface of 4EHP. Accordingly, a non-canonical 4EHP-BM, 
which displays a high content of hydrophobic residues is located within a 
characteristic distance to the canonical 4EHP-BM. Furthermore, an additional C-
terminal extension, termed the auxiliary region (A), is also present in these proteins 
(Figure 15). The auxiliary region comprises several elements that either displayed 
high sequence conservation among GIGYF proteins or additionally helical propensity 
(Figure 15).  
To analyze the contribution of the different binding elements of Hs GIGYF1/2 
to the interaction with 4EHP, we compared the association of Hs GIGYF1/2 proteins 
that contain or not the auxiliary region (C+NC+A vs. C+NC; Figure 15) with 4EHP in 
binding assays in vitro. These GIGYF proteins bound differently to the 4EHP mutants 
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(W-A and IM-AA) compared to wild-type. In these binding assays, only Hs 
GIGYF1/2 proteins that lack the auxiliary region (C+NC) were strongly affected in 
their interaction with 4EHP by the mutations on 4EHP. The GIGYF1/2 proteins 
containing the auxiliary region (C+NC+A) bound to wild-type or mutant 4EHP to the 
same extent (the pull-down assays were done with the help of Sigrun Helms). The W-
A and IM-AA mutations of 4EHP abolished the interaction with Hs 4E-BP1 in vitro. 
Therefore, the auxiliary regions of Hs GIGYF1/2 contribute to the assembly of the 
4EHP-GIGYF complex, as they compensate for the mutations on the dorsal and 
lateral surfaces of 4EHP and confer properties to the complex that are distinct from 
the bipartite model of the eIF4E-4E-BP1 complex. 
Moreover, ITC measurements of Hs GIGYF1/2 protein fragments confirmed 
the contribution of non-canonical and auxiliary sequences for binding to 4EHP. 
Compared to the canonical 4EHP-BM alone, a GIGYF protein containing the non-
canonical sequences in addition to the canonical motif displayed a strong gain in 
affinity for 4EHP (approximately 20-30 fold; C vs. C+NC fragments; Figure 15). An 
additional increase in the binding affinity was observed when the GIGYF protein 
fragments also included the auxiliary region (approximately 30-40 fold; C+NC vs. 
C+NC+A fragments; Figure 15). The final binding affinity of GIGYF proteins for 
4EHP is in the sub-nanomolar range (C+NC+A; Figure 15). Of further note is the fact 
that the presence of the auxiliary region of Hs GIGYF1/2 (C+NC+A) imposes a 
significant increase in the entropic penalty compared to the fragments lacking these 
sequences (C+NC). In agreement with the structural studies below, this increase in 
entropic contribution can be explained by additional disorder-to-order transitions 
upon binding of the auxiliary region to 4EHP.  
4. Results   	
	 59	
In order to get a detailed molecular insight into the 4EHP-GIGYF complex, I 
solved the crystal structure of the 4EHP-binding region of Hs GIGYF1/2 including 
the canonical motif, non-canonical sequences and the auxiliary region bound to 4EHP 
(Figure 16). Both 4EHP-complexes (Hs GIGYF1 and Hs GIGYF2) are highly similar 
to each other, and reveal unexpected insights into this interaction. 
 
	
Figure 16: Structures of the human GIGYF1/2 proteins bound to 4EHP. The 4EHP-binding region of 
GIGYF1 (purple) and GIGYF2 (blue) is shown in a cartoon representation with the particular binding elements 
(canonical, C: non-canonical, NC; auxiliary1-3, A1-3) highlighted by a black dashed circle. The secondary 
structure elements of GIGYF are indicated. The surface of 4EHP is shown in yellow, whereas the interface with 
GIGYF1/2 is highlighted in light purple or light blue, respectively. 
 
First, GIGYF proteins contact the dorsal and the lateral surface of 4EHP in a 
manner similar to how 4E-BPs bind to eIF4E. On the dorsal surface of 4EHP, GIGYF 
forms a canonical helix (YXYX4LΦ) that mediates conserved interactions with 4EHP 
analogous to those observed for the canonical 4E-BM of other 4E-BPs or eIF4G 
(YX4LΦ), as the motif and the dorsal surface are conserved features (Marcotrigiano et 
al., 1999). Moreover, the initial tyrosine of the canonical 4EHP-BM (YXYX4LΦ) 
does not fulfill a function in discriminating between eIF4E and 4EHP as it was 
previously proposed (Cho et al., 2005; Villaescusa et al., 2009). This tyrosine residue 
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only contributes to the binding with weak van der Waals contacts and could 
potentially be accommodated as well in a complex with eIF4E. The most interesting 
feature about the arrangement of GIGYF on the dorsal surface of 4EHP concerns the 
interactions with the auxiliary sequences. The canonical helix of GIGYF1/2 together 
with 4EHP form a composite surface to which the A1 motif binds in a shape-
complementary manner. A key factor involved in this interaction is an aromatic 
residue (phenylalanine in Hs GIGYF1, tyrosine in Hs GIGYF2) that is positioned at 
the prominent position +9 of the extended canonical 4E-BM, instead of the long 
aliphatic residue usually present in 4E-BPs (extended canonical 4E-BM of 4E-BPs: 
YX[R/K]X2LΦX2[R/K]; see above). Thus, besides the case of Dm Mextli described 
above, GIGYF proteins are another interesting example on the influence of the +9 
position of the extended canonical 4E-BM on the binding mode to members of the 
eIF4E-family of proteins. 
The coordination of the linker connecting canonical and non-canonical motifs 
of GIGYF by 4EHP is different from 4E-BPs bound to eIF4E, as GIGYF proteins 
lack the characteristic elbow-loop structure. A triad of a tyrosine, an isoleucine and a 
methionine mainly lines the lateral surface of 4EHP, forming a hydrophobic pocket 
with contributions from surrounding residues. Overall the lateral binding site of 4EHP 
is structurally very similar to eIF4E, and the mode of binding of GIGYF resembles 
other 4E-BPs as it involves placing of hydrophobic or aromatic residues at critical 
positions. Therefore it is surprising that a GIGYF1/2 peptide containing canonical 
motif and non-canonical sequences can still discriminate between eIF4E and 4EHP. 
In comparison with structures of the eIF4E-4E-BP complexes, the non-canonical 
interactions of GIGYF with 4EHP do not display any clear feature that would 
preclude binding to eIF4E. Indeed, GIGYF introduces a critical phenylalanine residue 
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into the hydrophobic pocket of 4EHP, which establishes an elaborate hydrophobic 
interaction network. Consequently, the similarity of interactions at the dorsal and 
lateral surfaces of 4EHP compared to eIF4E-complexes does not shed light on the 
binding specificity of GIGYF for 4EHP over eIF4E. Additional mutational studies on 
the 4EHP-binding region of GIGYF are therefore required to address this unsolved 
question.  
Following the non-canonical motif, GIGYF1/2 contain auxiliary sequences 
that contact and cross the dorsal surface of 4EHP and finally bind in a groove of 
4EHP almost opposite to the non-canonical interactions (Figure 16). The auxiliary 
region of GIGYF1/2 harbors a conserved PLAL motif (sequence stretch of proline-
leucine-alanine-leucine) as well as two additional helical elements (α2 and α3; Figure 
16). The PLAL motif binds to the composite surface formed by the canonical helix 
and 4EHP. The helices α2 and α3 are connected by a tightly coordinated linker 
sequence. Interestingly, the coordination of the auxiliary region of Hs GIGYF1/2 
involves many residues of 4EHP that are diverse in eIF4E, indicating that similar 
interactions cannot be formed within eIF4E-complexes and suggesting why GIGYF 
prefers 4EHP over eIF4E in vivo. 
To validate that the 4EHP-surface contacted by the auxiliary region of Hs 
GIGYF1/2 is specific to GIGYF, we analyzed the interaction of wild-type and mutant 
4EHP (i.e. residues involved in the interaction with the auxiliary region of Hs 
GIGYF1/2) with GIGYF2 (endogenous) or overexpressed 4E-BP1 in human cells (the 
cell-based assays were carried out by Lara Wohlbold). These residues are 4EHP-
specific and comprise an arginine and a glutamate residue, which coordinate the 
auxiliary region of Hs GIGYF1/2 and were substituted by leucine residues present at 
the corresponding position in eIF4E (RE-LL mutant). In this assay, the RE-LL mutant 
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of 4EHP did not interact with GIGYF2, although it bound to 4E-BP1. Therefore, this 
specific surface of 4EHP seems to fulfill an important role for the selection of GIGYF 
proteins over other 4E-BPs that might be present in cells. To further test the role of 
the auxiliary interactions for the selective binding of 4EHP to GIGYF, we performed 
competition assays in vitro (the competition assays were performed with the support 
of Sigrun Helms). In this assays, we challenged purified 4EHP-4E-BP1 complexes 
with Hs GIGYF2 peptides that comprised the canonical motif, non-canonical 
sequences and the auxiliary region and traced the amount of 4EHP-bound 4E-BP1 
over time. We compared 4EHP-4E-BP1 complexes in which the 4EHP molecule is 
either wild-type or carries the RE-LL mutation. In agreement with the pull-down 
assays, the Hs GIGYF2 peptide displaced 4E-BP1 efficiently from wild-type 4EHP-
complexes, but was strongly impaired in competing with 4E-BP1 in the context of the 
RE-LL mutant of 4EHP. Both assays show that 4EHP-GIGYF complexes gain 
affinity and specificity through a specific interface formed by the auxiliary region of 
GIGYF proteins and residues that are only present in 4EHP and not in eIF4E. Even if 
bipartite 4E-BPs, like the human 4E-BP1, can bind to both eIF4E and 4EHP in vitro, 
its binding affinity for 4EHP is lower compared to GIGYF proteins, as it does not 
contain similar auxiliary binding sites that contact additional surfaces of 4EHP. For 
that reason, we propose that the additional auxiliary interactions observed in the 
4EHP-GIGYF complex provide stability and specificity to this translational repressor 
complex in vivo, where both proteins are less abundant than other competing 4E-BPs. 
As observed in the pull-down assays, 4EHP and eIF4E bind to 4E-BP1. 
However, it is known that the interaction of 4E-BP1 with eIF4E is approximately 
tenfold stronger than with 4EHP (Rosettani et al., 2007). The molecular reason 
underlying this difference is not clear. To obtain a molecular insight into the 
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interactions of 4E-BP1 with 4EHP, we also determined the crystal structure of the 4E-
BP1 peptide containing the canonical motif and non-canonical sequences bound to 
4EHP (Figure 17). 
 
 
Figure 17: The structure of the human 4E-BP1 bound to 4EHP. (A) Structural overview of the human 4E-BP1 
(cyan) bound to 4EHP (yellow). The structural elements of 4E-BP1 (canonical helix, C helix; elbow loop; non-
canonical loop, NC loop) are indicated. (B) Superposition of the 4E-BP1 complexes with eIF4E and 4EHP in two 
views. The 4E-BP1 peptide bound to eIF4E (gray) is shown in pink and its structural elements are indicated. The 
cartoon on the right depicts the similar binding mode of 4E-BP1 to either eIF4E or 4EHP. (C) Detailed view on the 
coordination of the linker region of 4E-BP1 between 4EHP and eIF4E. The arginine at position +9 is colored in 
dark blue from its Cγ atom on because it appeared disordered in the crystal structure of the 4EHP complex. In 
contrast, in the eIF4E-complex an asparagine residue coordinates the same arginine. 
 
The overall complex is highly similar to the human eIF4E-4E-BP1 complex 
described above (Figure 17). Nevertheless, a single amino acid substitution between 
eIF4E and 4EHP within the binding site of 4E-BP1 affects the strength of the 
interaction. This substitution concerns a conserved asparagine residue in eIF4E, 
which forms hydrogen bonds bridging and coordinating the canonical 4E-BM and the 
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linker region of 4E-BP1. Since this residue is replaced by a serine in 4EHP, this 
coordination is absent and results in missing electron density of an otherwise strictly 
fixed arginine side chain of 4E-BP1 in the crystal structure. To analyze the effects of 
this specific position in binding, we generated a mutant of 4EHP in which the serine 
residue was substituted by asparagine as observed in eIF4E (S-N 4EHP mutant). 
Interestingly, this single amino acid substitution is sufficient to explain the reduced 
affinity of 4E-BP1 for 4EHP compared to eIF4E as seen in ITC measurements, since 
the 4EHP S-N mutant displays a dissociation constant (KD) similar to eIF4E and 
tenfold lower than wild-type 4EHP. This result shows that also molecular features in 
the common dorsal and lateral binding surface of eIF4E proteins contribute to the 
specificity for some binding partners. Once again, the +9 position of the extended 
canonical 4E-BM has a prominent role in the interaction with eIF4E-proteins. In this 
way, 4EHP likely evolved towards a specific complex with GIGYF by generating 
new binding surfaces for GIGYF1/2 not present in eIF4E on the one hand, and on the 
other hand by modifying interactions that are otherwise used by 4E-BPs like 4E-BP1. 
Another interesting aspect that might contribute to the selective assembly of 
the 4EHP-GIGYF complexes concerns their oligomeric state in solution. In the crystal 
environment, the 4EHP-GIGYF1/2 complexes form close contacts to a neighboring 
complex within the asymmetric unit (ASU), involving a large interface of around 
1000 Å2. The interface between the two complexes involves elements of the canonical 
4EHP-BM as well as of the auxiliary region of GIGYF1/2. To verify if this close 
inter-complex interaction in cristallo also occurs in solution, we performed small-
angle X-ray scattering (SAXS) measurements (Figure 18).  
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Figure 18: Small-angle X-ray scattering measurements on 4EHP-GIGYF complexes. (A) Crystallographic 
models of a single 4EHP-GIGYF complex (GIGYF in red) and the symmetric dimer of two 4EHP-GIGYF 
complexes (GIGYF in cyan) found in the asymmetric unit of the crystal. 4EHP is shown in gray. (B) Crystal 
structure of a 4EHP-GIGYF2 complex in which GIGYF is lacking the auxiliary region. For the single complex, 
GIGYF is colored in green and for the symmetric dimer in purple. Note that this complex also crystallized in a 
similar dimeric arrangement that is slightly distorted compared to the complex containing the auxiliary region. (C) 
SAXS profiles of different 4EHP-GIGYF complexes including the fits of the respective models. The data was 
collected from different complexes (wild-type, deletion of the auxiliary region of GIGYF and specific dimerization 
mutants) as indicated above each profile. The experimental data is shown as dots, the fits of the respective model 
as a colored line. The colors of the fits are indicated in each graph and correspond to the colors of the GIGYF 
peptides in the structures shown in panels A and B, which were used for the fitting of the data. 
 
The SAXS data revealed that 4EHP-GIGYF1/2 complexes form indeed dimers 
of two complexes in solution, as the scattering profile of the 4EHP-GIGYF protein 
solution could be explained by the symmetric dimer of two complexes observed in the 
ASU of the crystal, but not by a single complex (Figure 18). The oligomeric state of 
the 4EHP-GIGYF complexes changes towards a single complex when i) the auxiliary 
region of GIGYF is absent (ΔA complex), or ii) specific residues of the dimer 
interface are mutated (Figure 18). The dimerization mutants of 4EHP and the lack of 
the auxiliary region did not affect the formation of the complex between GIGYF and 
4EHP. The latter could also be confirmed by the crystal structure of the 
4EHP-GIGYF2 complex that does not contain the auxiliary region of GIGYF2, 
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showing that the arrangement of the canonical motif and the non-canonical sequences 
of GIGYF2 are not affected by the lack of the auxiliary region (Figure 18). In 
summary, the SAXS measurements show that 4EHP-GIGYF complexes have the 
propensity to form specific, symmetric dimers in solution, which requires the 
auxiliary region of GIGYF as well as 4EHP-specific residues. However, the 
biological relevance of this oligomeric arrangement of 4EHP-GIGYF complexes is 
not clear. It can only be speculated that this dimerization increases the avidity of 
4EHP close to the 5’cap structure of an mRNA, enhancing its efficiency to compete 
with eIF4E for binding and ultimately to repress translation. 
Taken together, the structural studies on 4EHP-GIGYF complexes revealed a 
detailed molecular insight into this 4EHP-selective complex. These structures 
illustrate the tight and extensive interaction between both partners, provide insights 
into the specificity of their complex formation and further demonstrate an 
unprecedented oligomeric arrangement. Nevertheless, it is still unclear why GIGYF 
proteins do not bind to eIF4E and, vice versa, why eIF4G does not bind to 4EHP in 
vitro. Even with the high-resolution structural insight into all the respective 
complexes, this issue remains unsolved. More studies are necessary to address the 
kinetics of individual eIF4E- and 4EHP-complexes, also with respect to the individual 
binding elements of the interacting partners. Due to the similarity of the canonical 4E-
BM and canonical 4EHP-BM, the answer to the binding specificity of GIGYF and 
eIF4G might lie in their non-canonical sequences. 
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5. DISCUSSION 
5.1 A revised molecular model for the repression of translation by 4E-BPs 
The conservation of the canonical motif among eIF4E-interacting partners 
enables 4E-BPs to compete with eIF4G for binding to eIF4E based on a mechanism 
of molecular mimicry (Marcotrigiano et al., 1999). Several studies indicate that 
additional, non-conserved contacts are established between eIF4G or 4E-BPs and 
eIF4E. Among different eIF4E-binding partners, these additional binding elements 
may exhibit distinct binding contributions (Kinkelin et al., 2012; Lukhele et al., 2013; 
Paku et al., 2012; Umenaga et al., 2011). However, a detailed structural insight into 
the eIF4E-complexes with either eIF4G or 4E-BPs was missing when I started my 
doctoral work. Therefore, the molecular model for the repression of translation by 
4E-BPs relied on the binding discrepancies between translational activators and 
repressors. Solely based on the structural insights of Dm CUP bound to eIF4E, this 
model proposed that a second, lateral binding site on eIF4E is exclusively used by 4E-
BPs for docking and displacing bound eIF4G (Kinkelin et al., 2012). 
My structural and functional work on 4E-BPs revealed that this lateral surface 
of eIF4E is a common binding site for different 4E-BPs. Moreover, my data on the 
Drosophila proteins suggests that eIF4G depends less on the lateral side of eIF4E for 
binding, making the lateral side binding a hallmark for the competitive mechanism of 
4E-BPs. Surprisingly however, the follow-up structural work on eIF4E-eIF4G 
complexes together with my colleague Stefan Grüner revealed that eIF4G proteins 
also contain non-canonical motifs that bind to the lateral side of eIF4E, similarly to 
4E-BPs (Figure 19).  
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Figure 19: Competition model of 4E-BP-based translational regulation. 1) eIF4G (green) is bound to eIF4E 
(gray) which leads to the activation of cap-dependent translation. However, the lateral interaction site with eIF4E 
contributes less and might be more dynamic in the case of eIF4G. 2) Non- or partially phosphorylated 4E-BPs 
(magenta) might capture a free lateral side of eIF4E and start to dissociate eIF4G. 3) Fully bound 4E-BPs repress 
translation initiation by preventing the assembly of the eIF4F complex on the 5’cap of an mRNA. 4) Conversely, 
4E-BPs get regulated by the mTOR signaling pathway and cannot bind to eIF4E when fully phosphorylated (p4E-
BP1), leading to the activation of translation by eIF4G. Yet, it is not completely understood how eIF4E-4E-BP 
complexes are regulated to release eIF4E to participate in translation. 
 
Despite the similarity in the binding mode between 4E-BPs and eIF4G, our 
binding studies and competition assays indicated that the sequence composition of the 
non-canonical motif and the N-terminal connecting linker region is the determinant 
for the lateral side dependence of eIF4G and 4E-BPs. The fact that the binding of 
eIF4G to the lateral side of eIF4E contributes much less to its overall affinity and that 
4E-BPs strongly require the lateral side of eIF4E to compete with eIF4G supported 
the idea that the non-canonical sequences of eIF4G might be more dynamic in the 
complex with eIF4E compared to 4E-BPs. Regarding the competition model of 4E-
BPs with eIF4E-eIF4G complexes, we could therefore speculate that 4E-BPs occupy 
a transiently free lateral side of eIF4E and start to dissociate eIF4G from the complex 
to achieve translational repression (Figure 19). However, more studies regarding the 
dynamics of the unbound as well as the eIF4E-bound state of 4E-BPs and eIF4G, or 
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even the capture of a putative intermediate trimeric eIF4E-4E-BP-eIF4G state are 
required to validate this. 
Another aspect that indicates differences in the lateral side binding between 
4E-BPs and eIF4G is provided by studies on the small molecule inhibitor 4EGI-1, 
which targets the eIF4E-eIF4G interaction (Moerke et al., 2007). A crystal structure 
of this compound bound to eIF4E revealed that it also binds to the lateral side of 
eIF4E (Papadopoulos et al., 2014). Moreover, a structural comparison shows that the 
binding of 4EGI-1 directly overlaps with the non-canonical motifs of eIF4G and 4E-
BPs at the lateral side of eIF4E, and thus might be mutually exclusive for both. 
Strikingly, 4EGI-1 seems to specifically affect the eIF4E-eIF4G interaction and was 
reported to be compatible with 4E-BP1 binding (Moerke et al., 2007; Papadopoulos et 
al., 2014; Sekiyama et al., 2015). In the light of our results, the stronger lateral side 
binding of 4E-BPs might not allow the inhibitor to fully access its binding site and 
therefore 4E-BP1 remains bound to eIF4E. Accordingly, the weaker lateral side 
binding of eIF4G might be competed out by 4EGI-1, enhancing the dissociation of 
eIF4G from eIF4E or blocking its stable association. Thus, these results agree with 
our structural and binding studies, and indicate that 4EGI-1 also utilizes the 
differential contribution in the lateral side binding of eIF4G and 4E-BPs to block 
translation initiation. Moreover, our data provides an alternative and complementary 
explanation to the proposed allosteric effect of this small molecule compound. In our 
model, 4EGI-1 directly competes with eIF4G for binding to the lateral surface of 
eIF4E, and upon binding it causes allosteric changes that ultimately lead to the 
dissociation of the eIF4E-eIF4G complex (Papadopoulos et al., 2014; Salvi et al., 
2016; Sekiyama et al., 2015).   
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5.2 Regulation of eIF4E-4E-BP complexes 
Although we have expanded our understanding on the molecular mechanism 
underlying the repression of translation by 4E-BPs, there are still many open 
questions concerning the regulation of eIF4E-4E-BP complexes. Indeed, 4E-BPs are 
regulated by phosphorylation through the mTORC1 complex, and 
hyperphosphorylated 4E-BPs cannot associate with eIF4E (Bah et al., 2015; Gingras 
et al., 1999a; Gingras et al., 2001; Miron et al., 2003). In contrast, 
hypophosphorylated 4E-BPs bind to eIF4E and might occupy a part of the cellular 
eIF4E-pool as a mean to control the availability of the cap-binding protein and fine-
tune global translational levels. In fact, a reduction of the cellular eIF4E levels does 
not impact on global protein synthesis in normal cellular conditions and even 
prevented the oncogenic transformation of cells (Truitt et al., 2015). Therefore, eIF4E 
is likely present in excess in cells and the pool of eIF4E available for translation is 
controlled by 4E-BPs depending on their phosphorylation status. The phosphorylation 
status of 4E-BPs also regulates their abundance, since hypophosphorylated 4E-BPs 
that are not bound to eIF4E are ubiquitinated and targeted for proteasomal 
degradation (Yanagiya et al., 2012). This regulatory mechanism adds another layer of 
translational control, since the activation of 4E-BPs must occur from their 
hyperphosphorylated or their eIF4E-bound pool. 
However, it remains unclear how eIF4E is released from 4E-BPs to participate 
in translation. A piece of this puzzle is laid with the cryo-electron microscopy 
structure of the mTORC1 complex, which provided a comprehensive insight into the 
architecture of this machinery, including its specific adaptor protein Raptor that 
recognizes 4E-BPs via binding to their C-terminal TOR signaling (TOS) motif (Aylett 
et al., 2016; Schalm et al., 2003). The structural insight into this complex suggests 
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that 4E-BPs are likely phosphorylated in their extended conformation, and not when 
they are bound to eIF4E as already proposed in previous studies (Youtani et al., 
2000). This might specifically concern the phosphorylation sites known to be 
modified only at the end of the phosphorylation cascade and which become 
inaccessible in the eIF4E-bound form [see Figure 5; (Gingras et al., 1999a; Gingras et 
al., 2001)]. Therefore, to increase the pool of eIF4E available for translation, it is 
necessary to dissociate the eIF4E-4E-BP complexes. This would enable the mTORC1 
complex to fully phosphorylate 4E-BPs in order to prevent re-association with eIF4E. 
To assess the dissociation of eIF4E-4E-BP complexes, however, more quantitative 
kinetic studies are required that also consider the different phosphorylation states of 
4E-BPs. One possibility is that the activation of the mTORC1 complex facilitates the 
dissociation of the eIF4E-complex by binding to 4E-BPs, which could affect their 
interaction with eIF4E. Another possibility would be that hypophosphorylated 4E-
BPs (i.e. modified only at the initial phosphorylation sites; see Figure 5) display an 
increased dissociation rate from eIF4E compared to their non-phosphorylated form, 
which would increase mTORC1 accessibility and therefore the likelihood of being 
phosphorylated. Indeed, our data on partially phosphorylated 4E-BPs suggests that 
phosphorylation affects 4E-BPs in their ability to compete with eIF4G when it is 
already bound to eIF4E. Conversely, hypophosphorylated 4E-BPs might also be 
easier displaced from eIF4E by other factors like eIF4G. Therefore, understanding the 
molecular mechanism underlying the regulation of 4E-BPs and the fine-tuning of 
cellular eIF4E levels requires a deeper insight into the kinetics of these complexes and 
their turnover in vivo.  
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5.3 The eIF4E-eIF4G interaction as a target for therapeutic applications in 
cancer 
A common perturbation in human cancers concerns malfunctions in the 
control of translation. These malfunctions ultimately increase overall protein 
synthesis, which in turn facilitates cancer progression and resistance to cancer 
treatments (Grzmil and Hemmings, 2012). Therefore, the translation machinery and 
its regulators are major therapeutic targets in cancer treatment, and a variety of 
inhibitors for almost every component involved in translation have been characterized 
(an overview can be found in Bhat et al., 2015).  
Among the translational components, the eIF4F complex offers some 
opportunities for therapeutic treatment (Steinberger et al., 2016). For example, efforts 
have been made to target the eIF4E-eIF4G interaction with small molecule inhibitors, 
and the 4EGI-1 compound discussed above is only one example. In my doctoral 
thesis, I used a peptide-based approach to target the eIF4E-eIF4G interaction. Our 
structural and functional studies on 4E-BPs resulted in a fusion peptide with elements 
from different 4E-BPs (see Figure 11). We could show that this chimeric 4E-BP 
displayed improved functional properties as a competitor of eIF4G and as an efficient 
translational repressor. These results exemplify the feasibility of 4E-BP based 
peptides as tools for therapeutic applications. The structural details provided by our 
research can be used as a template for structure-guided drug design, a strategy to 
improve existing compounds or new lead compounds in terms of affinity and 
selectivity (Valkov et al., 2012). In fact, the direct use of small peptides as 
pharmacological drugs has been evaluated, as there is a significant interest in 
targeting the eIF4E-eIF4G interaction (Fosgerau and Hoffmann, 2015; Zhou et al., 
2012). Alternatively, 4E-BP derived peptides have also been applied in cell based 
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assays as a tool to suppress cancer cell growth. For instance, fusion of a 4E-BP like 
peptide to an analog of the gonadotropin-releasing hormone (GnRH) reduced the 
tumor growth in ovarian tumor xenograft mouse models without toxic effects (Ko et 
al., 2009). Since the majority of epithelial ovarian cancer types express GnRH 
receptor (GnRH-RI), the 4E-BP like peptide was taken up into GnRH-RI expressing 
tumor cells (Ko et al., 2009). Alternative delivery strategies can also be used to target 
other types of tumors. An interesting approach utilizes the pH-induced 
transmembrane structure (pHLIP), a peptide that folds into transmembrane helix in 
low pH conditions. As the extracellular environment of solid tumors is usually acidic, 
the folding of the pHLIP peptide will be induced and will transport a fused 
macromolecule across the cellular barrier of such tissues (Cheng et al., 2015). 
Considering the various approaches, our research might provide a framework for 
targeting the eIF4E-eIF4G interaction in a multitude of biological and disease-
relevant contexts. 
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5.4 Regulation of specific eIF4E-4E-BP complexes: the eIF4E-Mextli complex 
Binding to eIF4E by eIF4E-binding partners other than eIF4G is generally 
thought to repress translation in a global or message specific manner, depending on 
the type of 4E-BP that is involved. Drosophila Mextli, however, seems to be an 
exception from this general assumption, since it is the only 4E-BP that was reported 
to promote translation besides eIF4G (Hernandez et al., 2013). Its modular domain 
architecture and interaction network are functionally mimicking eIF4G, however we 
could also show that the eIF4E-binding mode of Dm Mextli involving canonical, non-
canonical and auxiliary helices is unique among 4E-BPs. 
In the Dm eIF4E-Mextli complex, the accommodation of the auxiliary helix 
on the dorsal surface of eIF4E requires specific amino acid substitutions in the 
canonical motif. These are two arginine residues, which are present in the canonical 
motif of Ce Mextli, but which are replaced by residues with smaller side chains (i.e. a 
serine and a isoleucine) in Dm Mextli. These substitutions are required in the case of 
Dm Mextli to avoid clashes with the auxiliary helix, which in turn compensates for 
the missing interactions of the arginine side chains. Furthermore, the incompatibility 
between the long arginine side chains and the auxiliary helix of Dm Mextli implies 
that other previously studied 4E-BPs cannot form similar auxiliary arrangements. 
Together with the functional studies on the tripartite and bipartite binding 
modes of the Mextli proteins, the structural insights again underpin the relevance of 
the long aliphatic side chains that take similar positions in our previously defined 
extended canonical eIF4E-binding motif (YX[R/K]X2LΦX2[R/K]). The extended 
canonical motif is present in all bipartite 4E-BPs known so far and in eIF4G (where 
+9 position can also be a glutamine in some species instead), and in all cases the role 
of these long aliphatic side chains is to cover a large part of the dorsal surface of 
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eIF4E. Therefore, a more detailed knowledge on key interactions of 4E-BPs might 
allow a predictive assumption on the binding mode of yet uncharacterized 4E-BPs, 
and might lead to the improvement of motif-based searches to identify novel 4E-BPs 
in silico by reducing false-positive hits. 
Moreover, the unique tripartite eIF4E-binding mode influences the functional 
properties of Dm Mextli compared to bipartite 4E-BPs. Namely, the tripartite 
assembly of Dm Mextli with eIF4E guarantees the formation of a very stable complex 
that is resistant to the competition by bipartite 4E-BPs (Figure 20). This exceptional 
feature might allow Dm Mextli to fulfill its specific functions during embryogenesis 
and germline stem cell maintenance in Drosophila in the presence of other 4E-BPs. 
However, this raises the question of how the Dm eIF4E-Mextli complexes are 
regulated and why the binding of Mextli to eIF4E differs in worms like Ce.  
One possible scenario concerns the population of 4E-BPs and eIF4E in 
worms. In fact, worms do not contain many 4E-BPs. Besides Mextli, only IFET-1 (a 
homologue to 4E-T) has been described as a 4E-BP in worms (Sengupta et al., 2013). 
In contrast to the low number of 4E-BPs, worms contain different eIF4E isoforms as 
well as mRNAs with different cap-structures as a result of trans-splicing events 
(Keiper et al., 2000; Van Doren and Hirsh, 1990). Since some eIF4E isoforms were 
found to be specific for a certain mRNA cap, they are related to specific translational 
programs (Dinkova et al., 2005; Keiper et al., 2000; Miyoshi et al., 2002). This could 
reduce the necessity to compete for eIF4E-binding in worms, since there are already 
specialized types of eIF4E rather than a common pool. Nevertheless, which 4E-BPs 
exist in worms like Ce, whether they exhibit specificity for a particular eIF4E 
isoform, or if there are other regulatory mechanisms involved is so far unknown.  
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Figure 20: The regulatory mechanism controlling the binding of Dm Mextli to eIF4E remains unclear. The 
figure relates to the 4E-BP based competition model shown in Figure 19. Dm Mextli (cyan and dark blue) is added 
to this model based on the insights generated in this work. 1) Under certain cellular conditions or developmental 
processes in Drosophila, Mextli is able to bind to eIF4E and activates translation by functionally mimicking 
eIF4G. 2) However, the regulation of the Dm eIF4E-Mextli complex is unclear, since bipartite 4E-BPs are not able 
to displace Mextli. 
 
Several eIF4E proteins also exist in Drosophila, and Dm Mextli does not bind 
to all of the eight eIF4E paralogs present in flies (Hernandez et al., 1997; Hernandez 
et al., 2013). It is not known whether Dm Mextli uses a specific eIF4E paralog to 
initiate translation, and the cellular conditions in which Dm Mextli promotes 
translation are unclear. Dm Mextli might be mRNA-specific and only promote 
specific translational programs in addition to the eIF4G-mediated global translation in 
the cell. Additionally, the unique tripartite eIF4E-binding mode of Dm Mextli also 
allows it to sustain protein synthesis under conditions where 4E-BPs are hyperactive 
and shut down eIF4G-dependent translation. However, the resistance against the 
regulation by 4E-BPs implies that an alternative mechanism controls Dm eIF4E-
Mextli complexes (Figure 20). One possibility could be the regulation by 
phosphorylation similar to the global translational repressor 4E-BPs. Although one of 
5. Discussion   	
	 77	
the phosphorylation sites located within the eIF4E-binding region of Hs 4E-BP1-3 
(described above) is also present in Dm Mextli, there is no evidence that Mextli 
proteins are regulated by phosphorylation. Unlike the human 4E-BPs 1-3, Dm Mextli 
does neither contain a TOS motif that marks it as a substrate for the adaptor protein 
Raptor of the mTORC1 complex, nor does it contain potential phosphorylation sites 
that are suitable for a serine/threonine-specific protein kinase. Still, phosphoregulation 
of Dm eIF4E-Mextli complexes via a different pathway cannot be excluded, but more 
research is required to reveal which translational programs this complex controls and 
how it is regulated in vivo. 
 
5.5 The specificity of GIGYF for 4EHP gives rise to a unique translational 
repressor complex that competes with eIF4E 
The second eIF4E-family member, 4EHP, offers an alternative mechanism of 
translational regulation in addition to the binding of 4E-BPs to eIF4E. 4EHP is able to 
bind to the 5’mRNA cap but not to eIF4G, wherefore it regulates the translation of 
specific mRNAs (Cho et al., 2006; Cho et al., 2005; Fu et al., 2016; Villaescusa et al., 
2009). The GIGYF proteins 1 and 2 are specific interaction partners of 4EHP (Morita 
et al., 2012). Interestingly, GIGYF1/2 proteins only bind to 4EHP and not to eIF4E 
(Rom et al., 1998). The molecular determinants required for the specificity of binding 
to eIF4E- and 4EHP were unclear, especially due to the similarity between the eIF4E- 
and 4EHP-binding motifs between the binding partners (Marcotrigiano et al., 1999; 
Morita et al., 2012; Rosettani et al., 2007).  
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My work on the 4EHP-GIGYF translational repressor complexes provided the 
first structural insight into a 4EHP-specific protein bound to 4EHP. With the 
molecular details we could learn that 4EHP binds preferentially to GIGYF1/2 and not 
to bipartite 4E-BPs. This specificity of 4EHP is provided through the recognition of 
4EHP-specific surfaces by the auxiliary sequences of GIGYF1/2, which are absent in 
4E-BPs. Therefore, the GIGYF-specific interaction sites of 4EHP might enable the 
specific formation of the 4EHP-GIGYF translational repressor complex in vivo, 
especially since other bipartite 4E-BPs like 4E-BP1 are present in much higher 
amount in the cell than GIGYF1/2 and could therefore occupy 4EHP and prevent it 
from being recruited to its specific targets.  
However, the structural similarity of the canonical and non-canonical 4EHP-
binding motifs of GIGYF1/2 with eIF4E-4E-BP complexes makes it difficult to 
rationalize why eIF4G does not bind to 4EHP and, vice versa, why GIGYF1/2 
proteins do not bind to eIF4E. Specifically, the almost identical canonical binding 
motifs of GIGYF1/2 and eIF4G must confer binding to either eIF4E-protein. Indeed, 
GIGYF1/2 binds weakly to eIF4E in vitro. This also implies that the non-canonical 
binding regions play a role in the specific recognition of the correct eIF4E-protein. In 
agreement with this, a single amino acid substitution between eIF4E and 4EHP within 
their otherwise conserved binding region significantly affects the binding affinity to 
4E-BP1. Thus, even small differences in the binding interfaces in either binding 
partner might affect their relative affinities towards eIF4E- or 4EHP in vivo. 
Nonetheless, it remains unclear whether the non-canonical motifs are the sole 
determinants of the exclusive binding of the GIGYF1/2 proteins and eIF4G to 4EHP 
and eIF4E, respectively. In this case it would be of interest to determine the 
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contributions of specific residues, which likely requires further extensive mutational 
approaches in combination with quantitative binding studies. 
RNA-binding proteins (RBPs) are known to recruit the 4EHP-GIGYF 
translational repressor complex to specific mRNAs to repress translation (Fu et al., 
2016; Morita et al., 2012; Tao and Gao, 2015). Since 4EHP has an approximately 
200-fold lower affinity for an m7GTP cap analog than eIF4E, its tethering to an 
mRNA via GIGYF and a recruiting RBP might increase its ability to compete with 
eIF4E for the 5’ mRNA cap (Rosettani et al., 2007). In agreement with this model, my 
structural work provides insights on how 4EHP might replace eIF4E on the 5’ mRNA 
cap.  
First, the close proximity of the C-terminal auxiliary sequences of GIGYF to 
the cap-binding pocket of 4EHP in our structures could point to a role of the 
subsequent arginine/glycine-rich sequences of GIGYF in RNA-binding. Binding of 
GIGYF to RNA might stabilize 4EHP in close distance to the mRNA cap and 
therefore increase its local concentration to compete with eIF4E. However, 
arginine/glycine-rich low complexity regions usually bind non-specifically to RNAs, 
which brings several drawbacks to this idea (Thandapani et al., 2013). Non-specific 
RNA-binding does not guarantee the tethering of 4EHP in the 5’UTR of the mRNA 
close to the cap, as it potentially can allow binding to any sequence of the mRNA. 
Therefore, it is not clear how this RNA-binding capability could ultimately result in 
an advantage for 4EHP to compete with eIF4E present at the mRNA cap. Such an 
advantage, however, could be provided by yet unknown factors that facilitate the 
recognition of specific sequences in the mRNA. Alternatively, it seems more likely 
that binding of 4EHP to the cap is the initial step of the repression mechanism that 
subsequently locates the arginine/glycine-rich sequences in proximity of the 5’ UTR 
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of the mRNA. Binding of GIGYF to the mRNA would then support the interaction of 
4EHP with the cap structure of the mRNA. However, it remains to be determined if 
the arginine/glycine-rich sequences adjacent to the 4EHP-binding region of GIGYF 
indeed bind to RNA. 
Second, the specific dimeric arrangement of the 4EHP-GIGYF complexes in 
solution might increase the binding of 4EHP on the target mRNA through avidity 
effects. Additional factors might also contribute to the avidity effect of the 4EHP-
GIGYF complex. For instance, the C-terminus of GIGYF contains a predicted coiled-
coil region, which might facilitate the multimerization of GIGYF proteins. However, 
the oligomeric state of GIGYF proteins in vivo is not known and needs to be further 
analyzed. Moreover, target mRNAs might contain several repeats of the recognition 
motif for a specific RBP, which in turn recruits the 4EHP-GIGYF complex. For 
example, the AU-rich binding sequence of TTP is repeated multiple times within the 
ARE (AU-rich element) of the target mRNAs, as in the tumor necrosis factor (TNF) 
mRNA (Brooks and Blackshear, 2013). Therefore, the cooperation of all of those 
factors could result in binding of multiple 4EHP-GIGYF complexes on target 
mRNAs, which would strongly increase the probability of 4EHP to occupy the 
mRNA cap. 
Regarding the tight interaction between 4EHP and GIGYF proteins, an open 
question concerns the regulation of this complex. Interestingly, mouse 4EHP 
knockout cells have reduced expression of GIGYF, indicating that 4EHP and GIGYF 
are interdependent in terms of stability (Morita et al., 2012). So far, the molecular 
pathway involved in the control of the stability of 4EHP and GIGYF is unknown. 
Binding of GIGYF to 4EHP could preclude the exposure of potential sequences that 
target GIGYF for degradation, for instance via the proteasome. Therefore, the 
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expression levels of 4EHP might dictate the relative abundance of the 4EHP-GIGYF 
complex. Furthermore, it remains unclear if the interaction between GIGYF and 
4EHP itself is regulated. Based on the phosphoregulation of the global translational 
repressor 4E-BPs, phosphorylation of GIGYF residues could also play a role in this 
mechanism. Indeed, several potential tyrosine phosphorylation sites have been 
suggested in mouse GIGYF proteins (Giovannone et al., 2003). Additionally, 
proteomic databases on posttranslational modifications indicate several serine and 
threonine phosphorylation sites. Although none of those sites are located within the 
4EHP-binding region of GIGYF, two serine residues are located just N-terminal of 
the canonical 4EHP-binding motif of GIGYF proteins. These two sites might play a 
similar regulatory role as the N-terminal phosphorylation sites in 4E-BPs, which have 
been shown to induce a folding transition when phosphorylated that masks the 
canonical eIF4E-binding motif (Bah et al., 2015). Nevertheless, more binding assays 
as well as studies of protein dynamics in vitro are required to obtain a mechanistic 
understanding of those phosphorylation sites. The regulatory pathway that controls 
the activity of GIGYF proteins in vivo is also unclear and could be the object of future 
studies. 
 
6. Conclusion   	
	 82	
6. CONCLUSION 
4E-BPs are translational repressors that act on the initiation step of translation 
by interfering with the formation of the eIF4F complex on the 5’cap structure of an 
mRNA. Mechanistically, this repression is based on a direct competition with the 
translation initiation factor eIF4G for binding to eIF4E. Since a variety of proteins in 
the cell follow this principle, 4E-BPs comprise a broad range of factors that are 
involved in different cellular functions. Therefore, translational repression can act in a 
global manner as a response to environmental cues, or at the level of specific mRNAs. 
At the beginning of my doctoral work, the underlying molecular details of the 
competitive binding mechanism were incomplete. For this reason, my doctoral work 
initially focused on the interaction of different 4E-BPs and eIF4G with eIF4E. My 
biophysical and structural studies on 4E-BPs elucidated common binding principles 
for different 4E-BPs (4E-T, Thor and 4E-BP1) to eIF4E and showed that the key 
interactions are conserved between 4E-BPs and across species. Moreover, my studies 
provided the first complete structural insight into the binding of the global 
translational repressor 4E-BP1 to eIF4E and rationalized previous studies on this 
factor that indicated additional eIF4E-binding regions (Lukhele et al., 2013; Paku et 
al., 2012). To complement our insights into the competitive binding mechanism, I 
initiated and participated in a collaborative project that aimed at understanding the 
binding mode of eIF4E-eIF4G complexes, since eIF4G was also reported to contain 
additional eIF4E-binding sequences (Umenaga et al., 2011). In this structural study, 
we visualized the extended interactions between eIF4G and eIF4E and revealed that 
the additional eIF4E-binding occurs on the same surfaces of eIF4E contacted by 
4E-BPs. Therefore, the competition for eIF4E-binding is based on a complete 
molecular mimicry, beyond the conserved canonical eIF4E-binding motif. Moreover, 
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we could determine that the amino acid composition of the non-conserved additional 
eIF4E-binding regions of these proteins determine the ability of 4E-BPs to compete 
with eIF4G. Taken together, these studies provide a fundamental structural insight 
into the regulation of translation, which is of high relevance in therapeutic approaches 
to treat malignancies in which eIF4E activity is upregulated. 
In another project of my PhD, I was working on a highly specialized 
invertebrate-specific 4E-BP called Mextli, which was reported to act as a translational 
activator during certain developmental stages and cell types in Drosophila 
melanogaster (Hernandez et al., 2013). I used a structural approach to compare Mextli 
proteins from Dm and Ce, and with this I revealed striking differences in their eIF4E-
binding mode. Ce Mextli follows the bipartite binding mode similar to other 4E-BPs, 
while Dm Mextli evolved a complex, tripartite binding mode for eIF4E. Distinct 
structural differences to other 4E-BPs allow this tripartite arrangement of Dm Mextli, 
which confers specific functional properties to the complex not observed in any other 
eIF4E-4E-BP complex. By comparing the different binding modes of the Ce and Dm 
Mextli proteins, we could show that the Dm eIF4E-Mextli complex is very resistant to 
competition by bipartite 4E-BPs. This distinct functional property might enable Dm 
Mextli to fulfill its specific cellular function in the presence of other 4E-BPs. 
Therefore, Dm Mextli is the first example of a 4E-BP extending the bipartite binding 
mode. So far, there are no other examples of 4E-BPs that bind to eIF4E in a similar 
manner. However, the structural characteristics we could describe for Dm Mextli 
might help to identify similar binding modes and at the same time exclude that 
previously described 4E-BPs bind to eIF4E using a tripartite binding region.  
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In the last part of my doctoral work I focused on 4EHP translational repressor 
complexes. In contrast to eIF4E, 4EHP cannot bind to eIF4G and therefore acts as a 
translational repressor. Conversely, the GIGYF proteins only bind to 4EHP but not to 
eIF4E. In both cases, the molecular determinants for the discrimination between the 
eIF4E proteins are unclear, since the conserved canonical binding motif is highly 
similar between eIF4G and GIGYF proteins. My structural studies on 4EHP-GIGYF 
complexes demonstrated that GIGYF proteins gain affinity and achieve specificity 
because they contain additional auxiliary binding elements that contact 4EHP-specific 
surfaces. These binding sites on 4EHP are not used by 4E-BPs that also bind to 
eIF4E, and therefore provide the selectivity for the interaction with GIGYF. This 
unique binding mode might be especially important in vivo, where the low abundant 
4EHP-GIGYF complex is facing an excess of other 4E-BPs. Nevertheless, due to the 
similarity in the overlapping bipartite binding interface between eIF4E- and 4EHP-
complexes, it is difficult to rationalize why proteins like eIF4G and GIGYF are not 
able to bind to either eIF4E-protein. Future work to address this question might 
require comprehensive mutational and kinetic studies on the binding properties of 
those proteins. 
In conclusion, my doctoral work revealed a common structural binding mode 
for 4E-BPs binding to eIF4E proteins. With the Mextli proteins and the 4EHP-GIGYF 
complexes I further showed specific exceptions, which extend the conserved bipartite 
binding to establish novel functional properties of this interaction. Therefore, my 
results contributed to the understanding of translational regulation by 4E-BPs, 
elucidated functional properties of eIF4E-complexes and provided insights into the 
selectivity and specificity for eIF4E-proteins (Figure 21). 
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Figure 21: Translational control by eIF4E- and 4EHP-complexes. Different factors influence mRNA 
translation either on a global level or in a message specific way. eIF4G (light blue) and 4E-BPs (magenta) bound 
to eIF4E (dark blue) act as global translational activators and repressors, respectively. mRNA-specific eIF4E-
complexes might be formed for example by Mextli proteins (brown) or 4E-T (green). Alternatively, the 4EHP-
GIGYF (orange and red, respectively) complex is likely recruited to specific targets by different RNA-binding 
proteins (purple, labeled as ‘X’). However, open questions remain about the translational programs that are 
controlled by those mRNA-specific complexes and about the mechanisms that are involved to control mRNA 
expression.  
 
eIF4E- and eIF4E-related complexes are involved in diverse translational 
programs that act either globally or in a message-specific manner. My work 
contributed to the field of translational control by shedding light on structural and 
functional similarities and differences between these complexes (Figure 21). Many 
open questions remain regarding the cellular function of these complexes. To obtain a 
broader understanding about translation, future work should address whether there are 
specific targets that are regulated by certain 4E-BPs, and which additional factors are 
involved in their function (Figure 21). 
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9. ABBREVIATIONS 	
4E-BM eIF4E-binding motif 
4E-BP1-3 eIF4E-binding proteins 1-3 
4E-BPs eIF4E-binding proteins 
4E-T eIF4E-transporter protein 
4EHP eIF4E-homologous protein 
A sequences auxiliary sequences 
α1-3 sequence region with α-helical propensity or fold number 1-3 
ABCE1 ABC-family ATPase ABCE1 
AGO1-4 Argonaute proteins 1-4 
ARE AU-rich element 
ASD autism spectrum disorders 
ASU asymmetric unit 
ATP Adenosine triphosphate 
C motif canonical motif 
CCR4 Carbon catabolite repressor protein 4 
Ce Caenorhabditis elegans 
CYFIP1 Cytoplasmic FMR1-interacting protein 1 
Dm Drosophila melanogaster 
eEF1A eukaryotic elongation factor 1-alpha 
eEF2 eukaryotic elongation factor 2 
EEP endo/exonuclease phosphatase domain 
eIF2-α, -β, -γ eukaryotic translation initiation factor 2 subunits α, β or γ 
eIF2B eukaryotic translation initiation factor 2B 
eIF4A eukaryotic translation initiation factor 4A 
eIF4E eukaryotic translation initiation factor 4E 
eIF4F eukaryotic translation initiation factor 4F 
eIF4G eukaryotic translation initiation factor 4G 
eIFs eukaryotic translation initiation factors 
eRF1 eukaryotic translation termination factor 1 
eRF3 eukaryotic translation termination factor 3 
FMR fragile X mental retardation 
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GB1 B1 domain of protein G 
GIGYF Grb10-interacting GYF protein 
GnRH gonadotropin-releasing hormone 
GnRH-RI gonadotropin-releasing hormone receptor 
GTP guanosine triphosphate 
Hs Homo sapiens 
HSQC heteronuclear single quantum coherence 
IFE1-5 initiation factor of elegans 1-5 
IP immunoprecipitation 
ITC isothermal titration calorimetry 
KD dissociation constant 
KH hnRNP K homology domain 
m7GpppN 7-methylguanosine 5′-triphosphate dinucleotide 
m7GTP 7-methylguanosine 5′-triphosphate 
Met-tRNAMeti initiator methionyl-tRNA 
MIF4G middle domain of eukaryotic translation initiation factor 4G 
miRISC microRNA-induced silencing complex 
MMG monomethylguanosine 
mRNA messenger RNA 
mRNP messenger ribonucleoprotein 
NC motif non-canonical motif 
NMR nuclear magnetic resonance 
NOT Negative on TATA 
nt nucleotide 
p4E-BP1 phosphorylated 4E-BP1 
PABP poly(A)-binding protein 
PDB Protein databank 
pHLIP pH-induced transmembrane structure  
PI3K phosphoinositide 3-kinase 
PIC preinitiation complex 
poly(A) stretch of multiple adenosine monophosphates 
RBP RNA-binding protein 
RISC RNA-induced silencing complex 
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RNA ribonucleic acid 
SAXS small-angle X-ray scattering 
Sc Saccharomyces cerevisiae 
SD  Shine-Dalgarno  
SL spliced leader 
TC ternary complex 
TMG trimethylguanosine 
TNF tumor necrosis factor 
tRNA transfer RNA 
TTP Tristetraprolin 
UTR  untranslated region of an mRNA 
VPg viral protein genome-linked factor 				
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This section contains an overview of the crystal structures I solved and published 
during my doctoral work. The crystal structures listed in the following are referenced 
to the corresponding accession code of the worldwide protein data bank 
(http://www.wwpdb.org). 
 
protein / protein complex PDB accession code 
N. crassa Pan2 WD40 domain 4CZV 
D. melanogaster eIF4E-Thor complex 4UE8 
D. melanogaster eIF4E-4E-T complex 4UE9 
D. melanogaster eIF4E-eIF4G complex 4UEC 
H. sapiens eIF4E-4E-BP1 complex 4UED 
D. melanogaster eIF4E-4E-BP chimera 
(crystal form 1) 4UEA 
D. melanogaster eIF4E-4E-BP chimera 
(crystal form 2) 4UEB 
D. melanogaster eIF4E-Mextli complex 
(cap-bound state) 5ABU 
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C. elegans eIF4E-Mextli complex 
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H. sapiens 4EHP-GIGYF1 complex 5NVK 
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H. sapiens 4EHP-4E-BP1 complex 5NVN 
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4E-BPs require non-canonical 4E-binding motifs
and a lateral surface of eIF4E to repress translation
Ca´tia Igreja1, Daniel Peter1, Catrin Weiler1 & Elisa Izaurralde1
eIF4E-binding proteins (4E-BPs) are a widespread class of translational regulators that share
a canonical (C) eIF4E-binding motif (4E-BM) with eIF4G. Consequently, 4E-BPs compete
with eIF4G for binding to the dorsal surface on eIF4E to inhibit translation initiation. Some 4E-
BPs contain non-canonical 4E-BMs (NC 4E-BMs), but the contribution of these motifs to the
repressive mechanism—and whether these motifs are present in all 4E-BPs—remains
unknown. Here, we show that the three annotated Drosophila melanogaster 4E-BPs contain
NC 4E-BMs. These motifs bind to a lateral surface on eIF4E that is not used by eIF4G. This
distinct molecular recognition mode is exploited by 4E-BPs to dock onto eIF4E–eIF4G
complexes and effectively displace eIF4G from the dorsal surface of eIF4E. Our data reveal a
hitherto unrecognized role for the NC 4E-BMs and the lateral surface of eIF4E in
4E-BP-mediated translational repression, and suggest that bipartite 4E-BP mimics might
represent efficient therapeutic tools to dampen translation during oncogenic transformation.
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The regulation of protein synthesis at the initiation step is awidespread and reversible mechanism to control geneexpression in eukaryotes1,2. During translation initiation,
the small ribosomal subunit is recruited to mRNA by the
eukaryotic initiation factor 4F (eIF4F) complex, which comprises
the cap-binding protein eIF4E, the scaffolding protein eIF4G and
the DEAD-box RNA helicase eIF4A. The eIF4E protein
recognizes the mRNA m7GpppN cap structure and interacts
with eIF4G, which promotes translation initiation via the
recruitment of the 43S pre-initiation complex1. eIF4G binds
eIF4E through a conserved motif (or canonical eIF4E-binding
motif, C 4E-BM) of sequence TyrX4LeuF, where F is
hydrophobic, and X is any amino acid3–5.
The assembly of the eIF4F complex is regulated by a diverse
group of eIF4E-binding proteins (4E-BPs), which share a similar C
TyrX4LeuF motif with eIF4G. Therefore, 4E-BPs bind to the
same surface on eIF4E, sterically blocking its interaction with
eIF4G and preventing translation initiation4–7. The association of
4E-BPs with eIF4E is reversible and regulated by phosphorylation.
Unphosphorylated or hypophosphorylated 4E-BPs exhibit a high
affinity for eIF4E and repress translation, whereas hyper-
phosphorylated 4E-BPs lose their affinity for eIF4E2,8,9.
At a functional level, 4E-BPs play essential roles in the control
of translation during development and regulate neuronal
plasticity by repressing translation at a global or message-specific
level9–14. Through their inhibitory effect on translation, 4E-BPs
negatively regulate cell proliferation and act as tumor
suppressors9,11. However, the 4E-BP anti-oncogenic function is
compromised in many tumors, resulting in increased eIF4E
activity and protein synthesis, which is required for tumorigenic
transformation9. Consequently, a detailed molecular understand-
ing of the interaction between eIF4E and 4E-BPs is crucial to
design or improve drugs that may be useful in pathological
conditions in which eIF4E activity and global translation are
upregulated9,15,16.
The C motifs of eIF4G and 4E-BPs adopt similar a-helical
structures on binding to a conserved patch of hydrophobic
residues on the dorsal side of the eIF4E cap-binding pocket5,7,17.
Additional surfaces on eIF4E also contribute to the interaction
with eIF4G as well as with a subset of 4E-BPs by binding
to residues that are carboxy terminal to the C motifs, which
contain NC 4E-BMs17–20. To date, NC motifs have only
been identified and characterized in eIF4G, vertebrate 4E-BP1–
3 and D. melanogaster CUP17,19,21–23. The NC motifs of 4E-BPs
are not conserved between orthologous proteins across the animal
kingdom. Therefore, it is not known whether all 4E-BPs contain
NC motifs. Functionally, NC motifs have been proposed to play
an auxiliary role by cooperating with their cognate C motifs to
increase the binding affinity for eIF4E17,19,20,22.
The protein CUP is an insect-specific 4E-BP that controls the
translation of maternal messenger RNAs during oogenesis and
embryogenesis21,24–26. The crystal structure of Dm eIF4E bound
to a CUP peptide containing the C and NC 4E-BMs revealed that
both motifs adopt an a-helical conformation and contact two
orthogonal surfaces on eIF4E27. The C 4E-BM binds to the
conserved dorsal surface of eIF4E, as observed for the C motifs of
eIF4G and 4E-BP1,2. The NC motif docks in an antiparallel
fashion onto a lateral and conserved surface of eIF4E27.
A comparison of the Dm eIF4E–CUP complex with the
structure of yeast eIF4E in complex with a fragment of eIF4G
indicates that the NC motif of CUP and yeast eIF4G bind to
partially overlapping surfaces on the lateral side of eIF4E17,27.
Consequently, NC motifs could also contribute to the steric
incompatibility with eIF4G and participate in the competition
process. However, the contribution of NC motifs to the ability of
4E-BPs to displace eIF4G has not yet been elucidated.
To shed light on the role of NC motifs in 4E-BP-mediated
translational repression, we investigated whether different Dm
4E-BPs contain NC motifs and how these motifs contribute to the
displacement of eIF4G from eIF4E. We show that similar to CUP,
Thor (ortholog of 4E-BP1–3) and 4E-T (4E-transporter) bind to
eIF4E through a bipartite sequence that contains a C motif and a
NC motif. The newly identified NC motifs in Thor and 4E-T
share no sequence similarity with their vertebrate counterparts or
with CUP. Nevertheless, these motifs share an overlapping lateral
binding surface on eIF4E with the NC motif of CUP, which is
required for the binding of 4E-BPs but not of eIF4G. The binding
to an eIF4E surface that is not used by eIF4G allows 4E-BPs to
dock onto preexisting eIF4E–eIF4G complexes to begin to
displace eIF4G from the dorsal surface. Our data reveal a hitherto
unrecognized diversity of NC motifs and establish the relevance
of these motifs in the mechanism by which 4E-BPs repress
translation. More generally, our data indicate that bipartite 4E-BP
mimics have a competitive advantage over eIF4G and might
represent potent repressors for the treatment of malignancies, in
which eIF4E activity is upregulated.
Results
4E-BPs bind to a lateral surface of eIF4E. To gain insight into
the binding mode of different 4E-BPs to eIF4E, we compared the
interaction of Dm CUP, Thor and 4E-T with Dm eIF4E (Fig. 1a).
In coimmunoprecipitation and pull-down assays, we confirmed
that all the proteins interacted with endogenous eIF4E in Dm
Schneider (S2) cells (Supplementary Fig. 1a–e).
Dm CUP interacts with eIF4E through C and NC motifs27.
In particular, the CUP residues Tyr327, Leu332, Met333
and Arg336 in the C motif interact with residues on the dorsal
surface of eIF4E, including Trp106 and Leu167 (Fig. 1b,c and
Supplementary Fig. 2a,b). In addition, the CUP residues Leu364,
Leu368, Met371 and Ile373 in the NC motif contact a eIF4E
lateral surface that is centered at residues Ile96 and Ile112
(Fig. 1b,d and Supplementary Fig. 2a,b)27.
To determine whether Thor, 4E-T and eIF4G also recognize
the lateral surface of eIF4E, we substituted residues Ile96 and
Ile112 with Ala (eIF4E mutant II-AA) and performed coimmu-
noprecipitation assays in S2 cells. As a control, we used an eIF4E
mutant with a Trp106Ala substitution (W106A) on the dorsal
binding surface, because this substitution abolishes the binding of
CUP and eIF4G to eIF4E21,28,29. As expected, the W106A
substitution strongly reduced the binding of eIF4E to endogenous
eIF4G and to all three of the 4E-BPs (Fig. 1e–g, lanes 7). By
contrast, the II-AA mutations disrupted the association of eIF4E
with CUP, Thor and 4E-T but not with eIF4G (Fig. 1e–g, lanes 8).
Thus, in contrast to eIF4G, 4E-BPs recognize and depend on the
lateral surface to efficiently bind to eIF4E in cell lysates, in which
eIF4G (or other 4E-BPs) is also present.
Identification of NC 4E-BMs in Thor and 4E-T. The immu-
noprecipitation assays shown in Fig. 1e–g indicate that similar to
CUP, Thor and 4E-T contain NC motifs that interact with the
lateral binding surface of eIF4E. In human 4E-BP1,2, the NC
IPGVTS/T motif (located C-terminally to the C motif), increases
the binding affinity of the proteins for eIF4E by approximately
three orders of magnitude19,22. However, the IPGVTS/T motif is
not conserved across the animal kingdom (Supplementary
Fig. 2c). Nevertheless, several hydrophobic residues are present
in the corresponding region in Dm Thor (residues Pro76–Pro84;
Supplementary Fig. 2c).
To determine whether the Thor residues 76–84 constitute a
NC 4E-BMs, we substituted Cys78, Leu79 and Leu80 with alanine
(NC*) or deleted the motif (DNC, Supplementary Table 1). In
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the coimmunoprecipitation assays, the deletion of the Thor
residues 76–84 abolished the interaction with eIF4E (Fig. 2a,
lane 12), whereas the alanine substitutions decreased the eIF4E
binding (Supplementary Fig. 1d, lane 9, NC*). By contrast, the
substitution of the flanking residues Arg81, Gly82 and Thr83 by
alanine was ineffective (Fig. 2a, lane 10). As a control, amino-acid
substitutions in the C motif (C*, Supplementary Table 1) also
disrupted the interaction with eIF4E (Fig. 2a and Supplementary
Fig. 1d). Thus, the interaction of Thor with eIF4E requires both a
C and a downstream NC motif in cell lysates.
In human 4E-T, sequences downstream of the C motif also
contribute to the interaction with eIF4E30. Again, these sequences
are not conserved in insects (Supplementary Fig. 2d).
Nevertheless, based on the observation that in CUP and Thor,
the NC motifs are located B15–29 residues from the C motifs,
are hydrophobic and, in the case of CUP, exhibit helical
propensity, we inspected the Dm 4E-T sequence for motifs that
fulfill these criteria. We identified a region in the insect 4E-T
(residues 32–43) that could contain a potential NC motif and is
located at a similar position as is the motif in the human protein
(Supplementary Fig. 2d). In the coimmunoprecipitation assays,
alanine substitutions or deletions of various residues in this motif
(Supplementary Table 1) caused a drastic reduction in the 4E-T
binding to eIF4E (Fig. 2b, lanes 10 and 11, and Supplementary
Fig. 1e), similar to the disruption of the C motif (C*, Fig. 2b, lane
9, and Supplementary Fig. 2d). Thus, a NC 4E-BMs is also
present in the Dm 4E-T that is conserved in Drosophila species.
4E-BPs and eIF4G display similar affinities for eIF4E. Next, we
compared the binding efficiencies of the minimal eIF4E-binding
regions of the 4E-BPs (CþNC, Supplementary Table 1) in pull-
down assays. These regions were expressed with an amino-
terminal MBP-tag and a C-terminal GB1-tag31. In parallel, we
analyzed the minimal eIF4E-binding fragment of eIF4G
(residues 578–650), which includes the C motif and the
SDVVL motif that was identified in Hs eIF4G (corresponding
to Dm VKNVSI, Supplementary Fig. 2e), which plays an
auxiliary function in stabilizing the eIF4G interaction with
eIF4E23. The bipartite CþNC regions of the three 4E-BPs and
the eIF4G fragment pulled down the purified eIF4E at
comparable levels (Fig. 2c).
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Figure 1 | 4E-BPs bind to a lateral surface of eIF4E. (a) Schematic representation of eIF4G and the 4E-BPs that were analyzed in this study. All the
proteins contain a canonical (C) and a non-canonical (NC) 4E-BM. CUP and 4E-T contain a region with similarity to human 4E-transporter (4E-T) region.
eIF4G contains a PABP-interacting region and MIF4G and MA3 domains. The amino-acid positions at the domain/motif boundaries are indicated below the
protein outlines. (b) Cartoon representation of the overall structure of the eIF4E–CUP complex. eIF4E is shown in cyan and CUP in orange (PDB code
4AXG)27. Selected secondary structure elements are labeled in black for eIF4E and in orange for CUP. (c,d) Close-up views of the dorsal (c) and lateral (d)
interfaces between eIF4E and CUP. Selected interface residues are shown as cyan and orange sticks for eIF4E and CUP, respectively. The eIF4E and CUP
residues are labeled in black and orange, respectively, and underlined if they are mutated. (e–g) WB showing the interaction of HA–eIF4E (either WT or
mutated) with GFP-tagged full-length 4E-BPs (CUP, Thor and 4E-T) and endogenous eIF4G. The size markers (kDa) are shown to the right of each panel.
The original WB shown in this figure can be found in Supplementary Fig. 8.
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To obtain information on the affinities and thermodynamic
parameters, we performed isothermal titration calorimetry (ITC)
experiments. The bipartite regions of all three of the 4E-BPs and
eIF4G exhibited comparable binding affinities for eIF4E, with
dissociation constants (KDs) in the nanomolar range (Table 1 and
Supplementary Fig. 3). The KD values obtained for Dm Thor and
eIF4G are comparable to those that have been reported for the
human proteins5,19,22,23,32. Notably, although the binding of all
proteins to eIF4E is enthalpically driven, the entropic penalties
differ between these proteins, suggesting differences in the
binding mechanisms. In particular, the interaction between
CUP and eIF4E displayed the highest entropic penalty, which is
indicative of a lower degree of conformational freedom in the
bound state. Thus, CUP may undergo larger disorder-to-order
transitions on binding, which is consistent with the formation of
two a-helices27. 4E-T and Thor exhibited lower entropic
penalties, suggesting a more dynamic conformation in the
bound state.
To understand the contribution of the NC 4E-BMs to the
affinity of 4E-BPs for eIF4E, we analyzed the binding of 4E-BP
peptides containing only the C motifs or the complementary
sequences comprising the linker (L) region between the two
motifs and the NC motif (LþNC, Supplementary Fig. 4 and
Supplementary Table 1). The affinities of the C motifs in isolation
were one to three orders of magnitude lower than the CþNC
peptides, indicating that the NC motifs contribute significantly to
the overall affinity. Interestingly, the C motifs of all three 4E-BPs
exhibited significant differences in binding affinities, with the
affinity of the 4E-T peptide being approximately one and two
orders of magnitude higher than those of the CUP and Thor
peptides, respectively (Table 1 and Supplementary Fig. 4). The
differences between 4E-BPs were more pronounced for the Lþ
NC peptides, because only the CUP peptide interacted with eIF4E
at detectable levels. The binding of the CUP peptide (LþNC) was
enthalpically driven, with a KD comparable to that of the C motif.
These results indicate a similar contribution to the energetics of
binding by the C and NC motifs of CUP.
Finally, we determined the affinities of the bipartite
peptides (CþNC) for the eIF4E II-AA mutant. The affinities of
CUP and Thor peptides were reduced by one and two orders of
magnitude, respectively (Table 1 and Supplementary Fig. 5). In
contrast, 4E-T binding was not significantly affected perhaps
reflecting the higher affinity of its C 4E-BM. Similarly,
the mutations in the lateral surface of eIF4E did not affect
eIF4G binding.
We conclude that although 4E-BPs and eIF4G display similar
affinities for eIF4E, they use different binding modes. These
differences can be mainly attributed to the linker regions and the
NC motifs, consistent with their sequence diversity, although
differences in affinities for the C motifs were also detected.
Moreover, the results of the ITC experiments also indicate that
the affinity of 4E-BPs for eIF4E results from synergistic effects
between the C and NC motifs.
4E-BP NC motifs are sufficient to bind eIF4E. To further
analyze the binding modes of the 4E-BPs and eIF4G to eIF4E, we
performed pull-down assays with recombinant proteins that were
expressed in Escherichia coli. In contrast to the experiments in cell
lysates, the in vitro pull-down assays allowed us to investigate
the interactions of the individual proteins in the absence of other
4E-BPs, which could compete for binding and could obscure
the interpretation of the results. We tested recombinant frag-
ments of eIF4G, CUP and 4E-T and full-length Thor for binding
to either the eIF4E wild-type (WT) or II-AA mutant (that is, with
a disrupted lateral surface). eIF4G and the 4E-BPs pulled down
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Figure 2 | Identification of non-canonical motifs in Thor and 4E-T. (a) WB
showing the interaction of HA-Thor (full length, either WTor mutated) with
endogenous eIF4E in S2 cells. The proteins were immunoprecipitated using
anti-HA antibodies. The inputs (1%) and immunoprecipitates (30%) were
analyzed by WB using anti-HA and anti-eIF4E antibodies. The original WB
shown in this panel can be found in Supplementary Fig. 8. (b) WB showing
the interaction of GFP–4E-T (full length, WT or mutated) with endogenous
eIF4E. The proteins were immunoprecipitated using anti-GFP antibodies.
The inputs (1%) and immunoprecipitates (30%) were analyzed by WB
using anti-GFP and anti-eIF4E antibodies. The original WBs can be found
in Supplementary Fig. 8. (c) MBP pull down showing the interaction of
His6-tagged eIF4E (residues 69–248, trunc) with MBP-tagged 4E-BP
CþNC fragments (see Supplementary Table 1) and eIF4G (residues 578–
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shown to the right of each panel.
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comparable amounts of WT and mutant eIF4E (Fig. 3a, lanes 9
and 10; Fig. 3b, lanes 10 and 11; and Fig. 3c,d, lanes 13 and 14),
indicating that these proteins interact with the eIF4E mutant
lacking a functional lateral binding surface in vitro. The results
obtained in vitro contrast with the observation that the 4E-BPs
did not interact with the II-AA mutant in cell lysates (Fig. 1e–g).
One possible explanation for this difference is that cell lysates
contain eIF4G, which blocks the dorsal surface of eIF4E, leaving
only the lateral surface available for 4E-BPs. If the lateral surface
is in addition mutated, then 4E-BPs may not be able to interact
with eIF4E and displace bound eIF4G (see below).
The interaction of eIF4G and 4E-BPs with the eIF4E II-AA
mutant is most likely mediated by their C motifs that bind to the
dorsal surface of eIF4E. To confirm this assumption, we
introduced mutations in the C motifs (C* mutants,
Supplementary Table 1). Substitutions in the C motif of eIF4G
abolished its interaction with either WT or mutant eIF4E (Fig. 3a,
lanes 11 and 12). By contrast, the equivalent substitutions in the C
motifs of 4E-BPs did not prevent their binding to eIF4E,
reflecting a truly bipartite-binding mode (Fig. 3b, lane 12, and
Fig. 3c,d, lane 15). However, the CUP and Thor C* mutants were
strongly impaired in their binding to the eIF4E II-AA mutant
(Fig. 3b, lane 13; Fig. 3c, lane 16), indicating that the C* mutants
use the lateral surface of eIF4E. The 4E-T C* mutant showed
reduced binding to both WT and mutant eIF4E (Fig. 3d, lanes 15
and 16).
Substitutions in the NC motifs (NC*) did not prevent the
interaction of 4E-BPs with either WT or mutant eIF4E, most
likely because the C motifs are sufficient for binding (Fig. 3b,
lanes 14 and 15; Fig. 3c,d, lanes 17 and 18). The interaction of
the three 4E-BPs with WT eIF4E was strongly reduced when the
two motifs were mutated (CþNC*, Fig. 3b, lane 16, Fig. 3c,d,
lanes 19). Remarkably, some residual binding to eIF4E was
observed. These results suggest that the linker regions between
the motifs in CUP and 4E-T and additional residues in Thor
(which was full length) contact eIF4E and contribute to the
interaction. The results obtained for the Thor NC* and CþNC*
mutants were confirmed using a mutant with a deleted NC motif
(DNC, Supplementary Fig. 6a).
Collectively, our results indicate that 4E-BPs interact with
eIF4E using a bipartite-binding mode and recognize a lateral
surface on eIF4E that is not used by eIF4G. Two main
observations support these conclusions. First, mutations in the
C motifs abolish the interaction of eIF4G but not of 4E-BPs with
eIF4E. Second, mutations on the lateral surface of eIF4E abolish
or reduce the binding of 4E-BPs to eIF4E when their binding to
the dorsal surface is also compromised. Our results further
indicate that the eIF4G residues downstream of the C motif,
including the VKNVSI motif, do not use the binding surface
centered at residues Ile96 and Ile112 and are not sufficient for
binding to eIF4E when the C motif is mutated, which is in
agreement with the proposed auxiliary role of these sequences23.
Finally, it is important to note that although mutations in the C
motifs of Thor and 4E-T do not disrupt binding to eIF4E, a
deletion of the C motif prevents binding (LþNC peptides, see
ITC experiments). These results suggest that mutations in the C
motifs of these proteins do not completely abolish binding to the
eIF4E dorsal surface, or that the formation of an a-helical
structure (which is likely maintained in the mutants) is indirectly
required to facilitate the binding of the linker region and NC
motifs.
4E-BPs use the eIF4E lateral surface to compete with eIF4G.
The observation that 4E-BPs can bind to the eIF4E II-AA mutant
in vitro (that is, in the absence of competition) but not in cell
lysates (that is, in the presence of eIF4G) suggests that 4E-BPs are
not able to compete with eIF4G for binding to eIF4E when the
lateral binding surface is disrupted.
To further investigate the role of the lateral binding surface of
eIF4E in the competition mechanism, we performed competition
assays using preassembled eIF4E–eIF4G complexes containing
either eIF4E WT or the II-AA mutant and GST-tagged eIF4G
(residues 578–650). eIF4G formed stable complexes both with
WT and mutant eIF4E (Fig. 4a–c, lanes 4 and 5, respectively).
These preassembled eIF4E–eIF4G complexes were challenged
with increasing amounts of peptides containing the C and NC
(CþNC) motifs of 4E-BPs or the same eIF4G fragment. Proteins
that were associated with eIF4E were recovered by eIF4E pull-
down assays.
The CUP, 4E-T and Thor CþNC peptides displaced eIF4G
from the complex and associated with eIF4E (Fig. 4a–c, lanes 7–10
versus 6, Supplementary Figs 6b–d and 7a–c). The CUP and 4E-T
peptides were able to effectively displace eIF4G when present at
Table 1 | Thermodynamic parameters for the interaction of eIF4E with eIF4G and 4E-BP peptides.
KD (M) DH (kcalmol" 1) TDS (kcalmol" 1) DG (kcalmol" 1) Molar ratio
Peptideþ eIF4E
eIF4G 578-680 17±13# 10"9 " 18.5±2 7.97 " 10.51 0.99±0.08
CUP CþNC 9.1±0.5# 10" 9 " 34.5±0.35 23.86 " 10.78 1.05±0.02
CUP C 1.6±0.1# 10" 7 " 16.84±0.04 7.70 "9.13 1.01±0.01
CUP LþNC 1.03±0.03# 10" 7 " 18.5±0.2 9.10 "9.38 0.98±0.01
Thor CþNC 1.4±0.3# 10"9 " 16.8±1 4.90 " 11.87 0.95±0.02
Thor C 2.26±0.06# 10" 6 " 12.1±2.8 2.24 "9.82 1.06±0.01
Thor LþNC nb nb nb nb nb
4E-T CþNC 5.6±2.4# 10"9 " 22.8±3 11.73 " 11.11 0.95±0.01
4E-T C 1.6±0.2# 10" 8 " 18.6±0.7 8.16 " 10.45 0.95±0.01
4E-T LþNC nb nb nb nb nb
Peptideþ eIF4E (II-AA)
eIF4G 578-680 40±9.5# 10"9 " 16.24±0.04 6.32 "9.93 1.03±0.01
CUP CþNC 5.0±0.8# 10"8 " 18.6±0.7 8.79 "9.84 0.98±0.01
Thor CþNC 4.7±0.3# 10" 7 " 7.6±0.3 "0.91 "8.46 0.97±0.01
4E-T CþNC 8.8±2# 10"9 " 12.9±0.3 2.16 " 10.80 1.03±0.04
C, canonical; eIF4, eukaryotic initiation factor 4; L, linker; nb, no binding; NC, non-canonical.
See Supplementary Figs 3–5.
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two- and onefold molar excess, respectively. Under the same
conditions, the 4E-BP CþNC peptides did not efficiently displace
eIF4G from complexes that contained the eIF4E II-AA mutant
(Fig. 4a–c, lanes 13 versus 12, Supplementary Figs 6b–d and 7a–c).
Thus, binding to the lateral surface is required for 4E-BPs to
effectively compete with eIF4G. In agreement with this conclusion,
peptides containing only the 4E-BP C motifs did not displace
eIF4G from eIF4E, although they were tested at the highest molar
concentration (Fig. 4a–c, lanes 11 versus 10 and Supplementary
Fig. 7a–c).
In striking contrast to the 4E-BP peptides, the eIF4G peptide
hardly competed with GST-eIF4G for binding to eIF4E,
irrespective of whether eIF4E was WT or mutated (Fig. 4d, lanes
5–11, Supplementary Figs 6b and 7d). Mechanistically, our results
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Figure 3 | 4E-BPs interact with eIF4E using a bipartite-binding mechanism. (a) MBP pull-down assay showing the interaction of His6-eIF4E (full length,
either WT or II-AA mutant) and MBP-eIF4G (residues 578–650; either WT or canonical 4E-BM mutant (C*)). The input (25%) and bound fractions
(50%) were analyzed by SDS–PAGE followed by Coomassie blue staining. (b) GST pull-down assay showing the interaction of His6-eIF4E (WT or II-AA
mutant) and GST-CUP-GB1 (residues 311–440, WTor mutated in the canonical motif (C*), non-canonical motif (NC*) or both motifs (CþNC*)). (c) MBP
pull down showing the association of MBP-Thor (full length, WTor 4E-BM mutants) with His6-eIF4E (WTor II-AA mutant). The samples were analyzed as
described in a. (d) MBP pull-down assay showing the interaction of MBP–4E-T (fragment 1–58, WT or the indicated mutants) with eIF4E (WT or II-AA
mutant). eIF4E was expressed with a tag consisting of the streptavidin-binding peptide (strep), His6 and the NusA protein (SHN tag). (e) Schematic
representation of the different eIF4E–4E-BPs and eIF4E–eIF4G complexes that were analyzed in the pull-down assays. 4E, eIF4E (blue circle). Black circle,
m7GTP-cap structure. The 4E-BPs are shown in orange and the eIF4G in green. The asterisks indicate mutations in the corresponding motifs. These
mutations are described in Supplementary Table 1.
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indicate that 4E-BPs are more efficient competitors than is eIF4G
and must bind to the lateral surface of eIF4E to effectively
displace eIF4G from preassembled eIF4E–eIF4G complexes.
4E-BPs use the NC motifs to compete with eIF4G. Given that
binding of 4E-BPs to the lateral surface of eIF4E is required
for competition with eIF4G and that peptides containing only the
4E-BP C motifs cannot compete with eIF4G (Fig. 4), we next
investigated the requirement for NC motifs. To this end, we
performed competition assays using preassembled eIF4E–eIF4G
complexes and excess 4E-BP peptides lacking either the C or NC
motifs. The WT CUP CþNC peptide interacted with eIF4E and
efficiently displaced preassembled eIF4G (Fig. 5a, lane 9 versus 6).
Peptides containing either the C or the NC motifs of CUP did not
compete with eIF4G (Fig. 5a, lanes 7 and 8), although these
peptides bind to eIF4E in the absence of eIF4G (Fig. 5b, lanes 6
and 7), which is in agreement with the ITC experiments.
Similar results were obtained for Thor. Notably, deleting the
non-canonical motif in the context of full-length Thor was
sufficient to abolish its ability to compete with eIF4G (Fig. 5c,
lane 10 versus 7), although in the absence of eIF4G this deletion
mutant interacted with eIF4E (Supplementary Fig. 6a, lanes 17
and 18). Mutations in the canonical motif also abolished
competition, as expected (Fig. 5c, lane 9). We conclude that 4E-
BPs require both canonical and non-canonical motifs to compete
with eIF4G for eIF4E binding. Thus, the non-canonical motifs
play an essential role in the competition mechanism.
4E-BPs exhibit a kinetic competitive advantage over eIF4G.
Given that the 4E-BPs and eIF4G display similar affinities for
eIF4E, the differences in the ability to efficiently displace pre-
bound eIF4G in competition assays are likely explained by the
binding kinetics and the bipartite-binding mode. To obtain
additional information on the ability of 4E-BPs to compete with
eIF4G, we challenged preassembled eIF4E–eIF4G complexes
with five- to tenfold molar excess of 4E-BP and eIF4G peptides
and monitored the amount of eIF4G remaining bound to eIF4E
over time.
In the absence of competitors, eIF4G remained bound to
eIF4E, as expected (Fig. 5d, lane 4). In the presence of a tenfold
molar excess of eIF4G peptide, we observed a 50% dissociation of
prebound eIF4G after 4 h at 4 !C (Fig. 5d and Supplementary
Fig. 7e). In the presence of a fivefold molar excess of CUP and
4E-T peptides (CþNC), we observed a 50% eIF4G dissociation
in 2.5±0.5 and 22min, respectively, whereas the half-life of
the eIF4E–eIF4G complexes in the presence of tenfold molar
excess of Thor was 37±9min. (Fig. 5e–g, and Supplementary
Fig. 7f). The simplest explanation of these results is that the
bipartite-binding mode and the binding to an eIF4E surface that
is not used by eIF4G confer on 4E-BPs a kinetic competitive
advantage because they can bind preassembled eIF4E–eIF4G
complexes without the need for prior eIF4G dissociation.
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Figure 4 | 4E-BPs require binding to the lateral surface of eIF4E to
compete with eIF4G. (a–d) Purified eIF4E–eIF4G complexes (2 mM)
containing SHN-tagged eIF4E (full length, WT or II-AA mutant) and GST-
eIF4G (residues 578–650) were incubated with increasing amounts of CUP
(a), 4E-T (b), Thor (c) and eIF4G (d) peptides fused C terminally to GB1.
The 4E-BP peptides contained the canonical and non-canonical motifs
(CþNC) or only the C and are described in Supplementary Table 1. MBP
served as a negative control. The proteins that were bound to eIF4E were
pulled down using Strep-Tactin beads. The competitor peptides are labeled
in blue, and their positions are highlighted by blue, dashed boxes. The black
dashed boxes indicate the position of preassembled GST-eIF4G. Numbers
above the lanes indicate fold molar excess of the competitor peptides. The
corresponding quantification of the competition assays is shown in
Supplementary Fig. 7a–d (n¼ 2). Asterisks indicated a contaminant protein.
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eIF4G competes with 4E-BPs bound to the eIF4E II-AA
mutant. Next, we asked whether eIF4G could compete with
4E-BPs when their binding to the lateral surface of eIF4E was
disrupted. For this purpose, preassembled complexes containing
eIF4E (WT or II-AA mutant) bound to GST-4E-BP fragments
were challenged with excess amounts of MBP-eIF4G (residues
578–650). Proteins that were bound to eIF4E were recovered via
eIF4E pull down. MBP-eIF4G did not displace CUP, Thor, 4E-T
or eIF4G bound to WT eIF4E (Fig. 6a, lane 6 versus 5, and
Fig. 6b, lanes 8, 10 and 14). In contrast, MBP-eIF4G partially
displaced CUP (Fig. 6a, lane 8 versus 7) and completely displaced
full-length Thor (Fig. 6b, lane 12 versus 11) bound to the eIF4E
II-AA mutant. These observations indicate that eIF4G can com-
pete with 4E-BPs for binding to eIF4E only when their interaction
with the lateral surface of eIF4E is impaired. Thus, the dissocia-
tion of 4E-BPs from the lateral surface of eIF4E (for instance, on
phosphorylation) may be sufficient for their dissociation from
eIF4E to allow eIF4G to resume translation (Fig. 6c).
The non-canonical motifs mediate translational repression. To
determine the role of non-canonical motifs in translational
repression, we tested whether 4E-BPs repressed the expression of
a firefly luciferase (F-Luc) reporter when coexpressed in S2 cells.
A short uncapped and unadenylated RNA served as a transfection
control (control RNA). To rule out the possibility that the inhi-
bition of F-Luc expression resulted from changes in the F-Luc
mRNA levels, we analyzed these levels by northern blotting and
determined translation efficiencies (Fig. 7a,b).
The CUP N-terminal fragment or full-length Thor inhibited
the expression of the F-Luc reporter in a dose-dependent manner
(Fig. 7a–d). 4E-T caused mRNA degradation when overexpressed
and was excluded from the analysis (C.I. and E.I., unpublished
results). Mutations in either the canonical or non-canonical
motifs as well as the combined mutations suppressed CUP- and
Thor-mediated repression (Fig. 7a,b). The mutant proteins were
expressed at levels that were comparable to the highest tested level
for the WT protein (Fig. 7c,d, WB). Thus, both the canonical and
non-canonical motifs are required for Thor and CUP to repress
translation in a cellular context, which is in agreement with the
competition assays.
The non-canonical motifs regulate eIF4E localization. 4E-BPs
are nucleocytoplasmic shuttling proteins that transport eIF4E to
the nucleus26,33–35. Although eIF4E nuclear functions are not
clearly understood, the nuclear retention/import of eIF4E could
contribute to the efficient inhibition of cap-dependent translation.
In addition, human 4E-T can also induce the accumulation of
eIF4E in mRNA processing bodies or P-bodies36. To determine
whether the non-canonical motifs contribute to the regulation of
eIF4E subcellular distribution mediated by 4E-BPs, we analyzed
the localization of endogenous eIF4E by immunofluorescence in
S2 cells expressing WT or mutant 4E-BPs (Fig. 8).
At a steady-state, CUP and Thor distributed evenly throughout
the cytoplasm (Fig. 8a,e). By contrast, 4E-T accumulated in
cytoplasmic foci, which correspond to P-bodies as judged by the
colocalization with the P-body marker Trailer hitch (Fig. 8i and
Supplementary Fig. 7g). Endogenous eIF4E was also evenly
distributed in the cytoplasm in cells overexpressing WT CUP and
Thor as well as the mutant versions of these proteins (Fig. 8a–h,
middle panels). In contrast, in cells expressing 4E-T, eIF4E was
detected in P-bodies (Fig. 8i). Thus, 4E-T can drag eIF4E into
P-bodies. Accordingly, the number of eIF4E-positive P-bodies was
reduced in cells overexpressing 4E-T mutants (C*, NC*, CþNC*;
Fig. 8j–l), although the mutants still localized to P-bodies. Thus,
both the canonical and non-canonical motifs of 4E-T are required
to induce the accumulation of eIF4E in P-bodies.
Next, we treated S2 cells with Leptomycin B (LMB), a drug that
inhibits nuclear export by CRM1, which has been shown to
export 4E-BPs26,33,37. The LMB treatment induced the nuclear
accumulation of CUP and 4E-T proteins (Fig. 8m,u) and a partial
nuclear accumulation of Thor (Fig. 8q). Concomitantly,
endogenous eIF4E accumulated in the nucleus (Fig. 8m,q,u,
middle panels). eIF4E nuclear accumulation was dependent on
binding to the 4E-BPs because this accumulation was strongly
reduced in cells expressing the 4E-BP mutants (Fig. 8n–p,r–t,v–
x). None of the 4E-BPs required binding to eIF4E to translocate
to the nucleus in the LMB-treated cells (Fig. 8m–x, left panels).
Taken together, our data indicates that both the canonical and
non-canonical motifs are required for 4E-BPs to regulate eIF4E
subcellular distribution.
Discussion
In this study, we show that similar to CUP, Thor and 4E-T
employ a bipartite interface that is composed of canonical and
non-canonical motifs to bind to the dorsal and lateral surfaces of
eIF4E, respectively. While the dorsal binding surface of eIF4E is
also used by eIF4G5,7,17, the lateral binding surface is only used
by 4E-BPs and is required for 4E-BPs to displace eIF4G from
preassembled eIF4E–eIF4G complexes. Based on these results, we
propose that the lateral surface of eIF4E provides an exclusive
docking surface for 4E-BPs on eIF4E–eIF4G complexes. After
docking, 4E-BPs can begin to displace eIF4G by establishing
interactions with the eIF4E dorsal surface via their own canonical
motifs, further stabilizing their association with eIF4E (Fig. 6c).
The ability to bind laterally to the side of eIF4E that is not used
by eIF4G enable 4E-BPs to displace eIF4G even when their
binding affinities are similar and under conditions in which 4E-
BPs are not in great excess compared with eIF4G. Indeed, by
docking to preassembled eIF4E–eIF4G complexes, the 4E-BPs
increase their local concentration and can rapidly dissociate
bound eIF4G, inhibiting ongoing translation. Our model also
provides one possible explanation for why eIF4G is a poor
competitor compared with 4E-BPs. Indeed, eIF4G will not bind
eIF4E unless the prebound eIF4G or 4E-BPs dissociate. In this
Figure 5 | 4E-BPs require the non-canonical motifs to compete with eIF4G. (a) Purified eIF4E–eIF4G complexes were incubated with fivefold molar
excess amounts of CUP peptides containing either the C, the NC or both motifs (CþNC). The peptides were fused N terminally to MBP and C terminally to
GB1. The eIF4E–eIF4G complexes contained MBP-tagged eIF4E and GST-tagged eIF4G (residues 578–650). The eIF4E-bound proteins were pulled down
using m7GTP-sepharose beads and analyzed by SDS–PAGE. (b) MBP pull down showing the interaction of purified eIF4E (69–248) with the CUP fragments
shown in a. (c) Purified eIF4E–eIF4G complexes were incubated with fivefold molar excess of MBP-Thor (full length, either WTor the indicated mutants).
The eIF4E-bound proteins were pulled down using Strep-Tactin beads and analyzed as described in a. (d–g) Purified eIF4E–eIF4G complexes (1 mM)
containing SHN-eIF4E (full length) and GST-eIF4G (residues 578–650) prebound to Strep-Tactin beads were incubated with a 10-fold molar excess of
eIF4G (residues 578–650, d) and Thor (g) or a fivefold molar excess of CUP (e) and 4E-T (f) peptides fused C terminally to GB1. The 4E-BP peptides
contained the CþNC motifs. Proteins bound to eIF4E were recovered at the indicated time points. In all of the panels, the competitor proteins are labeled
in blue and highlighted by blue, dashed boxes. The black, dashed boxes mark the position of preassembled GST-eIF4G. Quantification of the dissociation
assays is shown in Supplementary Fig. 7e,f. Each experiment was repeated at least twice.
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context, it will be of interest to determine the contribution of the
canonical and non-canonical motifs to the association (Kon) and
dissociation (Koff) rate constants of 4E-BP proteins.
How can eIF4G bind back to eIF4E to resume translation? We
show that eIF4G can displace 4E-BPs when their binding to the
lateral surface of eIF4E is impaired. Although in our studies this
interaction was impaired by mutations, in vivo this impairment
could be achieved by posttranslational modifications such as
phosphorylation. Indeed, it is well established that the phosphoryla-
tion of 4E-BPs reduces their affinity for eIF4E2,8. Thus, it will be of
interest to dissect the impact of phosphorylation on the interaction
of 4E-BPs with either the lateral or dorsal surfaces of eIF4E.
Owing to their lack of conservation, it has remained unclear
whether non-canonical motifs are present in all 4E-BPs. Our
data indicate that the non-canonical motifs are intrinsic to the
ability of 4E-BPs to compete with eIF4G and thus are likely to be
present in all 4E-BPs that repress translation. At the functional
level, non-canonical motifs have been proposed to play an
auxiliary role and have been mainly implicated in the regulation
of the affinity of eIF4E for the mRNA cap structure through
allosteric effects7,17,27,28,38. Specifically, the binding of the
4E-BP1,2 non-canonical motifs to eIF4E increases the affinity
for the cap structure19,22,38. Here, we show that the non-
canonical motifs are essential, not auxiliary, for 4E-BP function
in inhibiting translation. Given the diversity of non-canonical
motifs and their different modes of interaction with eIF4E, it is
possible that their binding to the lateral surface of eIF4E
modulates the affinity for the cap in different ways, thereby
mediating different effects. For example, by increasing the
affinity of eIF4E for the cap structure, 4E-BPs may stabilize
translationally repressed mRNA targets as observed for CUP39.
Alternatively, by decreasing the affinity of eIF4E for the mRNA
cap, 4E-BPs may destabilize the repressed mRNA target through
decapping and subsequent decay.
In summary, our current understanding of 4E-BPs role in
translational repression is predominantly based on the study of
the low-molecular-weight 4E-BPs of the 4E-BP1–3 family. The
identification of additional, high-molecular-weight 4E-BPs
together with the characterization of their interaction mode with
eIF4E reveals an unexpected sequence diversity of the eIF4E-
binding regions and of the functional mechanisms. The
functional diversity of 4E-BPs is further enhanced by the
presence of additional domains in the high-molecular-weight
4E-BPs. These additional domains link eIF4E binding with other
cellular processes, such as mRNA decay, as described for CUP
and 4E-T36,39. Understanding the molecular basis for the
interaction of diverse 4E-BPs with eIF4E will provide valuable
insight into the variety of mechanisms that are employed by these
proteins to regulate gene expression. These studies promise to
uncover novel therapeutic strategies to selectively target
dysregulated translation in cancer.
Methods
DNA constructs. The plasmids expressing the luciferase reporters, control RNA
and GFP- or HA-tagged eIF4E, eIF4G, Tral and CUP (WT or mutated) have been
previously described39–42. The plasmids expressing HA-Thor-V5 and GFP-Thor
were obtained by inserting the corresponding DNA into the EcoRV and XhoI sites
of the pAc5.1-lN-HA or pAc5.1-GFP vectors, respectively. A plasmid expressing
HA-4E-T was obtained by inserting the corresponding DNA (CG32016 isoform B)
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Phosphorylation (P) of 4E-BPs destabilizes their association with eIF4E (3).
Therefore, eIF4G can bind to eIF4E and translation resumes (4). In humans,
4E-BP1–3 the phosphorylation sites are located in the linker region between
the 4E-BMs and in the sequences N-terminal to the canonical motif (not
shown). Dephosphorylation of 4E-BPs is required for binding to eIF4E (5).
Symbols are as in Fig. 3e.
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into the EcoRI and NotI restriction sites of the pAc5.1-lN-HA vector. For
expression in E. coli, the DNA encoding Thor (full length) and 4E-T (residues
1–58) was inserted into the XhoI-MfeI and AflII-NotI sites, respectively of the
pnEA-NvM vector43 (which provides an N-terminal MBP tag followed by a TEV
protease cleavage site). A DNA fragment coding eIF4G (residues 578–650) was
inserted into the XhoI and BamHI restriction sites of the pnEA-NvM or
pnEA-NvG (which provides an N-terminal GST tag) vector43.
A DNA fragment encoding full-length Dm eIF4E was inserted into the
NdeI-BamHI restriction sites of the pnEK-NvH vector (which provides an
N-terminal hexa-histidine (His6) tag) or the pnEK-NvSHN vector (which provides
an N-terminal Strep-NusA-His-tag). The DNA fragments encoding CUP, Thor
and 4E-T minimal eIF4E-binding fragments (CþNC), the individual canonical
(C) and non-canonical motifs (NC, in the case of CUP), and the LþNC peptides
were cloned into the NdeI-NheI restriction sites of the pnEA-NpM vector
with an N-terminal MBP tag followed by an HRV3C protease cleavage site43.
The DNA encoding the B1 domain of immunoglobulin-binding protein G (GB1)31
was inserted C terminally into the described fragments by site-directed
insertion using the QuikChange mutagenesis kit (Stratagene). The DNA encoding a
truncated eIF4E protein (residues 69–248) was cloned into the NdeI-NheI
restriction sites of the pnEA-NpH vector (which provides an N-terminal His6-tag
followed by a HRV3C protease cleavage site)43. All the mutants were generated by
site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene) and
the oligonucleotide sequences provided in Supplementary Table 3. All the
constructs and mutations were confirmed by sequencing and are listed in
Supplementary Table 1. The plasmids expressing full-length His6-eIF4E and
GST-CUP (residues 311–440) were kindly provided by F. Bono27.
Coimmunoprecipitation assays and western blotting. The coimmunoprecipi-
tations assays were performed as previously described41. For the pull downs using
m7GTP beads, 25 ml of immobilized g-aminophenyl-m7GTP (C10-spacer—Jena
Bioscience) beads was added to the cell lysates and the mixtures were rotated for
1 h at 4 !C. The beads were washed three times with NET buffer (50mM Tris (pH
7.4), 150mM NaCl, 1mM EDTA and 0.1% Triton X-100). The bound proteins
were eluted with 2# SDS–polyacrylamide gel electrophoresis (SDS–PAGE) sample
buffer and analyzed by western blotting (WB). All of the WB experiments were
developed with the ECL western blotting detection system (GE Healthcare) as
recommended by the manufacturer. The antibodies used in this study are listed in
Supplementary Table 2.
Protein expression and purification. Unless indicated otherwise, all the proteins
were expressed in E. coli BL21 Star (DE3) cells (Invitrogen) that were grown in LB
medium overnight at 20 !C. The lysis buffers were supplemented with DNaseI
(5 mgml" 1), lysozyme (1mgml" 1) and protease inhibitor cocktail (Roche). The
truncated His6-eIF4E (residues 69–248) that was used in the ITC experiments and
in Figs 2c and 5b was purified in lysis buffer containing 50mM HEPES (pH 7.2),
300mM NaCl, 20mM imidazole and 2mM b-mercaptoethanol using Ni2þ -affi-
nity chromatography (HisTrap HP 5ml, GE Healthcare) and eluted with a gradient
of 20–500mM imidazole. After the cleavage of the His6-tag with HRV3C protease
(homemade), the protein was further purified using a heparin column (HiTrap
Heparin HP 5ml, GE Healthcare), followed by size exclusion chromatography
(Superdex 75 16/60, GE Healthcare) in 20mM Na-phosphate (pH 7.0), 300mM
NaCl and 2mM dithiothreitol (DTT).
To obtain the preassembled eIF4E–eIF4G complexes used in Figs 4 and 5d–g,
full-length eIF4E (WT or the II-AA mutant) containing an N-terminal SNH-tag was
coexpressed with an N-terminal GST-tagged eIF4G (residues 578–650). The cells
were lysed by sonication in lysis buffer containing 50mM HEPES (pH 7.2), 300mM
NaCl and 2mM DTT. The complexes were purified from the cleared lysates using
Protino Glutathione Agarose 4B beads (Machery-Nagel). The complex was further
purified using a heparin column (HiTrap Heparin HP 5ml, GE Healthcare) and a
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final size exclusion chromatography (Superdex 200 16/60, GE Healtcare) in 20mM
HEPES (pH 7.2), 200mM NaCl and 2mM DTT.
For the ITC measurements and the competition assays shown in Figs 4 and
5d–g, the 4E-BP peptides corresponding to the canonical (C) motifs, the combined
(CþNC) motifs or LþNC were expressed with an HRV3C cleavable N-terminal
MBP-tag and a non-cleavable C-terminal GB1 domain. The cells were lysed by
sonication in lysis buffer containing 50mM HEPES (pH 7.2), 300mM NaCl and
2mM DTT. The proteins were purified from the cleared lysates using amylose resin
(New England Biolabs) followed by the cleavage of the MBP tag with HRV3C
protease overnight at 4 !C. The proteins were further purified by size exclusion
chromatography (Superdex 75 16/60, GE Healthcare) in 20mM Na-phosphate (pH
7.0), 300mM NaCl and 2mM DTT. For the eIF4G fragment (residues 578–650)
the MBP was removed after cleavage with TEV protease through an additional
anion exchange chromatography (HiTrap Q HP 5ml, GE Healthcare) before the
final gel filtration.
Protein pull-down assays. For the pull-down assays shown in Fig. 3 and
Supplementary Fig. 6a, the full-length His6- or SHN-tagged eIF4E (WT or II-AA
mutant) was coexpressed with GST or MBP-tagged protein fragments, including
CUP (residues 311–440), Thor (full length), 4E-T (residues 1–58) or eIF4G
(residues 578–650) in E. coli BL21 (DE3) STAR cells in autoinducing medium44
overnight at 20 !C. The cells were resuspended in lysis buffer (20mM Tris–HCl
(pH 7.5), 100mM NaCl, 1mM DTT) supplemented with EDTA-free protease
inhibitor (Roche) and lysed by sonication. The cleared lysates were incubated for
1 h with 20 ml of Protino Glutathione Agarose 4B beads (Macherey-Nagel) or
amylose resin (New England Biolabs). The beads were washed three times with
lysis buffer, and the bound proteins were eluted with lysis buffer containing 25mM
L-glutathione or 25mM maltose for 15min. The proteins were analyzed by
10–15% SDS–PAGE followed by Coomassie blue staining.
In Fig. 2c, eIF4G (residues 578–650) and the CþNC peptides of CUP, Thor
and 4E-T were expressed with a N-terminal MBP and a C-terminal GB1 tag. The
bacterial cells were resuspended in 5ml of lysis buffer containing 50mM HEPES
(pH 7.2), 200mM NaCl and 2mM DTT and lysed by sonication. Purified eIF4E
(residues 69–248) was added to the cleared lysates (40–80 ml), adjusted to 0.3ml
with lysis buffer and incubated with 30 mL of amylose resin for 1 h at 4 !C. The
beads were washed three times with lysis buffer and eluted with 64 ml of the same
buffer containing 25mM maltose. The proteins were analyzed by 15% SDS–PAGE
followed by Coomassie blue staining.
Competition assays. For the competition assays shown in Figs 5a,c and 6a,b,
complexes containing SHN- or MBP-tagged eIF4E (WT or II-AA mutant) bound
to GST-eIF4G (residues 578–650), GST-Thor (full length), GST-4E-T (residues
1–58) or GST-CUP (311–440) were obtained by coexpressing the corresponding
proteins in E. coli BL21 (DE3) STAR cells (30ml culture). The cells were resus-
pended in lysis buffer (5ml) that was supplemented with EDTA-free protease
inhibitor (Roche) and 1mg ml" 1 lysozyme and lysed by sonication. The cleared
lysates were incubated with 400 ml of Protino Glutathione Agarose 4B (Macherey-
Nagel) for 1 h. The beads were washed three times with lysis buffer, and the
proteins were eluted after 10min of incubation with lysis buffer containing 25mM
L-glutathione. The protein complexes were stored at " 20 !C or used in compe-
tition assays.
The purified recombinant complexes were mixed with excess amounts of the
indicated purified competitor proteins (Fig. 5c) or with bacterial lysates expressing
the competitor proteins (Figs 5a and 6) and incubated for 30min at 4 !C. After
incubation, 20 ml of immobilized g-Aminophenyl-m7GTP or Strep-Tactin
Sepharose (IBA), were added to the samples and incubated for another 40min at
4 !C. The beads were washed three times with lysis buffer and eluted with lysis
buffer containing 2.5mM desthiobiotin (Strep-Tactin Sepharose) or with 20 ml of
SDS–PAGE loading buffer (Aminophenyl-m7GTP beads). The proteins were
analyzed by 10–15% SDS–PAGE followed by staining with Coomassie blue staining.
For the titration experiments shown in Fig. 4, 2 mM of purified complexes
containing SHN-eIF4E (WT or II-AA mutant) bound to GST-eIF4G (residues
578–650) were incubated with increasing amounts (2–20 mM) of purified
competitor proteins for 20min at 4 !C. The eIF4E-bound proteins were recovered
via Strep-Tactin Sepharose pull down and eluted with lysis buffer containing
2.5mM desthiobiotin. The proteins were analyzed by 15% SDS–PAGE followed by
staining with Coomassie blue staining.
In the ‘kinetic assays’ shown in Fig. 5d–g, the purified complexes containing
SHN-eIF4E and GST-eIF4G (578–650; 1 mM) were incubated with Strep-Tactin
beads for 20min. The prebound complex was then challenged with 5 mM (CUP and
4E-T) or 10 mM (Thor and eIF4G) of competitor proteins for the indicated time
points. The eIF4E-associated proteins were pulled down, eluted and analyzed as
described above.
ITC analysis. The ITC experiments were performed using a VP-ITC micro-
calorimeter (MicroCal) at 20 !C. The solution of eIF4E (residues 69–248, WT or
mutant: 1–20 mM) in the calorimetric cell was titrated with tenfold concentrated
solutions of GB1-stabilized peptides corresponding to 4E-BPs CþNC (10 mM),
C (50 mM), LþNC (100 mM CUP, 200 mM Thor and 4E-T) or eIF4G (residues
578–650, 20 mM) that were dissolved in the same buffer (20mM Na-phosphate (pH
7.0) and 150mM NaCl). The titration experiments consisted of an initial injection
of 2 ml followed by 28 injections of 10 ml at an interval of 240 s. Each binding
experiment was repeated twice. The thermodynamic parameters were estimated
using a one-site binding model (Origin version 7.0), whereby the datapoint of the
first injection was removed for the analysis45.
Translation repression assays. S2 cells were transfected in 6-well plates using
Effectene transfection reagent (Qiagen) according to the manufacturers protocol.
The transfection mixtures contained: 0.1 mg of F-Luc reporter plasmid (F-Luc-V5),
0.3 mg of control RNA reporter, and increasing amounts of plasmids expressing
HA-CUP (fragment 1–402; 0.05–0.2 mg) and HA-Thor (full length, 0.1–0.5 mg).
The plasmids expressing the corresponding mutants or the HA peptide control
were transfected at the highest concentration. In all the experiments, the cells were
collected three days after transfection. The F-Luc activity was measured using the
Dual-Luciferase reporter assay system (Promega). The northern blotting was
performed as previously described42. The F-Luc mRNA levels were determined
by northern blotting and were normalized to those of the control RNA. The
normalized F-Luc mRNA levels were then used to normalize the F-Luc activity,
to obtain translation efficiencies.
Immunofluorescence. S2 cells expressing HA-tagged versions of CUP, Thor and
4E-T or the indicated mutants were treated with Leptomycin B (100 nM; Sigma) or
methanol as a control for 12 h. After the LMB treatment, the cells were allowed to
adhere to poly-D-lysine–coated coverslips for 15min and were fixed with 2%
paraformaldehyde for 10min. The cells were then permeabilized with 0.1% Triton
X-100 in PBS (10min) and stained with affinity-purified monoclonal anti-HA
(Covance 1:1,000) and polyclonal anti-eIF4E (1:2,000) antibodies in PBS con-
taining 1% BSA for 1 h. Alexa Fluor 594-labeled goat anti-rabbit and 488-labeled
anti-mouse antibodies (Invitrogen) were used at dilutions of 1:1,000 and 1:2,000,
respectively. The cells were mounted using Fluoromount-G (Southern Biotech).
The images were acquired at room temperature using a confocal microscope (TCS
SP2; Leica) that was fitted with a Plan-Apochromat # 100 NA 1.40 oil immersion
objective and a series of three photomultipliers (Hamamatsu Photonics) controlled
with the Leica confocal software (version 2.61). The images were prepared using
Photoshop (Adobe).
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Supplementary Figures 
 
Supplementary Figure 1. The interaction of eIF4E with 4E-BPs and eIF4G in S2 cell 
lysates. (a) Western blot showing the interaction of HA-tagged full length 4E-BPs (CUP, 
  
2 
Thor and 4E-T) or HA-eIF4G and endogenous eIF4E in S2 cell lysates. The proteins were 
immunoprecipitated using a polyclonal anti-eIF4E antibody (α-4E). The pre-immune (Pre-I) 
serum and an HA-tagged version of MBP served as negative controls. The inputs (1%) and 
immunoprecipitates (10%) were analyzed by western blotting using anti-HA and anti-eIF4E 
antibodies. (b,c) The interaction of HA-tagged full length 4E-BPs (CUP, Thor and 4E-T) and 
eIF4G with endogenous eIF4E was analyzed by coimmunoprecipitation using anti-HA 
antibodies (b) or by pull-down using m7GTP-Sepharose beads (c). HA-MBP served as a 
negative control. The inputs (10%) and immunoprecipitates (30%) were analyzed by western 
blotting using anti-HA and anti-eIF4E antibodies. (d) Western blot showing the interaction of 
HA-Thor (full-length either wild-type or mutants) with endogenous eIF4E in S2 cells. The 
proteins were immunoprecipitated using anti-HA antibodies and analyzed as described in 
(b,c). (e) Western blot showing the interaction of HA-4E-T (residues 1–511, wild-type or 
mutants) with endogenous eIF4E. The proteins were immunoprecipitated using anti-HA 
antibodies and analyzed as described in (b,c). The size markers (kDa) are shown to the right 
of each panel. Mutants are described in Supplementary Table 1. 
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Supplementary Figure 2. Sequence alignments. Residues conserved in all aligned 
sequences are highlighted with a dark color background and printed in white. Residues with 
>70% similarity are shown with a light color background. (a) Structure-based sequence 
  
4 
alignment of eIF4E proteins from Drosophila melanogaster (Dm), Mus musculus (Mm), 
Homo sapiens (Hs) and Saccharomyces cerevisae (Sc). Secondary structure elements of the 
Dm eIF4E (PDB code: 4AXG)27 are indicated above the sequences. The lateral and dorsal 
binding surfaces (BS) are indicated with a line below the sequences. Residues mutated in this 
study are indicated by filled circles above the sequence. Circles are colored in cyan or 
magenta for the dorsal and lateral surfaces, respectively. (b) Sequence alignment of the 
eIF4E-interacting regions of CUP orthologous proteins from insects. Species are as follows: 
Drosophila melanogaster (Dm), Drosophila pseudoobscura (Dps), Drosophila virilis (Dvi), 
Drosophila grimshawi (Dgr), Drosophila willistoni (Dwi). Secondary structure elements of 
the Dm CUP (PDB code: 4AXG) protein are indicated above the sequences. The canonical 
(C) and non-canonical (NC) 4E-BMs are boxed in black. Residues mutated in this study are 
indicated with filled circles above the sequence. Circles are colored in cyan or magenta for 
the canonical and non-canonical 4E-BMs, respectively. (c) Sequence alignment of Thor 
orthologous proteins. Species are as follows: Drosophila melanogaster (Dm), Tribolium 
castaneum (Tc), Anopheles gambiae (Ag), Danio rerio (Dr) and Homo sapiens (Hs). 
Additional symbols are as described in panel (b). (d) Alignment of the eIF4E-interacting 
region of 4E-T orthologous proteins. Species are Caenorhabditis elegans (Ce) and as in (a,c). 
Predicted secondary structure elements are indicated above the sequences. A putative non-
canonical 4E-BM identified in the Hs 4E-T protein is highlighted in green characters. 
Additional symbols are as described in panel (b). (e) Alignment of eIF4E-interacting regions 
of eIF4G orthologous proteins. Species are as in panels (a,d). A putative non-canonical 4E-
BM identified in the Hs eIF4G protein and the corresponding motif in Dm are indicated by a 
dashed box. Secondary structure elements of the Sc eIF4G (PDB 1RF8) protein are indicated 
below the sequences. Additional symbols are as described in panel (b). 
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Supplementary Figure 3. Thermodynamic parameters for the interaction of eIF4E with 
eIF4G and 4E-BP peptides. (a–d) ITC profiles of CUP (a), Thor (b), 4E-T (c) and eIF4G 
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(d) minimal regions for binding to eIF4E (wild-type (WT), residues 69–248). The top panels 
represent the raw data (μcal sec−1) whereas the bottom panels show the integrated data (kcal 
mole−1 of injectant) of heat changes that were best-fitted using a one-site binding model. The 
thermodynamic parameters correspond to heat changes that were detected when 4E-BPs (10 
µM) or eIF4G (20 µM) were injected into the calorimetric cell (1.4 mL) containing 1 µM 
(a,b,c) or 2 µM (d) eIF4E.  
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Supplementary Figure 4. Thermodynamic parameters for the interaction of eIF4E with 
4E-BP peptides. (a–f) ITC profiles for the interaction of eIF4E (WT, residues 69-248) and 
CUP (a,d), Thor (b,e) and 4E-T (c,f) peptides containing only the canonical motifs (a–c) or 
the L+NC regions (d–f). The measurements were performed as described in Supplementary 
Fig. 3. The solutions contained the peptides corresponding to the canonical motifs (50 µM) or 
the L+NC regions (100 µM for CUP and 200 µM for Thor and 4E-T). The eIF4E 
concentration in the calorimetric cell was 5 µM (for the C peptides), 10 µM (for CUP L+NC) 
and 20 µM (for Thor and 4E-T L+NC peptides). 
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Supplementary Figure 5. Thermodynamic parameters for the interaction of eIF4E II-
AA mutant with 4E-BP peptides. (a–d) ITC profiles for the interaction of eIF4E IIAA 
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mutant (residues 69-248) and CUP (a), Thor (b), 4E-T (c) and eIF4G (d) peptides. The 
measurements were performed as described in Supplementary Fig. 3. The solutions 
contained the 4E-BP C+NC peptides (10 µM) and 20 µM for the eIF4G peptide. The eIF4E 
II-AA mutant concentration in the calorimetric cell was 5 µM. 
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Supplementary Figure 6. Identification of a non-canonical 4E-BM in Thor and 
competition assays. (a) The association of MBP-Thor (full length, wild-type or 4E-BM 
mutant) with His6-eIF4E (WT or II-AA mutant) was analyzed by MBP pull-down as 
described in Fig. 3c. (b) Purified eIF4E–eIF4G complexes containing SHN-eIF4E (wild-type 
or II-AA mutant) and GST-eIF4G (578–650) were incubated with CUP, Thor and 4E-T 
fragments (C+NC) fused C-terminally to GB1. The proteins that were bound to eIF4E were 
  
11 
pulled down using Strep-Tactin beads and analyzed by SDS-PAGE. The competitor peptides 
are labeled in blue, and their positions are highlighted by blue, dashed boxes. The black, 
dashed boxes indicate the position of preassembled GST-eIF4G. (c,d) The purified eIF4E–
eIF4G complexes described in panel (b) were incubated with a 5-fold molar excess of CUP 
(c) (C+NC fragment) or MBP-Thor full length (d). The eIF4E-bound proteins were pulled 
down using Strep-Tactin beads and analyzed by SDS-PAGE. The size markers (kDa) are 
shown to the right of each panel.  
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Supplementary Figure 7. Quantitative analysis of the competition assays. (a–d) 
Quantification of GST-eIF4G remaining bound to eIF4E (WT or II-AA mutant) in the 
  
13 
presence of MBP (negative control), increasing amounts of 4E-BP peptides or eIF4G-GB1 in 
the experiments shown in Fig. 4a–d. The amounts of GST-eIF4G bound to eIF4E in each 
experimental condition were determined using the Image J software after Coomassie blue 
staining. To rule out the possibility that changes in the amount of GST-eIF4G bound to eIF4E 
resulted from variations in the loading volume, all values were normalized to the levels of 
SHN-eIF4E present in each condition. These values were set to 100 in the presence of MBP. 
Each experiment was repeated at least twice. (e,f) Quantification of the experiments shown in 
Fig. 5d–g. The amounts of GST-eIF4G remaining bound to eIF4E in the presence of MBP, 
4E-BP peptides or eIF4G-GB1 were normalized to those of eIF4E and set to 100 in the 
presence of MBP. The data represent averages of two (eIF4G and 4E-T) or three (CUP and 
Thor) independent experiments. (g) Dm 4E-T localizes to P-bodies. Confocal fluorescent 
micrographs of fixed S2 cells expressing HA-4E-T and GFP-Tral. The localization of HA-
4E-T was determined by indirect immunofluorescence using an anti-HA antibody. The 
merged pictures show the HA signal in red and the GFP-Tral signal in green. Bar: 5 μm. 
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Supplementary Figure 8. Original images of western blots used in Fig. 1e–g and Fig. 2a,b. 
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Supplementary Figure 9. Original images of western and northern blots used in Fig. 7c,d. 
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Supplementary Table 1. Mutants and constructs used in this study 
Protein Name of the construct Mutations / fragments Binding site / motif 
eIF4E 
(1–248) 
(isoform C) 
P48598-2 
W106A W106A Dorsal surface 
II-AA I96A, I112A Lateral surface 
trunc 69–248  
eIF4G 
(1–1666) 
(isoform A) 
O61380 
4G 578–650 eIF4E-binding region 
C* Y621A, L626A, L627A Canonical 
CUP 
(1–1117) 
Q9VMA3 
CUP 311–440 eIF4E-binding region 
C+NC 325–376 eIF4E-binding region short 
C 325–341 Canonical 
NC 362–376 Non-canonical 
L+NC 342–376 Linker+non-canonical 
C* Y327A, L332A Canonical 
NC* L364A, L368A Non-canonical 
C+NC* Y327A, L332A, L364A, L368A Double mutant 
N-term 1–402 N-terminus 
Thor 
(1–117) 
Q9XZ56 
Thor Full length  
C+NC 50–83 eIF4E-binding region short 
C 50–63 Canonical 
NC 77–83 Non-canonical 
L+NC 64–83 Linker+non-canonical 
C* Y54A, M59A Canonical 
NC* C78A, L79A, L80A Non-canonical 
R,G,T R81A, G82A, T83A Non-canonical 
∆NC ∆76–84 Non-canonical 
C+NC* Y54A, M59A, C78A, L79A, L80A Double mutant 
C*+∆NC Y54A, M59A, ∆76-85 Double mutant 
4E-T 
(1–1010) 
Q8IH18 
4E-T 1–58 eIF4E-binding region 
C+NC 9–44 eIF4E-binding region short 
C 9–21 Canonical 
NC 31–44 Non-canonical 
L+NC 22–44 Linker+non-canonical 
C* Y10A, L15A Canonical 
NC* L36A, L39A Non-canonical 
F,W,K-3xA F41A, W42A, K43A Non-canonical 
L,L,F,W,K-
5xA 
L36A, L39A, F41A, W42A, 
K43A Non-canonical 
∆NC ∆28–43 Non-canonical 
C+NC* Y10A, L15A, L36A, L39A Double mutant 
C*+∆NC Y10A, L15A, ∆28-43 Double mutant 
N-term 1–511 N-terminus 
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Supplementary Table 2. Antibodies used in this study 
Antibody Source Catalog Number Dilution Monoclonal/ 
Polyclonal 
Anti-HA-HRP (for 
Western blot) 
Roche 12 013 819 001 1:5,000 Monoclonal 
Anti-eIF4E  In house  1:3,000 Rabbit polyclonal 
Anti-GFP In house  1:2,000 Rabbit polyclonal 
Anti-eIF4G In house  1:3,000 Rabbit polyclonal 
Anti-HA (for 
Immunofluorescence) 
Covance MMS-101P 1:1,000 Monoclonal 
Anti-rabbit-HRP GE Healthcare NA934V 1:10,000 Polyclonal 
Alexa Fluor 594–
labelled goat anti–rabbit 
Invitrogen A-11080 
 
1:1,000 Polyclonal 
 
Supplementary Table 3. Mutagenesis primers used in this study 
Protein Mutations Primer sequence 5’- 3’(Forward) 
eIF4E 
W106A cttcgataccgtcgaggacttcgcgagcctatacaaccacatcaagccc 
II-AA 1 - gggaggacatgcaaaacgaggccaccagcttcgataccgtcga 2 - tctggagcctatacaaccacgccaagcccccatcagagatcaa 
eIF4G Y621A, L626A, L627A cggaaaaaaacaagctgaccgagaacaggctgctcagttacgcga 
CUP 
Y327A, L332A aagccggtcaagagcgctacccgctcccgcgcgatggacattcgcaac 
L364A, L368A ccacctgcgacgacattgaggcggagggaagggctcgccgcatgaatatttggcgc 
Thor 
Y54A, M59A ctcctggaggcaccaaacttatcgccgagcgggctttcgcgaagaatctccgtggctccccatt 
C78A, L79A, L80A ctccgccgtccaacgtgcccagtgctgcggcgaggggcactccgcgtactccctt 
R81A, G82A, T83A ccaacgtgcccagttgcttgctggctgccgctccgcgtactcccttccgcaagtg 
∆76–84 gccaaactccgccgtccaacgtgcgtactcccttccgcaagtgcgt 
4E-T 
Y10A, L15A caaagattagtgccagggcctcgaaagtagacgcgttagctctaagatatgaag 
L36A, L39A cgcaatgttcaacacgacttgaagcgcagacggcgggtttttggaaaattaatctgaa 
F41A, W42A, K43A gacttgaattgcagacgctaggtgcggcggcgattaatctgaacacagctgcgtt 
∆28–43 gccaaactccgccgtccaacgtgcgtactcccttccgcaagtgcgt 
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SUMMARY
The eIF4E-binding proteins (4E-BPs) represent a
diverse class of translation inhibitors that are often
deregulated in cancer cells. 4E-BPs inhibit translation
by competingwith eIF4G for binding to eIF4E through
an interface that consists of canonical and non-ca-
nonical eIF4E-binding motifs connected by a linker.
The lack of high-resolution structures including the
linkers, which contain phosphorylation sites, limits
our understanding of how phosphorylation inhibits
complex formation. Furthermore, the binding mecha-
nism of the non-canonical motifs is poorly under-
stood. Here, we present structures of human eIF4E
bound to 4E-BP1 and fly eIF4E bound to Thor, 4E-T,
and eIF4G. These structures reveal architectural ele-
ments that are unique to 4E-BPs and provide insight
into the consequences of phosphorylation. Guided
by these structures, we designed and crystallized a
4E-BP mimic that shows increased repressive activ-
ity. Our studies pave the way for the rational design
of 4E-BP mimics as therapeutic tools to decrease
translation during oncogenic transformation.
INTRODUCTION
The eIF4E-binding proteins (4E-BPs) inhibit protein synthesis at
a global or message-specific level and play important roles in
diverse cellular processes such as development and synaptic
plasticity (Banko et al., 2005; Bidinosti et al., 2010; Martineau
et al., 2013). Through their repressive effect on translation, 4E-
BPs inhibit cell proliferation and act as tumor suppressors, and
their activity is frequently dysregulated in cancer (Boussemart
et al., 2014; Dowling et al., 2010; Hsieh et al., 2012; Martineau
et al., 2013). Furthermore, dysregulation of the 4E-BP-eIF4E
interaction is thought to contribute to autism spectrum disorders
(ASDs) (Banko et al., 2005, 2007; Gkogkas et al., 2013). Conse-
quently, a detailed molecular understanding of the interaction
between eIF4E and 4E-BPs is of primary importance because
of the increasing interest in designing eIF4E inhibitors as thera-
peutic tools to reduce translation in diseases associated with
increased protein synthesis (Jia et al., 2012; Martineau et al.,
2013).
The 4E-BPs exert their inhibitory effect on protein synthesis by
interfering with the assembly of the eukaryotic initiation factor
eIF4F, which consists of the cap-binding protein eIF4E, the scaf-
folding protein eIF4G, and the RNA helicase eIF4A (Jackson et al.,
2010). eIF4E binds to the mRNA 50 cap structure and interacts
with eIF4G, which in turn initiates translation by recruiting the
43S preinitiation complex (Jackson et al., 2010). eIF4G interacts
with eIF4E through a conserved motif (termed the canonical 4E-
BM) of sequence YX4LF (where Y denotes Tyr, X denotes any
amino acid, L denotes Leu, and F denotes a hydrophobic resi-
due), which is also present in 4E-BPs (Mader et al., 1995; Marco-
trigiano et al., 1999). Because of the presence of this shared bind-
ing motif, 4E-BPs compete with eIF4G for binding to the same
conserved patch of hydrophobic residues on the dorsal side of
eIF4E, thereby blocking translation initiation (Gross et al., 2003;
Mader et al., 1995;Marcotrigiano et al., 1999;Matsuo et al., 1997).
Downstream of the canonical (C) motifs, 4E-BPs contain non-
canonical (NC) 4E-bindingmotifs (4E-BMs) connected by a linker
of 15–30 residues. Although the non-canonical motifs do not
share sequence similarity and are not conserved between ortho-
logs across species, they all seem to bind to the same lateral sur-
face of eIF4E, which is conserved and is not required for eIF4G
binding (Gosselin et al., 2011; Igreja et al., 2014; Kinkelin et al.,
2012; Lukhele et al., 2013; Mizuno et al., 2008; Paku et al.,
2012). The non-canonical motifs increase the affinity of 4E-BPs
for eIF4E by three orders of magnitude and are required for
4E-BPs to be able to compete with eIF4G and repress translation
(Igreja et al., 2014; Lukhele et al., 2013; Paku et al., 2012).
The interaction of 4E-BPs with eIF4E is inhibited by the phos-
phorylation of 4E-BPs at multiple sites (Gingras et al., 1999,
2001). In vertebrate 4E-BP1–3 and its Drosophila melanogaster
(Dm) ortholog Thor, two phosphorylation sites are located in
the linker region. In the absence of high-resolution structures
of eIF4E-4E-BP complexes in which the linker regions can be
visualized, it has been difficult to rationalize how phosphorylation
negatively regulates complex formation. Furthermore, despite
the essential role of the non-canonical motifs of 4E-BPs in trans-
lational repression, the molecular details of the interaction of
thesemotifs with eIF4E are known only for theDm 4E-BP protein
CUP (Kinkelin et al., 2012). However, because of the limited
sequence identity and the lack of the regulatory linker region,
the CUP model could not be used to derive general principles
regarding the interaction of 4E-BPs with eIF4E.
To obtain general and predictive insight into the binding mode
of 4E-BPs to eIF4E and its regulation, we adopted a comparative
approach, solving the structures of three 4E-BPs bound to eIF4E
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and of eIF4G bound to eIF4E. The structures reveal the binding
mode of the linker regions and the non-canonical motifs and pro-
vide insight into the mechanism by which phosphorylation pre-
vents 4E-BPs from repressing translation. Most important, our
studies provide a hitherto missing structural framework for the
rational design of translational inhibitors to treat malignancies
in which eIF4E activity and protein synthesis are upregulated.
RESULTS
Structural Overview
To understand the binding mode of 4E-BPs to eIF4E, we crystal-
lized and determined the structures ofDm eIF4E in complex with
the minimal binding fragments of two 4E-BPs (Thor and eIF4E-
transporter or 4E-T) at 1.10 and 2.15 A˚ resolution, respectively
(Figures 1A–1G; Tables 1 and S1). The Thor and 4E-T peptides
used in this study contained the canonical and non-canonical
4E-BMs connected by the linker region and retained the ability
of the full-length proteins to bind to eIF4E (Igreja et al., 2014).
To better understand the mechanism of the competition of 4E-
BPs with eIF4G, we also crystallized Dm eIF4E bound to a Dm
eIF4G peptide containing the canonical motif and the down-
stream auxiliary VKNVSI motif (Hs SDVVL; Figure S1), which sta-
bilizes the interaction of eIF4Gwith eIF4E (Umenaga et al., 2011).
The eIF4E-eIF4G complex was crystallized in the presence of an
m7GpppG cap analog, and the structure was determined at 2.4 A˚
resolution (Figures 1H, 1I, and S2; Table 1). Finally, we deter-
mined the crystal structure of human (Hs) 4E-BP1 in complex
with Hs eIF4E at 1.75 A˚ resolution (Figure 1D; Table 1), which
demonstrated conservation of the key structural features
observed in the Dm complexes.
The structures of Dm eIF4E and Hs eIF4E are similar to the
structures of free or bound eIF4E from diverse organisms, and
no major conformational changes in the proteins occur upon
4E-BP binding (Figures 1B–1H and S2A) (Gross et al., 2003; Kin-
kelin et al., 2012; Mizuno et al., 2008; Paku et al., 2012; Papado-
poulos et al., 2014; Siddiqui et al., 2012; Umenaga et al., 2011;
Volpon et al., 2006). Briefly, eIF4E adopts a crescent-shaped
conformation formed by a strongly bent b sheet of eight antipar-
allel b strands. The cap-binding cavity is located on the concave,
ventral surface (Figure 1H). The convex surface is decorated by
three a helices that form the dorsal binding surface of the protein.
The major difference between the various eIF4E structures is
observed in loops L1 and L3, which harbor the Trp residues
that coordinate the cap structure. These loops undergo struc-
tural rearrangements upon binding to the cap structure (Volpon
et al., 2006), as observed in the eIF4E-eIF4G complex bound
to a cap analog (Figure 1H). In the absence of the cap analog,
loop L1 adopts different conformations, and loop L3 is mainly
disordered (Figures 1B–1D versus Figure 1H).
In contrast to eIF4E, the 4E-BPs differ in their structural details.
Nevertheless, the interacting peptide sequences can be divided
into three common structural elements, each of which binds to a
defined and common surface on eIF4E (Figures 1B–1J and 2): (1)
an N-terminal a helix formed by the canonical motifs and binding
to the dorsal surface of eIF4E; (2) an elbow loop immediately
following the canonical a helix that bends the peptide backbone
by approximately 90!, orienting the linker regions downward to
engage the lateral surface of eIF4E (Figure 1G); and (3) a C-termi-
nal loop formed by the non-canonical motifs (NC loop). The NC
loop shows the largest structural differences among the 4E-
BPs (Figure 1E) and contacts a hydrophobic pocket on the lateral
surface of eIF4E, providing an additional anchoring point. The
hydrophobic pocket on the lateral surface of eIF4E is also con-
tacted by the non-canonical motif of CUP, which adopts an a he-
lical conformation (Figure 1J) (Kinkelin et al., 2012). However, the
elbow loop and the linker region are not visible in the structure of
the CUP-eIF4E complex (Figure 1J).
In the eIF4G-eIF4E complex, only the canonical motif and
additional short N- and C-terminal extensions were observed
(Figures 1H and S2B–S2F). The auxiliary VKNVSI was not visible
in our structure, suggesting that it may form transient interactions
ormay be susceptible to proteolysis. The solution structure of the
Saccharomyces cerevisiae eIF4E-eIF4G complex indicated that
the eIF4G residues C-terminal to the canonical motif wrap
around the unstructured N-terminal extension of eIF4E (Figures
S2E and S2F) (Gross et al., 2003). However, it is not known
whether a similar interaction forms between the metazoan
proteins, as Dm eIF4G exhibited a similar affinity for eIF4E inde-
pendently of whether the N-terminal extension was included
(Table S2) (Igreja et al., 2014). Consequently, the eIF4E N-termi-
nal extensionwas deleted in the construct used for crystallization
(Table S1).
The 4E-BP interface on eIF4E overlaps with, yet is more
extensive than, the eIF4G-eIF4E interface (Figures 2A–2D). It
comprises a dorsal surface shared by the canonical helices of
4E-BPs and eIF4G, a lateral surface shared by all 4E-BPs but
not used by eIF4G, and small surface patches unique to each
of the 4E-BPs (Figure 2E).
The Canonical Motifs
As expected, the canonical motifs of 4E-BPs and eIF4G fold into
an a helix, which is held in position by interactions analogous to
the ones previously reported for canonical peptides in complex
with eIF4E (Figures 3A–3H, S2G, and S2H) (Gross et al., 2003;
Kinkelin et al., 2012; Mizuno et al., 2008; Paku et al., 2012; Ume-
naga et al., 2011). Specifically, residues corresponding to LV in
the consensus sequence YX4LV form similar hydrophobic con-
tacts with the conserved Dm eIF4E residues V102, W106, and
L167 (V69, W73, and L135 in Hs eIF4E, respectively; Figures
3A–3D). The hydroxyl group of the invariant Tyr (Y) side chain
contacts the backbone of the conserved H70-P71-L72 motif in
eIF4E (H37-P38-L39 inHs eIF4E) and is in van der Waals contact
with V102 of Dm eIF4E (Hs V69) in all structures (Figures 3E–3H,
S2G, and S2H).
The canonical a helices are flanked on both sides by
conserved Arg/Lys residues that adopt a similar orientation in
all structures (Figures 2A–2D, 3A–3D, S1, and S2G), suggesting
an extended consensus sequence for the canonical motif (YX
[R/K]X2LVX2R/K). Accordingly, alignment and sequence profile
of the canonical motifs of all available eIF4G and 4E-BP se-
quences indicates that the Arg/Lys residues at positions 2 and
9 are well conserved (Figure S2I). The side chains of the C-ter-
minal Arg residues (R63Thor, R194E-T, R63BP1, R6284G, and
R336CUP) stack ontoW1064E (HsW734E), shielding its hydropho-
bic surface from solvent exposure (Figures 3A–3D and S2G).
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Figure 1. Overall Structures of 4E-BPs and eIF4G Bound to eIF4E
(A) Domain organization of eIF4G and the 4E-BPs analyzed in this study. The 4E-BPs contain a canonical (C) and a non-canonical (NC) 4E-BM. CUP and 4E-T
contain a region with similarity to human 4E-T; eIF4G contains a PABP-interacting region and MIF4G and MA3 domains. See also Figure S1.
(B–D) Overview of the structures of eIF4E bound to the indicated 4E-BPs. Selected secondary structure elements are labeled in black for eIF4E and in color for
4E-BPs.
(E) Superposition of the structures of eIF4E bound to 4E-T, Thor, and 4E-BP1 reveals differences in the conformation of the NC loops.
(F) Schematic representation of eIF4E bound to 4E-BPs.
(G) Alignment of the eIF4G and 4E-BP structures by superposition of their canonical helices indicates that the elbow loop is a common structural feature of
4E-BPs.
(H) Overview of the structure of eIF4E bound to eIF4G and cap analog. See also Figure S2.
(I) Schematic representation of eIF4E bound to eIF4G and m7GTP.
(J) Overview of the structure of the eIF4E-CUP complex (PDB accession number 4AXG; Kinkelin et al., 2012).
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Furthermore, in the 4E-BP structures, these Arg residues contact
the side chain of N1104E (Hs N774E), which is not formed in the
eIF4G structure (see Figure 4).
On the N-terminal portion of the canonical a-helix, the Arg/Lys
residues (R56Thor, K124E-T, R56BP1, R6224G, and R329CUP) con-
tact L1674E (Hs L135). Furthermore, in all structures except for
Thor, these residues form a salt bridge to a conserved acidic res-
idue in eIF4E (Dm D1644E, Hs E1324E; Figures 3B–3D). In Thor,
this salt bridge is formed by K60 at the V position of the
consensus motif (Figure 3A), which is a specific feature of the
Thor interaction.
The Elbow Loops
A key distinguishing feature of 4E-BPs is the linker region, which
extends the 4E-BP binding interfaces beyond the canonical a
helices and forms the characteristic elbow loop that enables
4E-BPs to engage two orthogonal surfaces on eIF4E (Figure 1G).
Despite the lack of sequence conservation, the elbow loops are
organized around common principles (Figures 4A–4F). They
begin immediately after the Arg residues flanking the canonical
helices on the C-terminal side (R63Thor,BP1 and R194E-T); they
comprise a helical half-turn that begins with a Pro (P66Thor,BP1)
or a Gly (G224E-T) residue located at the tip of the elbow; and
they end with similarly arranged Ser or Thr residues (S68Thor,
S244E-T, and T68BP1). The side chains of these Ser/Thr residues
contact the carbonyl oxygens of preceding residues (L62Thor,
L184E-T, R63BP1) and fix the backbone, as do the internal interac-
tions within the helical half-turn (Figures 4A–4C).
The elbow loops are anchored to the lateral surface of eIF4E
primarily through interactions with the conserved Asn (Dm
Table 1. Data Collection and Refinement Statistics
Dm eIF4E-Thor
Complex
Dm eIF4E-4E-T
Complex
Dm eIF4E-eIF4G
Complex
Hs eIF4E-4E-BP1
Complex
Dm eIF4E-Triple
Chimera Complex 1
Dm eIF4E-Triple
Chimera Complex 2
Space group P21 P6522 P212121 P21 P61 P212121
Unit cell
Dimensions (A˚)
a, b, c 35.5, 73.3, 38.3 40.0, 40.0, 443 54.9, 68.1, 104 42.1, 66.6, 43.1 94.5, 94.5, 132 38.7, 94.5, 167
Angles (!)
a, b, g 90, 112.5, 90 90, 90, 120 90, 90, 90 90, 118.3, 90 90, 90, 120 90, 90, 90
Data collection
Wavelength (A˚) 1.000 1.000 1.038 1.070 1.000 0.999
Resolution (A˚) 36.6–1.10 36.9–2.15 48.6–2.40 37.9–1.75 47.3–2.62 47.9–2.52
(1.13–1.10) (2.21–2.15) (2.46–2.40) (1.80–1.75) (2.69–2.62) (2.59–2.52)
Rsym 0.032 (0.324) 0.091 (0.707) 0.095 (0.790) 0.041 (0.309) 0.068 (0.846) 0.110 (0.582)
Mean I/sI 23.7 (4.0) 25.6 (4.5) 15.4 (2.3) 13.4 (2.5) 14.4 (2.1) 9.4 (2.1)
Completeness (%) 95.8 (88.7) 100 (100) 99.9 (99.8) 96.9 (98.1) 99.6 (99.5) 96.2 (97.1)
Multiplicity 6.0 (4.2) 34.7 (31.4) 6.5 (6.6) 2.9 (2.8) 4.9 (5.0) 4.7 (4.1)
Refinement
Resolution (A˚) 36.5–1.10 36.9–2.15 48.5–2.40 37.9–1.75 47.3–2.62 41.8–2.52
No. of reflections 70,121 12,796 15,777 20,588 19,990 20,794
Rwork/Rfree 0.145/0.161 0.235/0.271 0.210/0.253 0.192/0.237 0.205/0.262 0.205/0.245
No. of atoms 1,852 1,739 3,176 1,878 5,001 5,054
Protein 1,648 1,701 3,066 1,759 5,001 5,044
Ligand/ion 13 / 66 / / /
Water 191 38 44 119 / 10
B factors (A˚2) 19.8 50.0 53.6 32.8 70.1 44.4
Protein 18.6 50.1 53.7 32.4 70.1 44.4
Ligand/ion 33.5 / 56.9 / / /
Water 29.3 45.4 43.4 38.4 / 32.8
Ramachandran plot
Favored (%) 98.5 97.0 98.4 98.6 98.0 99.0
Disallowed (%) 0 0 0 0 0 0
Root-mean-square deviation
Bond lengths (A˚) 0.007 0.002 0.003 0.004 0.003 0.004
Bond angles (!) 1.168 0.564 0.667 0.780 0.647 0.671
Values in parentheses are for highest-resolution shell. Ligands: Dm eIF4E-Thor complex: tetraethylene glycol, two Na atoms; Dm eIF4E-eIF4G
complex: one m7GTP per eIF4E molecule.
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Figure 2. Surface Representation of the 4E-BP and eIF4G Binding Interfaces on eIF4E
(A–D) The eIF4E residues that are within 4 A˚ of the bound 4E-BP or eIF4G peptides are shown in color. Selected residues lining the binding surface are labeled in
black for eIF4E and in color for 4E-BPs and eIF4G. The 4E-BP and the eIF4G peptides are shown as sticks.
(E) Superposition of the eIF4E surfaces that bind eIF4G and 4E-BPs. The region of overlap between the eIF4G and 4E-BP binding surfaces is shown in yellow.
The surface shared by 4E-BPs but not used by eIF4G is colored in cyan. Surfaces used exclusively by Thor and 4E-T are shown in magenta and green,
respectively.
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N1104E and Hs N774E) and His residues (Dm H1114E, Hs H784E).
The Asn residue contacts the backbone carbonyl group of the
structurally equivalent residues S68Thor, T68BP1, and S244E-T,
as well as the side chains of the structurally conserved
R63Thor,BP1 and R194E-T located C-terminal to the canonical he-
lices (Figures 2 and 4D–4F). The aromatic ring of the conserved
His residue is locked in position upon ligand binding. In the 4E-
BP structures, this ring stacks on the peptide bonds preceding
and following the conserved T70Thor,BP1 phosphorylation site
(perpendicular and parallel p stacking, Figures 4D and 4E) or is
in van der Waals contact with the C304E-T side chain (Figure 4F,
corresponding to P71Thor,BP1).
The Non-Canonical Loops
A second anchoring point on the lateral surface of eIF4E is pro-
vided by a conserved hydrophobic pocket. This pocket is lined
by residues Y804E, I964E, and I1124E (F474E, I634E, and I794E in
Hs eIF4E, respectively) and is engaged by the residues that
form the non-canonical motifs of the 4E-BPs. Strikingly, how-
ever, the various 4E-BPs, including CUP, adopt very different
backbone conformations as they approach the pocket (Figures
1E, 1J, and 2). In particular, the pocket is engaged by the hydro-
phobic side chains of L79Thor, V81BP1, F414E-T, or I373CUP (Fig-
ures 4G–4I and S2J). Furthermore, the carbonyl oxygens of
these residues are fixed by a main-chain contact to the nitrogen
of Dm K1134E (Hs Q804E), which is internally buttressed at its
carbonyl oxygen by Dm Y1244E (Hs Y914E; Figures 4J–4L). The
three Dm 4E-BPs also form one additional common main-chain
contact from the nitrogen of R81Thor (K434E-T, R375CUP) to the
carbonyl oxygen of Dm H1114E, whereas the corresponding
Arg side chain locks the backbone of Dm I1124E in position
(Figures 4G, 4I, 4J, and 4L). These Arg/Lys residues are not
conserved in vertebrate 4E-T and 4E-BP1–3 (Figure S1).
Importantly, although the peptides of 4E-BP1, Thor, and 4E-T
show some internal stabilization by backbone hydrogen bonds
or hydrophobic contacts, they do not form defined secondary
structures. This property differs for CUP, in which the residues
that engage the eIF4E pocket and its vicinity are located on an
a helix (Figures 1J and S2J) (Kinkelin et al., 2012). However,
this helix seems to form only upon binding, as indicated by the
large entropic penalty associated with the binding of CUP to
eIF4E (Igreja et al., 2014).
Structure Validation
To validate the observed interactions, we substituted key inter-
face residues and tested complex formation in pull-down assays
in vitro using recombinant proteins and in coimmunoprecipita-
tion assays in human and Dm cells. Substitutions of residues in
either the canonical or the non-canonical motif of Thor or 4E-T
did not prevent complex formation in vitro in the absence of
eIF4G, indicating that the remaining sequences are sufficient
for binding to eIF4E (Figures S3A and S3B) (Igreja et al., 2014).
However, these mutations did abolish or impair the ability of
4E-BPs to compete with endogenous eIF4G for binding to
eIF4E in human and Dm cell lysates (Figures S4A–S4D) (Igreja
et al., 2014). Binding to eIF4E was abrogated when mutations
in the canonical and non-canonical motifs were combined (Fig-
ures S3A, S3B, and S4A–S4D C*+NC*).
Substitutions of each of the Arg/Lys residues in the canonical
or non-canonical motifs by glutamic acid (or alanine in the case
of Thor) did not affect the binding of Dm 4E-BPs to eIF4E in vitro
(Figures S3C–S3F). Binding to eIF4E was impaired only when the
three Arg/Lys residues (i.e., two in the canonical and one in the
non-canonical motif) were substituted (Figures S3C–S3E), indi-
cating that these residues contribute to the affinity of the interac-
tion. Furthermore, although the double mutations in the two Arg/
Lys residues in the canonical motif did not affect the binding of
Thor to free eIF4E, they did impair its ability to compete with
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Figure 3. Interaction of the Canonical Motifs of 4E-BPs and eIF4G
with the Dorsal Surface of eIF4E
(A–H) Close-up views of the interaction between the dorsal surface of eIF4E
and the canonical helices of 4E-BPs and eIF4G. Selected interface residues
are shown as gray sticks for eIF4E and as colored sticks for 4E-BPs and eIF4G.
See also Figures S2–S4.
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Figure 4. The Elbow and the Non-Canonical Loops
(A–C) Close-up views of the elbow loops and interactions within the loops. The side chains of L67Thor, K69BP1 and K234ET have been omitted for clarity.
(D–F) Close-up views of the interaction between eIF4E and the 4E-BP linker regions C-terminal to the elbow loops. Selected interface residues are shown as gray
and colored sticks for eIF4E and 4E-BPs, respectively. The side chain of K69BP1 has been omitted for clarity; R254ET and Q294ET are not visible in the structure.
Conserved phosphorylated residues in Thor and 4E-BP1 are boxed.
(legend continued on next page)
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eIF4G for binding to eIF4E (Figure S3G). We therefore conclude
that the Arg/Lys residues in the canonical motif participate in
complex formation and in the competition mechanism.
Phosphorylation of Linker Residues Interferes
with the Competition Mechanism
Our high-resolution crystal structures provide insight into the
conformation of the two conserved phosphorylation sites (S65
and T70) in the linker regions of Thor and 4E-BP1 (Figures 4D
and 4E). In both structures, the side chains of these residues
do not contribute to the binding interface, indicating that phos-
phorylation does not directly interfere with complex forma-
tion. Furthermore, phosphomimetic mutations at S65 and T70
(S65D, T70D) did not affect the interaction of a Thor fragment
(32–83) with eIF4E (Figure S5 and Table S2), as reported previ-
ously (Gingras et al., 2001; Karim et al., 2001). However, the mu-
tations disrupted the interaction with eIF4E when combined with
mutations in the canonical motif (Figure S4E), suggesting that
phosphorylation interferes with the 4E-BP binding mechanism.
We therefore tested the effect of phosphomimetic mutations
on the ability of the Thor fragment to displace eIF4G from preas-
sembled eIF4E-eIF4G complexes in competition assays in vitro.
Preassembled eIF4E-eIF4G complexes were challenged with
2-fold molar excess of Thor fragment. The amount of eIF4G re-
maining bound to eIF4E over time was determined (Figures 5A
and 5B). In the presence of MBP (maltose-binding protein),
eIF4G remained bound to eIF4E, as expected (Figure 5B, lanes
5 and 10). The wild-type Thor fragment displaced eIF4G from
preassembled eIF4E-eIF4G complexes more efficiently than
the fragment containing phosphomimetic mutations at S65
and T70 (Figures 5A and 5B). Indeed, the half-life of the eIF4E-
eIF4G complexes was 18 min in the presence of wild-type Thor,
compared with 60 min for the S65D, T70D mutant (Figures 5A
and 5B). Conversely, eIF4G displaced the Thor phosphomimetic
mutant from preassembled eIF4E-Thor complexes but failed to
efficiently displace Thor wild-type (Figures S4F and S4G).
To further validate the conclusions obtained using the phos-
phomimetic mutant, we performed isothermal titration calorim-
etry (ITC) measurements and competition assays with Thor
synthetic peptides (residues 50–83), either wild-type or phos-
phorylated at positions S65 and T70. In agreement with the re-
sults obtained with the phosphomimetic mutant, the wild-type
and phosphorylated peptides exhibited nanomolar affinities for
eIF4E (Figure S5 and Table S2). However, the phosphorylated
peptide was strongly impaired in its ability to displace eIF4G
from preassembled eIF4E-eIF4G complexes (Figures 5C and
5D). Note that similar amounts of wild-type and phosphorylated
peptide were used in the competition assay but the phosphory-
lated peptide stains less efficiently with Coomassie (Figure 5D).
We conclude that the phosphomimetic mutations faithfully reca-
pitulate the impact of phosphorylation of the linker residues.
To determine the effect of phosphorylation in translational re-
pression, we tested whether the S65D, T70D mutant repressed
the expression of a Renilla luciferase (R-Luc) reporter when
coexpressed in S2 cells. A short uncapped and unadenylated
RNA served as a transfection control (control RNA). To rule out
the possibility that the inhibition of R-Luc expression resulted
from changes inmRNA levels, we analyzed these levels by north-
ern blotting and determined the translation efficiencies (i.e., the
R-Luc activity normalized to R-Luc mRNA levels).
Remarkably, phosphomimetic mutations at S65 and T70 were
sufficient to prevent Thor from repressing translation of the
R-Luc reporter in Dm cells (Figures 5E and S4H). The proteins
were expressed to comparable levels (Figure 5F). We conclude
that the phosphorylation of linker residues is sufficient to reduce
the potency of 4E-BPs as translational repressors. Taken to-
gether, our results indicate that phosphorylation at S65 and
T70 residues does not affect binding to free eIF4E but does inter-
fere with the ability of 4E-BPs to displace eIF4G from preexisting
eIF4E-eIF4G complexes and repress translation.
Design of a Potent Bipartite 4E-BP Mimic
The binding mode observed in our structures and the observa-
tion that mutations in the non-canonical motifs prevent 4E-BPs
from competing with eIF4G (Figures S4A–S4D) (Igreja et al.,
2014) support a model in which 4E-BPs use the lateral surface
of eIF4E to dock on the eIF4E-eIF4G complex before eIF4G dis-
sociates and then compete for binding to the dorsal surface
through the canonical motifs. Conceptually, and as supported
by the present structures, this two-step competition mechanism
does not require conformational changes in eIF4E and is there-
fore distinct from the mechanism described for 4EGI-1 (Papado-
poulos et al., 2014). 4EGI-1 is a small molecule inhibitor of the
eIF4E-eIF4G interaction that binds in close proximity to the hy-
drophobic pocket on the lateral surface of eIF4E and presumably
displaces eIF4G from the dorsal surface by an allosteric mecha-
nism (Figure 6A) (Moerke et al., 2007; Papadopoulos et al., 2014).
The observable rearrangements in eIF4E upon 4EGI-1 binding
include an extension of helix a1 by one turn, which disrupts the
backbone stabilization by Y914E (Dm Y1244E), and a reorienta-
tion of the side chain of H784E (Dm H1114E) toward the hydro-
phobic pocket that is not possible in the presence of 4E-BPs
(Figures 6B–6E and S4I) (Papadopoulos et al., 2014).
Compared with the nanomolar affinities of the 4E-BPs, the af-
finity of 4EGI-1 for eIF4E (10-20 mM) is relatively low, and higher
concentrations of 4EGI-1 are required to displace eIF4G from
eIF4E (Moerke et al., 2007; Papadopoulos et al., 2014).We there-
fore propose that bipartite 4E-BP mimics are likely to be more
potent inhibitors of protein synthesis thanmonopartite inhibitors.
To test this prediction, we engineered a 4E-BP mimic based
on our structural information and on previously reported bio-
physical properties of the 4E-BP peptides (Igreja et al., 2014).
The rationally designed inhibitor comprised the high-affinity ca-
nonical motif of 4E-T, the non-canonical motif of CUP (which
forms a helix and binds to eIF4E in isolation; Kinkelin et al.,
2012; Igreja et al., 2014), and the linker region of Thor, which
(G–I) Interaction of the non-canonical loops with the lateral surface of eIF4E. See also Figure S2J.
(J–L) Close-up views of the non-canonical loops and interactions with residues lining the lateral hydrophobic pocket of eIF4E. Selected 4E-BP and eIF4E residues
are shown as sticks (C78–R81Thor, G80–S83BP1, and G40–I444ET). eIF4E secondary structure elements (b1 and b2) and the side chains of Dm I1124E (Hs I794E),
C78Thor, L80Thor, T82BP1, W424ET, and I444ET have been omitted for clarity.
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Figure 5. Effects of Phosphorylation of Thor Linker Residues
(A and B) Half-life of eIF4E-eIF4G complexes. Purified eIF4E-eIF4G complexes containing His6-tagged eIF4E andMBP-eIF4G (residues 578–650) were incubated
with a 2-fold molar excess of Thor (residues 32–83, either wild-type [WT] or the S65D, T70D phosphomimetic mutant). MBP served as a negative control. The
proteins bound to eIF4E were pulled down using Ni-NTA beads at the indicated time points. Mean values ± SD from five independent experiments (n = 5) are
shown. A representative SDS-PAGE gel is shown in (B). The competitor peptides are labeled in blue, and their positions are highlighted by blue dashed boxes. The
black dashed boxes indicate the position of MBP-eIF4G. See also Figures S4F and S4G.
(C andD) The half-life of eIF4E-eIF4G complexes in the presence of a 2-foldmolar excess of Thor synthetic peptides (residues 50–83, eitherWT or phosphorylated
at S65 and T70) was determined as described in (A) and (B). Note that the phosphorylated peptide does not stain well with Coomassie. See also Figure S5 and
Table S2.
(E and F) Translation efficiency of a R-Luc reporter in Dm cells expressing GFP or GFP-tagged Thor (WT or the S65D, T70D phosphomimetic mutant). Mean
values ± SD from three independent experiments are shown. The red dashed line indicates the translation efficiency for themaximum repressive activity exhibited
by Thor WT, whereas the black dashed line indicates the translation efficiency expected in the absence of repression. Protein expression was analyzed by
western blotting (F). The RNA levels were determined by northern blotting (Figure S4H).
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exhibits the most extensive intra- and intermolecular interaction
network. ITC experiments on this triple chimera showed that it
possesses 2.6-fold higher binding affinity for eIF4E than the
CUP or Thor peptides (Figure S5F and Table S2).
We also determined the structure of the triple chimera peptide
bound to Dm eIF4E in two crystal forms at 2.62 and 2.52 A˚
resolution (Figures 6F and S6A–S6E and Table 1). These struc-
tures demonstrated that the designed peptide binds to eIF4E
as expected and in different crystal packing environments. In
particular, the canonical helix of 4E-T, the linker region of Thor,
and the non-canonical helix of CUP adopted conformations
similar to those observed in the structures of the parental pro-
teins, with root-mean-square deviations no higher than 0.67 A˚
(Figures S6F–S6H).
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Figure 6. Translational Repression by a
4E-BP Mimic Peptide
(A–E) Overview of the structure of eIF4E bound to
the 4EGI-1 inhibitor (PDB accession number 4TPW;
Papadopoulos et al., 2014) and superposition with
the indicated 4E-BP structures. Selected second-
ary structure elements and residues are labeled in
black for eIF4E and in color for the 4E-BPs. See also
Figure S4I.
(F) Overview of the structure of eIF4E bound to the
triple chimera peptide (crystal form 2). Selected
secondary structure elements are labeled in black
for eIF4E and in color for the peptide. See also
Figures S6 and S7.
(G and H) The half-life of eIF4E-eIF4G complexes in
the presence of 1.5-fold molar excess of CUP or of
the triple chimera peptide was determined as
described in Figures 5A and 5B. See also Figures
S7A and S7B.
(I and J) The translation efficiency of a R-Luc re-
porter in Dm cells expressing GFP or GFP-tagged
Thor (WT) or the triple chimera was analyzed as
described in Figures 5E and 5F. Mean values ± SD
from three independent experiments are shown.
The expression of the GFP-tagged proteins was
analyzed by western blotting (J). The RNA levels
were determined by northern blotting (Figure S7C).
See also Figures S7D and S7E.
Next, we tested the ability of the
chimeric peptide to displace eIF4G in
competition assays in vitro. We observed
that the triple chimera displaced eIF4G
from preassembled eIF4E-eIF4G com-
plexes more efficiently than CUP or Thor
peptides when added at 1.5-fold molar
excess. Indeed, the half-life of the eIF4E-
eIF4G complexes was 5- and 3-fold
shorter in the presence of triple chimera
peptide compared with the CUP or Thor
peptides, respectively, at the same con-
centration (Figures 6G, 6H, S7A, and S7B).
Importantly, the chimeric peptide fused
to GFP repressed the expression of an
R-Luc reporter in Dm cells more efficiently
thanwild-type Thor, even when expressed
at a lower level (Figures 6I, 6J, and S7C). Additionally, the
chimeric peptide fused to GFP interacted with Hs eIF4E (Fig-
ure S7D) and competed with endogenous eIF4G for binding to
eIF4E in human cells (Figure S7E). These results provide a basis
for the rational design of potent 4E-BP mimics for therapeutic
applications.
DISCUSSION
Our study reveals common conserved principles of the interac-
tion between 4E-BPs and eIF4E as well as individual features
that guide the binding of the non-canonical motifs of 4E-BPs.
Furthermore, the structures presented here provide insight into
the mechanism by which phosphorylation prevents 4E-BPs
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from repressing translation. Finally, our structural analyses pro-
vide a basis for the rational design of eIF4E inhibitors for the
treatment of diseases in which eIF4E activity is upregulated.
4E-BP Binding Mechanisms
In combination with previous studies, our structures show that
the canonical motifs of diverse 4E-BPs and eIF4G use a similar
mechanism to bind eIF4E and that this binding mode is
conserved (Gross et al., 2003; Kinkelin et al., 2012; Mizuno
et al., 2008; Paku et al., 2012; Umenaga et al., 2011). In contrast,
the binding mode of the linker regions and non-canonical motifs
of 4E-BPs differ in themolecular details as expected on the basis
of the differences in sequence and length of these regions.
Nevertheless, these regions exhibit common structural features,
such as the elbow and the non-canonical loops, which are uni-
que to 4E-BPs.
Although the linker regions and non-canonical loops are
largely devoid of secondary structure elements, such as a heli-
ces and b strands, they adopt a defined conformation in the
bound state that is stabilized by intra- and intermolecular in-
teractions. Previous studies indicated that the corresponding
regions of Hs 4E-BP2 and sea urchin 4E-BP form ‘‘fuzzy com-
plexes’’ in solution, sampling alternative conformations in the
bound state and contacting larger surfaces on eIF4E (Gosselin
et al., 2011; Lukhele et al., 2013). However, the fact that we could
crystallize defined states and conformations that remain the
same in a different crystal packing environment in the context
of the designed chimera, indicates that these regions also have
a preferred conformation in the bound state, probably reflecting
the most stable state.
Competition with eIF4G
The 4E-BP interface on eIF4E overlaps with the interface of
eIF4G but is more extensive and buries a total surface area of
1,450 A˚2 (Thor), 1,370 A˚2 (4E-T), or 1,235 A˚2 (4E-BP1) relative to
655 A˚2 for eIF4G in our structure (Figure 2). The 4E-BP interface
comprises the dorsal surface of eIF4E shared with eIF4G and the
lateral surface of eIF4E shared by all 4E-BPs but not used by
eIF4G. Although we cannot exclude that metazoan eIF4G also
contacts the lateral surface of eIF4E, as observed in the solution
structure of Sc eIF4G (Gross et al., 2003), several lines of evi-
dence indicate that these potential additional contacts may be
transient in nature and do not require the lateral hydrophobic
pocket of eIF4E. First, mutations in the canonical motif of
eIF4G abolish binding to eIF4E, indicating that the sequences
flanking the canonical motif are not sufficient to mediate eIF4E-
binding. In contrast, 4E-BPs exhibit a truly bipartite binding
mode, and mutations in the canonical motifs do not disrupt
binding to eIF4E in vitro, because the linker and non-canonical re-
gions are sufficient for binding (Igreja et al., 2014). Second,
mutations in the lateral hydrophobic pocket of eIF4E prevent
4E-BPs from competing with eIF4G and from repressing trans-
lation, but these mutations do not affect eIF4G binding to eIF4E
(Igreja et al., 2014). These observations, together with the
binding mode observed in our structures, suggest that 4E-BPs
can bind to eIF4E-eIF4G complexes before eIF4G dissociates
and then benefit from the local enrichment to efficiently compete
for binding to the dorsal surface using the canonical motifs.
Nevertheless, eIF4G most likely establishes interactions with
eIF4E beyond the canonical motif that are not visible in our struc-
ture. Indeed, Hs and Dm eIF4G peptides containing the canoni-
cal motif and flanking sequences including the auxiliary motif
exhibit nanomolar affinities for eIF4E, in contrast to the micro-
molar affinities observed for the peptides containing only the
canonical motif (Umenaga et al., 2011). These additional interac-
tions may differ across species, as the auxiliary (VKNVSI) motif is
not conserved (Figure S1E).
Phosphorylation Interferes with the Competition
Mechanism
The binding of 4E-BPs to eIF4E is regulated by coordinated and
ordered phosphorylation events. In human 4E-BPs, phosphory-
lation at Thr residues upstream of the canonical motif constitutes
a priming event that allows, upon external stimuli, the phosphor-
ylation of the Thr and Ser residues in the linker region. Con-
sequently, two waves of phosphorylation events (independent
and dependent on external stimuli) are necessary to prevent
4E-BP1 from binding to eIF4E (Gingras et al., 1999, 2001). In
the absence of high-resolution structures in which these resi-
dues could be visualized, it has been difficult to determine the
impact of phosphorylation on the interaction of 4E-BPs with
either the lateral or dorsal surfaces of eIF4E.
The structures presented here indicate that the target sites in
the linker region (S65, T70) are not part of the interface with eIF4E
and hence are not directly involved in eIF4E binding. In agree-
ment with the solvent exposure of the respective side chains,
we show that phosphorylation of these residues (or phosphomi-
metic mutations) does not significantly affect Thor binding to
eIF4E in vitro (Figure S5 and Table S2). Similar observations
were reported in previous studies for human 4E-BP-1,2 (Bah
et al., 2014; Gingras et al., 2001; Karim et al., 2001). However,
we show that phosphorylation of linker residues does impair
the ability of Thor to displace eIF4G from preassembled eIF4E-
eIF4G complexes (Figures 5A–5D). More important, phosphomi-
metic mutations at the phosphorylation sites in the linker region
prevent Thor from repressing translation in vivo (Figures 5E
and 5F). On the basis of these observations and of the proximity
of the phosphorylated residues to the elbow loop, it is likely
that the primary effect of phosphorylation is interference
with the competition mechanism. This interference could
occur by a conformational stabilization of the peptide in
the free state and/or a destabilization of bound intermediates
that decrease the competitive advantage. Consistent with this
model, nuclear magnetic resonance studies using short Hs
4E-BP1 peptides containing the canonical motif and linker region
but lacking the non-canonical motifs (residues 51–67) demon-
strated a reduction of helix propensity upon phosphorylation
(Tait et al., 2010).
Nevertheless, the mechanism by which phosphorylation in-
hibits different 4E-BPs from binding to eIF4E remains to be fully
elucidated. In the case of 4E-BP2, phosphorylation of residues
N-terminal to the canonical motif induces the formation of a
four-stranded b domain that sequesters the canonical motif,
reducing the affinity for eIF4E by two orders of magnitude
(Bah et al., 2014). This event primes the phosphorylation of res-
idues in the linker region, which further reduces affinity by
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10-fold, suggesting that there may be additional order-to-disor-
der transitions upon phosphorylation that also involve the linker
residues. In the case of Dm Thor, phosphorylation at residues
upstream of the canonical motif is sufficient to prevent binding
to eIF4E (Miron et al., 2003), suggesting that the impact of phos-
phorylation of specific residues is likely to differ for the different
4E-BPs.
4E-BP Peptide Mimics as Therapeutic Tools
The dysregulation of cap-dependent translation is causally
linked to human diseases including cancer, ASDs, and fragile X
syndrome (Banko et al., 2005, 2007; Boussemart et al., 2014;
Gkogkas et al., 2013; Sharma et al., 2010). In cancer cells,
increased eIF4E activity facilitates the translation ofmRNAs cod-
ing for growth factors and oncogenic proteins (Dowling et al.,
2010). In ASD and fragile X syndrome, increased synthesis of
synaptic proteins results in augmented connectivity (Gkogkas
et al., 2013; Sharma et al., 2010). In this context, the develop-
ment of eIF4E inhibitors for therapeutic applications has been
the object of intensive research (Jia et al., 2012). The validity of
this approach is underscored by the observation that 4EGI-1 in-
hibits tumor growth in human breast and melanoma cancer xe-
nografts and reverses disease-associated phenotypes in mouse
models of ASD (Gkogkas et al., 2013; Moerke et al., 2007).
However, the affinity of 4EGI-1 for eIF4E is approximately
three orders of magnitude lower than the affinity of 4E-BPs
(Moerke et al., 2007). We therefore speculate that bipartite 4E-
BP mimics are likely to represent more potent inhibitors of trans-
lation, first, because of their higher affinity for eIF4E, and second,
because 4E-BPs sterically block the eIF4G-binding surface,
whereas 4EGI-1 interferes with eIF4G binding indirectly using
an allosteric mechanism (Papadopoulos et al., 2014).
As a proof of principle, we designed a peptide-based 4E-BP
mimic by combining the canonical motif of 4E-T with the non-ca-
nonical motif of CUP (i.e., the motifs with the highest respective
affinity for eIF4E). These motifs were connected by the linker re-
gion of Thor, which establishes the most extensive contacts with
eIF4E among all linkers. The triple chimeric peptide showed an
increased affinity compared to the equivalent peptides of Thor
and CUP and faster eIF4G displacement kinetics (Figure 6).
More remarkably, the chimeric peptide inhibited translation in
S2 cells at a concentration at which Thor was ineffective (Figures
6I and 6J). The peptide also efficiently disrupted endogenous
eIF4E-eIF4G complexes in human cells. These observations
illustrate the feasibility of designing high-affinity eIF4E binding
peptides as tools for therapeutic applications.
EXPERIMENTAL PROCEDURES
DNA Constructs
The plasmids used for the expression of Dm proteins (full length or fragments)
in Escherichia coli or S2 cells have been described previously (Igreja et al.,
2014). The plasmids for the expression of V5-SBP or GFP-tagged 4E-BP1
and 4E-BP3 in human cells were obtained by inserting the corresponding
DNA between the XhoI and BamHI sites of the pT7-V5-SBP and pT7-EGFP-
C1 vectors, respectively. Hs eIF4E cDNA sequence was introduced in the
EcoRI and BamHI restriction sites of the plN-HA-C1 vector. The plasmids
for expression inE. coli are described in detail in the Supplemental Information.
A synthetic DNA fragment coding for the triple chimera peptide was cloned be-
tween the EcoRV and XhoI restriction sites of the pAc5.1B-EGFP vector and
the pT7-EGFP-C1 vector for expression in Dm and Hs cells, respectively.
The triple chimera includes the canonical motif of 4E-T (residues 9–20), the
linker region of Thor (residues 65–72), the non-canonical motif of CUP (resi-
dues 362–376), and an additional Gly residue between the linker and the
non-canonical portion of the peptide. All the mutants used in this study were
generated by site-directed mutagenesis using the QuikChange mutagenesis
kit (Stratagene). All the constructs and mutations were confirmed by
sequencing and are listed in Table S1.
Protein Expression and Purification
All recombinant proteins were expressed in E. coli BL21 Star (DE3) cells (Invi-
trogen) grown in Luria brothmedium overnight at 20!C. The cells were lysed by
sonication in lysis buffer containing 50mMHEPES (pH 7.2), 300mMNaCl, and
2 mM dithiothreitol (DTT) supplemented with DNaseI (5 mg/ml), lysozyme
(1 mg/ml), and protease inhibitor cocktail (Roche). To purify the complexes
containing Dm eIF4E, His6-tagged Dm eIF4E (residues 69–248) and the
MBP-tagged 4E-BP or eIF4G, were expressed separately. The complexes
were formed after cell lysis by mixing the corresponding lysates. To obtain
complexes containing Hs eIF4E, His6-tagged Hs eIF4E (residues 36–217)
was co-expressed with MBP-tagged Hs 4E-BP1 (residues 50–83). All
complexes were purified from cleared cell lysates using amylose resin (New
England Biolabs), followed by cleavage of MBP- and His6-tags with HRV3C
protease overnight at 4!C and additional cleavage with TEV protease for the
complex withDm eIF4G. After cleavage of the tags, the complexes were sepa-
rated from MBP and His6 using a heparin column (HiTrap Heparin HP 5 ml; GE
Healthcare), further purified on a Superdex 75 column (GE Healthcare) and
stored in 10 mM HEPES (pH 7.2), 200 mM NaCl, 2 mM DTT, and 5% glycerol
at "80!C.
For the ITCmeasurements and competition assays, theGB1-stabilized pep-
tides were purified as described previously (Igreja et al., 2014). The complex
consisting of His6-tagged Dm eIF4E (residues 69–248) and MBP-tagged Dm
eIF4G (residues 578–650) used for the competition assays was purified from
cleared cell lysates using amylose resin (New England Biolabs), followed by
a heparin column (HiTrap Heparin HP 5 ml; GE Healthcare) and a final purifica-
tion on a Superdex 200 column (GE Healthcare).
Crystallization, Data Collection, and Structure Determination
A detailed description of the crystallization conditions and the structure deter-
mination process can be found in Supplemental Experimental Procedures. All
diffraction data sets were recorded on a PILATUS 6M detector at the PXII
beamline of the Swiss Light Source at a temperature of 100 K. The diffraction
data and refinement statistics are summarized in Table 1.
Coimmunoprecipitation Assays and Western Blotting
Coimmunoprecipitation assays in S2 cells and western blotting were per-
formed as described previously (Igreja et al., 2014). A detailed protocol for
the coimmunoprecipitation assays in human HEK293T cells can be found in
the Supplemental Information. Immunoprecipitated proteins were analyzed
by western blotting. All western blots were developed using the ECL western
blotting detection system (GE Healthcare). The antibodies used in this study
are listed in Table S3.
Pull-Downs, ITC Analysis, Competition and Translation Repression
Assays
The in vitro pull-down and competition assays, ITC analysis, and translation
repression assays were performed as described previously (Igreja et al.,
2014) and are described in the Supplemental Information.
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Figure S1, related to Figure 1. Sequence alignments 
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In all aligned sequences, conserved residues are highlighted with a dark-colored background 
and printed in white. Residues with >70% similarity are shown with a light color background. 
Secondary structure elements are indicated above the sequences for the Dm proteins and 
below the sequence for Saccharomyces cerevisiae eIF4G. The structurally conserved Arg/Lys 
residues in the canonical motifs of 4E-BPs and eIF4G and in the non-canonical motifs of Dm 
4E-BPs are indicated by blue asterisks and are boxed in blue. In the alignments of 4E-BP 
proteins, the canonical (C) and non-canonical (NC) motifs are boxed in black. 4E-BP and 
eIF4G residues within the motifs contacting eIF4E are indicated by red open circles; 
phosphorylated residues in Thor and 4E-BPs are indicated by circles colored in magenta for 
the sites visible in our structures or in cyan for additional known sites.  
(A) Structure-based sequence alignment of eIF4E orthologous proteins from Drosophila 
melanogaster (Dm), Mus musculus (Mm), Homo sapiens (Hs) and Saccharomyces cerevisiae 
(Sc). The Trp residues coordinating the m7GTP nucleotide are indicated by red asterisks. The 
lateral and dorsal binding surfaces (BS) are indicated by a line below the sequences.  
(B) Sequence alignment of the eIF4E-interacting regions of CUP orthologous proteins from 
insects. The species are as follows: Drosophila melanogaster (Dm), Drosophila 
pseudoobscura (Dps), Drosophila virilis (Dvi), Drosophila grimshawi (Dgr) and Drosophila 
willistoni (Dwi). Secondary structural elements of the Dm CUP are according to the structure 
of CUP in complex with eIF4E (PDB ID: 4AXG; Kinkelin et al., 2012). Residues that were 
not visible in the CUP structure are highlighted by a gray dashed bracket above the alignment. 
(C) Sequence alignment of Thor orthologous proteins. The species are as follows: Drosophila 
melanogaster (Dm), Tribolium castaneum (Tc), Anopheles gambiae (Ag), Danio rerio (Dr) 
and Homo sapiens (Hs). The residues forming the elbow loop are indicated by a triangle 
above the alignment.  
(D) Alignment of the eIF4E-interacting region of 4E-T orthologous proteins. The species are 
Caenorhabditis elegans (Ce) and Mus musculus (Mm); other species are as in (C).  
 !
(E) Alignment of the eIF4E-interacting region of eIF4G orthologous proteins. The species are 
as in panels (A) and (D). The secondary structural elements for Sc eIF4G are based on the 
NMR structure (PDB ID: 1RF8; Gross et al., 2003) and are indicated below the sequences. 
The residues visible in our structure are boxed in orange. The auxiliary VKNVSI motif (Hs 
SDVVL) is printed in bold orange characters. 
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Figure S2, related to Figures 1 and 3. Structures of 4E-BPs and eIF4G bound to eIF4E  
(A) Superposition of the structure of free human eIF4E (brown, PDB ID: 3TF2; Siddiqui et 
al., 2012) with the structure of Hs eIF4E (gray) bound to 4E-BP1 (magenta). 
(B) Cartoon representation showing the crystal packing in the structure of the Dm eIF4E-
eIF4G complex bound to m7GTP.  
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(C) Schematic representation of eIF4E dimerization in the structure of the Dm eIF4E-eIF4G 
complex bound to m7GTP. 
(D) Close-up view of the interaction between two eIF4E molecules in the asymmetric unit of 
the Dm eIF4E-eIF4G complex bound to m7GTP. 
(E) Overview of the structure of the Saccharomyces cerevisiae eIF4E-eIF4G complex (PDB 
ID: 1RF8; Gross et al., 2003). The solution structure of the Saccharomyces cerevisiae eIF4G-
eIF4E complex indicates that eIF4G residues C-terminal to the canonical motif wrap around 
the unstructured N-terminal extension of eIF4E.  
(F) Superposition of the canonical motif of Sc eIF4G onto the canonical motif of Dm eIF4G 
in the Dm eIF4E–eIF4G complex. Sc eIF4E has been ommitted for clarity.  
(G and H) Close-up views of the interaction between the dorsal surface of eIF4E and the 
canonical motif of CUP (PDB ID: 4AXG; Kinkelin et al., 2012). Selected interface residues 
are shown as gray sticks for eIF4E and as colored sticks for CUP.  
 (I) Sequence Logo of the YX4LΦ canonical 4E-BM. The alignment underlying the motif 
includes sequences of different characterized 4E-BPs (4E-BP1–3/Thor, 4E-T, CUP, Angel, 
Mextli, p20, Eap1 and Maskin) as well as eIF4G from different species. The motif was 
created using WebLogo (http://weblogo.berkeley.edu/logo.cgi; Crooks et al., 2004). 
(J) Interaction of the non-canonical α-helix of CUP with the lateral hydrophobic pocket of 
eIF4E (PDB ID: 4AXG). 
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Figure S3, related to Figure 3 and Table S1. Interaction of Dm 4E-BPs and eIF4E in 
vitro 
F  Binding of Dm eIF4E to CUP (residues 325–376;WT or mutants)
MBP
SHN-eIF4E
MBP-CUP
72
55
95
36
81 432 6 75
Input MBP pulldown
9 10 1211
28
R3
29
E
M
BP
W
T
R3
36
E
R3
29
E,
R3
36
E
R3
29
E,
R3
36
E,
R3
75
E
R3
29
E
M
BP
W
T
R3
36
E
R3
29
E,
R3
36
E
R3
29
E,
R3
36
E,
R3
75
E
130
kDa
E  Binding of Dm eIF4E to 4E-T (residues 9–44; WT or mutants)
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C  Binding of Dm eIF4E to Thor (residues 50–83; WT or mutants)
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A  Binding of Dm eIF4E (WT or II-AA mutant) to Thor (residues 50–83; WT or mutants) 
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D  Binding of Dm eIF4E to Thor (residues 50–83; WT or mutants)
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(A to F) MBP pulldowns showing the interaction of MBP-tagged 4E-BPs (wild-type or the 
indicated mutants) with full-length eIF4E (wild-type or II-AA mutant). eIF4E was expressed 
with a SHN tag consisting of the streptavidin-binding peptide (strep), His6 and the NusA 
protein. The eIF4E II-AA mutant carries alanine substitutions in residues that line the lateral 
hydrophobic pocket (I96A and I112). The MBP-tagged 4E-BP fragments used in the 
pulldown assays contained Thor residues 50–83, 4E-T residues 9–44 and CUP residues 325–
376 and were all C-terminally fused to GB1. Protein mutants are described in Table S1. The C 
and NC mutants are as follows; Thor C* (Y54A, M59A), Thor NC* (V75D, L79D), 4E-T C* 
(Y10A, L15A) and 4E-T NC* (F41D, W42D).  
(G) Purified complexes containing SHN-eIF4E bound to GST-eIF4G were incubated with 10 
fold molar excess of Thor fragments (residues 50–83; either wild-type or the R56E, R63E 
mutant) C-terminally fused to GB1. The eIF4E-bound proteins were pulled down using Ni-
NTA beads and analyzed by SDS-PAGE. The competitor proteins are labeled in blue and 
highlighted by a blue dashed box. The black dashed box marks the position of GST-eIF4G. 
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Figure S4, related to Figure 3, 5, Table S1 and Table S3. Interaction of 4E-BPs with 
eIF4E in Dm and human cells 
(A and B) Western blot showing the interaction of 4E-BP1 and 4E-BP3 (full-length, either 
wild-type or mutated) with endogenous eIF4E in human HEK293T cells. The full-length 4E-
BP1 and 4E-BP3 proteins were expressed with an N-terminal tag containing the streptavidin 
peptide followed by a V5 tag. The proteins were pulled down using streptavidin (Strep) beads. 
The inputs (0.75% for the V5 tagged proteins and 1.6% for eIF4E) and immunoprecipitates 
(1.5% for the V5 tagged proteins and 3% for eIF4E) were analyzed by western blotting using 
anti-V5 and anti-eIF4E antibodies. Alanine substitutions of the Tyr and Leu residues in the 
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canonical motifs (C*) or of Leu and Val residues in the non-canonical motifs (NC*) abolish 
or reduce binding of 4E-BPs to eIF4E in human cells (in the presence of endogenous eIF4G). 
(C) Western blot showing the interaction of HA-Thor (full-length, either wild-type or 
mutated) with endogenous eIF4E in S2 cells. The proteins were immunoprecipitated using 
anti-HA antibodies. The inputs (1.5% for Thor and 0.3% for eIF4E) and immunoprecipitates 
(15% for Thor and 30% for eIF4E) were analyzed by western blotting using anti-HA and anti-
eIF4E antibodies. Substitutions of residues in the canonical (C*: Y54A, M59A) or the non-
canonical (NC*: V75D, L79D) motif abolish Thor interaction with eIF4E in S2 cells (in the 
presence of eIF4G). Thus the mutations prevent Thor from displacing eIF4G from 
preassembled endogenous eIF4E-eIF4G complexes.  
(D) Western blot showing the interaction of GFP-tagged 4E-T (full-length, either wild-type or 
mutated) with endogenous eIF4E in S2 cells. The proteins were immunoprecipitated using 
anti-GFP antibodies. The inputs (1.5% for 4E-T and 0.3% for eIF4E) and immunoprecipitates 
(20%) were analyzed by western blotting using anti-GFP and anti-eIF4E antibodies. 
Substitutions in the canonical (C*: Y10A, L15A) or non-canonical (NC*: F41A, W42A) 
motif abolish binding of 4E-T to eIF4E in S2 cells (in the presence of eIF4G). Size markers 
(kDa) are shown to the right of each panel. Protein mutants are described in Table S1. 
(E) MBP pulldown assay showing the interaction of MBP-Thor (residues 32–83 wild-type or 
the indicated mutants) and full-length SHN-eIF4E. Thor fragments were all C-terminally 
fused to GB1.  
 (F and G) Half-life of eIF4E–Thor complexes. Purified eIF4E–Thor complexes (4 µM) 
containing SNH-tagged eIF4E (residues 69–248) and MBP-tagged Thor (full length, either 
wild-type or the S65D, T70D phosphomimetic mutant) immobilized on Ni-NTA beads were 
incubated with a 5-fold molar excess of eIF4G (residues 578–650) or MBP as a negative 
control. The eIF4G peptide was fused C-terminally to GB1. Proteins bound to eIF4E were 
recovered at the indicated time points, analyzed by SDS-PAGE (G) and quantify in three 
 !
independent experiments (F). Error bars in panel (F) represent standard deviations. In panel 
(G), the competitor eIF4G protein is labeled in blue and highlighted by a blue dashed box. 
The black dashed box marks the position of Thor.  
(H) Northern blot (NB) analyses of representative RNA samples corresponding to the 
experiment shown in Figure 5E,F.  
(I) Superposition of the structure of eIF4E (yellow) bound to the 4EGI-1 inhibitor (black; 
PDB ID: 4TPW) with the structure of the Dm eIF4E (gray) bound to CUP (red; PDB ID: 
4AXG). 
 
 
 !
Figure S5, related to Figures 5, 6 and Table S2. Calorimetric titration data for the 
interaction of eIF4E with eIF4G and 4E-BP-derived peptides 
(A to F) ITC profiles for the interaction of Dm eIF4E (full-length or residues 69–248) with 
the following peptides: (A) eIF4G (residues 578–650); (B and C) Thor (residues 32–83) either 
wild-type (B) or the S65D, T70D phosphomimetic mutant (C); (D and E) Thor synthetic 
peptide (residues 50–83) either wild-type (D) or phosphorylated at S65D, T70D (E); and (F) 
triple chimera peptide. The thermodynamic parameters are shown in Table S2.  
  
F   Triple-chimera + eIF4E (69–248)
A   eIF4G (578–650) + eIF4E (full-length) B   Thor (32–83; wild-type) + eIF4E (69–248)
Figure S5
C   Thor (32–83; S65D,T70D) + eIF4E (69–248)
D   Thor (50-83; wild-type) + eIF4E (69–248) E   Thor (50-83; pS65, pT70) + eIF4E (69–248)
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Figure S6, related to Figure 6. Structure of the triple chimera peptide in complex with 
eIF4E  
(A and B) Cartoon representation showing the crystal packing in the structures of two crystal 
forms of Dm eIF4E bound to the chimeric peptide.  
(C–E) Overview of the structures of Dm eIF4E bound to the chimeric peptide and 
superposition of the structures derived from the two crystal forms. Selected secondary 
structure elements are labeled in black for eIF4E and in color for the peptide. The structures 
of the two crystal forms superpose with an RMSD of 0.35 Å over 205 Cα. 
A B
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(F–H) Superposition of the structure of eIF4E bound to the triple chimera peptide with the 
structures of eIF4E bound to 4E-T (F), Thor (G) and CUP (H; PDB ID: 4AXG). 
 
 
Figure S7, related to Figure 6 and Table S3. Competition and translation repression 
assays using the triple chimera 
Figure S7
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(A and B) Purified eIF4E–eIF4G complexes (2 µM) containing His-tagged eIF4E (residues 
69–248) and MBP-tagged eIF4G (residues 578–650) immobilized on Ni-NTA beads were 
incubated with a 1.5-fold molar excess of Thor peptide (residues 32–83) or the triple chimera 
peptide. The peptides were fused C-terminally to GB1. Proteins bound to eIF4E were 
recovered at the indicated time points, analyzed by SDS-PAGE (B) and quantified. The 
competitor proteins are labeled in blue and highlighted by a blue, dashed box. The black, 
dashed box marks the position of MBP-eIF4G. The half-life of eIF4G-eIF4E complexes is 
shown in panel (A). Error bars represent standard deviations from 3 independent experiments 
(n=3). 
(C) Northern blot analyses of representative RNA samples corresponding to the experiment 
shown in Figure 6I,J.  
(D) Western blot showing the interaction of GFP-tagged chimeric peptide with endogenous 
HA-eIF4E in human HEK293T cells. The proteins were coimmunoprecipitated using anti-
GFP antibodies. GFP-MBP served as negative control. The inputs (2.5% for the GFP-tagged 
proteins and 1% for eIF4E) and immunoprecipitates (10% for the GFP-tagged proteins and 
25% for eIF4E) were analyzed by western blotting using anti-GFP and anti-HA antibodies.  
(E) Human HEK293T cells were transfected with GFP-tagged proteins including MBP, a 4E-
BP1 fragment (residues 50–83; either wild-type or the indicated C* and NC* mutants) and the 
chimeric peptide. Proteins bound to endogenous eIF4E were pulled down using m7GTP-
Sepharose and analyzed by western blotting using anti-eIF4E, anti-eIF4G and anti-GFP 
antibodies. See also Tables S1 and S3. 
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Table S1 related to Figure 1. Mutants and constructs used in this study 
Protein Name of the construct Fragments / mutations Binding site / motif 
Dm eIF4E 
(1–248) 
(isoform C) 
P48598-2 
4E Full-length  
II-AA I96A, I112A Lateral surface 
trunc 69–248  
Dm eIF4G 
(1–1666) 
(isoform A) 
O61380 
4G 578–650 Extended eIF4E-binding region 
CUP 
(1–1117) 
Q9VMA3 
C+NC 325–376 eIF4E-binding region  
R1 R329E 
Structurally conserved Arg/Lys 
residues 
R2 R336E 
R1,R2 R329E, R336E 
R1,R2,R3 R329E, R336E, R375E 
Thor 
(1–117) 
Q9XZ56 
Thor Full-length  
C+NC 50–83 eIF4E-binding region  
C* Y54A, M59A Canonical 
NC* V75D, L79D Non-canonical 
C*+NC* Y54A, M59A, V75D, L79D Canonical + non-canonical  
R1 R56E 
Structurally conserved Arg/Lys 
residues 
R2 R63E 
R1,R2 R56E, R63E 
RR-AA R56A, R63A 
R1,R2,R3 R56E, R63E, R81E 
Thor extended 32–83 Extended eIF4E-binding region 
S65D, T70D 32–83; S65D, T70D Phosphomimetic 
C* + S65D, T70D 32–83; Y54A, M59A, S65D, T70D Canonical + phosphomimetic 
peptide 50–83 Wild-type peptide 
phosphopeptide 50–83; pS65, pT70 Phosphorylated peptide 
4E-T 
(1–1010) 
Q8IH18 
C+NC 9–44 eIF4E-binding region  
C* Y10A, L15A Canonical 
NC* F41D, W42D Non-canonical 
C*+NC* Y10A, L15A, F41D, W42D Canonical + non-canonical 
K1 K12E 
Structurally conserved Arg/Lys 
residues 
R2 R19E 
R1,R2 K12E, R19E 
R1,R2,K3 K12E, R19E, K43E 
Hs eIF4E 
(1-217) 
 
4E Full-length  
trunc 36–217  
Hs 4E-BP1 
(1-118) 
C+NC 50–83 eIF4E binding region 
C* Y54A, L59A Canonical 
NC* L75A, V81A Non-canonical 
C*+NC* Y54A, L59A, L75A, V81A Canonical + non-canonical 
Hs 4E-BP3 
(1-100) 
C+NC 36–69 eIF4E binding region 
C* Y40A, L45A Canonical 
NC* L61A, V67A Non-canonical 
C*+NC* Y40A, L45A, L61A, V67A Canonical + non-canonical 
Triple 
chimera Chimeric peptide 
4E-T residues 9–20 
Thor residues 65–72 + Gly 
CUP residues 362–376 
Canonical 
Linker + Gly 
Non-canonical 
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Table S2 related to Figures 1 and  S5. Thermodynamic parameters for the interaction of 
eIF4G and 4E-BP derived peptides with eIF4E (full-length or 69–248) 
Peptide KD (M) ΔH (kcal 
mol-1) 
-TΔS (kcal 
mol-1) 
ΔG (kcal 
mol-1) 
Molar ratio 
Triple chimera 3.5 ± 0.2 · 10-9 -32.8 ± 0.9 21.7 -11.1 0.98 ± 0.05 
eIF4G 578–
650* (eIF4E 
full-length) 
5.7 ± 0.9 · 10-9 -15.0 ± 0.7 4.1 -10.9 0.99 ± 0.01 
Thor (32–83) 
Wild-type 
9.4 ± 1.4 · 10-9 -14.7 ± 0.7 4.0 -10.7 1.02 ± 0.01 
Thor (32–83) 
S65D,T70D 
11.9 ± 1.5 · 10-9 -17.2 ± 1.9 6.6 -10.6 0.99 ± 0.01 
Thor (50–83) 
wild-type  
10.5 ± 2.5 · 10-9 -12.8 ± 0. 7 2.1 -10.7 1.01 ± 0.01 
Thor (50–83) 
pS65, pT70  
16.9 ± 1.3 · 10-9 -15.0 ± 0.9 4.5 -10.5 1.00 ± 0.01 
 
The triple chimera exhibits nanomolar affinity for eIF4E, similar to the individual Dm 4E-BPs (Igreja 
et al., 2014). The high entropic penalty on the interaction is similar to that observed for the CUP 
peptide but different to Thor and 4E-T, in agreement with the observation that the non-canonical 
portion of the chimeric peptide also folds into an α-helix (Figure 6F). Values were determined as 
described in the Supplemental Experimental Procedures. 
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 Table S3 related to Figures 5 and 6. Antibodies used in this study 
Antibody Source Catalog 
Number 
Dilution Monoclonal/ 
Polyclonal 
Anti-V5 Invitrogen 554205 1:5,000 Monoclonal 
Anti-HA-HRP (western 
blot) 
Roche 12 013 819 001 1:5,000 Monoclonal 
Anti-HA 
(Immunoprecipitation) 
Covance MMS-101P 1:1,000 Monoclonal 
Anti- Dm eIF4E  In house  1:3,000 Rabbit polyclonal 
Anti- Hs eIF4E BETHYL 
laboratories 
A301-154A 1:2,000 Rabbit polyclonal 
Anti- Hs eIF4G BETHYL 
laboratories 
A301-776A 1:2,000 Rabbit polyclonal 
Anti-GFP In house  1:2,000 Rabbit polyclonal 
Anti-rabbit-HRP GE Healthcare NA934V 1:10,000 Polyclonal 
Anti-mouse-HRP GE Healthcare RPN4201 1:10,000 Polyclonal 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
DNA constructs 
For expression in E. coli, a DNA fragment coding for Hs eIF4E (residues 36–217) was 
inserted into the NdeI and NheI restriction sites of the pnYC-NpH vector (Diebold et al., 
2011), resulting in expressed polypeptides with an N-terminal His6-tag cleavable by HRV3C 
protease. DNA fragments coding for Hs 4E-BP1 (residues 50–83) or Dm Thor (residues 32–
83) were inserted into the NdeI and NheI restriction sites of the pnEA-NpM vector (Diebold 
et al., 2011), producing an N-terminal fusion with MBP cleavable by HRV3C protease. The 
DNA sequence coding for the B1 domain of immunoglobulin-binding protein G (GB1; Cheng 
et al., 2004) was inserted C-terminal to the 4E-BP fragments by site-directed mutagenesis. A 
synthetic DNA fragment coding for the triple chimera peptide was cloned between the XhoI 
and NheI restriction sites of the pnEA-NvM vector (Diebold et al., 2011). The GB1 tag was 
inserted C-terminally into the pnEA-NvM-triple chimera construct as described above. All the 
constructs and mutations are listed in Table S1.  
 
Coimmunoprecipitation assays in human cells 
For coimmunoprecipitations in human cells, HEK293T cells were grown in 10 cm dishes!and 
transfected using TurboFect transfection reagent (Thermo Scientific) according to the 
manufacturer’s recommendations.! The transfection mixtures contained a total of 10 µg 
plasmid including the SBP-V5 tagged proteins. Two days after transfection, the cells were 
washed with PBS and lysed in NET lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 
0.1% Triton-X 100, 1 mM EDTA] supplemented with 10% glycerol and protease inhibitors 
(Complete Protease Inhibitor Mix, Roche) for 10 min on ice. The cells were centrifuged at 
18,000 g for 15 min at 4°C. The cleared cell lysates were treated with RNase A for 30 min 
and centrifuged again at 18,000 ×g for 15 min. For SBP pulldowns, 50 µl streptavidin-
Sepharose (GE Healthcare) was directly added to the samples and the samples were rotated 
 !
for 1 h at 4°C. For m7GTP pulldowns, 25 µl of γ-Aminophenyl-m7GTP (Jena Biosciences) 
were added to the cell lysates and incubated for 1h at 4°C. The beads were washed three times 
with NET wash buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Triton-X 100, 1 mM 
EDTA] and once with NET buffer without detergent. Bound proteins were eluted with 100 µl 
of SDS-PAGE sample buffer and analyzed by western blotting.  
 
Crystallization 
Crystals of Dm eIF4E (residues 69–248) in complex with Thor (residues 50–83) were 
obtained at 18°C using the hanging-drop vapor diffusion method one day after mixing the 
protein solution (12 mg/ml, 0.2 µl) with reservoir (0.2 µl) containing 18% PEG 3350, 0.2 M 
KNO3 and 0.5% n-octyl-β-D-glucoside. Crystals of Dm eIF4E (residues 68–248) in complex 
with 4E-T (residues 9–44; 10 mg/ml) were obtained at 18°C using the hanging-drop vapor 
diffusion method. Crystals grew in 2–3 days after mixing the protein solution with reservoir 
solution containing 0.1 M Tris-HCl (pH 8.5), 28% PEG 400 and 0.05 M LiSO4. Crystals of 
Dm eIF4E (residues 68–248) in complex with Dm eIF4G (residues 578–650; 14 mg/ml) and 
m7GpppG (New England BioLabs) were obtained in 0.1 M MES (pH 6.5) and 25% PEG 2000 
monomethyl ether (MME) at 20°C using the sitting-drop vapor diffusion method. The crystals 
were improved by microseeding in related conditions [0.1 M MES (pH 6.0) and 20% PEG 
2000 MME at 18°C]. A single crystal of Hs eIF4E (residues 36–217) in complex with Hs 4E-
BP1 (residues 50–83) was obtained in the Morpheus 96-well screen condition E12 (Molecular 
Dimensions) at 20°C using the sitting-drop vapor diffusion method. Crystals of Dm eIF4E 
(residues 69–248) in complex with the triple-chimera (crystal form 1, Table 1) were obtained 
at 20°C in the Morpheus 96-well screen condition E10 (Molecular Dimensions) using the 
sitting-drop vapor diffusion method. A second crystal form of this complex (crystal form 2, 
Table 1) was obtained in 0.1 M MES (pH 6.5) and 22% PEG 300 using the hanging drop 
 !
vapor diffusion method. When necessary, crystals were soaked in mother liquor supplemented 
with 10–15% glycerol for cryoprotection before flash-freezing in liquid nitrogen. 
 
Data collection and structure determination 
Data for all crystals were collected at 100K on a PILATUS 6M detector at the PXII beamline 
of the Swiss Light Source. Diffraction images of the Dm eIF4E–Thor complex were recorded 
at a wavelength of 1.000 Å. Diffraction data extended to a resolution of 1.10 Å. The data were 
processed with XDS and scaled using XSCALE (Kabsch, 2010). The structure was solved by 
molecular replacement using PHASER (McCoy et al., 2007) and one copy of the Dm eIF4E 
(PDB-ID: 4AXG; Kinkelin et al., 2012) as a model. To avoid model bias, the molecular 
replacement solution of the Dm eIF4E molecule was used to rebuild an initial model of eIF4E 
using ARP/wARP autobuilding from the CCP4 package (Langer et al., 2008; Winn et al., 
2011). To complete the structure, iterative cycles of model building and refinement were 
carried out with COOT (Emsley et al., 2010) and PHENIX (Afonine et al., 2012). The Thor 
peptide chain was built manually into the difference density in COOT, and the structure of the 
complex was further refined with PHENIX. In the final model, 98.5% of all residues were in 
the favored regions of the Ramachandran plot and there were no outliers. 
Crystals of the Dm eIF4E–4E-T complex diffracted to 2.15 Å resolution, and data were 
collected at a wavelength of 1.000 Å. Data processing, model building and refinement were 
performed as described above except that the structure of the Dm eIF4E–Thor complex was 
used as a search model. In the final model, 97.0% of all residues were in the favored regions 
of the Ramachandran plot and there were no outliers. 
Diffraction data for crystals of the Dm eIF4E–eIF4G complex were collected at a wavelength 
of 1.038 Å and extended to 2.40 Å resolution. Data processing, model building and 
refinement were performed as described above except that the asymmetric unit contained two 
copies of the search model (Dm eIF4E from the eIF4E-Thor complex). The final model of the 
 !
Dm eIF4E–eIF4G complex contains 98.4% of all residues in the favored regions of the 
Ramachandran plot and no outliers. 
Diffraction data for the crystals of the Hs eIF4E–4E-BP1 complex were collected at a 
wavelength of 1.070 Å and extended to 1.75 Å resolution. Data processing, model building 
and refinement were performed as described above, with the exception that the structure of Hs 
eIF4E (PDB-ID: 4TPW; Papadopoulos et al., 2014) was used as a search model. The final 
model contains 98.6% of all residues in the favored regions of the Ramachandran plot and no 
outliers.  
Diffraction data for the crystals of Dm eIF4E in complex with the triple-chimera peptide 
(crystal form 1) were collected at a wavelength of 1.000 Å and extended to 2.62 Å resolution. 
A second crystal form (crystal form 2) of the Dm eIF4E-triple chimera complex diffracted to 
2.52 Å resolution and data were collected at a wavelength of 0.999 Å. For both crystal forms, 
data processing, model building and refinement was done as described above, with the 
exception that the asymmetric unit contained three copies of the search model (Dm eIF4E 
from the eIF4E–Thor complex) and that the initial model of the complex was re-build using 
the PHENIX AutoBuild wizard (Terwilliger et al., 2008). The final models of the Dm eIF4E-
triple-chimera (crystal forms 1 and 2) contain 98.0% and 99.0% of all residues in the favored 
regions of the Ramachandran plot, respectively, and no outliers. 
The stereochemical properties of all structures were verified with MOLPROBITY (Chen et 
al., 2010), and structural images were prepared with PyMOL (http://www.pymol.org). The 
diffraction data and refinement statistics are summarized in Table 1. 
 
ITC analysis 
The ITC experiments were performed using a VP-ITC microcalorimeter (MicroCal) at 20°C 
as described previously (Igreja et al., 2014). The solution of eIF4E (residues 69–248, 2 µM) 
in the calorimetric cell was titrated with tenfold concentrated solutions of GB1-stabilized 
 !
peptides [eIF4G, Thor fragment, or triple chimera peptide (20 µM)] that were dissolved in the 
same buffer (20 mM Na-phosphate (pH 7.0) and 150 mM NaCl). Alternatively, synthetic 
Thor peptides (wild-type or phosphorylated; EMC microcollections) were used. The titration 
experiments consisted of an initial injection of 2 µL followed by 28 injections of 10 µL at 
intervals of 240 s. The thermodynamic parameters were estimated using a one-site binding 
model (Origin version 7.0); the datapoint of the first injection was removed for the analysis 
(Mizoue and Tellinghuisen, 2004). Errors represent standard errors from three independent 
experiments. 
 
Competition and pulldown assays 
The in vitro pulldown and competition assays were performed as described previously (Igreja 
et al., 2014), with the exception that the purified complexes containing Dm His6-eIF4E 
(residues 69–248) and Dm MBP-eIF4G (residues 578–650; 2 µM) used in the competition 
assays were incubated with Ni-NTA beads for 20 min. The bound complexes were challenged 
with the indicated amounts of competitor for the indicated time points. After incubation the 
beads were pelleted and washed three times with 750 µL buffer containing 50 mM Tris-HCl 
(pH 7.5), 100 mM NaCl, 20 mM Imidazole and 2 mM DTT. Proteins bound to the Ni-NTA 
beads were eluted with the same buffer containing 500 mM Imidazole. The proteins were 
analyzed by 15% SDS-PAGE followed by Coomassie blue staining. For the competition 
assay shown in Figure S4F,G, complexes consisting of MBP-tagged Thor (full length, wild 
type or mutant) and SHN-tagged eIF4E (full length) were obtained by coexpression. The 
proteins were purified from cleared lysates using amylose resin (New England Biolabs) and 
either stored at -80 or immobilized on Ni-NTA beads (4 µM).  The immobilized complexes 
were incubated with 5-fold molar excess of GB1-stabilized eIF4G fragment (residues 578–
650). The proteins were pulled down at the indicated time points, eluted and analyzed as 
described above. 
 !
 
Translation repression assays 
S2 cells were transfected in 6-well plates using Effectene transfection reagent (Qiagen) 
according to the manufacturer’s protocol. The transfection mixtures contained 1 µg of R-Luc 
reporter plasmid, 0.1 µg of a plasmid expressing a control RNA (uncapped, derived from 7SL 
RNA), and increasing amounts of plasmids expressing GFP-tagged triple chimera peptide or 
full-length Thor (wild-type or phosphomimetic mutant, 0.05–0.5 µg). The plasmid expressing 
the GFP control was transfected at the concentration necessary to obtain expression at a level 
similar to the highest expression level of GFP-Thor. In all of the experiments, the cells were 
collected 3 days after transfection. R-Luc activity was measured using the Dual-Luciferase 
reporter assay system (Promega) and northern blotting was performed as described previously 
(Igreja et al., 2014). The R-Luc mRNA levels were determined by northern blotting and were 
normalized to those of the control RNA. The normalized R-Luc mRNA levels were then used 
to normalize the R-Luc activity to obtain translation efficiencies. 
  
 !
 
SUPPLEMENTAL REFERENCES  
Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., Headd, J.J., Moriarty, N.W., 
Mustyakimov, M., Terwilliger, T.C., Urzhumtsev, A., Zwart, P.H., and Adams, P.D. (2012). 
Towards automated crystallographic structure refinement with phenix.refine. Acta 
Crystallogr. D. Biol. Crystallogr. 68, 352-367. 
Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., 
Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom structure 
validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12-
21. 
Cheng, Y., and Patel, D.J. (2004). An efficient system for small protein expression and 
refolding. Biochem. Biophys. Res. Commun. 317, 401-405. 
Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo: A Sequence 
Logo Generator. Genome Res. 14, 1188-1190. 
Diebold, M.L., Fribourg, S., Koch, M., Metzger, T., and Romier, C. (2011). Deciphering 
correct strategies for multiprotein complex assembly by co-expression: application to 
complexes as large as the histone octamer. J. Struct. Biol. 175, 178-188. 
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of 
Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486-501. 
Kabsch, W. (2010). Xds. Acta Crystallogr. D. Biol. Crystallogr. 66, 125-132. 
Langer, G., Cohen, S.X., Lamzin, V.S., and Perrakis, A. (2008). Automated macromolecular 
model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 3, 1171-
1179. 
 !
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, 
R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674. 
Mizoue, L.S., and Tellinghuisen, J. (2004). The role of backlash in the "first injection 
anomaly" in isothermal titration calorimetry. Anal. Biochem. 326, 125-127. 
Terwilliger, T.C., Grosse-Kunstleve, R.W., Afonine, P.V., Moriarty, N.W., Zwart, P.H., 
Hung, L.-W., Read, R.J., and Adams, P.D. (2008). Iterative model building, structure 
refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. 
D64, 61–69. 
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, 
R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011). Overview of the CCP4 suite and 
current developments. Acta Crystallogr. D. Biol. Crystallogr. 67, 235-242. 
Mextli proteins use both canonical
bipartite and novel tripartite binding
modes to form eIF4E complexes
that display differential sensitivity
to 4E-BP regulation
Daniel Peter, Ramona Weber, Carolin Köne, Min-Yi Chung, Linda Ebertsch, Vincent Truffault,
Oliver Weichenrieder, Cátia Igreja, and Elisa Izaurralde
Department of Biochemistry, Max Planck Institute for Developmental Biology, 72076 Tübingen, Germany
The eIF4E-binding proteins (4E-BPs) are a diverse class of translation regulators that share a canonical eIF4E-binding
motif (4E-BM) with eIF4G. Consequently, they compete with eIF4G for binding to eIF4E, thereby inhibiting
translation initiation.Mextli (Mxt) is an unusual 4E-BP that promotes translation by also interactingwith eIF3. Here
we present the crystal structures of the eIF4E-binding regions of the Drosophila melanogaster (Dm) and Caeno-
rhabditis elegans (Ce) Mxt proteins in complex with eIF4E in the cap-bound and cap-free states. The structures
reveal unexpected evolutionary plasticity in the eIF4E-binding mode, with a classical bipartite interface for CeMxt
and a novel tripartite interface forDmMxt. Both interfaces comprise a canonical helix and a noncanonical helix that
engage the dorsal and lateral surfaces of eIF4E, respectively. Remarkably, DmMxt contains a C-terminal auxiliary
helix that lies anti-parallel to the canonical helix on the eIF4E dorsal surface. In contrast to the eIF4G and CeMxt
complexes, theDm eIF4E–Mxt complexes are resistant to competition by bipartite 4E-BPs, suggesting thatDmMxt
can bind eIF4Ewhen eIF4G binding is inhibited. Our results uncovered unexpected diversity in the bindingmodes of
4E-BPs, resulting in eIF4E complexes that display differential sensitivity to 4E-BP regulation.
[Keywords: CUP; eIF4F; eIF4G; 4E-BP; Mextli; translational regulation]
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The inhibition of cap-dependent translation initiation is a
widespread and reversible mechanism for regulating gene
expression in eukaryotes (Kong and Lasko 2012). This type
of regulation ismediated by a diverse family of eIF4E-bind-
ing proteins (4E-BPs), which play essential roles in diverse
biological processes, including cell proliferation, develop-
ment, and neuronal plasticity (Banko et al. 2005; Dowling
et al. 2010; Kong and Lasko 2012; Gkogkas et al. 2013).
Canonical cap-dependent translation initiation requires
the assembly of the ternary eukaryotic initiation factor
eIF4F, which consists of the cap-binding protein eIF4E,
the adaptor protein eIF4G, and the RNA helicase eIF4A
(Jackson et al. 2010). The eIF4G protein serves as a scaffold
to mediate multiple protein–protein interactions that are
essential for cap-dependent translation initiation. Specifi-
cally, eIF4G interacts with eIF4E bound to the mRNA 5′
cap structure and recruits the 43S preinitiation complex
(PIC) through interactions with eIF3, thereby coupling
translation initiation with the recognition of the mRNA
cap structure (Jackson et al. 2010).
The interaction of eIF4G with eIF4E is mediated by a
conserved motif, termed the canonical eIF4E-binding mo-
tif (4E-BM) of sequence YX4LΦ (where Y is Tyr, X is any
amino acid, L is Leu, and Φ is a hydrophobic residue)
(Mader et al. 1995; Marcotrigiano et al. 1999). This inter-
action is competitively inhibited by the 4E-BPs, which,
like eIF4G, contain a canonical 4E-BM (Mader et al. 1995;
Marcotrigiano et al. 1999). The canonical 4E-BMs found in
eIF4G and 4E-BPs adopt similar α-helical conformations
and compete for binding to a conserved patch of hydropho-
bic residues on the dorsal surface of eIF4E that is opposite
the cap-binding pocket (Mader et al. 1995; Matsuo et al.
1997; Marcotrigiano et al. 1999; Gross et al. 2003).
Corresponding authors: elisa.izaurralde@tuebingen.mpg.de, catia.igreja@
tuebingen.mpg.de
Article published online ahead of print. Article and publication date are on-
line at http://www.genesdev.org/cgi/doi/10.1101/gad.269068.115. Freely
available online through the Genes & Development Open Access option.
© 2015 Peter et al. This article, published in Genes & Development, is
available under a Creative Commons License (Attribution-NonCommer-
cial 4.0 International), as described at http://creativecommons.org/
licenses/by-nc/4.0/.
GENES & DEVELOPMENT 29:1835–1849 Published by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/15; www.genesdev.org 1835
 Cold Spring Harbor Laboratory Press on June 28, 2017 - Published by genesdev.cshlp.orgDownloaded from 
C-terminal to the canonical motif, 4E-BPs contain non-
canonical 4E-BMs that are connected by variable linkers.
Structural studies have revealed that, despite a lack of se-
quence similarity in their linkers and noncanonical mo-
tifs, all 4E-BPs bind to a conserved lateral surface of eIF4E
(Mizuno et al. 2008; Gosselin et al. 2011; Kinkelin et al.
2012; Paku et al. 2012; Lukhele et al. 2013; Igreja et al.
2014; Peter et al. 2015). Through this interaction, the non-
canonical motifs increase the affinity of 4E-BPs for eIF4E
by three orders of magnitude (Paku et al. 2012; Lukhele
et al. 2013; Igreja et al. 2014; Peter et al. 2015) and are nec-
essary for 4E-BPs to be able to compete with eIF4G and re-
press translation (Igreja et al. 2014; Peter et al. 2015).
Mextli (Mxt) is an invertebrate-specific 4E-BP involved
in germline stem cell maintenance and early embryogen-
esis in Drosophila melanogaster (Hernández et al. 2013).
Like all 4E-BPs,Mxt contains a canonical 4E-BMand com-
petes with eIF4G for binding to eIF4E (Fig. 1A; Hernández
et al. 2013). However, in contrast to other 4E-BPs,Mxtwas
reported to promote cap-dependent translation initiation
through interactions with eIF3 (Hernández et al. 2013).
Mxt is currently the only known 4E-BP besides eIF4G
that has been reported to stimulate translation. Therefore,
understanding its eIF4E-binding mode will shed light
on alternative mechanisms for initiating cap-dependent
translation. To understand the binding mode of Mxt to
eIF4E, we solved the crystal structures of the eIF4E-bind-
ing regions of D. melanogaster (Dm) and Caenorhabditis
elegans (Ce)Mxt bound to their respective eIF4Es in either
the presence or absence of an m7GpppG cap analog. The
canonical and noncanonical motifs of Mxt adopt an α-he-
lical conformation upon binding to the dorsal and lateral
surfaces of eIF4E, respectively, forming a bipartite binding
interface. This type of interface has been observed for
other eIF4E–4E-BP complexes, including eIF4E complexes
with human 4E-BP1 and Dm CUP, Thor, and 4E-T
Figure 1. Mxt proteins associate with eIF4E
through bipartite or tripartite binding sequenc-
es. (A) Mxt contains a MIF4G-like domain, an
hnRNP K-homology (KH) domain, and C-ter-
minal 4E-BMs. The eIF4E-binding region of
D. melanogaster (Dm) Mxt contains three 4E-
BMs (canonical [C], noncanonical [NC], and
auxiliary [A] helix [α3]) connected by a nonca-
nonical (nc-L) and auxiliary (a-L) linkers. The
eIF4E-binding region of Caenorhabditis ele-
gans (Ce) Mxt is bipartite and composed of ca-
nonical and noncanonical 4E-BMs connected
by a noncanonical linker. The amino acid posi-
tions at the domain/motif boundaries are indi-
cated below the protein outlines and are based
on the structures presented in the present
study. (B) Interaction of HA-tagged Dm eIF4E
(either wild type or mutant) with GFP-tagged
full-length Dm Mxt. The inputs (3%) and im-
munoprecipitates (30% for Mxt and 20% for
eIF4E) were analyzed by Western blotting us-
ing anti-HA and anti-GFP antibodies. (C ) In-
teraction of endogenous Dm eIF4E with the
tripartite (C +NC+ α3) and bipartite (C +NC)
Dm Mxt peptides N-terminally fused to GFP.
The proteins were pulled down with m7GTP-
Sepharose beads. The inputs (5% for Mxt frag-
ments and 1% for eIF4E) and immunoprecipi-
tates (20% for Mxt and 10% for eIF4E) were
analyzed by Western blotting. (D) Ni-NTA
pull-down assay showing the association of
hexahistidine [His6]-tagged Dm eIF4E (full-
length; either wild type or the II-AA mutant)
with maltose-binding protein (MBP)-tagged
Dm Mxt fragments C-terminally fused to
GB1. The inputs (10%) and bound fractions
(25%) were analyzed by SDS-PAGE followed
by Coomassie blue staining. SH-NusA served
as negative control. (E) Ni-NTA pull-down as-
say showing the association of His6-tagged Ce
eIF4E (1–215; wild type or VI-AA mutant)
with the MBP-tagged Ce Mxt eIF4E-binding
region (471–507; either wild type or carrying mutations in the canonical motif [C∗]). Samples were analyzed as described in D. The
size markers (in kilodaltons) are shown at the right of each panel.
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(Kinkelin et al. 2012; Lukhele et al. 2013; Peter et al. 2015).
However, in Dm Mxt, the bipartite binding surface ex-
tends beyond the noncanonicalmotif and forms a third in-
terface through an auxiliary linker and helix that contact
eIF4E in a novel binding mode. This novel tripartite bind-
ing mode confers resistance to competition by other 4E-
BPs, potentially providing amechanism to sustain cap-de-
pendent translation under conditions in which the inter-
action of eIF4G with eIF4E is inhibited. More generally,
our study also identifies diverse binding modes of 4E-
BPs that are valuable for the rational design of new trans-
lation inhibitors for the treatment of malignancies—such
as cancer, autism spectrum disorders (ASDs), and fragile X
syndrome—that are associated with the up-regulation of
eIF4E activity and protein synthesis (Banko et al. 2005;
Dowling et al. 2010; Gkogkas et al. 2013; Martineau
et al. 2013).
Results
Mxt binds to the dorsal and lateral surfaces of eIF4E
The 4E-BPs bind to the dorsal and lateral surfaces of eIF4E
using canonical and noncanonical 4E-BMs, respectively
(Kinkelin et al. 2012; Paku et al. 2012; Lukhele et al.
2013; Igreja et al. 2014; Peter et al. 2015). To determine
whether Dm Mxt contains a noncanonical motif that
binds to the lateral surface of eIF4E, we used coimmuno-
precipitation assays in Dm Schneider 2 (S2) cells and
examined the effects of Ile96Ala and Ile112Ala substitu-
tions (II-AA) in the lateral hydrophobic pocket of eIF4E.
The II-AA mutations abolished the interaction of Dm
eIF4EwithMxt and CUP but not with eIF4G (Fig. 1B; Sup-
plemental Fig. S1A,B), as has been observed previously for
other 4E-BPs (Igreja et al. 2014). In contrast, a Trp106Ala
substitution (W106A) on the dorsal binding surface of
eIF4E abolishes or strongly reduces binding to Mxt,
CUP, and eIF4G, as would be expected for proteins con-
taining canonical 4E-BMs (Fig. 1B, lane 7; Supplemental
Fig. S1A, lane 7; Igreja et al. 2014; Peter et al. 2015). These
results indicate that, in contrast to eIF4G but similar to
other 4E-BPs,DmMxt requires both the dorsal and lateral
surfaces to efficiently bind to eIF4E in cell lysates that
contain eIF4G (or other 4E-BPs) and may compete with
Mxt for binding to eIF4E.
DmMxt contains a noncanonical 4E-BM
and auxiliary binding sequences
The immunoprecipitation assay shown in Figure 1B indi-
cates thatDmMxt contains a noncanonical motif that in-
teracts with the lateral binding surface of eIF4E. Although
the noncanonical motifs are not conserved among differ-
ent 4E-BPs, they contain common features: (1) They are lo-
cated ∼15–30 residues downstream from the canonical
motifs, (2) they contain hydrophobic residues, and (3)
in the case of CUP, they exhibit helical propensity. We
inspected the Dm Mxt sequence for motifs that ful-
filled these criteria and identified a motif downstream
from the canonical motif that exhibited helical propen-
sity and contained hydrophobic residues. This motif was
termed a noncanonicalmotif based on the structural stud-
ies presented below (NC, residues 602–608) (Fig. 1A; Sup-
plemental Fig. S2A,B).We also identified a second patch of
residues with helical propensity (residues 627–636) that
was 38 residues downstream from the canonical motif,
which was termed an auxiliary helix (α3) (Fig. 1A; Supple-
mental Fig. S2A,B). The residues connecting the nonca-
nonical motif and auxiliary helix are the auxiliary linker
(Fig. 1A).
To determinewhether the auxiliary helix contributes to
eIF4E binding, we expressed C-terminal Mxt fragments
with or without this auxiliary helix (fragments C +NC
and C +NC + α3, termed bipartite and tripartite, respec-
tively) (Supplemental Table S1) and tested their binding
to endogenous eIF4E in pull-down assays using m7GTP-
sepharose beads. The two Dm Mxt fragments associated
with cap-bound eIF4E, but the tripartite fragment ex-
hibited stronger binding (relative to the input) than the
bipartite fragment (Fig. 1C, lanes 5,6 vs. lanes 2,3, respec-
tively), suggesting that the auxiliary helix contributes to
eIF4E binding.
To further confirm the contribution of Mxt auxiliary
sequences to the interaction with eIF4E, we performed
in vitro pull-down assays using bacterially expressed ver-
sions of the Mxt fragments described above. In contrast
to the coimmunoprecipitation assays in cell lysates, the
pull-down assays tested the interaction of Mxt with
eIF4E in the absence of other 4E-BPs that might compete
for binding to eIF4E. Recombinant full-length Dm eIF4E
(expressed with a hexahistidine [His6] tag) pulled down
similar amounts of the two Mxt fragments (Fig. 1D, lanes
7,10). The binding of the bipartiteMxt fragment was abol-
ished by the II-AA mutations on the lateral surface of
eIF4E (Fig. 1D, lane 8). In contrast, the tripartite Mxt frag-
ment retained some binding (Fig. 1D, lane 11), suggesting
that the auxiliary sequences interact with a different sur-
face of eIF4E and can partially compensate for the negative
effects of the II-AAmutation.Mxt fragments did not inter-
act with His6-NusA as a negative control (Fig. 1D, lanes
6,9). Thus,DmMxt contains a canonical and a noncanon-
ical 4E-BM as well as an additional downstream auxiliary
sequence that contributes to the interaction with eIF4E.
The auxiliary sequences increase the affinity
of DmMxt for eIF4E
To test the affinities of the bipartite and tripartite Dm
Mxt fragments for eIF4E, we performed isothermal titra-
tion calorimetry (ITC) experiments. The bipartite Mxt
fragment has a binding affinity for eIF4E comparable
with the affinities observed for other 4E-BPs (Paku et al.
2012; Lukhele et al. 2013; Igreja et al. 2014; Peter et al.
2015), with dissociation constants (KDs) in the nanomolar
range (5× 10−9 ± 3 × 10−9 M) (Supplemental Table S2; Sup-
plemental Fig. S3A). Including the auxiliary sequences in
the tripartite fragment resulted in a 10-fold increase in af-
finity (0.5 × 10−9 ± 0.09 × 10−9 M) (Supplemental Table S2;
Supplemental Fig. S3B). Notably, the binding of the tripar-
tite Mxt fragment to eIF4E was enthalpically driven, with
Structure of Mextli bound to eIF4E
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a high entropic penalty (Supplemental Table S2).This pen-
alty canbeexplainedbyagreater flexibility in theunbound
state compared with the bound state, whereas favorable
enthalpy indicates an extensive interaction network. Nu-
clear magnetic resonance (NMR) analysis together with
the crystal structures presented below are consistent with
these results and indicate that theMxt peptide is predom-
inantly unfolded in solution but folds into three α helices
upon binding to eIF4E (Fig. 2; Supplemental Fig. S3D,E).
The affinity of the tripartite Mxt peptide for the eIF4E
II-AA mutant was reduced by three orders of magnitude
(0.3 × 10−6 ± 0.1 × 10−6 M) (Supplemental Table S2; Sup-
plemental Fig. S3C). This reduction supports the results
shown in Figure 1D and provides further evidence for
the contribution of the lateral surface of eIF4E to complex
formation.
Dm and CeMxt evolved different binding modes to
interact with eIF4E
Adefining feature of theMxt protein family is anN-termi-
nal MIF4G-like domain followed by a K-homology (KH)
domain, both of which are highly conserved (Fig. 1A;Mar-
cotrigiano et al. 2001; Hernández et al. 2013). The se-
quences C-terminal to the KH domain are variable in
length and are less conserved except for the C terminus,
which contains the canonical and noncanonical motifs
and the connecting linker, which are also conserved
amongMxt sequences from different species (Supplemen-
tal Fig. S2A,B).
In contrast, the auxiliary linker and helix in Dm Mxt
are not conserved. Based on the auxiliary sequences, we
define three Mxt families. The first family includes Dm
Figure 2. Structures ofDm andCeMxt proteins bound to eIF4E. (A) Overview of the structure of the 4E-binding region ofDmMxt bound
to eIF4E in two orientations. The region of theMxt peptidewith structural similarity to other 4E-BPs is colored in teal. The auxiliary link-
er and helix are colored inmagenta. Selected secondary structure elements are labeled in black for eIF4E or blue andmagenta forMxt. The
boundm7GpppG cap analog is shown in sticks. (B) Schematic representation of Mxt bound to eIF4E, highlighting key structural features.
The asterisk represents the mRNA cap structure. (C ) Overview of the structure of the 4E-binding region ofCeMxt bound to eIF4E in two
orientations. The Mxt peptide is colored in orange. Selected secondary structure elements are labeled in black for eIF4E and dark red for
Mxt. The boundm7GTP cap analog is shown in sticks. (D) Schematic representation ofCeMxt bound to eIF4E. (E) Structural overlay of the
Dm and Ce eIF4E–Mxt complexes. For clarity, the eIF4E molecule from the Ce eIF4E–Mxt complex has been removed. Common struc-
tural features are labeled in purple.
Peter et al.
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Mxt and orthologs from dipteran and nondipteran insects;
the auxiliary linker and helix are conserved, suggesting
that these proteins interact with eIF4E using amode of in-
teraction similar to that of Dm Mxt (Supplemental Fig.
S2A,B, family I). The second family includesMxt proteins
from nondipteran insects and arthropods, and their auxil-
iary sequences aremore divergent; the length of the auxil-
iary linker varies, and a region with helical propensity is
present downstream from the noncanonical motif (Sup-
plemental Fig. S2B, family II). However, it is unclear
whether these divergent auxiliary sequences contribute
to eIF4E binding. Finally, the third family contains Mxt
proteins from some arthropods and nematodes that lack
the auxiliary linker and helix, as a stop codon is located
immediately downstream from the noncanonical motif
(Fig. 1A; Supplemental Fig. S2B, family III). These proteins
are predicted to interact with eIF4E through the canonical
and noncanonical motifs as observed for bipartite 4E-BPs,
with no contribution from additional sequences.
To confirm these predictions, we tested the interaction
ofCeMxt (fragment 471–507) withCe eIF4E.Ce eIF4E in-
teracted with theCeMxt peptide (Fig. 1E, lane 7). This in-
teraction was abolished by mutations in the canonical
motif ofCeMxt aswell asmutations on the lateral surface
ofCe eIF4E (VI-AAmutant, Supplemental Table S1), indi-
cating that Ce Mxt binds eIF4E using the canonical and
noncanonical motifs.
The structure of Dm and CeMxt bound to eIF4E
To gain insight into the bindingmodes ofDm andCeMxt
to eIF4E, we crystallized the eIF4E-binding region of the
proteins in complex with the corresponding eIF4Es and
determined the structure of the complexes in the absence
or presence of a cap analog (Table 1; Fig. 2A–D; Supple-
mental Fig. S4). For each organism, the structures in the
cap-free and cap-bound states are very similar. They
superpose with root mean square deviations (RMSDs) of
0.38 Å over 233 Cα atoms and 207 Cα atoms for the Dm
and Ce structures, respectively (Supplemental Fig. S4).
Similarly, no major conformational changes were ob-
served in the eIF4E structures upon Mxt binding, as re-
ported previously for various 4E-BPs (Gross et al. 2003;
Volpon et al. 2006; Mizuno et al. 2008; Kinkelin et al.
2012; Paku et al. 2012; Peter et al. 2015).
The most surprising feature was observed in the Dm
Mxt complex,where the auxiliary linker and helix contact
eIF4E using an unprecedented binding mode (Fig. 2A,B).
Specifically, the Dm Mxt peptide adopts a U-shaped
arrangement on the surface of eIF4E, folding into three
α helices—a canonical helix (α1), a noncanonical helix
(α2), and an auxiliary helix (α3)—connected by linker se-
quences. The linker sequences consist of a noncanonical
linker and auxiliary linker (Fig. 2A,B). This conformation
was observed in the two structures of the Dm eIF4E–Mxt
complex despite different crystal packing (Supplemental
Fig. S4), indicating that the observed arrangement reflects
a physiologically relevant interaction.
TheCeMxt peptide folds into a canonical (α1) helix and
a noncanonical (α2) helix and terminates after seven addi-
tional amino acids that form a terminal turn (Fig. 2C,D).
Overall, the canonical and noncanonical helices and the
connecting noncanonical linker of Dm and Ce Mxt bind
eIF4E using a bipartite binding mode similar to that
described for other 4E-BPs (Fig. 2E; Supplemental Fig.
S5; Peter et al. 2015).
The presence of Arg/Lys residues at positions 2 and 9
of the canonical motif distinguishes bipartite from
tripartite binding modes
The canonical motifs ofDm andCeMxt fold into an α he-
lix that is held in position by interactions analogous to
those previously reported for the canonical motifs of
eIF4G and 4E-BPs in complex with eIF4E (Fig. 3A,B; Gross
et al. 2003; Mizuno et al. 2008; Umenaga et al. 2011; Kin-
kelin et al. 2012; Paku et al. 2012; Peter et al. 2015). The
most conserved interactions aremediated by residues cor-
responding to LФ in the YX4LФ consensus sequence (Dm
Mxt L586 and L587 and Ce Mxt L478 and M479). These
residues form similar hydrophobic contacts with con-
served Val and Trp residues in helix α1 of eIF4E (Dm
V102 andW106 andCeV64 andW68) (Fig. 3A,B). Further-
more, the hydroxyl group of the Tyr side chain in the ca-
nonical motifs (Dm Y581 and Ce Y473) contacts the
backbone of the conserved H-P-L motif at the N terminus
of strand β1 of eIF4E, as was observed in previous struc-
tures (Fig. 3A,B; Supplemental Fig. S1B).
The most obvious difference between the canonical
motifs of Ce and Dm Mxt is that the Ce motif contains
Arg residues at positions 2 and 9 (Fig. 3C,D). These Arg
(or Lys) residues are also found in the canonical motifs
of other 4E-BPs and eIF4G and contribute to the interac-
tion with eIF4E, likely by shielding hydrophobic surface
patches of eIF4E from solvent exposure (Kinkelin et al.
2012; Peter et al. 2015). In the canonical motif of Dm
Mxt, the Arg residues are replaced by Ile583 and Ser590
(Fig. 3A,C,D). The substitution of long, bulky side chains
at both positions by residues with shorter side chains is
required to accommodate the auxiliary helix (α3), which
would otherwise clash with the Arg/Lys residues in
the canonical helix (see below). Notably, the canonical
motifs of Mxt orthologs from families I and II, which
contain auxiliary sequences, lack Arg/Lys residues at
positions 2 and 9 (Supplemental Fig. S2A,B). This observa-
tion suggests that the substitutions of these residues
coevolved with the acquisition of the tripartite binding
mode.
The noncanonical linker of CeMxt does not adopt
a defined conformation
Most of the known structures of 4E-BPs contain an elbow
loop immediately after the canonical helix that bends
the peptide backbone by ∼90°, directing the noncanonical
linker downward to engage the lateral surface of eIF4E
(Peter et al. 2015). Despite the lack of sequence conserva-
tion, the elbow loops exhibit common features that
are also observed in Dm Mxt but are absent in Ce Mxt
(Fig. 4A–C). Specifically, the Dm Mxt elbow loop shows
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remarkable similarity to the Thor elbow loop (Fig. 4A,B;
Supplemental Fig. S5A,B). The Mxt elbow loop starts
with residue S590 (structurally equivalent to R63Thor)
and contains a helical half-turn that begins with a Pro res-
idue located at the tip of the elbow (P593Mxt and P66Thor).
The elbow loops of DmMxt and Thor end with similarly
arranged Ser residues (S595Mxt and S68Thor). The side
chains of these Ser residues contact the carbonyl oxygens
of the preceding residues (Y589Mxt and L62Thor) and fix the
backbone, which is further stabilized by internal interac-
tions within the helical half-turn (e.g., between S592Mxt
and the amide group of H594Mxt) (Fig. 4A,B; Supplemental
Fig. S5A,B). TheDmMxt elbow loop is tethered to the lat-
eral surface of eIF4E through interactions of S595Mxt and
L598Mxt with the side chains of eIF4E residues S107,
N110, and H111 (Fig. 4A).
One important difference between the Dm and CeMxt
structures is that the noncanonical linker of Ce Mxt
adopts a slightly different conformation in each of the
three molecules found in the crystal that lacks the cap an-
alog (Fig. 4C; Supplemental Fig. S4F). In the complex with
the cap analog, the linker binds in yet another mode and
is partially disordered, indicating that this linker is proba-
bly flexible and does not adopt a fixed conformation in sol-
ution (Fig. 4C).
The Mxt noncanonical motifs adopt an α-helical
conformation
The noncanonical motif of Ce andDmMxt engages a lat-
eral pocket of eIF4E that is lined by hydrophobic residues
(Dm Y80, I96, and I112 and Ce Y42, V58, and I74), provid-
ing an additional binding site (Fig. 4D–H). A striking fea-
ture of Mxt proteins is the formation of an α helix (α2) at
this surface, which has been previously observed only in
the complex of CUP bound to eIF4E (Supplemental Fig.
S5C; Kinkelin et al. 2012). Despite a similar α-helical ar-
rangement, the noncanonical helices of Dm and Ce Mxt
are tilted by ∼21°–23° relative to the CUP helix (Supple-
mental Fig. S5D–F).
Table 1. Data collection and refinement statistics
Dm eIF4E–Mxt complex
(cap-bound)
Dm eIF4E–Mxt complex
(cap-free)
Ce eIF4E–Mxt complex
(cap-bound)
Ce eIF4E–Mxt complex
(cap-free)
Space group P212121 P21 P41212 P21212
Unit cell
Dimensions
a, b, c 44.9 Å, 56.4 Å, 99.1 Å 65.9 Å, 82.0 Å, 84.7 Å 71.0 Å, 71.0 Å, 85.3 Å 91.2 Å, 158 Å, 55.2 Å
Angles
α, β, γ 90°, 90°, 90° 90°, 90.1°, 90° 90°, 90°, 90° 90°, 90°, 90°
Data collection
Wavelength 1.000 Å 1.000 Å 1.000 Å 1.000 Å
Resolution 48.6–2.16 Å
(2.22–2.16 Å)
44.0–2.13 Å
(2.19–2.13 Å)
43.3–1.66 Å
(1.70–1.66 Å)
47.2–1.95 Å
(2.0–1.95 Å)
Rsym 0.125 (0.559) 0.058 (0.441) 0.060 (1.27) 0.117 (1.17)
Mean I/σI 9.0 (2.2) 13.0 (2.0) 24.5 (2.0) 11.8 (2.0)
Completeness 99.3% (99.3%) 98.2% (90.5%) 100% (100%) 100% (100%)
Multiplicity 6.3 (4.5) 4.5 (3.3) 13.1 (12.0) 8.3 (8.6)
Refinement
Resolution 40.9–2.16 Å 44.0–2.13 Å 43.3–1.66 Å 45.5–1.95 Å
Number of
reflections
13,971 49,675 26,447 58,874
Rwork/Rfree 0.195/0.238 0.192/0.232 0.173/0.194 0.172/0.209
Number of atoms 2046 7937 1934 5918
Protein 1912 7790 1759 5464
Ligand/ion 53 — 38 20
Water 81 147 137 434
B-factors 41.7 Å2 65.4 Å2 31.6 Å2 34.1 Å2
Protein 41.5 Å2 65.7 Å2 30.8 Å2 33.7 Å2
Ligand/ion 52.6 Å2 — 46.4 Å2 43.6 Å2
Water 39.7 Å2 48.6 Å2 38.0 Å2 37.5 Å2
Ramachandran plot
Favored 99.1% 97.5% 99.0% 97.5%
Disallowed 0% 0% 0% 0%
RMSD
Bond lengths 0.002 Å 0.01 Å 0.005 Å 0.008 Å
Bond angles 0.603° 1.05° 0.95° 1.05°
Values in parentheses are for the highest-resolution shell.
Ligands: m7GpppG (for the cap analog) and one Cl− ion in the Dm eIF4E–Mxt complex (cap-bound); m7GTP (for the cap analog), four
Zn2+ ions, and one Cl− ion in the Ce eIF4E–Mxt complex (cap-bound); and two Mg2+ ions and three glycerol molecules in the
Ce eIF4E–Mxt complex (cap-free).
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The noncanonical helix of Dm Mxt is shorter and its
contribution to the interaction with the lateral pocket of
eIF4E is less pronounced than in Ce Mxt and Dm CUP.
The major hydrophobic contacts of DmMxt with the lat-
eral pocket of eIF4E are mediated by the side chain of
M605 in the noncanonical helix and I612 in the linker fol-
lowing the helix (Fig. 4D). TheCeMxt noncanonical helix
contains an additional helical turn and uses M493 to es-
tablish further contacts with the lateral surface of eIF4E
(Fig. 4E,F).
In the turn following the noncanonical helices, the
main chain conformation of Dm and CeMxt aligns with
CUP; all three proteins have an Ile residue (I612DmMxt,
I504CeMxt, and I373CUP) at a similar position that stacks
on the conserved eIF4E Tyr residue (Dm Y80 and Ce
Y42) of the hydrophobic pocket (Fig. 4D,E; Kinkelin
et al. 2012). TheMxt peptide backbone is further tethered
to eIF4E through interactions between the carbonyl oxy-
gen of Dm I612Mxt and the nitrogen of Dm K1134E (Ce
I504Mxt to Ce Q754E) and between the amide nitrogen of
Dm R614Mxt and the carbonyl oxygen of Dm H111Mxt
(Ce I506Mxt to Ce H734E) (Fig. 4G,H).
The auxiliary linker of Dm Mxt leads back toward the
eIF4E dorsal surface
The distinguishing features of the Dm eIF4E–Mxt struc-
ture are the auxiliary linker and α helix (α3), which togeth-
er further anchorMxt to the eIF4E surface. The side chains
ofN1104E andH1114E are central to theU-shaped arrange-
ment of theDmMxt peptide. These residues contact both
of the linker regions of Mxt (Fig. 5A–C). Specifically, the
nitrogens of the H1114E imidazole ring are in hydrogen-
bonding distance to the main chain carbonyl oxygens of
W596Mxt (in the noncanonical linker) and N615Mxt (in
the auxiliary linker), stabilizing the linkers above the lat-
eral surface of eIF4E (Fig. 5C). Furthermore, the side chain
of H1114E forms van der Waals contacts with the side
chains of L598Mxt and W602Mxt (Fig. 5A,C).
Near the dorsal surface of eIF4E, the side chain of
N1104E coordinates the backbone of the noncanonical
linker and auxiliary linker in a similar fashion. Its amide
group contacts the carbonyl oxygen of S595Mxt in the
elbow loop and the backbone nitrogen of F625Mxt near
the auxiliary helix (Fig. 5A,B). Additional stabilization of
both of the linkers is probably achieved by van der Waals
contacts between W596Mxt (noncanonical linker) and
R624Mxt (auxiliary linker) (Fig. 5A,B).
The auxiliary helix of Dm Mxt
The auxiliary α helix α3 of DmMxt is stabilized by inter-
actions with eIF4E and runs anti-parallel to the canonical
α helix (Fig. 5D,E). The aromatic ring of F625Mxt (immedi-
ately before α helix α3) covers a hydrophobic patch on
the eIF4E surface that is formed by W106, L163, and
Y109 (Fig. 5D). Residue Y630Mxt locks the center of the
auxiliary α helix to this patch and forms a hydrogen
bond with D1644E (Fig. 5D). In addition, Y630Mxt contacts
L587Mxt on the canonical α helix α1, extending a hydro-
phobic interfacebetweenthe twohelices that also includes
L631Mxt and forms a small hydrophobic core together
with the patch on the eIF4E surface (Fig. 5D).
Figure 3. The canonical motifs ofDm andCeMxt. (A) Close-up
view of the canonical helix ofDmMxt bound to the dorsal surface
of eIF4E in two orientations. Selected interface residues are
shown as gray sticks for eIF4E and teal sticks for DmMxt. Resi-
dues at positions 2 and 9 of the canonical motif are underlined.
(B) Close-up view of the canonical helix of CeMxt bound to the
dorsal surface of eIF4E in two orientations. Selected interface res-
idues are shown as gray sticks for Ce eIF4E and orange sticks for
Ce Mxt. The Arg residues at positions 2 and 9 of the canonical
motif are underlined. (C ) Structural overlay of the Dm and Ce
Mxt canonical helices. Selected interface residues of Mxt are
shown as colored sticks. The Arg residues flanking the canonical
helix of Ce Mxt and the corresponding residues in Dm Mxt are
underlined. For clarity, the molecule of Ce eIF4E from the super-
position has been removed. (D) The extended consensus sequence
for the canonical 4E-BM (Peter et al. 2015) and the corresponding
sequences for the indicated 4E-BPs and eIF4G.
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The interactions formed by theDmMxt auxiliary helix
are partially equivalent to the interactions established by
the long aliphatic Arg side chains in the canonical α helix
of CeMxt (Fig. 5E). For example, the interaction between
DmMxt residue Y630 and Dm eIF4E D164 is equivalent
to the interaction between Ce Mxt R475 and Ce eIF4E
E130. Furthermore, Dm Mxt F625 shields the surface of
eIF4E covered by CeMxt R482 (Fig. 5E).
Consequently, although the tripartite eIF4E-binding
sequence of Dm Mxt is longer than the bipartite binding
sequence of CeMxt and other 4E-BPs, the buried surface
area on eIF4E is not significantly increased in the Dm
eIF4E–Mxt complex (1498 Å2) compared with the Ce
eIF4E–Mxt complex (1370 Å2) or other eIF4E–4E-BP com-
plexes reported previously (Supplemental Table S3; Sup-
plemental Fig. S6; Peter et al. 2015). In particular, the
canonical helix of Dm Mxt covers a rather small area on
the dorsal surface of eIF4E compared with the canonical
helices of Ce Mxt. However, the auxiliary helix of Dm
Mxt compensates for the missing binding surface (Supple-
mental Table S3; Supplemental Fig. S6).
Validation of the eIF4E–Mxt interface
To validate the observed interactions, we substituted key
interface residues and tested for complex formation with
in vitro pull-down and coimmunoprecipitation assays.
In the tripartite Dm Mxt peptide (C +NC + α3), substi-
tutions of residues in the canonical (C∗), noncanonical
(NC∗), or auxiliary (α3∗) motifs or in the linker regions did
not prevent complex formation in vitro, indicating that
the remaining sequences were sufficient for binding to
eIF4E (Supplemental Fig. S7A, lanes 13–16,18). The associ-
ation ofDmMxtwith eIF4Ewas prevented onlywhenmu-
tations in the canonical and noncanonical motifs were
combined (Supplemental Fig. S7A, lane 17). However, in
the bipartiteDmMxt fragment (C +NC), mutations in ei-
ther the canonical or the noncanonical motif strongly re-
duced eIF4E-binding (Supplemental Fig. S7A, cf. lanes 20,
21 and 14,16 respectively). Thus, in the tripartite peptide,
theauxiliarysequencescancompensate for thedeleterious
effects of the mutations in the canonical or noncanonical
motifs. Unlike the results obtained in vitro, results from
cell lysates (i.e., in the presence of eIF4G and other 4E-
BPs) showthatmutations in thecanonical ornoncanonical
motifs abolished the interaction of full-length Dm Mxt
with endogenous eIF4E; mutations in the linkers and aux-
iliary helix reduced binding (Supplemental Fig. S7B).
We also analyzed the impact on complex formation of
amino acid substitutions in the Dm eIF4E residues N110
and H111. As described above, these residues coordinate
specific interactions with theDmMxt linker regions (Fig.
5A–C). Mutations in these residues (NH-EE mutant) abol-
ished binding between full-length eIF4E and full-length
Mxt in S2 cells (Supplemental Fig. S7C). In contrast, these
mutations reduced but did not eliminate binding to full-
length Thor or 4E-T (Supplemental Fig. S7D) and did not
affect binding to full-length eIF4G or CUP (Supplemental
Figure 4. The noncanonical linker and helix.
(A,B) Close-up views of the elbow loop of Dm
Mxt showing interactions within the elbow
loop and eIF4E. Residues within the elbow
loop of Mxt and the interface residues of
eIF4E are shown as sticks. The side chains of
Y589Mxt, H594Mxt, and W596Mxt and eIF4E
secondary structure elements α1 and β2 (in B)
were omitted for clarity. (C ) Schematic repre-
sentations of the noncanonical linker (nc-L)
of Dm and Ce Mxt highlighting the different
conformations of the Ce noncanonical region.
(D,E) Close-up view of the Dm and Ce Mxt
noncanonical helices bound to the lateral hy-
drophobic pocket of eIF4E. Selected residues
mediating the interactions are shown in gray
sticks for eIF4E and teal or orange sticks for
Dm or Ce Mxt, respectively. (F ) Overlay and
schematic representation of the noncanonical
helices of DmMxt (in teal) and CeMxt (in or-
ange). Common structural features are labeled
in purple. The hydrophobic residues interact-
ing with the lateral surface of eIF4E are shown
as sticks and are labeled with Φ. (G,H) Close-
up views of interactions between the Mxt
noncanonical helices and residues lining the
lateral hydrophobic pocket of eIF4E. For clari-
ty, the secondary structure elements β1 and
β2 of eIF4E were omitted.
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Fig. S7E).These resultsareconsistentwithDmMxtusinga
different bindingmode to interact with eIF4E.
Unlike the results obtained for the bipartite fragment of
DmMxt, mutations in the noncanonical motif of CeMxt
reduced but did not abolish binding to Ce eIF4E in vitro
(Supplemental Fig. S7F). This suggests a stronger contri-
bution of the canonical helix to the interactions with
eIF4E and is likely due to the presence of the Arg residues
at positions 2 and 9.
The bipartite and tripartite binding modes confer
different abilities to compete with eIF4G
To investigate how the bipartite and tripartite binding
modes of Mxt proteins affect their ability to compete
with eIF4G, we performed competition assays using pre-
assembled eIF4E–eIF4G complexes. Preassembled Dm
eIF4E–eIF4G complexes were challenged with a twofold
molar excess of bipartite and tripartite Dm Mxt frag-
ments. The amount of eIF4G bound to eIF4E was deter-
mined over time (Fig. 6A,B). The tripartite Dm Mxt
fragment (C +NC + α3) displaced eIF4G from preassem-
bled eIF4E–eIF4G complexes faster than the bipartite frag-
ment (C +NC) (Fig. 6A,B). The half-life of the eIF4E–eIF4G
complexes was 40 min ± 5 min in the presence of the tri-
partite fragment compared with >60 min for the bipartite
fragment (Fig. 6A,B).
Under the same conditions, a bipartite CUP peptide
(C +NC) displaced eIF4G more rapidly, resulting in a
half-life of 25min ± 5min (Fig. 6A,C). Thus,DmMxt frag-
ments are less able to displace eIF4G from preassembled
eIF4E–eIF4G complexes, although their affinity for eIF4E
is either higher than or comparablewith that of CUP (Sup-
plemental Table S2; Igreja et al. 2014).
Nevertheless, as shown for CUP and other 4E-BPs, the
tripartite Dm Mxt peptide requires binding to the lateral
surface of eIF4E to displace eIF4G from preassembled
eIF4E–eIF4G complexes. The tripartiteDmMxt fragment
displaced 80% of eIF4G bound to wild-type eIF4E but
failed to displace eIF4G that was prebound to the eIF4E
II-AA mutant even after a 180-min incubation (Supple-
mental Fig. S7G,H).
Next,weanalyzed the abilityofCeMxt to competewith
preassembled Ce eIF4E–eIF4G complexes. Surprisingly,
Figure 5. The auxiliary linker and auxiliary helix of
DmMxt. (A) Close-up view of the U-shaped arrange-
ment of the DmMxt peptide and the interactions de-
termining the arrangement of the peptide path. The
surface of eIF4E is shown in gray. The positions of
the conserved eIF4E residues N110 and H111 are
highlighted in purple, and selected residues involved
in the arrangement of Dm Mxt around the surface
of eIF4E are shown as teal and magenta sticks. (B,C )
The eIF4E residues interacting with the Mxt linkers
(noncanonical linker [nc-L] and auxiliary linker [a-
L]). The side chains of H594Mxt (B) and R614Mxt (C )
were removed for clarity. (D) Close-up view of the
auxiliary helix ofDmMxt bound to the dorsal surface
of eIF4E in two orientations. Selected residues are
shown in gray sticks for eIF4E and teal or magenta
sticks for DmMxt. (E) Overlay of the canonical heli-
ces ofDm and CeMxt proteins reveals equivalent in-
teractions between the Arg residues flanking the
canonical helix of Ce Mxt and the auxiliary helix of
Dm Mxt. Selected residues are shown as colored
sticks. The Arg residues in the canonical motif of
CeMxt are underlined.
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CeMxt completely displaced eIF4G after a 5-min incuba-
tionwhen added at twofoldmolar excess (data not shown).
In the presence of equimolar amounts of CeMxt peptide,
the half-life of the Ce eIF4E–eIF4G complexes was 10
min (Fig. 6E,F). These results suggest that either Ce Mxt
is a very efficient eIF4G competitor or the Ce eIF4E–
Figure 6. CeMxt, but not Dm Mxt, is a potent eIF4G competitor. (A–D) Half-life of Dm eIF4E–eIF4G complexes in the presence of a
twofoldmolar excess of the indicated purified andGB1-tagged competitor peptides.MBP served as a negative control.A shows data points
from three or four independent experiments (n = 3 or n = 4). B–D show representative SDS-PAGE gels for each competition assay. The
competitor peptides are labeled in blue, and their positions are highlighted by blue dashed boxes. The black dashed boxes mark the po-
sitions of MBP–eIF4G. The lanes labeled SM (starting material) show the purified peptides and complexes used in the competition assay.
(E,F ) Half-life ofCe eIF4E–eIF4G complexes in the presence of equimolar amounts ofCeMxt competitor peptide analyzed as described in
A–D. (G–J) Half-life of Dm eIF4E–eIF4G complexes in the presence of equimolar amounts of the indicated competitor peptides.
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eIF4G complexes are particularly sensitive to competi-
tion. We then tested whether Ce Mxt also displaced
eIF4G from preassembled Dm eIF4E–eIF4G complexes,
and, indeed, Ce Mxt rapidly displaced Dm eIF4G (Fig.
6G–J). The half-life of Dm eIF4E–eIF4G complexes in the
presence of Ce Mxt was ∼3.5 min. In contrast, under the
same conditions, the tripartite Dm Mxt peptide slowly
competed with Dm eIF4G, consistent with Figure 6A,B.
Remarkably, the ability of the Ce Mxt peptide to dis-
place Dm eIF4G was comparable with that of an engi-
neered chimeric 4E-BP peptide, which contains the
canonical motif of Dm 4E-T, the linker region of Thor,
and the noncanonical helix of CUP (Peter et al. 2015).
This peptide is a more efficient eIF4G competitor than
the corresponding 4E-BPs (Peter et al. 2015), indicating
that Ce Mxt is a more potent eIF4G competitor than
Dm Thor, CUP, or 4E-T.
The bipartite and tripartite binding modes confer
differential sensitivity to 4E-BP competition
To gain further insight into the specific properties of the
bipartite and tripartite binding modes, we also asked
whether eIF4G or the chimeric 4E-BP peptide could dis-
lodgeMxt peptides thatwere prebound to eIF4E.Complex-
es containing Dm eIF4E bound to bipartite and tripartite
Dm Mxt fragments were challenged with a fivefold mo-
lar excess of eIF4G (residues 578–650) or the chimeric
4E-BP peptide. Proteins bound to eIF4E were monitored
by eIF4E pull-down after a 180-min incubation. The
eIF4G and chimeric peptides failed to displace the tripar-
tite Dm Mxt fragment (Fig. 7A,B, lanes 10–12) but could
displace the bipartite Dm Mxt fragment (Fig. 7A,B, lanes
7–9). Under the same conditions, the half-life of the Ce
eIF4E–Mxt complexes in the presence of fivefoldmolar ex-
cess of the chimeric 4E-BP peptidewas 25min (Fig. 7C,D).
Thus, the tripartite bindingmodeofDmMxt confers resis-
tance to competition by eIF4G and 4E-BPs.
The Arg/Lys residues in the canonical motif are
important for competition with eIF4G
Overall, our data indicate that the bipartite Ce Mxt pep-
tide is a potent eIF4G competitor, whereas the bipartite
DmMxt peptide only weakly displaces eIF4G. The tripar-
titeDmMxt peptide shows an intermediate behavior. We
hypothesized that the inability of the bipartite Dm Mxt
peptide to compete with eIF4G may be caused by the ab-
sence of Arg residues at positions 2 and 9 in the canonical
motif (Fig. 3D); these Arg residues are present in Ce Mxt
and other 4E-BPs. In the tripartite DmMxt, the auxiliary
helix partially compensates for the lack of Arg residues in
the canonical motif, improving the ability of this frag-
ment to compete with eIF4G.
To test this hypothesis, we asked whether the bipartite
Dm Mxt peptide could be converted into an effective
eIF4G competitor if residues I583Mxt and S590Mxt in the
canonical motif were replaced by Arg residues (bipartite
Mxt IS-RR mutant). Remarkably, the mutations restored
the ability of the bipartite Dm Mxt peptide to displace
Dm eIF4G from preassembled eIF4E–eIF4G complexes
to the level observed for the bipartite CUP peptide (Fig.
6A–C).
Conversely, eIF4G did not displace the preboundmutat-
ed bipartite Mxt peptide from eIF4E but displaced the
wild-type bipartite peptide (Fig. 7A,B). In contrast, the chi-
meric 4E-BP peptide displaced the bipartite Mxt peptide
regardless of the mutations, but the mutations extended
the half-life of the eIF4E-bipartite Mxt complexes from
14 to 136 min in the presence of the chimeric 4E-BP pep-
tide (Fig. 7A,B,E–G).
In summary, the Dm bipartite Mxt peptide behaves as
the equivalent peptide fromCeMxt and other 4E-BPs, pro-
vided that the extended consensus is restored in the ca-
nonical motif with Arg/Lys at positions 2 and 9. In the
absence of Arg/Lys residues, the peptide does not effi-
ciently compete with eIF4G for binding to eIF4E and is
rapidly displaced by eIF4G and 4E-BPs.
Discussion
Structural evolution of 4E-BPs and the regulation
of translation initiation
Unlikemany known 4E-BPs,DmMxt is an unusual 4E-BP
in that it is thought to stimulate translation (Hernández
et al. 2013). Here we show that Mxt associates with
eIF4E using a bipartite binding mode in C. elegans and
an unprecedented tripartite binding mode in D. mela-
nogaster. Our data suggest thatMxt evolved these distinct
binding strategies to form complexes with eIF4E that dis-
play distinct functional properties. In the case ofDmMxt,
the tripartite binding mode compromises the proteins’
ability to compete with eIF4G for binding to eIF4E, most
likely because Dm Mxt has a more complex folding in
the bound state. However, once the resulting circularly
closed structure is formed, it is more difficult for eIF4G
or other 4E-BPs to displace it. As a consequence, the
Dm eIF4E–Mxt complex is particularly stable and likely
helps to maintain DmMxt function in translation in the
presence of other 4E-BPs that would normally displace
eIF4G. In contrast, the bipartite binding mode of Ce Mxt
confers a competitive advantage over eIF4G but is sensi-
tive to competition by other 4E-BPs. Thus, Ce Mxt may
bind to eIF4E under conditions in which binding of other
4E-BPs is inhibited; for example, by phosphorylation.
It is intriguing thatMxt uses different bindingmodes in
different species, whereas, for example, human 4E-BP1
and its ortholog in D. melanogaster, Thor, have almost
identical structures (Peter et al. 2015). Our observations
suggest that molecular competition for eIF4E binding by
the 4E-BPs to regulate translation initiationmay represent
an important driving force underlying the rapid evolution
of the Mxt-binding mode.
The auxiliary sequences coevolved with the substitution
of Arg/Lys residues in the canonical helix
The auxiliary sequences of Dm Mxt are less conserved
than the canonical and noncanonical motifs among Mxt
Structure of Mextli bound to eIF4E
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orthologs and are absent in CeMxt as well as in Mxt pro-
teins from other organisms (Supplemental Fig. S2A,B).
Sequence analysis indicates that the presence of the aux-
iliary sequences correlates with the absence of Arg/Lys
residues at positions 2 and 9 of the canonical motif (Sup-
plemental Fig. S2A,B; Peter et al. 2015). This may be ex-
pected because the auxiliary helix would clash with the
side chains of Arg/Lys residues upon binding to the dorsal
surface of eIF4E.
The presence of auxiliary sequences in Dm Mxt raises
the question of whether equivalent sequences have been
overlooked in other 4E-BPs. However, as mentioned earli-
er, auxiliary helices at a position equivalent to that ob-
served in DmMxt are incompatible with the presence of
Arg/Lys residues at positions 2 and 9 of the canonical mo-
tif. This suggests that 4E-BPs containing these residues in
their canonicalmotifs are unlikely to bind eIF4E in aman-
ner similar to that ofDmMxt. (Figs. 3A–C, 5D,E). In addi-
tion, mutations in Dm eIF4E residues N110 and H111
eliminated binding to Dm Mxt but not other 4E-BPs or
eIF4G, indicating that the binding modes are different.
Nevertheless, it is conceivable that auxiliary sequences
in known 4E-BPs may contribute to eIF4E binding by con-
tacting other surfaces of eIF4E.
Figure 7. Dm eIF4E–Mxt complexes are resistant to 4E-BP competition. (A,B) The indicatedDm eIF4E–Mxt complexes were incubated
witha fivefoldmolarexcessofDmeIF4Gorchimeric4E-BPpeptides.TheeIF4E-boundproteinswerepulleddownusingNi-NTAbeadsafter
a 180-min incubation and analyzed as described in Figure 6, A and B. The competitor proteins are highlighted by blue dashed boxes and are
labeled in blue. The positions of theMBP-DmMxt complexes aremarked by black dashed boxes. The lanes labeled SM (startingmaterial)
show the purified peptides and complexes used in the competition assay. (C,D) Half-life of Ce eIF4E–Mxt complexes in the presence of a
fivefold molar excess of chimeric 4E-BP peptide. (E–G) Half-life of Dm eIF4E–Mxt complexes containing bipartite Mxt peptide (C +NC,
wild type,or IS-RRmutant) complexes in thepresenceof a fivefoldmolarexcessof chimeric4E-BPpeptide.MBPservedasanegativecontrol.
Peter et al.
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Implications of distinct eIF4E-binding modes for the
regulation of complex assembly
The interaction of vertebrate 4E-BP1–3 andDmThor with
eIF4E is regulated by sequential phosphorylation events at
Ser/Thr–Pro sites located upstream of the canonical motif
and in the elbow loop (Gingras et al. 1999, 2001). These
phosphorylation events regulate the folding of the canon-
ical helix and the conformation of the elbow loop (Bah
et al. 2015; Peter et al. 2015). In Dm Mxt, the conforma-
tion of the elbow loop is strikingly similar to that of Dm
Thor. In addition to its structural similarity to Thor, the
elbow loop of DmMxt also includes a Ser–Pro phosphor-
ylation site at an equivalent structural position (S592Mxt
and P593Mxt correspond to S65Thor and P66Thor, respec-
tively). Although no post-translational modifications are
currently known for DmMxt at this position, the conser-
vation of this phosphorylation site suggests that similar
mechanisms might regulate the association of Dm Mxt
with eIF4E. The complex tripartite binding mode of Dm
Mxt and the stability of the complexes formed with
eIF4E also suggest that othermechanisms are likely to reg-
ulate the formation of these complexes. Similarly, the
flexibility of the noncanonical linker in Ce Mxt suggests
that binding to eIF4E may involve different mechanisms
than for vertebrate 4E-BP1-3.
In summary, the variability and evolution in the bind-
ing modes and properties of various 4E-BPs indicate that
structural variation among other 4E-BPs might cover
additional surfaces on eIF4E, conferring unique properties
to the complexes and resulting in different regulatory
mechanisms. These differencesmay have important func-
tional implications; for example by specifying the cell
type and conditions in which a specific 4E-BP exerts its
regulatory role in translation.More generally, the growing
repertoire of 4E-BP-bindingmechanisms offers new oppor-
tunities for the design of eIF4E inhibitors for therapeutic
applications.
Materials and methods
DNA constructs
The DNA constructs used in this study are described in the Sup-
plemental Material and are listed in Supplemental Table S1. All
of the constructs and mutations were confirmed by sequencing.
Protein expression and purification
All of the recombinant proteins were expressed in Escherichia
coli BL21 Star (DE3) cells (Invitrogen) grown in LB medium over-
night at 20°C. For 15N-labeling of the GB1-stabilizedMxt peptide
(residues 577–640), cells were grown in M9 minimal medium
with ammonium–15N chloride (Sigma-Aldrich) as a nitrogen
source. The cells were lysed by sonication in lysis buffer contain-
ing 50 mMHEPES (pH 7.2), 300 mMNaCl, and 2 mM DTT sup-
plemented with 5 µg/mL DNase I, 1 mg/mL lysozyme, and
protease inhibitor cocktail (Roche). To purify the eIF4E–Mxt
complexes, His6-tagged Dm eIF4E (residues 69–248) and Ce
eIF4E3 (residues 30–215) were coexpressed with the maltose-
binding protein (MBP)-tagged Dm Mxt (residues 577–640) and
CeMxt (residues 471–507), respectively. The complexes were pu-
rified from cleared cell lysates using amylose resin (New England
Biolabs) followed by removal of the MBP and His6 tags with
HRV3C protease cleavage overnight at 4°C. After cleavage of
the tags, the complexes were separated from free MBP and His6
using a heparin column (5 mL of HiTrap Heparin HP; GE Health-
care) and further purified on a Superdex 75 column (GE Health-
care). Purified proteins were stored at −80°C in a buffer
containing 10 mM HEPES (pH 7.2), 200 mM NaCl, 2 mM DTT,
and 5% glycerol.
For the ITC measurements and competition assays shown in
Figures 6 and 7 and Supplemental Figures S3 and S7, the GB1-sta-
bilized peptides (Mxt, eIF4G, and chimeric 4E-BP) were purified
as described previously, with the exception that the GB1-stabi-
lizedDmMxt peptide (residues 577–640) was subjected to an ad-
ditional round of anion exchange chromatography (5 mL of
HiTrap Q HP; GE Healthcare) to remove residual MBP (Igreja
et al. 2014; Peter et al. 2015). The 15N-labeled GB1-stabilized
Mxt peptide (residues 577–640) used for the NMR experiments
was purified using the same procedure. The Dm eIF4E construct
(residues 69–248) used for ITCmeasurements and the full-length
Dm eIF4E construct used forNMRwere purified as previously de-
scribed (Igreja et al. 2014). The complexes of His6-tagged Dm
eIF4E (residues 69–248) with MBP-tagged Dm eIF4G (residues
578–650) or of His6-tagged Ce eIF4E (full-length) with MBP-
taggedCe eIF4G (residues 315–491) that were used for the compe-
tition assays were purified as previously described (Igreja et al.
2014).
To obtain the eIF4E–Mxt complexes used in the competition
assays shown in Figure 7, His6-tagged eIF4E (residues 69–248)
was coexpressed with MBP-tagged Mxt fragments (residues
577–620, residues 577–640, or the 577–620 IS-RR mutant) that
were C-terminally fused to GB1. The complexes were purified
from cleared cell lysates using amylose resin (New England Biol-
abs). For the competition assays shown in Supplemental Figure
S7, the complexes containing GST-tagged Dm eIF4G (residues
578–650) and SHN-tagged Dm eIF4E (full-length; either wild
type or II-AA mutant) were expressed and purified as previously
described (Igreja et al. 2014). The SHN tag consists of a streptavi-
din-binding peptide (strep), His6, and the NusA protein.
Crystallization, data collection, and structure determination
A detailed description of the crystallization conditions and the
structure determination process are included in the Supplemen-
tal Material. All diffraction data sets were recorded on a Pilatus
6M detector at the PXII beamline of the Swiss Light Source at a
temperature of 100 K. The diffraction data and refinement statis-
tics are summarized in Table 1.
Coimmunoprecipitation assays and Western blotting
Coimmunoprecipitation assays in S2 cells and Western blotting
were performed as described previously (Igreja et al. 2014). The
pull-down assay using m7GTP beads (Jena Biosciences, AC-155)
was performed as previously described (Igreja et al. 2014). All
Western blots were developed using the ECL Western blotting
detection system (GE Healthcare). The antibodies used in this
study are listed in Supplemental Table S4.
Pull-down experiments, ITC, and NMR analysis
The in vitro pull-down assays were performed as previously de-
scribed (Igreja et al. 2014; Peter et al. 2015). The ITC and NMR
measurements are described in the Supplemental Material.
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Competition assays
The competition assays were performed as previously described
(Igreja et al. 2014; Peter et al. 2015). For the competition assays
shown in Figure. 6, A–D and G–J, purifiedDm eIF4E–eIF4G com-
plexes containing His6-eIF4E (residues 69–248) and MBP-eIF4G
(residues 578–650) were incubated with purified and GB1-tagged
4E-BP peptides, including CUP C +NC, Dm Mxt C +NC, Dm
Mxt C +NC+ α3, Dm Mxt C +NC IS-RR mutant, Ce Mxt C +
NC, and 4E-BP chimera. MBP served as a negative control. The
eIF4E-bound proteins were pulled down using Ni-NTA beads at
the indicated time points and eluted with imidazole for analysis
by SDS-PAGE. The amount of eIF4G bound to eIF4E was quanti-
fied and normalized to the levels of eIF4E present at each time
point. These values were set to 100 in the presence of MBP.
Data points from three or four independent experiments were
plotted, and the resulting curves were determined using the Lev-
enberg-Marquardt algorithm (exponential decay).
For the experiments shown in Figures 6, E and F, and 7, C andD,
purified Ce eIF4E–eIF4G complexes containing His6-Ce eIF4E
(residues 1–215) andMBP-Ce eIF4G (residues 315–491) were incu-
bated with purified GB1-tagged Ce Mxt peptide (residues 471–
507) or chimeric 4E-BP peptide.MBP served as a negative control.
The amount of MBP-Ce eIF4G bound to eIF4E at each time point
was determined as described above. For the experiment shown in
Figure 7, A and B, purified Dm eIF4E–Mxt (C +NC, C +NC+ α3,
or IS-RR) complexes were incubated with a fivefold molar excess
of Dm eIF4G (residues 578–650) or chimeric peptides that were
C-terminally fused to GB1. In the experiment shown in Figure
7, E–G, purified Dm eIF4E–Mxt (C +NC wild type or IS-RR mu-
tant) complexes were incubated with a fivefold molar excess of
chimeric peptide C-terminally fused to GB1. The eIF4E-bound
proteins were pulled down using Ni-NTA beads and analyzed
by SDS-PAGE as described above. The amount of competitor
used in each experiment is indicated in the figure legends.
Accession numbers
Coordinates for the structures described in this study have been
deposited in the Protein Data Bank under accession numbers
5ABU (Dm eIF4E–Mxt complex with cap analog), 5ABV (Dm
eIF4E–Mxt), 5ABX (Ce eIF4E–Mxt complex with cap analog),
and 5ABY (Ce eIF4E–Mxt complex).
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DNA constructs 
The plasmids used for the expression of Dm eIF4E, eIF4G, CUP (full-length or 
fragments) and chimeric 4E-BP in Escherichia coli (E. coli) or Dm S2 cells have been 
described previously (Igreja and Izaurralde 2011; Peter et al. 2015). The plasmids for 
the expression of HA- or GFP-tagged Dm Mxt in S2 cells were obtained by inserting 
the corresponding cDNA into the EcoRI and ApaI sites of the pAc5.1B-λN-HA and 
pAc5.1B-EGFP vectors. For expression in E. coli, DNA fragments encoding Dm Mxt 
residues 577–620 (C+NC, bipartite) and 577–640 (C+NC+α3, tripartite) were inserted 
into the XhoI and BamHI restriction sites of the pnEA-NpM vector (Diebold et al. 
2011), producing an N-terminally fused MBP cleavable by HRV3C protease. A 
cDNA fragment encoding the Ce Mxt eIF4E-binding region [residues 471–507 
(C+NC)] was inserted into the NdeI and NheI restriction sites of the pnEA-NpM 
vector. The cDNA encoding full length Ce eIF4E3 and fragments thereof (residues 
30–215, trunc 1; and residues 1–215, trunc 2) were inserted into the NdeI and XhoI 
restriction sites of the pnYC-NpH vector, generating N-terminal fusions with the 
hexahistidine (His6) tag cleavable by HRV3C protease. The cDNA fragment coding 
for the eIF4E-binding region of Ce eIF4G (residues 315–491) was inserted into the 
NdeI and XhoI restriction sites of the pnEA-NpM vector. The cDNA encoding the B1 
domain of immunoglobulin-binding protein G (GB1) (Cheng and Patel 2004) was 
inserted at the C-terminal end of the Mxt fragments by site-directed mutagenesis. All 
of the mutants used in this study were generated by site-directed mutagenesis using 
the QuikChange mutagenesis kit (Stratagene) and are listed in Supplemental Table 
S1. 
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NMR measurements 
 All spectra were recorded at 298 K. The 15N-HSQC experiment for the GB1-
stabilized Mxt peptide (residues 577–640) was recorded at 600 MHz on a Bruker 
AVIII-600 spectrometer. The 15N-TROSY experiments for the eIF4E–Mxt-GB1 
complex were measured at 800 MHz on a Bruker AVIII-800 spectrometer. The 15N-
labeled Mxt-GB1 protein was saturated with a 1.5-fold molar excess of unlabeled full-
length Dm eIF4E. The molecular weight of the proteins used in the NMR-experiments 
was determined based on their tumbling behavior in solution. Both diffusion 
experiments (before and after the addition of full length Dm eIF4E to the Mxt-GB1 
protein) were recorded at 600 MHz.  
 
Crystallization 
Crystals of Dm eIF4E (residues 69–248) copurified with a Dm Mxt fragment 
(residues 577–640) and supplemented with a 1.5-fold molar excess of m7GpppG cap 
analog (New England BioLabs) were obtained by the hanging-drop vapor-diffusion 
method at 18°C. Crystals appeared one day after mixing the protein solution (12 
mg/ml) with a reservoir solution containing 0.1 M MMT buffer and 23% PEG 1500. 
MMT buffer consists of a 1:2:2 molar ratio of DL-malic acid, 2-(N-
morpholino)ethanesulfonic acid (MES), and Tris (pH 4.0), according to the PACT 
Suite Buffer protocols (Qiagen). Crystals of Dm eIF4E (residues 69–248) in complex 
with Dm Mxt (residues 577–640; 20 mg/ml) without the cap analog were obtained by 
the same method. Crystals appeared in one day over a reservoir of 0.1 M Bis-Tris (pH 
6.0) and 23% PEG 3350. The complex of Ce eIF4E (residues 30–215), Ce Mxt 
(residues 471–507) and the m7GpppG cap analog (New England BioLabs) was 
crystallized using the same method. Crystals appeared after two to three days over a 
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reservoir of 0.1 M sodium acetate (pH 5.0), 0.01 M ZnCl2 and 18% PEG 6000. The 
same Ce complex but without the cap-analog was crystallized over a reservoir of 0.1 
M Tris (pH 8.0), 0.2 M MgCl2 and 17% PEG 6000, with crystals appearing after one 
day. For cryoprotection, crystals were soaked briefly in the reservoir solution 
supplemented with 10–15% glycerol followed by flash-freezing in liquid nitrogen.  
 
Structure determination 
Diffraction data were collected at a wavelength of 1.000 Å on a PILATUS 6M 
detector at the PXII beamline of the Swiss Light Source. Data were processed with 
XDS and scaled using XSCALE (Kabsch 2010). 
Crystals of the Dm eIF4E-Mxt complex and the cap analog diffracted to a resolution 
of 2.16 Å. The structure was solved by molecular replacement using PHASER 
(McCoy et al. 2007) with the Dm eIF4E structure (PDB-ID 4UE8) (Peter et al. 2015) 
as the search model. The molecular replacement solution was used to rebuild an initial 
model of Dm eIF4E using the PHENIX AutoBuild wizard (Terwilliger et al. 2008) to 
prevent model bias. To complete and improve the initial model of eIF4E, iterative 
cycles of model building and refinement were carried out using COOT (Emsley et al. 
2010) and PHENIX (Afonine et al. 2012) against the unmodified native dataset. The 
Mxt peptide and the m7GpppG cap analog were then built into the weighted Fo-Fc 
difference density using COOT, and the structure of the complex was further refined 
using PHENIX. The stereochemical restraints library for the m7GpppG cap analog 
was generated using GRADE (Smart et al. 2011) for subsequent refinement. For the 
final model, 99.12% of all residues are in the favored regions of the Ramachandran 
plot and there are no outliers. 
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Crystals of the Dm eIF4E–Mxt complex without the cap analog diffracted to a 
resolution of 2.13 Å. The crystal belongs to space group P21 with a β-angle of 90.1° 
and further data analysis with PHENIX.XTRIAGE (Zwart et al. 2005) indicated the 
presence of translational pseudosymmetry, generating a strong peak in the Patterson 
map (37.3% of the origin). Nevertheless, the structure was solved by molecular 
replacement as described above with the difference being that the asymmetric unit 
contained four copies of the search model. The structures were rebuilt using the 
PHENIX AutoBuild wizard (Terwilliger et al. 2008) to prevent model bias. The initial 
models of eIF4E were then manually completed in COOT (Emsley et al. 2010) and 
refined using PHENIX (Afonine et al. 2012). The Mxt peptide was built into the 
weighted Fo-Fc difference density in COOT and the complex was refined using 
BUSTER with automated NCS restraints and TLS refinement (Bricogne et al. 2011; 
Smart et al. 2012). For the final model, 97.5% of all residues are in the favored 
regions of the Ramachandran plot and there are no outliers. 
 Crystals of the Ce eIF4E-Mxt complex without the cap analog diffracted to a 
resolution of 1.66 Å. Because of bound Zn2+ ions from the crystallization condition, 
there was a strong anomalous signal that was used to derive unbiased experimental 
phases. Zn2+-sites were identified with SHELX (Sheldrick 2010) and were used to 
build an initial model of the Ce eIF4E-Mxt complex using PHENIX AutoSol 
(Terwilliger et al. 2009). The model was manually completed and improved in COOT 
(Emsley et al. 2010) and refined using PHENIX (Afonine et al. 2012). Because the 
m7GpppG cap analog was not fully visible, an m7GTP molecule was placed into the 
weighted Fo-Fc difference density in COOT, and the Zn2+-sites were confirmed by 
examining the anomalous difference Fourier map. The final model was refined using 
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PHENIX and 99% of all residues are in the favored regions of the Ramachandran plot 
and there are no outliers. 
Crystals of the Ce eIF4E-Mxt complex with no cap analog diffracted to a 
resolution of 1.95 Å. The structure was solved by molecular replacement using 
PHASER (McCoy et al. 2007). The experimentally phased structure of the Ce eIF4E-
Mxt complex including the cap analog was used as the search model. To prevent 
model bias, the three complexes found in the asymmetric unit were rebuilt using the 
PHENIX AutoBuild wizard (Terwilliger et al. 2008). The models were improved in 
COOT (Emsley et al. 2010) and refined using PHENIX (Afonine et al. 2012). For the 
final model, 97.5% of all residues are in the favored regions of the Ramachandran 
plot and there are no outliers. 
The stereochemical properties for all of the structures were verified using 
MOLPROBITY (Chen et al. 2010). Structural images were prepared using PyMOL 
(http://www.pymol.org). The diffraction data and refinement statistics are 
summarized in Table 1. 
 
ITC analysis 
Dm eIF4E (residues 69–248) used for ITC measurements was purified as described 
previously (Igreja et al. 2014). The ITC experiments were performed using a VP-ITC 
microcalorimeter (MicroCal) at 20°C as described previously (Igreja et al. 2014; Peter 
et al. 2015). The solution of wild-type eIF4E (residues 69–248, 1.0 or 2.0 µM) or 
eIF4E II-AA mutant (residues 69–248, 9.5 µM) in the calorimetric cell was titrated 
with tenfold concentrated solutions of GB1-stabilized Mxt peptides (residues 577–
620, 20 µM; residues 577–640, 10 µM for eIF4E WT and 95 µM for eIF4E II-AA 
mutant) that were dissolved in the same buffer (20 mM Na-phosphate pH 7.0 and 150 
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mM NaCl). The titration experiments consisted of an initial injection of 2 µl followed 
by 28 injections of 10 µl at 240 s intervals. Each binding experiment was repeated 
three times. The thermodynamic parameters were calculated using a one-site binding 
model (Origin version 7.0). The datapoint of the first injection was removed for the 
analysis (Mizoue and Tellinghuisen 2004).  
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Supplemental Table S1. Mutants and constructs used in this study. 
 
 
  
Protein Name of the construct Fragments / mutations Binding site / motif 
Dm eIF4E-2 
(1–248) (isoform 
C) 
P48598-2 
4E Full length  
II-AA I96A, I112A Lateral surface 
W106A W106A Dorsal surface 
NH-EE N110E, H111E  
trunc 69–248  
Dm eIF4G 
(1–1666) 
(isoform A) 
O61380 
4G 578–650 Extended eIF4E-binding region 
Dm Mxt 
(1–653) 
Q9VR35 
Mxt Full length  
C+NC+α3 577–640 Tripartite eIF4E-binding region  
C+NC 577–620 Bipartite eIF4E-binding region 
C* Y581A, L586A, L587A Canonical motif mutant 
Elbow1* W596D Elbow 1oop mutant 
Nc-L* L598D Non-canonical linker mutant 
NC1* W602D Non-canonical motif 
mutants NC2* M605D IL-AA I612A L613A 
C*+IL-AA Y581A, L586A, L587A, I612A,L613A 
Canonical motif + auxiliary 
linker mutant 
α3* F625E Auxiliary helix mutant FY-EE F625E, Y630E 
IS-RR I583R, S590R Arg mutant 
CUP 
(1–1117) 
Q9VMA3 
C+NC 325–376 eIF4E-binding region  
1–417  CUP N-terminal eIF4E-binding region 
Ce Mxt 
(1–507) 
Q9XW13 
C+NC 471–507 eIF4E-binding region 
C* Y579A, L584A, M585A Canonical motif mutant 
NC 1* I497D, I504D Non-canonical motif 
mutants NC 2* M493D, I497D, I504D NC 3* M493D 
Ce eIF4G 
(1–1156) 
Q21531 
4G 315–491 Extended eIF4E-binding region 
Ce eIF4E3 
(1–251) 
O61955 
W68A W68A Dorsal surface mutant 
VI-AA V58A, I74A Lateral surface mutant 
trunc 1 30–215  
trunc 2 1–215  
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Supplemental Table S2. Thermodynamic parameters for the interaction of eIF4E 
with Mxt peptides. 
 
eIF4E (69–248) wild type 
 
Mxt 
peptide 
KD 
(M) 
ΔH 
(kcal mol-1) 
-TΔS 
(kcal mol-1) 
ΔG 
(kcal mol-1) 
Molar ratio 
577–620 5.0 ± 3.4 × 10-9 -13.1 ± 0.4 1.9 -11.2 0.98 ± 0.02 
577–640 0.52 ± 0.09 × 10-9 -32.4 ± 0.6 19.9 -12.5 1.00 ± 0.03 
 
eIF4E (69–248) II-AA mutant 
 
577–640 0.3 ± 0.12 × 10-6 -18.3 ± 1.3 9.5 -8.8 1.00 ± 0.02 
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Supplemental Table S3. Interface areas of 4E-BP-eIF4E complexes. 
The covered surface areas on eIF4E by the indicated 4E-BPs or Dm eIF4G and the 
individual motifs have been calculated using the PISA program from the CCP4 suite.  
Protein motif area (Å2) 
Dm Mxt Canonical helix (α1) 471 
 Canonical + auxiliary helix 
(α1+α3) 
655 
 Complete 4E-binding region 1498 
Ce Mxt Canonical helix (α1) 611 
 Complete 4E-binding region 1370 
Dm Thor Canonical helix 632 
 Complete 4E-binding region 1450  
Dm CUP Canonical helix 539 
Dm 4E-T Canonical helix 584 
 Complete 4E-binding region 1370  
Dm eIF4G Canonical helix 529  
Hs 4E-BP1 Canonical helix 550 
Complete 4E-binding region 1235 
 
Supplemental Table S4. Antibodies used in this study. 
Antibody Source Catalog 
Number 
Dilution Monoclonal/ 
Polyclonal 
Anti-HA-HRP 
(Western blot) 
Roche 12 013 819 
001 
1:5,000 Monoclonal 
Anti-HA (IP) Covance MMS-101P 1:1,000 Monoclonal 
Anti-Dm eIF4E  In house  1:3,000 Rabbit 
polyclonal 
Anti-Dm eIF4G In house  1:3,000 Rabbit 
polyclonal 
Anti-GFP In house  1:2,000 Rabbit 
polyclonal 
Anti-Dm 4E-T Kindly 
provided by 
P. Lasko 
 1:2,000 Rabbit 
polyclonal 
Anti-rabbit-HRP GE 
Healthcare 
NA934V 1:10,000 Polyclonal 
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Supplemental Figure Legends 
 
Supplemental Figure S1. Structure-based alignment of eIF4E sequences. (A) 
Western blot showing the interaction of HA-tagged Dm eIF4E (either wild-type or 
mutated) with endogenous eIF4G and GFP-tagged Dm CUP (residues 1–417). The 
inputs (0.6% for eIF4G, 3% for eIF4E and 2% for CUP) and immunoprecipitates 
(25% for eIF4G and 20% for eIF4E and CUP) were analyzed by western blotting 
using anti-HA, anti-eIF4G and anti-GFP antibodies. (B) Structure-based sequence 
alignment of eIF4E orthologous proteins from Drosophila melanogaster (Dm). There 
!!
12!
are eight eIF4E isoforms in D. melanogaster: 4E-1 (P48598) and 4E-2 (P48598-2; 
used in this study) are encoded by the same gene and result from alternative splicing, 
4E-3 (Q9VSG), 4E-4 (Q9VRY0), 4E-5 (Q9VSB6), 4E-6 (Q9VAR1), 4E-7 
(Q9W5B3) and 4E-HP (Q8T3K5) (Hernandez et al. 2005). Dm Mxt interacts with 
eIF4E-1, -2, -3, -4 and -7 in yeast two-hybrid assays (Hernandez et al., 2013).!
Conserved residues are highlighted with a black background and printed in white. 
Residues with >70% similarity are shown with a light gray background. Secondary 
structure elements for Dm eIF4E-2 (used in this study) are indicated above the 
sequences. The Trp residues coordinating the m7GTP nucleotide are indicated by red 
asterisks. The lateral and dorsal binding surfaces (BS) are indicated by a line below 
the sequences. Residues mutated in this study are indicated with red open circles 
above the sequences. The dashed red box highlights residues N110 and H111 that 
coordinate interactions with the linker regions in the tripartite binding region of Dm 
Mxt.  (C) Structure-based alignment of Ce eIF4E sequences. Five eIF4E proteins have 
been described in C. elegans: 4E-1 (IFE-1, O45551), 4E-2 (IFE-2, Q21693), 4E-3 
(IFE-3, O61955, used in this study), 4E-4 (4E-HP, Q22888) and 4E-5 (IFE-5, 
P56570) (Jankowska-Anyszka et al. 1998). Symbols and labels are as in panel (B). 
Secondary structure elements for Ce eIF4E-3 are indicated above the sequences. 
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Supplemental Figure S2. Structure-based alignment of the eIF4E-binding region of 
Mextli proteins. (A) Structure-based sequence alignment of Mxt orthologous proteins 
from Drosophila species [Drosophila melanogaster (Dm), Drosophila willistoni 
(Dwi), Drosophila grimshawi (Dgr), Drosophila simulans (Dsi), Drosophila sechellia 
(Dse), Drosophila yakuba (Dya), Drosophila erecta (Der), Drosophila ananassae 
(Dan), Drosophila pseudoobscura (Dps), Drosophila persimilis (Dpe), Drosophila 
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virilis (Dvi), Drosophila mojavensis (Dmo)], from non-Drosophila Dipterans 
[mosquitos: Aedes aegypti (Aae), Anopheles gambiae (Aga)], from non-Dipterans 
Insects [bee: Apis mellifera (Ame); wasp: Nasonia vitripennis (Nv); ants: Atta 
cephalotes (Ace), Solenopsis invicta (Sin); silkmoth: Bombyx mori (Bmo); human 
body louse: Pediculus humanus (Hm); beetle: Tribolium castaneum (Tcas)], from 
non-Insects Arthropods [centipede: Strigamia maritime (Smm); flea: Daphnia pulex 
(Dpu); mite: Tetranychus urticae (Tur)] and from Nematodes [worms: 
Caenorhabditis brenneri (Cbe), Caenorhabditis elegans (Ce), Caenorhabditis 
remanei (Cre), Caenorhabditis briggsae (Cbr)]. Invariant residues are highlighted 
with a dark-blue background and printed in white. Residues with >70% similarity are 
shown with a light blue color background. Secondary structure elements are indicated 
above and below the sequences for the Dm and Ce proteins, respectively. Residues at 
positions 2 and 9 of the canonical motifs of Mxt are indicated with a magenta 
background. The canonical (C), non-canonical (NC) and auxiliary 4E-BMs are boxed 
in black. Mxt residues in the motifs contacting eIF4E are indicated by red open 
circles. (B) Secondary structure prediction for the eIF4E-binding region of Mxt 
orthologous proteins using the Ali2D software (http://toolkit.tuebingen.mpg.de/). The 
degrees of confidence for β-strands (in blue) and α-helices (in red) are indicated by 
increasing color intensities. Species are the same as in panel (A). 
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Supplemental Figure S3. The tripartite Dm Mxt peptide is unfolded in solution. (A–
C) Isothermal titration calorimetry data for the interactions of Dm eIF4E (residues 
69–248, wild type or II-AA mutant) with the indicated Dm Mxt peptides. The 
thermodynamic parameters are shown in Table S2. (D) 15N-HSQC spectra of purified 
15N-labeled Dm Mxt C+NC+α3 peptide C-terminally fused to GB1. The spectrum 
displays two distinct sets of peaks: a well dispersed spectrum with high intensity 
peaks corresponding to the folded GB1 protein (green) and a second spectrum with 
lower intensity and a limited 1H resonance dispersion, which is characteristic of 
disordered proteins (Mxt; blue). Diffusion experiments indicate that the Mxt-GB1 
fusion protein is monomeric in solution (approximately 14 kDa). Black lines indicate 
overlapping spectra for Mxt and GB1. (E) 15N-TROSY spectra of purified 15N-labeled 
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Dm Mxt C+NC+α3 peptide C-terminally fused to GB1 after addition of purified 
unlabeled Dm eIF4E. Two distinct sets of spectra are also identified. In the GB1 
protein spectra (gray), the peaks do not show any chemical shift, suggesting that GB1 
does not interact with eIF4E. The spectra corresponding to the Mxt peptide (red) 
gained tremendously in resonance dispersion upon addition of eIF4E. Many peaks left 
the disordered region of the spectra reflecting a disorder-to-order transition upon 
binding to eIF4E. The molecular weight of the eIF4E-Mxt-GB1 complex estimated by 
diffusion experiments corresponds to a 1:1 stoichiometry.  
!!
17!
 
!!
18!
Supplemental Figure S4. Structure of the Dm and Ce eIF4E-Mxt complexes in the 
absence of the cap analog. (A) Cartoon representation showing the cap-free crystal 
form of the Dm eIF4E-Mxt complex. The asymmetric unit of the crystal contained 
four complexes. (B) Overview of one Dm eIF4E–Mxt complex from the cap-free 
crystal form. The region of the Mxt peptide with structural similarity to other 4E-BPs 
is colored in yellow. The auxiliary linker and helix are colored in blue. Selected 
secondary structure elements are labeled in black for eIF4E and in color for Mxt. (C) 
Structural overlay of the Dm eIF4E–Mxt in the cap bound and cap-free state. The two 
complexes superimpose with an RMSD of 0.38 Å over 233 Cα atoms. (D) Cartoon 
representation showing the crystal form of the Ce eIF4E-Mxt complex in the absence 
of the cap analog. The asymmetric unit of the crystal contained three complexes. (E) 
Overview of one complex from the cap-free crystal form. (F) Structural overlay of the 
Ce Mxt-eIF4E complexes in the cap-bound (green) and cap-free (red) form. Selected 
secondary structure elements are labeled in black for eIF4E and in color for Mxt. The 
two complexes superimpose with an RMSD of 0.38 Å over 207 Cα atoms.  
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Supplemental Figure S5. Comparison of the Dm eIF4E-Mxt complex with the CUP 
and Thor complexes. (A) Overlay of the Dm eIF4E-Thor complex (PDB ID: 4UE8; 
Peter et al., 2015) and the Dm eIF4E-Mxt complex. The eIF4E molecule from the 
eIF4E-Thor complex has been removed for clarity. (B) Overlay of the elbow loops of 
Dm Mxt and Dm Thor reveals structurally similar residues, shown in colored sticks. 
(C) Overlay of the Dm eIF4E-CUP complex (PDB ID: 4AXG; Kinkelin et al., 2012) 
and the Dm eIF4E-Mxt complex bound to the cap analog. The eIF4E molecule from 
the eIF4E-CUP complex has been removed for clarity. (D–F) Close-up views of the 
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relative orientations of the non-canonical helices of Dm Mxt, Ce Mxt and Dm CUP 
bound to the lateral hydrophobic pocket of eIF4E. Helices are represented as 
cylinders.  
 
Supplemental Figure S6. Binding interfaces of Dm and Ce Mxt on eIF4E. (A, B) 
Surface representation of eIF4E in complex with Dm and Ce Mxt. Residues of eIF4E 
within a distance of 4 Å from the bound Mxt peptide are shown in color. Selected Mxt 
residues that mediate major surface contacts at the dorsal and lateral surfaces of eIF4E 
are shown in sticks. The residues present at positions 2 and 9 of the Dm and Ce 
canonical motifs are underlined. For Ce Mxt, the contribution of the nc-L from the 
cap-free crystal structure is indicated in salmon. 
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Supplemental Figure S7. Validation of the eIF4E-Mxt interface. (A) E. coli lysates 
expressing MBP-tagged Dm Mxt fragments (WT or mutated), C-terminally fused to 
GB1, were incubated with SHN-tagged full length eIF4E. Protein complexes were 
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pulled down using amylose resin. Inputs (0.5%) and bound fractions (30%) were 
visualized on a SDS-PAGE gel followed by Coomassie staining. (B) The interaction 
of HA-tagged Dm Mxt (full length, either wild-type or mutated) with endogenous 
eIF4E was tested in Dm S2 cells. The proteins were immunoprecipitated using anti-
HA antibodies. The inputs (2% for Mxt and 0.5% for eIF4E) and immunoprecipitates 
(15% for Mxt and 25% for eIF4E) were analyzed by western blotting using anti-HA 
and anti-eIF4E antibodies. (C–E) Western blotting showing the interaction of HA-
tagged Dm eIF4E (full length, wild-type or mutants) with GFP-tagged Dm Mxt (full 
length, C), Thor (D) or CUP (1–417, E) and endogenous 4E-T and eIF4G (D,E). Input 
samples (1.5% for eIF4E, Thor and 4E-T; 10% for Mxt; 0.3% for eIF4G and 2% for 
CUP) and immunoprecipitates (15% for eIF4E; 30% for Mxt and 25% for Thor, 4E-T, 
eIF4G and CUP) were analyzed as described in (B). (F) Ni-NTA pulldown assay 
showing the association of His6-tagged Ce eIF4E (30–215) with MBP-tagged Ce Mxt 
eIF4E-binding region (471–507, either wild-type or carrying the indicated mutations). 
Samples were analyzed as described in (A). Protein mutants are described in Table 
S1. Inputs (0.2%) and bound fractions (12.5%) were analyzed on a SDS-PAGE gel 
followed by Coomassie staining. (G) Purified Dm eIF4E-eIF4G complexes (2µM) 
containing SHN-tagged eIF4E (full length, WT or the II-AA mutant) and GST-eIF4G 
(residues 578–650) were incubated with two-fold molar excess of the Dm Mxt 
tripartite peptide (C+NC+α3) C-terminally fused to GB1. MBP served as negative 
control. The eIF4E-interacting proteins were pulled down using Ni-NTA beads. The 
competitor proteins are labeled in blue and marked by blue dashed boxes. The black 
dashed box indicates the position of GST-eIF4G. Lanes 1–4 show the purified 
peptides and complexes (starting material, SM) used in the competition assay. (H) 
The amounts of GST-eIF4G bound to eIF4E in each experimental condition were 
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determined using the Image J software after Coomassie blue staining. To rule out the 
possibility that changes in the levels of GST-eIF4G resulted from variations in the 
loading volume, all values were normalized to the levels of SHN-eIF4E present in 
each condition. These values were set to 100% in the presence of MBP. The mean 
values ± SD from three independent experiments are shown.  
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SUMMARY
Eukaryotic initiation factor 4G (eIF4G) plays a central
role in translation initiation through its interactions
with the cap-binding protein eIF4E. This interaction
is a major drug target for repressing translation and
is naturally regulated by 4E-binding proteins (4E-
BPs). 4E-BPs and eIF4G compete for binding to the
eIF4E dorsal surface via a shared canonical 4E-bind-
ingmotif, but also contain auxiliary eIF4E-binding se-
quences, which were assumed to contact non-over-
lapping eIF4E surfaces. However, it is unknown how
metazoan eIF4G auxiliary sequences bind eIF4E.
Here, we describe crystal structures of human and
Drosophila melanogaster eIF4E-eIF4G complexes,
which unexpectedly reveal that the eIF4G auxiliary
sequences bind to the lateral surface of eIF4E, using
a similar mode to that of 4E-BPs. Our studies provide
amolecular model of the eIF4E-eIF4G complex, shed
light on the competition mechanism of 4E-BPs, and
enable the rational design of selective eIF4G inhibi-
tors to dampen dysregulated translation in disease.
INTRODUCTION
Eukaryotic initiation factor 4G (eIF4G) plays a central role in trans-
lation initiation in eukaryotes (Jackson et al., 2010). Conse-
quently, its function is required for cell growth and differentiation,
organism development, and it has been implicated in the patho-
genesis of various conditions such as tumor growth and age-
related diseases (reviewed in Howard and Rogers, 2014). During
initiation, eIF4G mediates protein-protein interactions that are
essential for 43S preinitiation complex (PIC) recruitment to cap-
ped mRNAs. The 43S PIC consists of a 40S ribosomal subunit,
the ternary eIF2-GTP-Met-tRNAi complex, eIF3, and additional
initiation factors and interacts with eIF4G through the eIF3 com-
plex (Jackson et al., 2010). In turn, eIF4Gassociateswith the cap-
binding protein eIF4E and the RNA helicase eIF4A to assemble
into the eIF4F complex, thereby linking translation initiation with
mRNA 50 cap structure recognition (Jackson et al., 2010).
eIF4G interacts with eIF4E via a conserved motif, which is
termed the canonical eIF4E-binding motif (canonical 4E-BM),
with the consensus sequence YX4LF (where Y, X, L, and F
denote Tyr, any amino acid, Leu, and any hydrophobic residue,
respectively; Mader et al., 1995; Marcotrigiano et al., 1999).
This motif also appears in a diverse class of eIF4E-binding
proteins (4E-BPs) that generally inhibit translation initiation by
competing with eIF4G for binding to eIF4E (Haghighat et al.,
1995; Mader et al., 1995). The canonical 4E-BMs of eIF4G and
4E-BPs adopt an a-helical conformation upon binding to a
conserved hydrophobic patch on the dorsal surface of eIF4E,
which lies opposite the cap-binding pocket (Marcotrigiano
et al., 1999; Matsuo et al., 1997). In addition, sequences that
are located C-terminally to the canonical motif also contribute
to the interaction between 4E-BPs and eIF4E. These sequences
comprise a linker region and a non-canonical motif, which
together increase the affinity of 4E-BPs for eIF4E by 2 to 3 orders
of magnitude. Although the non-canonical motifs of 4E-BPs are
not conserved in sequence, they all bind to a conserved hydro-
phobic lateral surface of eIF4E and are required for 4E-BPs to
compete with eIF4G and repress translation (Igreja et al., 2014;
Kinkelin et al., 2012; Lukhele et al., 2013; Paku et al., 2012; Peter
et al., 2015a; Sekiyama et al., 2015).
The sequences flanking the canonical motif of eIF4G also
contribute to its interaction with eIF4E (Gross et al., 2003; Ume-
naga et al., 2011). The NMR structure of the Saccharomyces
cerevisiae (Sc) eIF4E-binding region of eIF4G in complex with
eIF4E revealed that these flanking auxiliary sequences fold into
a bracelet-like structure that wraps around the N terminus of
eIF4E and that do not contact the lateral surface of eIF4E (Gross
et al., 2003). These observations have led to amodel in which 4E-
BPs use their non-canonical sequences to dock onto the avail-
able lateral surface of eIF4E-eIF4G complexes, enabling them
to efficiently compete with eIF4G for binding to the dorsal sur-
face (Igreja et al., 2014; Peter et al., 2015a).
However, it is not knownwhether a similar bracelet structure is
formed in metazoan eIF4E-eIF4G complexes because the N-ter-
minal regions of eIF4E and eIF4G that are involved in bracelet for-
mation are not conserved. Furthermore, no structural information
is available for metazoan eIF4E-eIF4G complexes extending
beyond the canonical 4E-BM of eIF4G. Importantly, the NMR
structure of Sc eIF4E-eIF4G was determined in the presence of
a solubilizing detergent. The use of detergent-based conditions
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(which reduces hydrophobic interactions) for the structural deter-
mination of the Sc complex inevitably raises the question as to
whether the observed conformation of Sc eIF4G non-canonical
sequences is physiologically relevant and representative of the
eIF4G-binding mode.
The absence of a complete molecular model for the associa-
tion of metazoan eIF4G with eIF4E limits our molecular under-
standing of translation initiation and its inhibition by 4E-BPs.
To obtain a comprehensive mechanistic, structural, and evolu-
tionary understanding of eIF4E-eIF4G complex assembly, we
determined the structures of human (Hs) and Drosophila
melanogaster (Dm) eIF4G proteins bound to the corresponding
eIF4E. Unexpectedly, and in contrast to the previous model
that was based on the structure of the Sc eIF4E-eIF4G complex,
our structural data reveal that the eIF4G auxiliary sequences
engage the lateral surface of eIF4E in a similar manner to that
of 4E-BPs. This similarity explains why 4E-BPs compete effi-
ciently with eIF4G for binding to eIF4E. Furthermore, we show
that the amino acid composition of the linker regions and the
non-canonical motifs of 4E-BPs are crucial for providing 4E-
BPs with a competitive advantage over eIF4G. Together, our
studies provide molecular insight into eIF4E-eIF4G complex as-
sembly, a revised model for the action of 4E-BPs, and a struc-
tural framework for the rational design of small-molecule transla-
tion inhibitors for use as therapeutic agents for diseases that are
associated with increased protein synthesis.
RESULTS
The N-terminal Regions of Hs and Dm eIF4E Are Not
Required for Binding to eIF4G
eIF4E proteins comprise a conserved folded domain preceded
by an N-terminal unstructured extension of variable length and
sequence (Figures 1A andS1A). Despite the lack of conservation,
the N-terminal extension of Sc eIF4E (residues A21–V35; Fig-
ure 1A) is required for high-affinity binding to eIF4G (Gross
et al., 2003). To investigate whether the N-terminal unstructured
regions of metazoan eIF4Es contribute to the interaction with
eIF4G, we tested the ability of N-terminally truncated Hs and
Dm eIF4E proteins to bind fragments of the corresponding
eIF4Gs using in vitro pull-down assays. The eIF4G fragments
included the canonical (C) 4E-BM and the flanking auxiliary se-
quences that have previously been shown to be involved in bind-
ing to eIF4E in several species. These flanking sequences include
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Figure 1. Formation of the Metazoan eIF4E-eIF4G Complex Does Not Require the eIF4E N-Terminal Region
(A) Schematic representation of Hs, Dm, and Sc eIF4E proteins. The N-terminal truncations analyzed in this study are indicated by vertical dashed lines. The
conserved folded domain is highlighted in dark gray.
(B) Schematic organization of the eIF4E-binding regions of Hs, Dm, and Sc eIF4G proteins. The N-terminal region (N), the canonical (C) and non-canonical (NC)
4E-BMs, and the connecting linker (L) are indicated.
(C and D) Interaction of N-terminally truncated eIF4E proteins and the eIF4E-binding regions ofHs (C) andDm (D) eIF4G. The untagged recombinantHs eIF4E (full-
length, D23 or D35) or purified Dm eIF4E (full-length or D68) was pulled down using m7GTP-sepharose beads in the presence of eIF4G fragments. The lanes
labeled starting material (SM) show the lysates (2%) and purified proteins (7.5%) used in the pull-down assays. The bound fractions (50% in C and 27% in D) were
analyzed by SDS-PAGE and Coomassie blue staining. See also Figure S1A and Table S1.
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residues that are N-terminal (N) to the canonical motif, as well as
C-terminal residues, which we divided into the linker region (L)
and the non-canonical motif (NC) based on the structures pre-
sented below (Figures 1B and S1B; Table S1; Gross et al.,
2003;Hershey et al., 1999;Umenaga et al., 2011). The eIF4E con-
structs contained progressive deletions of N-terminal residues
corresponding to residues that are involved in the eIF4E-eIF4G
interaction in Sc (Figure 1A; Gross et al., 2003). We observed
that the N-terminal deletions did not affect the ability of Hs or
Dm eIF4E to bind to eIF4G in this assay (Figures 1C and 1D).
To validate these observations, we determined the affinity of
the eIF4E-binding region of Dm eIF4G for Dm eIF4E protein var-
iants lacking the first 30 and 68 N-terminal residues (D30 and
D68, corresponding to full-length Sc eIF4E and Sc eIF4E D35,
respectively) using isothermal titration calorimetry (ITC). We
chose Dm proteins for this purpose because they exhibited
much greater stability than the human proteins in solution, which
is necessary for biophysical analysis. The dissociation constant
(KD) of the eIF4G peptide (Ns+C+L+NC; residues S601–N675)
for the eIF4E D30 and D68 variants was in the low nanomolar
range (4.2 ± 0.2 and 5 ± 1.4 nM, respectively), and no differences
in binding thermodynamics were observed in the presence or
absence of the eIF4E N-terminal extension (Figures S2A and
S2B; Table S2). These results contrast with the findings reported
in Sc, in which the deletion of the first 35 N-terminal residues of
eIF4E reduced the affinity for eIF4G by two orders of magnitude
(4.2 nM versus 314.4 nM; Gross et al., 2003). Thus, the eIF4E
N-terminal extension is not essential for the assembly of the
Dm eIF4E-eIF4G complex, suggesting that the interaction of
eIF4G auxiliary sequences with eIF4E diverged during evolution.
Crystal Structures ofMetazoan eIF4E-eIF4G Complexes
Reveal a Lateral Binding Site for eIF4G
To gain insight into the assembly of the metazoan eIF4E-eIF4G
complex, we determined the structures of Hs and Dm eIF4E in
complex with the eIF4E-binding peptide of the corresponding
eIF4G (Hs 592–653 and Dm 601–660; Figure S1B; Table S1).
The Dm complex was crystallized both in the absence and pres-
ence of the m7GpppG cap analog, whereas the Hs complex was
crystallized only in the presence of m7GpppG (Figures 2A–2G
and S3A–S3D; Table 1).
The structures of Hs and Dm eIF4E in the complexes are
similar to the previously determined structures of free and bound
eIF4E from diverse organisms, and no major conformational
changes occur upon eIF4G binding, as previously described
(Figure S3D; Marcotrigiano et al., 1999; Peter et al., 2015a).
The overall fold of eIF4E is highly conserved and consists of a
strongly curved b sheet of eight antiparallel strands that adopt
a horseshoe-like conformation. The cap-binding cavity is
located on the concave, ventral surface (Figures 2A, 2B, and
2E). The convex surface is covered by three a helices that form
the dorsal binding surface of the protein (Figures 2B, 2D, and 2E).
The structures of Hs and Dm eIF4E bound to the cap analog
superpose with a root-mean-square deviation (RMSD) of
0.46 A˚ over 137 Ca atoms (Figure S3D). The differences
observed in the N-terminal region of eIF4E (Figures 2A versus
2C) are due to a truncation (D68) of the Dm eIF4E protein for
the purpose of crystallization. Although full-length eIF4E was
used in the human complex, the first 29 residues (M1–A29) are
not visible in the electron density map (Figure S1A).
Unexpectedly, and in contrast to previous observations of the
NMR structure of the Sc eIF4E-eIF4G complex (Gross et al.,
2003; Figures 2H and S4A), the Hs and Dm eIF4G peptides con-
tact the lateral surface of eIF4E in amode that is structurally anal-
ogous to that observed for diverse 4E-BPs (Figures 2A–2G and
S4B–S4D; Peter et al., 2015a, 2015b; Sekiyama et al., 2015).
Indeed, the two eIF4G peptides feature three common structural
elements: (1) a canonical helix that binds the dorsal surface of
eIF4E; (2) a linker region following the canonical helix that forms
an elbow loop, which orients the peptide backbone toward the
lateral surface of eIF4E; and (3) a non-canonical motif that en-
gages the lateral surface of eIF4Emainly through hydrophobic in-
teractions. Thus, our structures extend the eIF4E-eIF4G interface
beyond the previously characterized canonical helix, providing
unprecedented information on the bindingmodeof themetazoan
eIF4G. This binding mode is clearly distinct from the bracelet-
like structure formed around the eIF4E N terminus on the dorsal
surface of eIF4E observed in the NMR structure of the Sc
eIF4E-eIF4G complex (Gross et al., 2003; Figures 2H and S4A).
Structural Details of the Interaction of eIF4E with eIF4G
The Hs and Dm eIF4G peptides engage the dorsal and lateral
surfaces of eIF4E through interactions that are mediated by
the canonical and non-canonical 4E-BMs and the connecting
linker (Figures 3A–3F) and bury comparable total surface areas
(Table S3).
The canonical helices of Hs and Dm eIF4G interact with eIF4E
through the conserved residues in the consensus sequence in a
similar manner to that observed in other eIF4Gs and 4E-BPs in
complex with eIF4E (Figures 3A and 3B; Gross et al., 2003; Kin-
kelin et al., 2012; Marcotrigiano et al., 1999; Peter et al., 2015a,
2015b). The tyrosine residue of the canonical consensus 4E-BM
(HsY612 orDmY621) forms a hydrogen bond to the backbone of
the conserved His-Pro-Leu motif of eIF4E (Hs H37-P38-L39 or
Dm H70-P71-L72; Figures 3A and 3B). The hydrophobic resi-
dues at the C terminus of the canonical motif (LF; Hs L617 and
L618 or Dm L626 and L627) interact with conserved residues
on the dorsal surface of eIF4E (Hs V69, W73, and L135 or Dm
V102, W106, and L167).
The canonical motifs of metazoan eIF4Gs and other 4E-
BPs contain Arg/Gln/Lys residues at positions 2 and 9, leading
to an extended canonical consensus sequence [YX(R/K)
X2LFX2(R/K/Q)]. These residues contribute to the interaction
with eIF4E, likely by shielding hydrophobic surface patches of
eIF4E from solvent exposure (Kinkelin et al., 2012; Peter et al.,
2015a). Furthermore, the Arg residues at position 2 of the meta-
zoan eIF4Gs (HsR614 andDmR623) further stabilize the binding
of the canonical helix by forming a salt bridge with an acidic res-
idue in eIF4E (Hs E132 or Dm D164; Figures 3A and 3B), which is
conserved in metazoans (Figure S1A).
Following the canonical helix, themetazoan eIF4G linker forms
an elbow loop (Figures 3C and 3D and S5A–S5C). The elbow
loops begin immediately after the Arg/Gln residues at position
9 of the canonical motifs (Hs Q621 and Dm R630) and comprise
a half helical turn beginning with a residue located at the tip of the
elbow (Hs F624 andDmK633) and endingwith similarly arranged
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serine residues (Hs S626 and Dm S635). The side chains of the
Ser residues contact the carbonyl oxygens of the preceding res-
idues (Hs F620 and Dm L629; Figures S5A and S5B), thus fixing
the backbone. Further stabilization is provided by internal back-
bone-mediated hydrogen bonds within the half helical turn (Fig-
ures S5A and S5B). The elbow loops are anchored to the surface
of eIF4E through interactions with conserved eIF4E Asn (Hs N77
and Dm N110) and His (Hs H78 and Dm H111) residues. These
interactions orient the linker region toward the lateral surface
of eIF4E.
A major difference between the yeast and metazoan com-
plexes is observed in the conformation of the non-canonical mo-
tifs. In the metazoan complexes, the non-canonical motifs fold
into a loop that engages the lateral surface of eIF4E (Figures
3E and 3F). These non-canonical loops are stabilized on the
lateral surface of eIF4E by hydrophobic interactions and bury
comparable surface areas in both species (Table S3). Specif-
ically, the hydrophobic residues in the non-canonical motifs
(Hs L633, I636, V639, and V640 and Dm V641, I646, and L647)
engage the lateral surface of eIF4E, which is linedwith conserved
hydrophobic residues (Hs F47, I63, L75, and I79 and Dm Y80,
I96, L108, and I112; Figures 3E and 3F). Thus, binding to the
lateral hydrophobic surface of eIF4E is a conserved feature of
metazoan eIF4Gs and diverse 4E-BPs. In the yeast complex,
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Figure 2. Structures of Hs and Dm eIF4G Proteins Bound to eIF4E
(A and B) Surface and cartoon representations of the eIF4E-binding region of Hs eIF4G (green) in complex with cap-bound eIF4E (gray) in two orientations. The
bound m7GTP cap analog is shown as sticks. Selected secondary structure elements are labeled.
(C and D) Surface and cartoon representations of the structure of Dm eIF4G (orange) bound to eIF4E (gray) in two orientations. Selected secondary structure
elements are labeled.
(E–H) Schematic representations of eIF4E (E) and of eIF4E bound to Hs (F), Dm (G), and Sc (H) eIF4G. See also Figures S3 and S4; Table S3.
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the corresponding non-canonical motif adopts a helical confor-
mation and closes themolecular bracelet embracing the N termi-
nus of eIF4E without contacting the lateral surface of eIF4E
(Gross et al., 2003; Figures 2H and S4A).
The eIF4G residues that lie N-terminal to the canonical motifs
are arranged differently in the Dm and Hs complexes. In the Dm
complex, this N-terminal region adopts a defined loop conforma-
tion on the dorsal surface of eIF4E, burying several hydrophobic
residues (Dm eIF4G residues I603, Y605, and W610; Figures 3G
and 3H). This organized loop is less complex than the molecular
bracelet that is present in the yeast eIF4E-eIF4G complex (Gross
et al., 2003; Figures 2H and S4A) and does not require the N ter-
minus of eIF4E. Instead, the loop is stabilized and anchored to
the canonical helix by an extensive intramolecular hydrogen
bond network involving the side chains of several residues
(N604, N606, Q609, D622, and Q625; Figure 3H). In the Hs com-
plex, the equivalent N-terminal eIF4G residues (Q592–L606)
were not visible in the electron density map, suggesting either
high flexibility or susceptibility to proteolytic degradation during
crystallization.
Functional Significance of the eIF4G Linker and
Non-Canonical Motif for eIF4E Binding
To determine the contribution of the auxiliary structural elements
to the assembly of the eIF4E-eIF4G complexes, we generated
eIF4E and eIF4G mutants and tested their binding in pull-down
Table 1. Data Collection and Refinement Statistics
Space Group
Hs eIF4E-eIF4G Complex
(Cap-Bound)
Dm eIF4E-eIF4G Complex
(Cap-Free)
Dm eIF4E-eIF4G Complex
(Cap-Bound)
P21 P1 P212121
Unit Cell
Dimensions (A˚) a, b, and c 45.3, 70.3, and 79.9 46.3, 49.7, and 58.6 45.6, 66.2, and 75.6
Angles (!) a, b, and g 90.0, 99.4, and 90.0 102.7, 103.9, and 116.1 90.0, 90.0, and 90.0
Data Collection
Wavelength (A˚) 0.9785 0.9999 0.9999
Resolution (A˚)a 44.65–1.53 (1.56–1.53) 41.42–2.20 (2.27–2.20) 45.62–2.19 (2.26–2.19)
Rsym 0.052 (1.013) 0.121 (0.609) 0.081 (1.066)
Mean I/sI 11.6 (1.2) 6.2 (1.7) 17.0 (2.3)
CC (1/2) 0.998 (0.565) 0.992 (0.683) 0.999 (0.850)
Completeness (%) 99.8 (99.9) 96.6 (91.0) 100.0 (99.6)
Multiplicity 3.7 (3.8) 3.0 (2.5) 12.6 (11.4)
Total number of reflections 278,363 (14,011) 62,442 (4,296) 154,909 (11,807)
Number of unique reflections 74,453 (3,718) 20,740 (1,700) 12,336 (1,036)
Refinement
Resolution (A˚) 44.65–1.53 41.42–2.20 39.10–2.19
No. of reflections 74,411 20,729 12,278
Rwork/Rfree 0.139/0.162 0.208/0.234 0.209/0.231
Number of Atoms
Protein 3,574 3,616 1,783
Cap analog 66 – 33
Other ligands 42 12 –
Water 346 157 35
B Factors (A˚2)
Protein 33.5 43.1 70.6
Cap analog 58.1 – 82.2
Other ligands 53.8 60.2 –
Water 43.1 35.1 56.5
Ramachandran Plot
Favored (%) 98.1 99.1 98.1
Disallowed (%) 0.0 0.0 0.0
Rmsd
Bond lengths (A˚) 0.008 0.002 0.003
Bond angles (!) 0.918 0.468 0.478
aValues shown in parentheses are for the highest resolution shell.
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Figure 3. Molecular Details of Hs and Dm
eIF4E-eIF4G Complexes
(A and B) Close-up view of the canonical helix of
Hs eIF4G (A) and Dm eIF4G (B) bound to the
dorsal surface of the respective eIF4E. In (B),
Dm eIF4G residues S601–S616 were omitted for
clarity.
(C and D) Close-up views of the linker regions
of Hs eIF4G (C) and Dm eIF4G (D) contacting
the respective eIF4Es. The dashed lines indicate
hydrogen bonds or salt bridges.
(E and F) Close-up views of the interactions be-
tween the non-canonical (NC) loops of Hs eIF4G
(E) and Dm eIF4G (F) and the lateral hydrophobic
surface of the corresponding eIF4Es.
(G) Close-up view of the N-terminal loop of Dm
eIF4G assembled on the dorsal surface of Dm
eIF4E. Selected residues are shown as sticks.
(H) Intramolecular hydrogen bond (dashed lines)
network at the N-terminal region of Dm eIF4G.
See also Figure S5.
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assays in vitro using recombinant proteins as well as in coimmu-
noprecipitation assays inHsHEK293T cells and inDmSchneider
(S2) cells.
The interaction of Hs eIF4G with eIF4E was abolished by mu-
tations in the canonical motif (C*; Table S1) both in vitro and
in vivo (Figures 4A and 4B). In contrast, amino acid substitutions
in the non-canonical motif (NC*; Table S1) did not interfere with
eIF4E binding in vitro (Figure 4A, lane 9), but did abolish binding
in human cell lysates (Figure 4B, lane 8), probably because the
mutant protein cannot compete with other 4E-BPs that are pre-
sent in cell lysates for binding to eIF4E. Accordingly, the eIF4E-
binding peptide ofHs eIF4G fused toGFP competedwith endog-
enous full-length eIF4G for binding to eIF4E to a similar extent as
4E-BP1 in human cells (Figure 4C, lanes 7 and 8). However, this
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Figure 4. Contribution of eIF4G Structural Elements to eIF4E Binding
(A) The interaction ofHsHis6-eIF4E with the eIF4E-binding region ofHs eIF4G (N+C+L+NC; wild-type or C* and NC*mutants) was tested using Ni-NTA pull-down
assays. The starting material (2% of the lysate or 3% of the purified protein) and bound fractions (25%) were analyzed as described in Figure 1.
(B) The interaction ofHsGFP-eIF4G (full-length, wild-type or mutated) with HA-eIF4E in human HEK293T cells was tested by immunoprecipitation using anti-GFP
antibodies. The inputs (0.75% for GFP-proteins and 0.5% for HA-eIF4E) and immunoprecipitates (15% for GFP-proteins and 25% for HA-eIF4E) were analyzed
by western blotting.
(C) Competition between Hs eIF4G and Hs 4E-BP1 in vivo. The lysates from human HEK293T cells expressing the indicated GFP-proteins were incubated with
m7GTP-sepharose beads. The input fractions (1% for GFP-proteins and 0.75% for eIF4E and eIF4G) and bound fractions (15% for GFP-proteins, 5% for eIF4E,
and 20% for eIF4G) were analyzed by western blotting using anti-eIF4E, anti-eIF4G, and anti-GFP antibodies. The GFP-tagged proteins includedMBP, a 4E-BP1
fragment (C+L+NC), and a fragment of Hs eIF4G (C+L+NC; wild-type or C* or NC* mutants). The position of the 4E-BP1 fragment is indicated by a black dot.
(D) The interaction of Dm His6-eIF4E (full-length; wild-type or lateral surface mutant [II-AA]) with Dm eIF4G (N+C+L+NC; wild-type or C* mutant) was analyzed by
Ni-NTA pull-down assay. The starting material (3% for eIF4G and 8% for eIF4E) and bound fractions (13% for eIF4E WT and 40% for eIF4E II-AA) were analyzed
by SDS-PAGE.
(E) Interaction of HA-tagged full-length Dm eIF4G (wild-type, C* or NC* mutants) with endogenous eIF4E in S2 cell lysates was analyzed by immunoprecipitation
using anti-HA antibodies. The inputs (0.75% for eIF4G and 0.15% for eIF4E) and immunoprecipitates (30%) were analyzed by western blotting using anti-HA and
anti-eIF4E antibodies.
(F) Cap pull-down assay showing the association of purified, untagged Dm eIF4E (full-length) with the indicated Dm eIF4G fragments. The starting material (SM,
3% purified eIF4E and 2.5% cell lysates) and bound fractions (25%) were visualized on SDS-PAGE followed by Coomassie staining. See also Tables S1 and S4.
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competition was abrogated by mutations in the eIF4G canonical
or non-canonical motif (Figure 4C, lanes 9 and 10). Thus, the
non-canonical motif of Hs eIF4G is not required for binding to
eIF4E in the absence of competitor proteins (in vitro), but is
necessary in the presence of other 4E-BPs (in human cell ly-
sates), indicating a role in stabilizing the eIF4E-eIF4G interaction.
Similarly, mutations in the canonical motif (C*; Table S1) abol-
ished the interaction of Dm eIF4G with eIF4E both in vitro and in
S2 cell lysates (Figures 4D, lane 8 and 4E, lane 7). In contrast, the
interaction was not detectably impaired by mutations or dele-
tions in the non-canonical motif in either condition (Figures 4E,
lane 8 and 4F, lane 9). Accordingly, mutations on the lateral sur-
face of eIF4E (I96A and I112A; II-AA) did not affect the binding of
Dm eIF4G to eIF4E (Figure 4D, lane 10 versus 7).
Different Contributions of the Linker and Non-Canonical
Motifs of eIF4G and 4E-BPs to the Affinity for eIF4E
To determine the contribution of the eIF4G auxiliary sequences
to the overall affinity for eIF4E and to gain insight into how
these eIF4G sequences compare to the equivalent sequences in
4E-BPs, we performed a detailed ITC analysis of the interactions
of Dm eIF4E with Dm eIF4G and the Dm 4E-BP1 ortholog, Thor.
The affinity of the isolated canonical (C) motif of eIF4G for
eIF4E (D30) was approximately 90-fold lower (KD = 380 ±
69 nM) than the affinity of the peptide that additionally contained
the auxiliary sequences flanking the motif (Ns+C+L+NC; KD =
4.2 ± 0.2 nM; Figure S2; Table S2). To determine the contribution
of the sequences preceding (Ns) or following (L+NC) the canon-
ical motif (C) individually, we measured the affinity of the corre-
sponding eIF4G peptides for eIF4E in independent experiments.
The affinity of eIF4G peptides containing the canonical motif was
increased 15-fold when the N-terminal sequenceswere included
(Ns+C; KD = 25 ± 2.9 nM; Table S2) and was increased 10-fold
when the linker and non-canonical motif were present
(C+L+NC; KD = 37 ± 6.5 nM). Importantly, addition of the N-ter-
minal sequence of eIF4G (Ns+C peptide) was accompanied by a
much favorable binding enthalpy (DDH = "7.9 kcal/mol) and an
increase in the entropic penalty of binding [D("TDS) = 6.3 kcal/
mol; Table S2] relative to the canonical motif (C). These results
are consistent with the observation that the N-terminal region es-
tablishes a stabilizing network of intramolecular hydrogen bonds
(Figure 3H) and likely undergoes a disorder-to-order transition
when binding to eIF4E. In contrast, no such enthalpy-entropy
compensation was observed for the addition of the linker and
non-canonical motif (C+L+NC peptide), but primarily entropy-
driven binding in the absence of an enthalpic contribution
[D("TDS) = "1.4 kcal/mol; Table S2], consistent with mainly hy-
drophobic interactions. Similar enthalpic and entropic differ-
ences were obtained when the (Ns) or (L+NC) sequences were
deleted from the (Ns+C+L+NC) peptide (Table S2), indicating
that overall peptide length has little effect.
In sharp contrast to eIF4G, in which the (L+NC) sequences
cause a #10-fold increase on the affinity for eIF4E, in the case
of Thor, this increase was #1,600-fold (Table S2). Indeed,
including the (L+NC) sequences lowers the dissociation constant
of the isolated canonical motif (C) of Thor from 2,260 ± 60 nM to
1.4 ± 0.3 nM (C+L+NC; Table S2). These results indicate that the
lateral surface of eIF4E is much more important for the interac-
tion with Thor than it is for eIF4G. Accordingly, mutations
on the lateral surface of eIF4E reduced the affinity of eIF4G
(Ns+C+L+NC) and Thor (C+L+NC) for eIF4E by 3- and 300-
fold, respectively (Table S2). The decreased dependence of
eIF4G on the lateral surface of eIF4E is also reflected by a
different crystal form of the same eIF4E-eIF4G complex prepara-
tion, in which eIF4G does not bind to the lateral surface of
eIF4E, and most of the linker and non-canonical motif is not
visible (Figures S3B and S3C; Table 1).
Taken together, our results indicate that despite having struc-
tural similarities, the linker and non-canonical motif of eIF4G
contribute less to the overall affinity for eIF4E than the equivalent
sequences in 4E-BPs. Nevertheless, these sequences are
required to maintain the stability of the eIF4G-eIF4E complex in
the presence of competitor proteins.
The Linker and Non-Canonical 4E-BMs Provide a
Competitive Advantage to 4E-BPs over eIF4G
The observation that eIF4G and 4E-BPs bind to overlapping
eIF4E surfaces raises the question of how, in molecular terms,
4E-BPs compete with eIF4G to repress translation. Given the
different contributions of the linker regions and the non-canoni-
cal motifs of eIF4G and Thor to eIF4E binding, it is possible
that the differences in their ability to compete with each other
are determined by these sequences. To evaluate the contribu-
tion of the individual sequence elements in conferring a compet-
itive advantage for binding to eIF4E in competition assays
in vitro, we designed chimeric peptides in which the canonical
motif (C), the linker region (L), or the non-canonical motif (NC)
of the Dm Thor was replaced by the corresponding sequence
from the Dm eIF4G.
First, we compared the ability of a Thor peptide (C+L+NC) and
the equivalent eIF4G peptide (C+L+NC) to displace the entire
eIF4E-binding region of eIF4G (N+C+L+NC) from preassembled
eIF4E-eIF4G complexes. The complexes were challenged with a
3-fold molar excess of the competitor peptides, and the proteins
associated with eIF4E were recovered by eIF4E pull down at
various time points. To compare the different competitor pro-
teins, we estimated the time that each peptide required to
displace 50% of the eIF4G molecules from preassembled
eIF4E-eIF4G complexes, which we operationally defined as the
‘‘half-life’’ of the complex. In the presence of the Thor peptide,
the half-life of the eIF4E-eIF4G complex was 11 ± 3 min. Under
the same conditions, the corresponding eIF4G peptide did not
efficiently displace eIF4G after a 60 min incubation (Figures
5A–5D), consistent with its 26-fold lower affinity (Table S2).
We next tested a chimeric peptide in which the linker and
the non-canonical motif of Thor were replaced by their direct
counterparts in eIF4G (chimera-1, CThor+L4G+NC4G). This pep-
tide exhibited a 78-fold reduction in affinity (KD = 109 ± 8 nM)
compared to the Thor peptide (KD = 1.4 ± 0.5 nM), thereby con-
firming that the linker and the non-canonical motif of eIF4G
contribute to a lesser extent to the overall binding affinity for
eIF4E. Accordingly, the chimera-1 peptide did not efficiently
displace eIF4G from preformed complexes in competition as-
says (Figures 5A and 5E).
In contrast, a chimeric peptide containing the canonical motif
of eIF4G fused to the linker and the non-canonical motif of Thor
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Figure 5. The Linker and Non-Canonical Motif of 4E-BPs Confer a Competitive Advantage over eIF4G
(A–H) In vitro competition assay. Dm eIF4E-eIF4G complexes were incubated in the presence of a 3-fold molar excess of the indicated competitor peptides.
(A and B) Show the quantification of eIF4G (N+C+L+NC) remaining bound to eIF4E in the presence of the competitor proteins at different time points (nR 3). The
half-life of the eIF4E-eIF4G complex (t1/2, mean ± SDs from three independent experiments) in the presence of the competitor protein and the KD values for the
competitor peptides are indicated.
(C–H) Show Representative SDS-PAGE gels for each competition assay. The competitor and eIF4G peptides are boxed in blue and black, respectively. The lanes
labeled starting material (SM) show the purified peptides and complexes used in the competition assay. See also Figure S2 and Tables S1 and S2.
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(chimera-2, C4G+LThor+NCThor) bound to eIF4E with nanomolar
affinity (KD = 3 ± 1.4 nM as compared to KD = 1.4 ± 0.5 nM for
Thor) and was as effective as the Thor peptide in displacing
eIF4G from eIF4E in competition assays, thus reducing the
half-life of the eIF4E-eIF4G complex to 13 ± 5 min (Figures
5A and 5F). These results indicate that the linker and the
non-canonical motif (L+NC) of Thor confer a competitive
advantage in displacing eIF4G from eIF4E, whether they are
fused to the canonical motif of Thor or to that of eIF4G
(Figure 5A).
Next, we investigated the contribution of the linker regions. A
peptide in which the linker of Thor was replaced by the linker
of eIF4G (chimera-3, CThor+L4G+NCThor) bound to eIF4E with
similar affinity to Thor and chimera-2 (4.2 ± 0.9 nM; Table S2).
In competition assays, however, chimera-3 was less effective
at displacing eIF4G than Thor and chimera-2, and the half-life
of the eIF4E-eIF4G complex was 39 ± 1.2 min (Figures 5A and
5G). Conversely, when the linker of eIF4G was replaced by
the linker of Thor to produce chimera-4 (C4G+LThor+NC4G), the
half-life of the eIF4E-eIF4G complex was 44 ± 7.5 min (Figures
5B and 5H). ITC measurements indicated that the affinity of
chimera-4 for eIF4E was increased 3-fold compared to the
eIF4G peptide (13 ± 1.6 nM versus 37 ± 6.5 nM, respectively;
Table S2). The observation that chimera-4 (C4G+LThor+NC4G)
competes less efficiently than chimera-2 (C4G+LThor+NCThor)
indicates that the competitive advantage of Thor in binding
to eIF4E is conferred by both the linker region and the non-
canonical motif.
The Linker SequenceModulates the Affinity of the eIF4E
Interaction
Using the structural data presented in this study, we systemati-
cally analyzed the observed atomic interactions of both meta-
zoan eIF4Gs as well as Dm Thor and Hs 4E-BP1 when bound
to eIF4E, in an attempt to identify features that might contribute
to the binding advantage of 4E-BPs over eIF4G. A notable
feature that distinguishes the linker regions of eIF4Gs from the
linkers of Dm Thor or Hs 4E-BP1–3 is the presence of conserved
Pro residues in the latter (Figure 6A).
Because the presence of Pro residues uniquely restricts the
conformational flexibility of the peptide backbone (MacArthur
and Thornton, 1991; Huang and Nau, 2003), we investigated
how the presence of these residues in the linker affects the affin-
ity of 4E-BPs for eIF4E and the competitive ability of 4E-BPs in
displacing eIF4G from preformed complexes. We substituted
two residues in the linker region of the Dm eIF4G peptide
(C+L+NC) in positions that are structurally equivalent to those
in the Thor peptide with Pro residues (K633P and Q638P;
eIF4G-PP mutant; Figures S5B and S5C). Remarkably, this pep-
tide exhibited the same properties as chimera-4, in which the
entire linker of eIF4G was replaced by the linker of Thor and dis-
placed 50% of bound eIF4G in 37 ± 10 min compared with
>60 min for the wild-type eIF4G (Figures 6B and 6C). These sub-
stitutions also increased the affinity of the eIF4G peptide for
eIF4E from a dissociation constant of 37 ± 6.5 nM (for eIF4G)
to 8 ± 3.5 nM (for eIF4G-PP) to levels that were similar to those
observed for chimera-4 (Table S2). The gain in affinity was asso-
ciated with a more favorable binding entropy compared to the
eIF4G C+L+NC peptide [D("TDS) = " 2.0 kcal/mol; Table S2],
possibly indicating that the conformational freedom of the un-
bound peptide was indeed reduced by the insertion of Pro resi-
dues in the linker. Thus, a proline-rigidified linker can apparently
improve affinity and competition efficiency. Finally, we gener-
ated a Thor peptide in which the two Pro residues were replaced
by their structurally equivalent residues from eIF4G (P66K,
P71Q, Thor-KQ mutant). Interestingly, these substitutions did
not alter the affinity of the peptide for eIF4E, but did slow down
the competition kinetics (Figures 6D and 6E; Table S2).
In conclusion, our results indicate that despite having similar
binding modes, the sequences in the linker region and the non-
canonical motif confer a competitive advantage on 4E-BPs
over eIF4G for binding to eIF4E.
DISCUSSION
Recognition of eIF4E via theDorsal and Lateral Surfaces
In this study, we determined the crystal structures of two meta-
zoan eIF4E-eIF4G complexes, which revealed a much more
extensive interface than was previously inferred from metazoan
structures in which mainly the canonical motif was visible (Mar-
cotrigiano et al., 1999; Peter et al., 2015a). We observed that
eIF4G binds to the lateral side of eIF4E, in addition to the
known dorsal interface, using a binding mode similar to that
employed by 4E-BPs (Figures 2F and 2G; Kinkelin et al.,
2012; Peter et al., 2015a, 2015b; Sekiyama et al., 2015). The
two metazoan structures are highly similar to each other (Fig-
ure S3D), indicating that the observed mode of interaction is
widely conserved across species. However, an NMR structure
of the Sc eIF4E-eIF4G complex (Gross et al., 2003; Figures 2H
and S4B) originally suggested a different interaction mode in
which the linker region and the non-canonical motif adopt
different conformations and do not contact the lateral surface
of eIF4E.
The different conformations of the eIF4G linker and non-
canonical motif in the Sc and metazoan complexes may reflect
the poor conservation of these sequences. However, it is impor-
tant to note that the NMR structure of the Sc complex was
determined in the presence of CHAPS (Gross et al., 2003).
This zwitterionic detergent has been shown to bind to the lateral
surface of Sc eIF4E, thus preventing its association with human
4E-BP2 (Matsuo et al., 1997). Consequently, the detergent may
in fact interfere with hydrophobically driven contacts such as
those of the non-canonical motifs of 4E-BPs and eIF4G with
the lateral surface of eIF4E. Thus, the conformation of Sc
eIF4G bound to eIF4E as observed in the structure of the Sc
eIF4E-eIF4G complex might not represent the physiologically
relevant state required for the initiation of cap-dependent
translation.
Together with previous studies (Kinkelin et al., 2012; Peter
et al., 2015a, 2015b; Sekiyama et al., 2015), our data reveal a
conserved eIF4E recognition mode that is shared by eIF4G
and 4E-BPs. This mode comprises a canonical and a non-ca-
nonical motifs that are connected by a linker region, which allows
eIF4G and 4E-BPs to bind to the dorsal and lateral surfaces of
eIF4E. The structural similarity indicates that eIF4G mimicry by
4E-BPs is not restricted to the canonical helix, but that it extends
476 Molecular Cell 64, 467–479, November 3, 2016
over the entire interface. This unexpected finding has important
implications not only for the development of models to explain
eIF4G and 4E-BP function in the cell, but also for the design of
synthetic translation inhibitors.
Competition between eIF4G and 4E-BPs
The unexpected observation that the metazoan eIF4Gs and
4E-BPs both contact the dorsal and the lateral surface of
eIF4E extends our structural understanding of the mechanism
of competition by showing that the lateral surface of eIF4E is
no longer exclusive to 4E-BPs and that eIF4G and 4E-BPs
also compete on this surface. These interactions need to be
considered when developing models of eIF4G-based transla-
tion regulation.
Although our results indicate that the linker and non-canoni-
cal motif of eIF4G contribute to the stability of the eIF4E-eIF4G
complex, there are clear differences in the energetic contribu-
tions of individual sequence elements of eIF4G or 4E-BP
(Thor)-derived peptides, suggesting that their respective mo-
lecular interaction mechanisms may be distinct despite the
structural similarity. The linker and the non-canonical motifs
of eIF4G both make substantially less significant contributions
to the affinity of eIF4G for eIF4E than was observed for Thor.
Furthermore, the linker between the canonical and non-canon-
ical motif seems to be more flexible in eIF4G than in Thor,
which would allow the two motifs to engage/disengage eIF4E
more independently than in the case of Thor and in a consec-
utive manner. This flexibility has consequences for both the
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Figure 6. The Amino Acid Composition in the Linker Regions Modulates the Competitive Behavior of the 4E-BP and eIF4G Peptides
(A) Sequence alignment of the eIF4E-interacting regions of human 4E-BP1–3, Drosophila Thor, and eIF4G proteins. Canonical (C) and non-canonical (NC) motifs
are boxed in black. The Pro residues present in the linker region of 4E-BP1–3 and Thor, but absent in eIF4G, are in bold and highlighted with a cyan background.
The conserved residues and residues with >70% similarity are highlighted with an orange and yellow background, respectively.
(B–E) Competition assay. Dm eIF4E-eIF4G complexes were incubated in the presence of the indicated competitor peptides as described in Figure 5.
(B and D) Quantification of the amount of eIF4G remaining associated with eIF4E. The KD values determined by ITC are indicated.
(C and E) Representative SDS-PAGE gels for each competition assay. See also Figure S2 and Table S2.
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binding affinity and the temporal stability of the complex that
become apparent when the linker sequences are mutated.
Additionally, in the bound state, the more flexible eIF4G pep-
tides may sample more conformations, thus providing more
opportunities for the 4E-BP competitors to access the tran-
siently available lateral surface on eIF4E; such a mechanism
provides a rationale for the competitive advantage of the 4E-
BPs for binding to eIF4E.
The Lateral Surface of eIF4E Is a Key Target for
Translational Inhibitors
The eIF4E-eIF4G interface is a key target for the development of
small-molecule inhibitors that selectively disrupt this interaction,
thereby leading to the arrest of cap-dependent translation initia-
tion. These inhibitors can be used as therapeutic tools to repress
translation in diseases that are associated with increased protein
synthesis (Jia et al., 2012). The most extensively characterized
inhibitor is 4EGI-1, which has been shown to displace eIF4G
from eIF4E in a dose-dependent manner, while demonstrating
a high degree of selectivity and no effect on the eIF4E interac-
tions with 4E-BP1 (Moerke et al., 2007).
Surprisingly, however, 4EGI-1 was found to bind to the hydro-
phobic lateral surface of eIF4E, which made it difficult to explain
how it would displace eIF4G from the dorsal surface. An allo-
steric mechanism has been proposed and is supported by
NMR experiments and molecular dynamics simulations (Papa-
dopoulos et al., 2014; Salvi et al., 2016; Sekiyama et al., 2015).
Our finding that the eIF4G interaction extends to the lateral sur-
face of eIF4E now provides an additional explanation for the
inhibitory mechanism of 4EGI-1, wherein it directly competes
with eIF4G for binding to the lateral surface (Figures S5D and
S5E). It is conceivable that the affinity of 4EGI-1 is sufficient to
displace the weakly binding non-canonical motif of eIF4G, thus
selectively destabilizing the eIF4E-eIF4G complex and/or accel-
erating its dissociation, whereas the strongly binding non-ca-
nonical motif of 4E-BP1 with its rigidifying linker is substantially
more resistant to such action.
Regarding the future design of small-molecule translational in-
hibitors, our studies indicate that a highly selective translational
inhibitor that would target the interaction of eIF4G with eIF4E
without affecting the interactions with 4E-BPs may be chal-
lenging to attain. For therapeutic applications, however, a highly
potent small-molecule inhibitor that also displaces 4E-BPs
should prove equally useful since this would still result in the
reduction of eIF4E-dependent translation. Furthermore, 4E-BP
activity has been shown to be frequently downregulated under
pathological conditions (e.g., via hyperphosphorylation; Jia
et al., 2012; Martineau et al., 2013); in this case, the synthetic in-
hibitor would effectively compete only with eIF4G for the lateral
surface of eIF4E.
In conclusion, we have identified and characterized the key
structural principles that govern the assembly and stability of
the metazoan eIF4E-eIF4G complex. The identification of an
extended and conserved eIF4E-eIF4G interface not only ad-
vancesourmechanistic understandingof cap-dependent transla-
tion initiation, but also offers vantage points to guide the develop-
ment of translational inhibitors with greater potency, with the
prospect of using such molecules as therapeutic tools to target
exacerbated eIF4Eactivity in diseases such as cancer andautism
spectrumdisorders (Gkogkas et al., 2013;Martineau et al., 2013).
EXPERIMENTAL PROCEDURES
DNA Constructs
All the mutants used in this study were generated by site-directed mutagen-
esis using the QuikChange mutagenesis kit (Stratagene). All mutants were
confirmed by DNA sequencing and are listed in Table S1.
Protein Expression and Purification
All proteins were expressed in E. coli BL21 Star (DE3) cells (Invitrogen) grown
in LB medium overnight at 20!C. A detailed description of the purification
procedures is provided in the Supplemental Experimental Procedures.
Pull-Downs, ITC Analysis, and Competition Assays
The in vitro pull-down and competition assays and the ITC analysis were per-
formed as described previously (Igreja et al., 2014; Peter et al., 2015a) and are
described in the Supplemental Information.
Crystallization, Data Collection, and Structure Determination
The purified eIF4E-eIF4G complexes were subjected to crystallization trials
directly after purification. When indicated, cap analog (m7GpppG; NEB) was
added to the purified eIF4E-eIF4G complexes prior to crystallization, at a 1.1-
to 1.2-fold molar excess. Crystals of the Hs eIF4E (residues M1–V217)-Hs
eIF4G (residues Q592–D653) complex were obtained after mixing 0.2 mL of
the purified protein (18 mg/mL [540 mM] in 10 mM HEPES-NaOH [pH 7.5],
200 mM NaCl, and 2 mM DTT supplemented with m7GpppG [648 mM]) with
0.2 mL of reservoir solution containing 0.1 M HEPES/NaOH (pH 7.25) and 25%
(w/v) PEG6000. Crystal grew at 20!C over a 7-day period using the sitting-
drop vapor diffusion method. Crystals of the Dm eIF4E (residues K69–L248)-
Dm eIF4G (residues S601–N660) complex (18 mg/mL in 10 mM HEPES-NaOH
[pH 7.5], 200 mM NaCl, and 2 mM DTT) were obtained by the hanging-drop
vapor-diffusion method at 18!C. These crystals grew within 7 days after mixing
0.8 mL of protein solution with 0.8 mL of reservoir solution containing 0.1 M Tris-
HCl (pH8.25), 0.2MMgCl2, and32%(w/v)PEG4000. Thecrystals containing the
cap analog were obtained after mixing 0.2 mL of the purified protein (21 mg/mL
[734 mM] in HEPES-NaOH [pH 7.5], 200 mM NaCl, and 2 mM DTT) in the pres-
ence of m7GpppG (807 mM) with 0.2 mL of reservoir solution containing 0.1 M
Tris-HCl (pH 8.0), 0.01 M ZnCl2, and 20% (w/v) PEG6000. Crystals grew at
20!C in 3 to 5 days using the sitting-drop vapor diffusion method. All crystals
were briefly transferred into mother liquor supplemented with 17%–20% (v/v)
glycerol for cryoprotection and flash-frozen in liquid nitrogen.
Diffraction data for the Hs eIF4E-eIF4G complex bound to cap analog were
recorded at a wavelength of 0.97857 A˚ on a DECTRIS PILATUS 6M detector at
the PROXIMA 1 beamline of the SOLEIL synchrotron (France). The diffraction
data for the Dm eIF4E-eIF4G complexes were collected at a wavelength of
0.9999 A˚ at 100 K and on a PILATUS 6M detector at the PXII beamline of
the Swiss Light Source. A detailed description of the structure determination
process can be found in the Supplemental Experimental Procedures. The ste-
reochemical properties for all structures were verified using MOLPROBITY
(Chen et al., 2010), and the structural images were prepared using PyMOL
(http://www.pymol.org). Data collection and refinement statistics are summa-
rized in Table 1.
ACCESSION NUMBERS
The accession numbers for the coordinates for the structures reported in this
paper are PDB: 5T46 (Hs eIF4E–eIF4G–cap analog), 5T47 (Dm eIF4E–eIF4G),
and 5T48 (Dm eIF4E–eIF4G–cap analog).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.molcel.2016.09.020.
478 Molecular Cell 64, 467–479, November 3, 2016
AUTHOR CONTRIBUTIONS
S.G. purified most of the proteins used in this study, performed and analyzed
the ITC experiments, collected crystal diffraction data, and solved the struc-
tures under the supervision of E.V. and O.W. S.G., D.P., E.V., and O.W.
analyzed structural data. R.W. and D.P. performed competition assays.
S.G., R.W., D.P., L.W., and M.-Y.C. performed pull-down and coimmunopre-
cipitation assays under the supervision of C.I. E.I. oversaw the project as prin-
cipal investigator. D.P. and C.I. initiated the project. C.I. coordinated the study.
S.G., E.V., C.I., O.W., and E.I. wrote the manuscript with contributions from all
authors.
ACKNOWLEDGMENTS
We thank R. Bu¨ttner and T. Raisch for setting up crystallization screens, F.
Sandmeir for help in protein purification, A. Bla¨ßle for help in data analysis,
and C. Weiler for technical assistance. We acknowledge the staff at the PXII
beamline of the Swiss Light Source for excellent support with data collection
and also the beamline staff at Proxima 1 of SOLEIL Synchrotron for granting
beam time and providing assistance with data collection. This work was sup-
ported by the Max Planck Society.
Received: June 10, 2016
Revised: August 22, 2016
Accepted: September 14, 2016
Published: October 20, 2016
REFERENCES
Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M.,
Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010).
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.
Gkogkas, C.G., Khoutorsky, A., Ran, I., Rampakakis, E., Nevarko, T.,
Weatherill, D.B., Vasuta, C., Yee, S., Truitt, M., Dallaire, P., et al. (2013).
Autism-related deficits via dysregulated eIF4E-dependent translational con-
trol. Nature 493, 371–377.
Gross, J.D., Moerke, N.J., von der Haar, T., Lugovskoy, A.A., Sachs, A.B.,
McCarthy, J.E., and Wagner, G. (2003). Ribosome loading onto the mRNA
cap is driven by conformational coupling between eIF4G and eIF4E. Cell
115, 739–750.
Haghighat, A., Mader, S., Pause, A., and Sonenberg, N. (1995). Repression of
cap-dependent translation by 4E-binding protein 1: competition with p220 for
binding to eukaryotic initiation factor-4E. EMBO J. 14, 5701–5709.
Hershey, P.E., McWhirter, S.M., Gross, J.D., Wagner, G., Alber, T., and Sachs,
A.B. (1999). The Cap-binding protein eIF4E promotes folding of a functional
domain of yeast translation initiation factor eIF4G1. J. Biol. Chem. 274,
21297–21304.
Howard, A., and Rogers, A.N. (2014). Role of translation initiation factor 4G in
lifespan regulation and age-related health. Ageing Res. Rev. 13, 115–124.
Huang, F., and Nau, W.M. (2003). A conformational flexibility scale for amino
acids in peptides. Angew. Chem. Int. Ed. Engl. 42, 2269–2272.
Igreja, C., Peter, D., Weiler, C., and Izaurralde, E. (2014). 4E-BPs require non-
canonical 4E-binding motifs and a lateral surface of eIF4E to repress transla-
tion. Nat. Commun. 5, 4790.
Jackson, R.J., Hellen, C.U., and Pestova, T.V. (2010). The mechanism of eu-
karyotic translation initiation and principles of its regulation. Nat. Rev. Mol.
Cell Biol. 11, 113–127.
Jia, Y., Polunovsky, V., Bitterman, P.B., and Wagner, C.R. (2012). Cap-depen-
dent translation initiation factor eIF4E: an emerging anticancer drug target.
Med. Res. Rev. 32, 786–814.
Kinkelin, K., Veith, K., Gru¨nwald, M., and Bono, F. (2012). Crystal structure of a
minimal eIF4E-Cup complex reveals a general mechanism of eIF4E regulation
in translational repression. RNA 18, 1624–1634.
Lukhele, S., Bah, A., Lin, H., Sonenberg, N., and Forman-Kay, J.D. (2013).
Interaction of the eukaryotic initiation factor 4E with 4E-BP2 at a dynamic
bipartite interface. Structure 21, 2186–2196.
MacArthur, M.W., and Thornton, J.M. (1991). Influence of proline residues on
protein conformation. J. Mol. Biol. 218, 397–412.
Mader, S., Lee, H., Pause, A., and Sonenberg, N. (1995). The translation initi-
ation factor eIF-4E binds to a common motif shared by the translation factor
eIF-4 gamma and the translational repressors 4E-binding proteins. Mol. Cell.
Biol. 15, 4990–4997.
Marcotrigiano, J., Gingras, A.C., Sonenberg, N., and Burley, S.K. (1999). Cap-
dependent translation initiation in eukaryotes is regulated by a molecular
mimic of eIF4G. Mol. Cell 3, 707–716.
Martineau, Y., Azar, R., Bousquet, C., and Pyronnet, S. (2013). Anti-oncogenic
potential of the eIF4E-binding proteins. Oncogene 32, 671–677.
Matsuo, H., Li, H., McGuire, A.M., Fletcher, C.M., Gingras, A.C., Sonenberg,
N., and Wagner, G. (1997). Structure of translation factor eIF4E bound to
m7GDP and interaction with 4E-binding protein. Nat. Struct. Biol. 4, 717–724.
Moerke, N.J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M.Y., Fahmy, A.,
Gross, J.D., Degterev, A., Yuan, J., Chorev, M., et al. (2007). Small-molecule
inhibition of the interaction between the translation initiation factors eIF4E
and eIF4G. Cell 128, 257–267.
Paku, K.S., Umenaga, Y., Usui, T., Fukuyo, A., Mizuno, A., In, Y., Ishida, T., and
Tomoo, K. (2012). A conservedmotif within the flexible C-terminus of the trans-
lational regulator 4E-BP is required for tight binding to the mRNA cap-binding
protein eIF4E. Biochem. J. 441, 237–245.
Papadopoulos, E., Jenni, S., Kabha, E., Takrouri, K.J., Yi, T., Salvi, N., Luna,
R.E., Gavathiotis, E., Mahalingam, P., Arthanari, H., et al. (2014). Structure of
the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals
an allosteric mechanism for dissociating eIF4G. Proc. Natl. Acad. Sci. USA
111, E3187–E3195.
Peter, D., Igreja, C., Weber, R., Wohlbold, L., Weiler, C., Ebertsch, L.,
Weichenrieder, O., and Izaurralde, E. (2015a). Molecular architecture of 4E-
BP translational inhibitors bound to eIF4E. Mol. Cell 57, 1074–1087.
Peter, D., Weber, R., Ko¨ne, C., Chung, M.Y., Ebertsch, L., Truffault, V.,
Weichenrieder, O., Igreja, C., and Izaurralde, E. (2015b). Mextli proteins use
both canonical bipartite and novel tripartite binding modes to form eIF4E com-
plexes that display differential sensitivity to 4E-BP regulation. Genes Dev. 29,
1835–1849.
Salvi, N., Papadopoulos, E., Blackledge,M., andWagner, G. (2016). The role of
dynamics and allostery in the inhibition of the eIF4E/eIF4G translation initiation
factor complex. Angew. Chem. Int. Ed. Engl. 55, 7176–7179.
Sekiyama, N., Arthanari, H., Papadopoulos, E., Rodriguez-Mias, R.A., Wagner,
G., and Le´ger-Abraham,M. (2015). Molecular mechanism of the dual activity of
4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphos-
phorylated 4E-BP1. Proc. Natl. Acad. Sci. USA 112, E4036–E4045.
Umenaga, Y., Paku, K.S., In, Y., Ishida, T., and Tomoo, K. (2011). Identification
and function of the second eIF4E-binding region in N-terminal domain
of eIF4G: comparison with eIF4E-binding protein. Biochem. Biophys. Res.
Commun. 414, 462–467.
Molecular Cell 64, 467–479, November 3, 2016 479
Molecular Cell, Volume 64
Supplemental Information
The Structures of eIF4E-eIF4G Complexes
Reveal an Extended Interface
to Regulate Translation Initiation
Stefan Grüner, Daniel Peter, Ramona Weber, Lara Wohlbold, Min-Yi Chung, Oliver
Weichenrieder, Eugene Valkov, Cátia Igreja, and Elisa Izaurralde
!!
!
SUPPLEMENTAL FIGURES 
 
Figure S1, related to Figure 1. Sequence alignments 
(A) Structure-based sequence alignment of eIF4E orthologous proteins from Homo sapiens 
(Hs), Drosophila melanogaster (Dm) and Saccharomyces cerevisiae (Sc). Conserved residues 
are highlighted with a black background and printed in white. Residues with >70% similarity 
are shown with a gray background. The Trp residues coordinating the mRNA cap structure are 
indicated by red asterisks. The residues mutated in this study are indicated by red circles. The 
lateral and dorsal binding surfaces (BS) are indicated by a line below the sequences. The 
positions of the N-terminal deletions on the different eIF4E proteins are indicated by vertical 
red dashed lines. Secondary structure elements of Hs eIF4E are indicated above the sequences 
with the exception of L9 and β8, which are indicated for Dm eIF4E because the corresponding 
residues are not defined in our human eIF4E structure. 
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(B) Sequence alignment of the eIF4E-interacting regions of eIF4G orthologous proteins. 
Species abbreviations are as in panel (A). The eIF4G sequences visible in the crystal structures 
are highlighted by a light gray background. Conserved residues are highlighted with an orange 
background and printed in white. Residues with >70% similarity are shown with a yellow 
background. The canonical (C) and non-canonical (NC) motifs are boxed in black. Key eIF4G 
residues within the motifs contacting eIF4E and mutated in this study are indicated by green 
open circles. The residues forming the elbow loops in the Hs and Dm proteins are indicated by 
a triangle above the alignment. The secondary structure elements indicated above the Sc 
sequences are based on the structure of the Sc eIF4E–eIF4G complex [PDB ID: 1RF8; Gross et 
al., 2003). 
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Figure S2, related to Figure 1, Figure 5, Figure 6 and Table S2. Isothermal titration 
calorimetry (ITC) data for the interaction of Dm eIF4E with the indicated peptides 
(A to M) Representative isothermal titration calorimetry (ITC) thermograms for the 
interactions of Dm eIF4E proteins (∆30, ∆68, wild-type or II-AA mutant) with the indicated 
Dm eIF4G, Dm Thor and Chimera peptides C-terminally fused to GB1. The fitted 
thermodynamic parameters are shown in Table S2. Upper panels show raw data in (µcal sec-1), 
and lower panels represent the integration of heat changes associated with each injection (kcal 
mol-1 of injectant). Data were fitted using a one-site binding model.  
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Figure S3, related to Figure 2. Crystal structures and packing of Dm eIF4E–eIF4G 
complexes  
(A) Cartoon representation of the Dm eIF4E–eIF4G complex in the absence of cap analog. The 
asymmetric unit of the crystal contains two copies of the complex (complex I, chains A and B 
and complex II chains C and D). The non-canonical motif was better defined in complex II. 
eIF4E is shown in gray and eIF4G in orange. 
(B) Schematic representation of the crystal form of the Dm eIF4E–eIF4G complex in the 
presence of cap analog m7GpppG. Only the electron density for the m7GTP-moiety was visible. 
eIF4E is shown in gray and eIF4G in cyan. The asymmetric unit contained one complex 
(complex I). In this crystal form, the non-canonical motif of eIF4G is not visible in the electron 
density. Instead, the expression tag and the N-terminal region of the eIF4G molecule from a 
symmetry-related complex (complex I’) occupy the lateral surface of eIF4E, with residues 
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!
H599-N604 from the symmetry mate taking the position of residues N643-P648 as observed in 
PDB-ID 5T47.  
(C) Structural superposition of the Dm eIF4E–eIF4G complexes with and without cap analog. 
The RMSD is 0.33 Å over 127 Cα atoms of eIF4E. Cap-free eIF4E is omitted for clarity. The 
N-terminal region and the canonical motif of eIF4G are highly similar between the two crystal 
forms. Selected secondary structure elements are labeled in black for eIF4E and in color for 
eIF4G.  
(D) Overlay of Dm and Hs eIF4E–eIF4G complexes. The RMSD is 0.39 Å over 123 Cα atoms 
of eIF4E. Hs and Dm eIF4G are colored in green and orange, respectively. Hs and Dm eIF4E 
are colored in gray and purple, respectively.   
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Figure S4, related to Figure 3. Structural comparisons of the fungal and metazoan 
eIF4E–eIF4G and eIF4E–4E-BP complexes  
(A) Surface representations of Sc eIF4E in complex with Sc eIF4G (PDB ID: 1RF8; Gross et 
al., 2003). eIF4G is shown in blue. The m7GDP ligand is shown as sticks. Residues M1–A21 
of Sc eIF4E and I391–T404 of Sc eIF4G are omitted for clarity. 
(B) Superposition of eIF4E in complex with Hs and Dm eIF4G. The eIF4E molecule from the 
Dm complex is omitted for clarity. The eIF4G molecules are shown as cartoon representation 
with Hs eIF4G colored in green and Dm eIF4G in orange. 
(C) Comparison of the Dm eIF4E-eIF4G complex (this study) with the Dm eIF4E–Thor 
complex (PDB ID: 4UE8; Peter et al., 2015a). Dm eIF4G and Thor are colored in orange and 
purple, respectively.  
(D) Superposition of the Hs eIF4E–eIF4G complex (this study) with the Hs eIF4E–4E-BP1 
complex (PDB ID: 4UED; Peter et al., 2015a). Hs eIF4G and Hs 4E-BP1 are colored in green 
and magenta, respectively.  
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Figure S5, related to Figure 4. Metazoan eIF4G linker interactions and modulation of Hs 
eIF4E–eIF4G interactions by 4EGI-1 
(A–C) Close-up views of the Hs (A) and Dm (B) eIF4G elbow loops compared to the Dm Thor 
elbow loop (C) (PDB ID: 4UE8; Peter et al., 2015a). Selected residues are shown as sticks. 
Hydrogen bonds are indicated by dashed lines. Pro residues in the Thor linker region and the 
corresponding residues in the Dm eIF4G linker mutated in this study are underlined.  
(D) Superposition of the Hs eIF4E-eIF4G structure with the structure of eIF4E bound to the 
4EGI-1 inhibitor (PDB ID: 4TPW; Papadopoulos et al., 2014). The eIF4E and eIF4G 
molecules are shown in cartoon representation, with selected secondary structure elements 
labeled in black for eIF4E and green for eIF4G. The 4EGI-1 inhibitor is shown as black sticks.  
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(E) Close-up view of superposed eIF4E molecules bound to either eIF4G or 4EGI-1, with 
eIF4E shown in surface representation. Selected residues from the non-canonical motif of 
eIF4G and 4EGI-1 are shown as sticks.  
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SUPPLEMENTAL TABLES 
Table S1 related to Figure 1 and 4–6. Mutants and constructs used in this study 
Protein Name of the construct Fragments / mutations Comments 
Dm eIF4E 
(1–248) (isoform 
C) 
P48598-2 
4E Full-length (1–248)  
II-AA I96A, I112A Lateral surface mutant 
∆30 31–248  
∆68 69–248 eIF4E used for crystallization 
Dm eIF4G 
(1–1666) 
(isoform A) 
O61380 
N+C+L+NC 578–675 Extended eIF4E-binding region 
Ns+C 601–634 N-term short + canonical 
NL+C 578–634 
N-term long + canonical 
(pulldown) 
C+L+NC 617–675 Canonical +linker + non-canonical 
C 617–634 Canonical  
NS+C+L+NC 601–675 eIF4E-binding region 
NS+C+L+NC 601–660 
eIF4E-binding region used for 
crystallization 
C* Y621A, L626A, L627A Canonical mutant 
NC* V641A, I646A  Non-canonical mutant 
eIF4G-PP 617–675 (K633P, Q638P) Linker mutant 
Hs eIF4E 
(1–217) 
P06730 
4E Full–length (1–127) eIF4E used for crystallization 
∆23 24–217  
∆35 36–217  
Hs eIF4G 
Isoform A 
(1–1599) 
Q04637 
N+C+L+NC 592–653 eIF4E-binding region used for crystallization 
NL+C+L+NC 571–676 eIF4E-binding region (pulldown) 
C+L+NC 608–647 Canonical +linker + non-canonical 
C* Y612A, L617A, L618A Canonical 
NC* L633A, V639A Non-canonical 
Thor 
(1–117) 
Q9XZ56 
C+L+NC 50–83 eIF4E-binding region  
Thor-KQ 50–83 P66K, P71Q  
CThor+L4G+NC4G Chimera 1 Dm Thor 50–63 + Dm eIF4G 631–675   
C4G+LThor+NCThor Chimera 2 Dm eIF4G 617–630 + Dm Thor  64–83  
CThor+L4G+NCThor Chimera 3 
Dm Thor 50–63 + Dm 
eIF4G 631–638 + Dm Thor 
NC 72–83 
 
C4G+LThor+NC4G Chimera 4 
Dm eIF4G 617–630 + Dm 
Thor 64–71+Dm eIF4G 
639–675 
 
 
For the in vitro experiments, Dm eIF4G, Dm Thor and the chimeric peptides were tagged C-terminally 
with GB1 (see Supplemental Experimental Procedures). 
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Table S2, related to Figure 5, 6 and S2. Thermodynamic parameters for the interaction of Dm 
eIF4E with the indicated eIF4G, Thor and Chimera peptides 
Peptide KD (nM) ΔH (kcal 
mol-1) 
-TΔS (kcal 
mol-1) 
ΔG (kcal 
mol-1) 
Molar  
ratio 
eIF4G peptide + eIF4E ∆68 
eIF4G Ns+C+L+NC 5  ± 1.4 -15.0 ± 0.5 3.9 ± 0.6 -11.1 ± 0.2 1.02 ± 0.02 
eIF4G or Thor peptide + eIF4E ∆68 II-AA 
eIF4G Ns+C+L+NC 16 ± 2.6 -15.1 ± 0.2 4.6 ± 0.3 -10.4 ± 0.1 0.99 ± 0.02 
*Thor C+L+NC 470 ± 30 -7.6 ± 0.3 -0.9 -8.5 0.97 ± 0.01 
eIF4G peptide + eIF4E ∆30 
eIF4G Ns+C+L+NC 4.2 ± 0.2 -15.2 ± 0.2 4.0 ± 0.2 -11.2 ± 0.1 1.01 ± 0.01 
eIF4G C+L+NC 37 ± 6.5 -7.8 ± 0.6 -2.1 ± 0.6 -10.0 ± 0.1 1.00 ± 0.04 
eIF4G Ns+C 25 ± 2.9 -15.8 ± 0.3 5.6 ± 0.3 -10.2 ± 0.1 1.00 ± 0.01 
eIF4G C 380 ± 69 -7.9 ± 0.1 -0.7 ± 0.2 -8.6 ± 0.1 1.00 ± 0.01 
eIF4G-PP 8 ± 3.5 -6.8 ± 0.2 -4.1 ± 0.3 -10.8 ± 0.2 1.00 ± 0.01 
Chimeric peptides + eIF4E ∆30 
Chimera 1 
CThor+L4G+NC4G 
109 ± 8  -11.5 ± 0.1 2.2 ± 0.1 -9.3 ± 0.1 1.01 ± 0.01 
Chimera 2 
C4G+LThor+NCThor 
3 ± 1.4 -10.0 ± 0.9 -1.4 ± 0.9 -11.4 ± 0.3 0.99 ± 0.01 
Chimera 3 
CThor+L4G+NCThor 
4.2 ± 0.9 -10.1 ± 0.3 -1.1 ± 0.3 -11.2 ± 0.1 1.00 ± 0.02 
Chimera 4 
C4G+LThor+NC4G 
13 ± 1.6 -7.4 ± 1.2 -3.2 ± 1.2 -10.6 ± 0.1 1.00 ± 0.01 
Thor peptide + eIF4E ∆68 
*Thor C+L+NC 1.4 ± 0.3 -16.8 ± 1 4.9 -11.9 0.95 ± 0.02 
*Thor C 2260 ± 60 -12.1 ± 2.8 2.2 -9.8 1.06 ± 0.01 
Thor peptide + eIF4E ∆30 
Thor C+L+NC 1.4 ± 0.5 -15.7 ± 0.5 3.9 ± 0.5 -11.9 ± 0.2 0.99 ± 0.01 
Thor-KQ 1.1 ± 0.5 -15.5 ± 0.4 3.5 ± 0.4 -12.0 ± 0.2 1.00 ± 0.01 
 
Values are averages of at least three experiments and errors represent standard deviations. All 
fragments contained a C-terminal GB1-tag connected via a GSASG linker to the respective protein 
fragment (see Supplemental Experimental Procedures). * Taken from Igreja et al., (2014). 
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Table S3, related to Figure 3. Binding surfaces of eIF4E–eIF4G and eIF4E–4E-BP1 
complexes  
Species Ligand eIF4G or 4E-BP peptides Total buried surface 
area in Å2 
Hs eIF4G All (607–642) 2873 
Canonical (607–621) 1398 
Linker (622–629) 707 
Non-canonical (630–642) 995 
4E-BP1 
(4UED.pdb) 
All (49–83) 2441 
Canonical (50–63) 1366 
Linker (64–71) 452 
Non-canonical (72–83) 780 
Dm eIF4G All (601–656) 2988 
N-terminus (601–616) 394 
Canonical (617–630) 1111 
Linker (631–638) 477 
Non-canonical (639–656) 1227 
Thor 
(4UE8.pdb) 
All (47–83) 2827 
Canonical (50–63) 1434 
Linker (64–71) 659 
Non-canonical (72–83) 964 
 
Buried surface areas were calculated using the PISA server at the European Bioinformatic 
Institute (http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver). For calculation of the buried 
surface area of Dm and Hs eIF4E–eIF4G chains C and D were used in both cases.  
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Table S4, related to Figures 4. Antibodies used in this study 
Antibody Source Catalog Number Dilution Monoclonal/ 
Polyclonal 
Anti-HA-HRP (Western 
blot) 
Roche 12 013 819 001 1:5,000 Monoclonal 
Anti-HA 
(Immunoprecipitation) 
Covance MMS-101P 1:1,000 Monoclonal 
Anti-Dm eIF4E In house  1:3,000 Rabbit polyclonal 
Anti-Hs eIF4E BETHYL 
laboratories 
A301-154A 1:2,000 Rabbit polyclonal 
Anti-Hs eIF4G BETHYL 
laboratories 
A301-776A 1:2,000 Rabbit polyclonal 
Anti-GFP In house  IP Rabbit polyclonal 
Anti-GFP Roche  11814460001 1 :2,000 Monoclonal 
Anti-rabbit-HRP GE Healthcare NA934V 1:10,000 Polyclonal 
Anti-mouse-HRP GE Healthcare RPN4201 1:10,000 Polyclonal !
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
DNA constructs 
For expression in E. coli, a DNA fragment encoding Hs eIF4E (residues M1–V217) was 
inserted into the XhoI and NheI restriction sites of the pnYC vector, to express untagged 
eIF4E, and of the pnYC-NpH vector (Diebold et al., 2011), to express Hs eIF4E with an N-
terminal His6-tag cleavable by a HRV3C protease. The same DNA fragment was also inserted 
into the XhoI and BamHI sites of the pnYC-CvH vector to express Hs eIF4E with a C-terminal 
His6-tag cleavable by TEV protease. The DNA fragments encoding Hs eIF4E N-terminal 
deletions (residues S24–V217 and K36–V217) were inserted into the NdeI and NheI restriction 
sites of the pnYC vector. DNA fragments encoding Dm eIF4E (residues M1–L248, A31–L248 
and K69–L248) were inserted into pnYC-NpH and pnYC-CvH as described above. Dm eIF4G 
DNA fragments were inserted into the NdeI and XhoI restriction sites of the pnEA-NpM vector 
for expression with an N-terminal maltose binding protein (MBP)-tag cleavable by HRV3C 
protease. DNA fragments encoding Hs eIF4G and chimeric peptides were also inserted into the 
pnEA-NpM vector using the BamHI and NheI restriction sites (Table S1). The Dm and Hs 
eIF4G DNA fragments were also inserted into a modified pnEA-NpM vector additionally 
encoding a C-terminal fusion of the B1 domain of immunoglobulin-binding protein G (GB1; 
Cheng and Patel, 2004), connected by a GSASG linker sequence. The plasmid used for the 
expression of Dm Thor 50–83-GB1 has been described previously (Igreja et al., 2014). The 
plasmids used for the expression of HA-tagged Dm eIF4G in S2 cells and of GFP-tagged Hs 
eIF4E-BP1 or HA-tagged Hs eIF4E in human cells, have also been described previously (Peter 
et al., 2015a). The plasmids for the expression of GFP-tagged full-length (FL) Hs eIF4G or the 
corresponding eIF4E-binding region (residues E608–T647) were obtained by inserting the 
corresponding cDNAs between the XhoI and HindIII (FL) and XhoI and BamHI sites of the 
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pT7-EGFP-C1 vector, respectively. All constructs used in this study are listed in 
Supplementary Table S1. 
 
Protein expression and purification 
All proteins were expressed in E. coli BL21 Star (DE3) cells (Invitrogen) grown in LB medium 
overnight at 20°C. To purify the eIF4E–eIF4G complexes used in crystallization, N-terminally 
His6-tagged Dm eIF4E (residues K69–L248) or Hs eIF4E (residues M1–V217) was co-
expressed with MBP-tagged Dm eIF4G (residues S601–N660) or Hs eIF4G (residues Q592–
D653), respectively. For competition assays, C-terminally His6-tagged full length Dm eIF4E 
was coexpressed with MBP-tagged Dm eIF4G (residues P578–N675) fused C-terminally to the 
GB1 domain. 
All protein purification steps were performed at 4°C. The cells were lysed by sonication or 
using the Avestin Emulsiflex-C3 homogenizer in lysis buffer containing 20 mM Na-phosphate 
(pH 7.5), 300 mM NaCl and 2 mM dithiothreitol (DTT) supplemented with lysozyme (1 
mg/mL), DNase I (5 µg/mL) and protease inhibitor cocktail (Roche). All complexes were 
purified from the cleared lysates using amylose resin (New England Biolabs) followed by 
overnight cleavage of tags with HRV3C protease and dialysis into 20 mM HEPES-NaOH (pH 
7.5), 100 mM NaCl and 2 mM DTT. The complexes were further purified using a HiTrap 
Heparin column (GE Healthcare) and eluted using a gradient from 100 to 500 mM NaCl. In the 
case of the Hs eIF4E–eIF4G complex, an additional purification on amylose resin and SP 
cation exchange chromatography on a HiTrap SP column (GE Healthcare) was performed. As 
a final step, all complexes were subjected to size exclusion chromatography on a Superdex 75 
column (GE Healthcare) equilibrated in 10 mM HEPES-NaOH (pH 7.5), 200 mM NaCl and 2 
mM DTT (for complexes used in crystallization) or 10 mM Na-phosphate (pH 7.5), 200 mM 
NaCl and 2 mM DTT (for complexes used in the competition assays). The complexes used in 
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the competition assays were additionally supplemented with 5% (v/v) glycerol and all proteins 
were stored at -80°C after flash-freezing in liquid nitrogen. 
The C-terminally GB1-tagged peptides used in the ITC measurements and competition assays 
were purified as described above with the following changes. After removal of the MBP tag, 
the proteins were diluted to 20 mM HEPES-NaOH (pH 7.5), 75 mM NaCl and 2 m DTT and 
subjected to anion exchange chromatography on a HiTrap Q column (GE Healthcare) to 
remove the cleaved MBP. The proteins were further purified by size exclusion chromatography 
on a Superdex 75 column equilibrated in 10 mM Na-phosphate (pH 7.5), 150 mM NaCl and 2 
mM DTT, followed by purification over amylose resin to remove the remaining MBP. The 
Thor-GB1 peptide used in the competition assays was purified as described previously (Igreja 
et al., 2014). 
For the ITC measurements, eIF4E proteins were expressed with an N-terminal His6-tag and the 
cells were lysed in lysis buffer containing 25 mM imidazole. The cell lysates were applied to a 
Ni2+-charged IMAC column (GE Healthcare) and eluted with a gradient of 25-500 mM 
imidazole. After the cleavage of the His6-tag with HRV3C protease, the proteins were dialyzed 
in 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl and 2 mM DTT and further purified using a 
HiTrap Heparin column (GE Healthcare). The Dm eIF4E proteins were subjected to a final 
purification on a Superdex 75 (GE Healthcare) in 10 mM Na-phosphate (pH 7.5), 150 mM 
NaCl and 2 mM dithiothreitol (DTT). Note that the precision protease treatment to remove the 
N-terminal His6- and MBP-tags leaves behind four extra amino acids (GPHM) from the 
expression vector at the N-terminus of the proteins.  
 
Data collection and structure determination 
Diffraction data were processed using XDS (Kabsch, 2010) and scaled using AIMLESS as part 
of the CCP4 package (Evans, 2006; Evans, 2011; Winn et al., 2011). All structures were solved 
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by molecular replacement using PHASER (McCoy et al., 2007). In the case of the Hs eIF4E–
eIF4G complex bound to cap analog, the human eIF4E structure (PDB 4TPW, Papadopoulos et 
al., 2014) was used as a search model. To solve the structures of the Dm eIF4E–eIF4G 
complexes, molecular replacement was performed using the Dm eIF4E structure (PDB 4UE8; 
Peter et al., 2015a) as a search model. The molecular replacement solutions were used to 
rebuild the initial models of all complexes using ARP/wARP (Langer et al., 2008). To 
complete and improve the initial models, iterative cycles of model building and refinement 
were performed using COOT (Emsley et al., 2010) and PHENIX (Afonine et al., 2012), 
respectively. Final refinement rounds were carried out with non-crystallographic symmetry 
(NCS) torsional restraints for both the Hs eIF4E–eIF4G complex bound to cap analog (PDB 
ID: 5T46) and the Dm eIF4E–eIF4G complex (PDB ID: 5T47). For the Hs eIF4E–eIF4G 
complex, atoms other than water were refined with anisotropic individual B-factors. For the 
Dm eIF4E–eIF4G complexes (PDB IDs: 5T47, 5T48), translation/libration/screw (TLS) 
parameters were refined for the peptide chains in addition to individual B-factors. Ligand 
restraints for refinement were generated using GRADE (Smart et al., 2012). The unmodified 
guanosine base of the m7GpppG cap analog used in the crystallization condition was not 
visible in electron density map. Therefore the cap analog was modeled as m7GTP. 
The final model of the Hs eIF4E–eIF4G complex with to cap analog comprises two eIF4E–
eIF4G complexes, two m7GTP, seven glycerol and 346 water molecules in the asymmetric 
unit. The following residues are missing in the model: eIF4E M1–N30 and S207–V217 (chain 
A), eIF4E M1–A29 and S207–V217 (chain C), eIF4G Q592–E607 and K643–D653 (chain B) 
and eIF4G Q592–L606 and K643–D653 (chain D). The final model of the Dm eIF4E–eIF4G 
complex comprises two eIF4E–eIF4G complexes, two glycerol and 157 water molecules in the 
asymmetric unit. The following residues are missing from the model: eIF4E S86–W89 and 
T234–N241 (chain A), eIF4E R222–N223 and T234–K243 (chain C), eIF4G S601–I602 and 
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Q649–N660 (chain B) and eIF4G I657–N660 (chain D). The final model of the Dm eIF4E–
eIF4G complex with cap analog comprises one eIF4E–eIF4G complex, one m7GTP and 35 
water molecules in the asymmetric unit. The following residues are missing from the model: 
eIF4E G239–S240 (chain A) and eIF4G K632–N660 (chain B). 
The diffraction data and refinement statistics are summarized in Table 1. 
 
Isothermal titration calorimetry 
The ITC experiments were performed using a VP-ITC microcalorimeter (Microcal) at 20°C as 
previously described (Igreja et al., 2014; Peter et al., 2015a). Briefly, a 2 to 10 µM solution of 
Dm eIF4E (residues A31–L248 or K69–L248; WT or II-AA mutant) in the calorimetric cell 
was titrated with tenfold concentrated solutions of GB1-stabilized eIF4G fragments (20 to 100 
µM). All proteins were dissolved in 10 mM Na-phosphate (pH 7.0) and 150 mM NaCl. Each 
titration experiment consisted of a first injection of 2 µL followed by 28 injections of 10 µL at 
240 s intervals. At least three independent experiments were performed. The collected data 
were analyzed using ORIGIN software 7.0 (Microcal). Correction for the heat of dilution and 
mixing was achieved by subtracting the final baseline, which consisted of small peaks of 
similar size. The first data point was removed from the analysis (Mizoue and Tellinghuisen, 
2004), and the thermodynamic parameters were estimated by fitting a single-site binding 
isotherm yielding the equilibrium association constant (Ka) and enthalpy of binding (ΔH). 
Representative thermograms are shown in Figure S2. 
 
Coimmunoprecipitation assays and western blotting 
The coimmunoprecipitation assays from S2 cell or human HEK293T cell lysates and western 
blotting were described previously (Igreja et al., 2014; Peter et al., 2015a). Western blots were 
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developed using the ECL Western blotting detection system (GE Healthcare), following the 
manufacturer’s recommendations. The antibodies used in this study can be found in Table S4. 
 
In vitro competition and pulldown assays 
The competition and pulldown assays were performed as described previously (Igreja et al., 
2014; Peter et al., 2015a). In the pulldown assays shown in Figures 1 and 4, bacterial lysates 
expressing recombinant eIF4E or purified eIF4E (2 µM; 50 µg) were incubated with m7GTP-
sepharose beads (Jena Bioscience) or Ni-NTA beads for 30 min. The immobilized eIF4E was 
then incubated for 30 min with recombinant eIF4G fragments tagged N-terminally with MBP 
and C-terminally with GB1. Proteins associated with eIF4E were eluted with imidazole (in the 
case of the Ni-NTA pulldown) or with SDS-PAGE sample buffer and analyzed by SDS-PAGE 
followed by Coomassie staining. For the competition assays shown in Figures 5 and 6, purified 
Dm eIF4E–eIF4G complexes containing eIF4E-His6 and eIF4G-GB1 (residues P578–N675) 
were incubated with Ni-NTA beads for 30 min in 50 mM Na-phosphate (pH 7.0) and 200 mM 
NaCl. The immobilized complexes were then incubated with a three-fold molar excess of 
purified and GB1-tagged competitor peptides as indicated or with MBP as a negative control. 
After the indicated time points, the supernatant was discarded. The beads were washed three 
times in the same buffer, and the eIF4E-associated proteins were eluted with imidazole for 
analysis by SDS-PAGE, followed by Coomassie staining. The amount of eIF4G bound to 
eIF4E was quantified using the ImageJ software and normalized to the levels of eIF4E present 
at each time point. These values were set to 100 in the presence of MBP. Data points from at 
least three independent experiments were plotted together and the resulting fitting curves were 
determined using the Levenberg-Marquardt algorithm for a single exponential decay function. 
The R2 values associated with the fitting of the exponential decay curves were between 0.88 
and 0.97. 
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Sequence analysis 
eIF4E and eIF4G sequences were aligned using MAFFT as accessible in Jalview (Waterhouse 
et al., 2009).  
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Abstract 
The eIF4E-homologous protein (4EHP) is thought to repress translation by competing with 
eIF4E for binding to the 5'-cap structure of specific mRNAs, to which it is recruited through 
interactions with various proteins, including the GRB10-interacting GYF proteins 1 and 2 
(GIGYF1/2). Despite its similarity to eIF4E, 4EHP does not interact with eIF4G and 
therefore fails to initiate translation. In contrast to eIF4G, GIGYF1/2 selectively bind to 
4EHP but not to eIF4E. Here, we present crystal structures of the 4EHP-binding regions of 
GIGYF1 and GIGYF2 in complex with 4EHP, which reveal the molecular basis for the 
selectivity of the GIGYF1/2 proteins for 4EHP. Complementation assays in a GIGYF1/2-null 
cell line using structure-based mutants indicate that 4EHP requires interactions with 
GIGYF1/2 to downregulate target mRNA expression. Our studies provide structural insights 
into the assembly of 4EHP–GIGYF1/2 repressor complexes and reveal that rather than 
merely facilitating 4EHP recruitment to transcripts, GIGYF1/2 proteins are required for 
repressive activity.  
	 Peter	et	al.		
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Introduction 
The initiation of cap-dependent translation involves a series of sequential steps that start with 
the assembly of the eukaryotic initiation factor 4F (eIF4F) on the mRNA 5'-cap structure 
(Jackson et al. 2010). The eIF4F complex consists of the cap-binding protein eIF4E, the RNA 
helicase eIF4A, and the scaffold protein eIF4G, which bridges the interaction between the 
other two subunits in the complex. eIF4G also interacts with eIF3 and mediates the 
recruitment of the pre-initiation complex (PIC, comprising a 40S ribosomal subunit and 
associated factors) to the mRNA to initiate translation (Jackson et al. 2010). 
The assembly of the eIF4F complex is regulated by multiple mechanisms. One major 
mechanism involves a broad class of eIF4E-binding proteins (4E-BPs) that compete with 
eIF4G for binding to eIF4E, thereby inhibiting translation initiation (Mader et al. 1995; 
Marcotrigiano et al. 1999). eIF4G and the 4E-BPs share a conserved, canonical 4E-binding 
motif (C) with the sequence YX4LΦ (where Y, X, L and Φ represent Tyr, any amino acid, 
Leu, and a hydrophobic residue, respectively), which binds to the dorsal surface of eIF4E 
opposite to the cap-binding pocket (Matsuo et al. 1997; Marcotrigiano et al. 1999; Gross et al. 
2003). Both eIF4G and the 4E-BPs also contain variable non-canonical 4E-binding motifs 
(NC) that bind to an eIF4E hydrophobic lateral surface increasing the affinity of the 
interaction (Kinkelin et al. 2012; Paku et al. 2012; Lukhele et al. 2013; Igreja et al. 2014; 
Peter et al. 2015a,b; Sekiyama et al. 2015; Grüner et al. 2016). Because eIF4G and 4E-BPs 
bind to the same surfaces on eIF4E their binding is mutually exclusive, resulting in 
translation activation and inhibition, respectively. 
An alternative mechanism that inhibits the recruitment of the eIF4F complex involves 
the recognition of the mRNA 5'-cap by another member of the eIF4E family, the 4E-
homologous protein (4EHP, also known as eIF4E2; Joshi et al. 2004; Rom et al. 1998). 
Despite its sequence and structural similarity to eIF4E (Supplemental Fig. S1A, Rosettani et 
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al. 2007), 4EHP does not interact with eIF4G and thus fails to initiate translation (Rom et al. 
1998; Joshi et al. 2004; Hernandez et al. 2005).  
4EHP is recruited to specific mRNAs by RNA-binding proteins and thus acts as a 
sequence-specific rather than a general translational repressor. For example, Drosophila 
melanogaster (Dm) 4EHP is specifically recruited to and represses translation of caudal and 
hunchback mRNAs through interactions with the RNA-binding proteins Bicoid and Brain 
tumor, respectively (Cho et al. 2005; Cho et al. 2006). Mammalian 4EHP has been implicated 
in posttranscriptional mRNA regulation through its interaction with the nucleocytoplasmic 
shuttling protein 4E-T (eIF4E-transporter), which is a component of P-bodies (Kubacka et al. 
2013). In mouse oocytes, the homeobox protein Prep1 recruits 4EHP to inhibit the translation 
of Hoxb4 mRNA (Villaescusa et al. 2009). 4EHP also forms a translational repressor 
complex with GIGYF2 (GRB10-interacting GYF protein 2, hereafter GYF2), a protein 
involved in the insulin signaling pathway (Giovannone et al. 2009; Morita et al. 2012). This 
repressor complex is recruited to specific mRNAs by the Zn-finger protein ZNF598 (Morita 
et al. 2012). Alternatively, the 4EHP–GYF2 complex is recruited to mRNAs containing AU-
rich elements in their 3'-UTRs by tristetraprolin (TTP; Tao and Gao 2015; Fu et al. 2016). 
Thus, through its association with diverse binding partners, 4EHP regulates the translation of 
mRNAs involved in a broad range of biological process, and disruption of its expression 
results in perinatal lethality in mice (Morita et al. 2012).  
Current models suggest that 4EHP-binding proteins (4EHP-BPs) interact with 4EHP 
through a canonical 4EHP-binding motif with the sequence YXYX4LΦ that is present in 
GYF1/2 proteins (Fig. 1A; Supplemental Fig. S1B). Although this motif consists of a 
canonical 4E-binding motif extended by only two N-terminal residues (YX; Cho et al. 2005; 
Morita et al. 2012), GYF2 does not bind to eIF4E in vivo (Morita et al. 2012). Conversely, 
eIF4G, which contains a canonical motif, binds to eIF4E but not to 4EHP (Rom et al. 1998; 
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Joshi et al. 2004; Hernandez et al. 2005). In contrast, some 4E-BPs, such as Hs 4E-BP1–3 
and 4E-T, which lack the additional YX residues, interact with both eIF4E and 4EHP (Rom 
et al. 1998; Rosettani et al. 2007; Kubacka et al. 2013). This suggests that the canonical motif 
is unlikely to be the sole specificity determinant for 4EHP or eIF4E and that the structural 
basis for this molecular discrimination is unknown. Additionally, structural insights into 
4EHP complexes are limited to a complex with the 4E-BP1 canonical motif, which binds to 
4EHP in vitro but not in vivo (Rom et al. 1998; Rosettani et al. 2007).  
To obtain molecular insights into the assembly of 4EHP repressor complexes, we have 
determined the crystal structures of 4EHP in complex with the binding regions of human 4E-
BP1, GYF1 and GYF2. The structures reveal that in addition to the known canonical motifs 
that bind to the dorsal surface of 4EHP, 4E-BP1 and GYF1/2 also make contacts with the 
lateral surface of 4EHP using non-canonical motifs, indicating that lateral binding is a 
common feature observed in both 4EHP and eIF4E complexes. Remarkably, GYF1/2 
proteins, but not 4E-BP1, contain C-terminal auxiliary sequences that extend the interface, 
contacting 4EHP residues that are not conserved in eIF4E. Our studies reveal the molecular 
basis for the selectivity of GYF1/2 proteins for 4EHP over eIF4E and provide mechanistic 
insights into the regulation of cap-dependent translation initiation by 4EHP repressive 
complexes.  
	 Peter	et	al.		
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Results 
GYF1/2 proteins bind to the dorsal and lateral surfaces of 4EHP 
Given that the canonical motif in 4E-BP1 binds to the dorsal surface of 4EHP in a similar 
way as it binds to eIF4E in vitro (Rosettani et al. 2007), we initially investigated whether the 
non-canonical sequences in 4E-BP1 could also bind to the lateral surface of 4EHP as 
observed in eIF4E–4E-BP1 complexes (Igreja et al. 2014; Peter et al. 2015a). We substituted 
residues I85 and M101 on the lateral surface of 4EHP with alanine (IM-AA mutant, 
Supplemental Fig. S1A; Supplemental Table S1). These residues are structurally equivalent 
to eIF4E residues I63 and I79, which are required for the non-canonical motifs in 4E-BPs to 
bind to the lateral surface of eIF4E (Igreja et al. 2014; Peter et al. 2015a). As a control, a 
4EHP mutant carrying the W95A substitution on the dorsal surface (mutant W-A, 
Supplemental Table S1, corresponding to eIF4E W73A mutant) was designed to disrupt 
canonical motif binding. 
The substitutions in either the dorsal or the lateral surface of V5-SBP-tagged 4EHP 
disrupted interactions with GFP-tagged 4E-BP1 in human HEK293T cells (Fig. 1B, lanes 7 
and 8). Conversely, substitutions in either the canonical (C* mutant) or non-canonical motif 
(NC* mutant) of 4E-BP1 abolished its interaction with 4EHP (Supplemental Fig. S2A). 
These results indicate that the interactions between the non-canonical 4E-BP1 sequences and 
the 4EHP lateral surface are also critical for complex stability. 
The interaction between GYF2 and 4EHP requires a canonical 4EHP-binding motif at 
the N-terminus of the protein (YXYX4LФ; Morita et al. 2012; Fig. 1A; Supplemental Fig. 
S1B). Accordingly, alanine substitutions of the four conserved residues (Y, Y, L and Ф) in 
this motif abolished full-length GYF1/2 binding to V5-SBP-4EHP in human cells 
(Supplemental Fig. S2B,C). However, it is not known whether GYF proteins contain non-
canonical sequences. We therefore examined the effects of substitutions at the dorsal and 
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lateral surfaces of 4EHP on interactions with GYF1/2 proteins. The substitutions at either 
surface reduced but did not abolish 4EHP binding to endogenous GYF2 in human cells (Fig. 
1C, lanes 8 and 9 vs. 7). The interaction was abolished only when the substitutions on both 
surfaces were combined (Fig. 1C, lane 10). In contrast, the dorsal and lateral substitutions 
disrupted binding with endogenous GYF1 (Supplemental Fig. S2D). Thus, 4EHP uses its 
dorsal and lateral surfaces to interact with the GYF1/2 proteins, suggesting that these proteins 
also contain non-canonical motifs.   
 
GYF1/2 proteins contain non-canonical and auxiliary 4EHP-binding sequences 
The non-canonical motifs in 4E-BPs are typically located 12–30 residues C-terminal to the 
canonical motifs and contain hydrophobic residues (Igreja et al. 2014; Peter et al. 2015a,b). 
During a search for potential non-canonical motifs in GYF1/2 proteins, we identified a 
hydrophobic motif, 12 residues C-terminal to the canonical motif containing a conserved Phe 
that we termed the non-canonical motif (NC; Fig. 1A; Supplemental Fig. S1B). The 
following 30 residues (which we termed auxiliary sequences, A) are also well conserved and 
contain several short motifs that may potentially interact with 4EHP, as was previously 
observed in the Dm protein Mextli in complex with eIF4E (Peter et al. 2015b).  
To more precisely define the GYF1/2 sequences that interact with 4EHP, we performed 
in vitro pulldown assays using recombinant proteins expressed in E. coli. In particular, we 
tested the binding of 4EHP to GYF1/2 fragments comprising the canonical motif and the non-
canonical sequences (i.e., non-canonical linker and motif; L+NC) with and without the 
auxiliary sequences (fragments C+L+NC and C+L+NC+A; Supplemental Table S1), as well 
as a fragment comprising only the canonical motif (C). 4EHP expressed with a hexa-histidine 
(His6) tag pulled down all three GYF1/2 fragments expressed with an N-terminal maltose 
binding protein (MBP) tag (Fig. 1D; Supplemental Fig. S2E), indicating that the canonical 
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motifs are sufficient for 4EHP binding in vitro. The eIF4E-binding region of human 4E-BP1 
interacted with 4EHP to a similar extent (Fig. 1D; Supplemental Fig. S2E, lane 11). 
However, the GYF1/2 fragments bound to eIF4E much less efficiently than 4E-BP1 (Fig. 1E; 
Supplemental S2F), indicating that GYF1/2 proteins exhibit selectivity for 4EHP over eIF4E 
in vitro in the absence of cellular factors.  
In contrast to the results obtained in vitro, endogenous GYF1/2 proteins interacted with 
4EHP but not with eIF4E in cell lysates, as previously reported (Fig. 1F; Supplemental Fig. 
S2G; Rom et al. 1998; Morita et al. 2012). Similar results were obtained with overexpressed 
GYF1/2 (Supplemental Fig. S2H,I), suggesting that although GYF1/2 proteins can bind to 
eIF4E in vitro, their binding affinity may be too low to compete with other 4E-BPs present in 
cell lysates for binding to eIF4E. As expected, the 4E-T protein interacted with both eIF4E 
and 4EHP (Fig. 1F; Kubacka et al. 2013). In contrast, although endogenous 4E-BP1 did not 
bind to 4EHP in cell lysates (Fig. 1F; Supplemental Fig. S2G; Rom et al. 1998), it did bind 
when it was overexpressed (Fig. 1B). Thus, in cell lysates, the selectivity of GYF1/2 proteins 
and 4E-BP1 for 4EHP and eIF4E, respectively, is likely to be determined by their affinities 
and concentrations relative to those of other competing proteins.  
 
GYF1/2 auxiliary sequences increase affinity for 4EHP 
Although the GYF1/2 fragments with and without auxiliary sequences associated with wild-
type 4EHP in in vitro pulldown assays (Fig. 1G; Supplemental Fig. S2J, lanes 10 and 13), 
they were differentially affected by mutations on the 4EHP dorsal and lateral surfaces. The 
GYF1/2 fragments including the auxiliary sequences were insensitive to the mutations (Fig. 
1G; Supplemental Fig. S2J, lanes 10 to 12). In contrast, the binding of the fragments lacking 
the auxiliary sequences was reduced or abolished by the mutations (Fig. 1G; Supplemental 
Fig. S2J, lanes 14,15). Thus, the GYF1/2 auxiliary sequences contribute to the stability of the 
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complexes with 4EHP and compensate for the destabilizing effects of the mutations in the 
dorsal and lateral 4EHP surfaces.  
To evaluate the thermodynamic contribution of the GYF1/2 canonical, non-canonical 
and auxiliary sequences to the affinity for 4EHP, we performed isothermal titration 
calorimetry (ITC) experiments. GYF1/2 peptides containing only the canonical motif (C) 
exhibited dissociation constants (KDs) for 4EHP in the high nanomolar range (360 ± 120 
nMGYF1 and 290 ± 160 nMGYF2; Supplemental Fig. S3A,B; Table S2). Addition of the non-
canonical linker and motif (C+L+NC peptides) increased the affinity for 4EHP by 20–30-fold 
(KDs of 12 ± 2 nMGYF1 and 14 ± 1 nMGYF2, Supplemental Fig. S3C,D; Table S2), confirming 
the importance of the non-canonical sequences for complex formation. Importantly, addition 
of the auxiliary sequences increased the affinity even further by 30-40-fold (C+L+NC+A 
peptides; KDs of 0.4 ± 0.2 nMGYF1 and 0.3 ± 0.1 nMGYF2; Supplemental Fig. S3E,F; Table S2) 
relative to that of the peptides lacking the auxiliary sequences.  
Collectively, the affinity measurements indicate that the GYF1/2 auxiliary sequences 
contribute substantially to the affinity for 4EHP by further stabilizing the interactions 
mediated by the canonical motif and the non-canonical sequences. 
 
The overall architecture of the 4EHP–GYF1/2 and 4EHP–4E-BP1 complexes 
To understand the structural basis of complex formation and selectivity, we determined the 
crystal structures of human 4EHP bound to GYF1 and GYF2 fragments (C+L+NC+A 
peptides; residues 33–103GYF1 and 35–105GYF2) at 2.9 Å and 2.3 Å resolution, respectively 
(Fig. 2A–E; Supplemental Fig. S4A,B, Table 1). We also determined the crystal structure of 
4EHP bound to a peptide comprising the 4E-BP1 canonical motif and non-canonical 
sequences (C+L+NC) and the corresponding peptide in GYF2 at 1.9 Å and 2.0 Å resolution, 
respectively (Fig. 2F–H; Supplemental Fig. S4C,D; Table 1).  
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The cap-binding protein 4EHP adopts a eIF4E-like fold (Fig. 2C–G; Rosettani et al. 
2007) and its dorsal and lateral surfaces are very similar to those of eIF4E at the structural 
and sequence levels (Supplemental Fig. S1A and Fig. S4E,F). Upon 4E-BP1 or GYF1/2 
binding no major conformational changes are observed between the 4EHP structures 
presented in this study compared with a previously determined structure of 4EHP bound to 
the 4E-BP1 canonical motif (Rosettani et al. 2007). 
The 4E-BP1 and GYF1/2 canonical motifs adopt a helical conformation on the dorsal 
surface of 4EHP, whereas the non-canonical sequences bind to the lateral surface of 4EHP 
using a similar binding mode as described for 4E-BP1 in complex with eIF4E (Fig. 2C–J; 
Supplemental Fig. S4E,F; Peter et al. 2015a; Sekiyama et al. 2015). The binding mode and 
conformation for the GYF2 fragment comprising the canonical motif and the non-canonical 
sequences was not influenced by the auxiliary region, as the two GYF2 structures in complex 
with 4EHP are very similar across common elements irrespective of whether the auxiliary 
region was present (Fig. S4G).  
The distinguishing structural feature observed in the 4EHP–GYF1/2 complexes 
containing the auxiliary sequences is the unprecedented binding mode between these 
sequences and 4EHP (Fig. 2A–E). The auxiliary sequences extend the binding interface to 
2190 Å2 compared to 1380 Å2 in their absence. The auxiliary sequences in GYF1/2 can be 
delineated into three short sequence motifs, termed auxiliary motifs 1–3 (A1, A2 and A3), 
and connect to the non-canonical motif by the auxiliary linker 1 (a-L1) and are interconnected 
by auxiliary linkers 2 and 3 (a-L2 and a-L3; Fig. 1A, Fig. 2A,B; Supplemental Fig. S1B).  
 
The GYF1/2 canonical helix stabilizes the interaction with 4EHP and the auxiliary sequences 
The canonical helices in GYF1/2 and 4E-BP1 bind to the 4EHP dorsal surface through 
interactions analogous to those observed for the eIF4G and 4E-BPs canonical motifs in 
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complex with eIF4E (Fig. 3A,B; Supplemental Fig. S5A–D; Marcotrigiano et al. 1999; Gross 
et al. 2003; Kinkelin et al. 2012; Peter et al. 2015a,b; Grüner et al. 2016). The most conserved 
interactions are mediated by residues corresponding to LФ in the YXYX4LФ consensus 
sequence (M46, L47GYF1; M48, L49GYF2; L59, M60BP1) and the second Tyr side chain in the 
canonical 4EHP-binding motif (Y41GYF1, Y43GYF2 corresponding to Y54BP1; Fig. 3A,B; 
Supplemental Fig. S5A–D).  
The first Tyr in the canonical 4EHP-binding motif (YXYX4LФ) was suggested to 
contribute to the binding specificity of 4EHP-binding proteins (Cho et al. 2005; Villaescusa 
et al. 2009). Our structural analysis does not support such a role for this tyrosine (Y39GYF1, 
Y41GYF2). Although its aromatic ring is in contact with P554EHP (Fig. 3A; Supplemental Fig. 
S5C,D), this interaction is not unique to 4EHP-binding proteins, as P554EHP forms a similar 
contact with I52BP1 at an equivalent position in the motif in the 4E-BP1 complex 
(IXYX4LФBP1; Fig. 3B).  
An important difference between 4E-BP1 and GYF1/2 canonical motifs is that the latter 
do not possess an Arg/Lys/Gln residue at position 9 in the extended canonical motif 
[extended motif: YX(R/K)X2LФX2(R/K/Q)]. This residue typically contributes to the 
interaction with eIF4E (Marcotrigiano et al. 1999; Peter et al. 2015a,b). Instead, GYF1/2 
proteins contain an aromatic residue at this position (Y50GYF1, F52GYF2; Fig. 3A; 
Supplemental Fig. S1B and S5C,D), which establishes hydrophobic contacts with W954EHP 
and stabilizes the GYF1/2 auxiliary motifs through intramolecular interactions with the 
invariant Pro residue in the PLAL motif (P76GYF1, P78GYF2, see below), thus rationalizing the 
conservation of both residues. 
 
The non-canonical linkers contribute to structural stability in the 4EHP complexes  
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Following the canonical helix, the non-canonical linkers orient the peptide chains to engage 
with the 4EHP lateral surface (Fig. 2A–G). In the structures of 4E-BPs bound to eIF4E, these 
linkers adopt a specific ‘elbow loop’ conformation (Peter et al. 2015a,b). An analogous 
structural feature is observed in the 4EHP–4E-BP1 complex, where P66BP1, P71BP1 and 
P72BP1 restrict the flexibility of the backbone conformation in the elbow loop (Fig. 3D; 
Supplemental Fig. S5E,F). Stabilizing hydrophobic contacts, such as between the invariant 
H1004EHP (corresponding to H784E) and P71BP1, ensure that the overall elbow conformation is 
almost identical in the eIF4E- and 4EHP-bound complexes (Fig. 3D; Supplemental Fig. 
S5E,F).  
One important difference, however, is that the N774E side chain is in hydrogen bonding 
distance to R63BP1 guanidium group in position 9 of the extended canonical motif and to the 
T68BP1 carbonyl oxygen in the linker region in the eIF4E–4E-BP1 complex (Supplemental 
Fig. S5F; Peter et al. 2015a). In the 4EHP complex, these contacts cannot be maintained by 
S99, and consequently, R63BP1 does not contribute to complex stability (Fig. 3D; 
Supplemental Fig. S5E,F).   
Comparison of the GYF1/2 conformations in complex with 4EHP reveals that the 
linker region is also arranged in a single preferred conformation (Fig. S4H) that is distinct 
from the elbow loop conformation observed in the complexes with 4E-BP1 (Fig. 3C vs. Fig. 
3D). The invariant H1004EHP plays a crucial role in anchoring the GYF1/2 linker to the 4EHP 
surface through van der Waals contacts with I58GYF2 (V56GYF1), while its imidazole ring is 
also in hydrogen bonding distance to the D55GYF2 (E53GYF1) carbonyl oxygen (Fig. 3C; 
Supplemental Fig. S5G,H). The principal stabilizing hydrophobic interaction in the GYF1/2 
linker region is between the invariant P59GYF2 (P57GYF1) and F974EHP, which is structurally 
equivalent to the interaction between P72BP1 and F974EHP (Fig. 3C,D; Supplemental Fig. 
S5E–H).  
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Non-canonical loops mediate conserved contacts at the 4EHP lateral surface 
The non-canonical loops in 4E-BP1 and the GYF1/2 proteins engage a hydrophobic pocket 
on the lateral surface of 4EHP, which is lined by residues Y64, I85 and M101 (corresponding 
to eIF4E residues F47, I63 and I79, respectively; Fig. 3E,F; Supplemental Fig. S5I–L). The 
conformation of the GYF1/2 non-canonical loops is stabilized by an extensive and conserved 
network of contacts across the 4EHP lateral surface. The 4E-BP1 and GYF1/2 non-canonical 
loops differ in conformation and only align at major contact points (Fig. 3E vs. Fig. 3F). 
Strikingly, a carbon-π interaction through which the conserved aromatic residue 
(Y644EHP equivalent to F474E) makes contacts with I70GYF2 (V68GYF1) to anchor this loop at 
the lateral surface of 4EHP (Fig. 3E; Supplemental Fig. S5K,L) is conserved in the 4EHP–
4E-BP1 complex (Y644EHP–V81BP1) as well as in all eIF4E–4E-BP and eIF4E–eIF4G 
complex structures (Peter et al. 2015a; Grüner et al. 2016), underscoring the role of this 
aromatic residue (Y644EHP, F474E) in positioning the non-canonical loops at the lateral surface 
of eIF4E proteins. The invariant F67GYF2 (F65GYF1) is critically positioned at the sharp turn of 
the peptide and stabilizes this conformation via hydrophobic contacts with Y644EHP, K834EHP 
and I854EHP. The C-terminal residues in the GYF1/2 and 4E-BP1 non-canonical loops (V68, 
Q70GYF1; I70, Q72GYF2; and V81, S83BP1) mediate similar backbone interactions with the 
4EHP residues H100 and V102 (Fig. 3E,F; Supplemental Fig. S5I-L).  
 
4EHP-specific interactions with GYF1/2 auxiliary motifs close to the cap-binding site  
The auxiliary linker-1 (a-L1) and the invariant PLAL motif at the start of the auxiliary 
sequences adapt to a composite surface formed between the GYF1/2 canonical helix and the 
4EHP surface (Fig. 4A–D). The linker (a-L1) is fixed in position via H1004EHP, which can 
participate in polar contacts with the carbonyl oxygens of Q70GYF1 or D71GYF1 (Q72GYF2 or 
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E73GYF2). The R1034EHP guanidinium group is in hydrogen bonding distance to the Q75GYF1 
(P77GYF2) carbonyl oxygen, which rationalizes the conservation of the R103 residue in 4EHP 
but not in eIF4E. The invariant P76GYF1 (P78GYF2) in the PLAL motif coordinates an 
intramolecular carbon-π interaction with Y50GYF1 (F52GYF2). Importantly, key interactions of 
4EHP with the auxiliary linker-1 (a-L1) and PLAL motif are mediated by 4EHP-specific 
residues, e.g., E149, which fixes the orientation of the GYF1/2 chain via hydrogen bonds to 
L77GYF1 (L79GYF2) and A78GYF1 (A80GYF2) as well as R1464EHP, which contacts E80GYF1 
(V82GYF2) and L77GYF1 (L79GYF2; Fig. 4C,D). Therefore, the auxiliary linker-1 and the PLAL 
motif interactions are highly specific and involve residues present only in 4EHP (R103 and 
E149) and thus would not be possible with eIF4E.  
The auxiliary sequences A2 and A3 arrange into two helical elements (auxiliary 
helices α2 and α3, respectively; Fig. 2A–E), which are connected by a conserved VNS linker 
(linker 3; a-L3). Helix α2 (A2) shows some conformational heterogeneity across all complex 
structures (Supplemental Fig. S4H), most likely due to weak contacts at the interface (Fig. 
4E–H). In contrast, auxiliary linker-3 (a-L3) aligns well between the six complex structures. 
The linker VNS sequence enters a surface groove on 4EHP and interacts closely with 4EHP, 
e.g., through invariant S96GYF1 (S98GYF2), which maintains a backbone hydrogen bond to 
R1384EHP, while its hydroxyl group is in polar contact with the 4EHP-specific residue E177 
(Fig. 4G,H). As a consequence of these interactions, helix α3 (A3) is positioned in close 
proximity to the 4EHP cap-binding pocket (Fig. 2C,D) and is stabilized in this orientation 
through hydrophobic contacts between V99GYF1 (V101GYF2) and L100GYF1 (L102GYF2) with 
the aliphatic side chain of R138 and I211 in 4EHP (Fig. 4G,H). However, the GYF1/2 
peptides containing all the 4EHP-binding elements did not contribute to the 4EHP affinity for 
the m7GpppG cap analog as observed by ITC (Supplemental Table S2 and Fig. S3G,H), 
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suggesting that additional GYF1/2 sequences may contribute to enhance 4EHP binding to 
capped mRNAs. 
 
The auxiliary sequences contribute to complex stability in vivo 
To assess the biological significance of the interactions mediated by the auxiliary sequences, 
we substituted 4EHP residues R103 and E149, which interact with the GYF1/2 PLAL motif, 
with leucine residues, as is observed in eIF4E (4EHP RE-LL mutant). The RE-LL 
substitutions strongly reduced binding to endogenous GYF2 compared to wild-type 4EHP or 
the 4EHP dorsal and lateral mutants in human cells (Fig. 5A, lanes 7-10). All of the 
mutations disrupted binding to endogenous GYF1 (Supplemental Fig. S6A, lanes 7-10). As a 
control, binding of 4E-BP1 was not affected by the RE-LL substitutions (Fig. 5A, lane 10), 
indicating that the mutations do not disrupt the 4EHP fold.  
We also analyzed the impact of amino acid substitutions in the GYF1/2 proteins on 
complex formation. Substitutions in the GYF1/2 non-canonical (NC*) or auxiliary motifs 
(A1* and A2+3*) did not affect binding to overexpressed 4EHP in human cells. This is 
consistent with structural data showing that R103 and E149 in 4EHP interact via their side 
chains with the backbone atoms of the GYF1/2 auxiliary sequences (Fig. 5B; Supplemental 
Fig. S6B, compare lanes 12-14 and 10). However, binding was disrupted when the mutations 
in the non-canonical and auxiliary motifs were combined (Fig. 5B; Supplemental S6B, lanes 
15 and 16 vs 10). Together with the data showing that the mutations in the canonical motif 
prevent GYF1/2 binding to 4EHP (Fig. 5B; Supplemental Fig. S6B) this indicates that the 
canonical motif is necessary but not sufficient for 4EHP-binding in vivo. 
We further assessed the relevance of R103 and E149 toward complex stability in 
competition assays using pre-assembled 4EHP–4E-BP1 complexes containing either the 
wild-type or the RE–LL 4EHP mutant. These complexes were challenged with an equimolar 
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amount of the GYF2 fragment comprising all 4EHP-interacting elements. The amount of 4E-
BP1 that remained bound to 4EHP was determined over time (Fig. 5C–E). The GYF2 
fragment displaced 50% of 4E-BP1 from the pre-assembled 4EHP–4E-BP1 complexes in 5 ± 
1.2 min. Under the same conditions, the GYF2 fragment displaced only 40% of 4E-BP1 
bound to the 4EHP RE-LL mutant after 60 min incubation (Fig. 5C–E). Collectively, the 
competition experiments together with the observation that the GYF1/2 proteins do not 
associate with the 4EHP RE-LL mutant in cell lysates (Fig. 5A; Supplemental Fig. S6A) 
indicate that the auxiliary sequences afford GYF2 a competitive advantage over 4E-BP1 for 
binding to 4EHP.   
 
The canonical and auxiliary regions promote complex self-association in solution   
In the asymmetric unit in the 4EHP–GYF1/2 crystals, the GYF1/2 canonical and auxiliary 
motifs are part of a large interface (1008 Å2) connecting two neighboring complexes 
(Supplemental Fig. S7A–C), suggesting dimerization. We analyzed the solution properties of 
these complexes by small-angle X-ray scattering (SAXS). The SAXS parameters for the 
4EHP–GYF2 complex were indeed consistent with those of a dimer (Supplemental Fig. 
S7A,D,E). We also observed that the self-association of the complexes was concentration-
dependent (Supplemental Table S3). However, the SAXS measurements of complexes 
lacking the GYF2 auxiliary sequences, were consistent with a monomeric state (Fig. S7F,G 
and Supplemental Table S3).  
The putative dimer interface is stabilized by residues that are 4EHP- and GYF-specific, 
including R202, M161 and Q159 in 4EHP and E46GYF1 (E47GYF2) in GYF1/2 (Supplemental 
Fig. S1A,B and S7A,B). We designed mutations in GYF2 and 4EHP to disrupt dimerization 
(dimerization mutant, D*; Supplemental Table S1). These mutations did not affect complex 
assembly, as the mutated proteins still co-purified as a complex (Supplemental Fig. S7H) and 
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retained the same affinity for their partner as the wild-type proteins (Supplemental Fig. S3I,J; 
and Table S2). Importantly, however, the SAXS scattering profile of the mutated complex 
demonstrated the best fit to a monomeric state (Supplemental Fig. S7I and Table S3), 
indicating that the mutations effectively disrupt dimerization and validate the observed 
interface. 
 
A 4EHP-specific residue reduces 4E-BP1 binding 
To probe the molecular basis for the binding preference of 4E-BP1 for eIF4E over 4EHP 
observed in cell lysates, we measured the binding affinity of the 4E-BP1 peptide for 4EHP 
and eIF4E using ITC. The affinity of the 4E-BP1 peptide for 4EHP was 10-fold lower 
compared with eIF4E (KD = 55 ± 14 nM and KD = 5 ± 2 nM, respectively; Supplemental Fig. 
S3K,L and Table S2) and 100-fold lower compared to the GYF1/2 peptides for 4EHP 
(Supplemental Table S2).  
A possible explanation for the lower affinity of 4E-BP1 for 4EHP compared to eIF4E is 
that R63BP1 directly interacts with N77 in the eIF4E complex, but this residue is replaced by a 
Ser (S99) in 4EHP, which breaks this critical contact (Supplemental Fig. S5E,F). 
Interestingly, a 4EHP mutant in which Ser99 was substituted with Asn (4EHP S99N) showed 
a 10-fold gain in affinity for 4E-BP1 to a level comparable with eIF4E (4 ± 1 nM and 5 ± 2 
nM, respectively; Supplemental Fig. S3M and Table S2). The S99N 4EHP mutant also bound 
to endogenous 4E-BP1 (Supplemental Fig. S7J, lanes 8 vs 7), although not to the same level 
as observed for eIF4E. Binding of GYF2 was not affected by the S99N mutation because 
GYF proteins have an aromatic residue at the equivalent R63BP1 position (Y50GYF1 and 
F52GYF2), which mediates hydrophobic contacts with 4EHP. 
The affinity measurements indicate that endogenous 4E-BP1 is unlikely to effectively 
compete with GYF1/2 proteins for 4EHP binding under equilibrium conditions in cell lysates. 
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This is consistent with the in vivo data that shows that 4E-BP1 bound to 4EHP only when 
overexpressed (Fig. 1B). Furthermore, a single amino acid substitution is responsible for the 
different affinities of eIF4E and 4EHP for 4E-BP1. 
 
4EHP requires interaction with GYF1/2 proteins to downregulate mRNA expression 
To assess the functional relevance of the 4EHP–GYF1/2 complex in repressing mRNA 
targets, we tethered λN-HA-tagged 4EHP to an R-Luc reporter containing five binding sites 
for the λN tag (BoxB hairpins) in the 3'-UTR. To uncouple the effects on translation from the 
effects on mRNA stability, the reporter contained an internal polyadenosine stretch of 95 
residues followed by the 3'-end of the non-coding RNA MALAT1, which is generated 
through endonucleolytic cleavage by RNase P and is thus not polyadenylated (Wilusz et al. 
2012). An F-Luc-GFP reporter served as a transfection control. The λN-HA-4EHP protein 
repressed the expression of the R-Luc-5BoxB-A95-MALAT1 reporter relative to the λN-HA 
peptide (Fig. 6A), without causing corresponding changes in mRNA levels (Fig. S8A,B). The 
levels of a reporter lacking the BoxB hairpins were not affected (Supplemental Fig. S8C–E), 
indicating that 4EHP recruitment is prerequisite for repression.  
We used CRISPR-Cas9 gene editing to generate a GYF1/2-null HEK293T human cell 
line in which the GYF1/2 levels were reduced below 10% of their control levels, whereas the 
expression of endogenous 4EHP was not affected (Fig 6B, lane 4 vs 1). In this cell line, the 
repression of the R-Luc mRNA reporter by tethered 4EHP was impaired (Fig. 6A), even 
though 4EHP was expressed at levels comparable to those observed in control cells (Fig. 6C, 
lanes 2 vs 4). The 4EHP-mediated repression was restored by transient expression of wild-
type GFP-tagged GYF2 but not by the GYF2 canonical mutant (C*) that does not interact 
with 4EHP (Fig. 6A), despite comparable expression levels (Fig. 6C, lanes 5 and 6). Thus, 
4EHP requires interactions with GYF1/2 proteins for full repressive activity.  
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In agreement with this conclusion, 4EHP activity in tethering assays correlated with 
GYF1/2 binding and was independent of cap binding. Indeed, 4EHP mutants with impaired 
GYF1/2 binding (+/-) exhibited reduced repressive activity, and repression was abolished by 
combined mutations that disrupt binding to GYF1/2 (Fig. 6D,E; Supplemental Fig. S8F,G). 
Unexpectedly, however, a 4EHP mutant that does not bind to the cap (cap*; Fig. S8H), but 
still binds to GYF1/2 (Supplemental Fig. S8I), repressed the expression of the reporter 
mRNA in a GYF1/2-dependent manner (Fig. 6D; Supplemental Fig. S9A,B). The 4EHP 
mutants did not repress the expression of a control mRNA lacking the BoxB binding sites 
(Supplemental Fig. S9C–E). 
Our results suggest that the GYF1/2 proteins confer repressive activity to the 4EHP–
GYF1/2 complexes (Fig. 6F,G). Accordingly, GYF2 repressed mRNA reporter expression in 
tethering assays. GYF2 activity was independent of 4EHP because the GYF2 canonical 
mutant, still repressed the expression of the R-Luc-6xMS2-A95-MALAT1 reporter as 
efficiently as wild-type GYF2 (Fig. 6F,G). GYF2 did not repress a reporter lacking the MS2 
binding sites (Supplemental Fig. S9F,G).  
Finally, to investigate 4EHP activity without artificial tethering we used an R-Luc 
reporter that included two copies of the AU-rich element present in the 3' UTR of the TNF-α 
mRNA (R-Luc-ARE-A90-MALAT1). This reporter was repressed in control cells expressing 
TTP (Fig. 6H). TTP-induced repression was relieved in GYF1/2-null cells (Fig 6H), although 
TTP was expressed at levels comparable to those observed in control cells (Fig. 6I, lene 4 vs 
2). In the GYF1/2-null cell line repression was restored only when GYF2 and 4EHP were 
coexpressed but not when each protein was expressed individually (Fig. 6H,I). No restoration 
was observed when 4EHP was coexpressed with a GYF2 canonical mutant (C*). In contrast 
to the observations in tethering assays, a 4EHP mutant that does not bind the cap (cap*) was 
impaired in restoring TTP-mediated repression, although it was expressed at levels 
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comparable to wild-type (Fig. 6H,I). Collectively, these results indicate that the assembly of 
the 4EHP-GYF2 complex is required for full repression of target mRNA expression.  
  
	 Peter	et	al.		
	
21	
	
Discussion 
GYF1/2 proteins are able to discriminate between 4EHP and eIF4E, but the molecular basis 
for this discrimination remained unknown (Morita et al. 2012). Here, we show that the 4EHP-
binding region of GYF1/2 proteins comprises canonical and non-canonical motifs connected 
by a linker, which recognize the dorsal and lateral surfaces of 4EHP, respectively, in a similar 
manner to that observed for the diverse 4E-BPs and eIF4G bound to eIF4E (Kinkelin et al. 
2012; Peter et al. 2015a,b; Sekiyama et al. 2015; Grüner et al. 2016). Thus, dorsal and lateral 
binding is conserved and widespread among eIF4E family proteins. Given this common 
binding interface, GYF1/2 proteins achieve their remarkable selectivity for 4EHP by virtue of 
unique auxiliary sequences (C-terminal to the non-canonical motif) that contact a surface on 
4EHP, which is more divergent among eIF4E paralogs. In particular, the 4EHP-specific 
residues R103, R140 and E149 interact with GYF1/2 auxiliary sequences and are important 
for complex formation in vivo. These interactions stabilize the complex assembly by 
increasing the affinity of the interaction and may have evolved to ensure that in vivo GYF1/2 
proteins efficiently compete for 4EHP binding with other potential binding partners such as 
4E-BP1, which is more abundant than GYF1/2 but has lower affinity for 4EHP (this study; 
Hein et al. 2015).  
Intriguingly, as a consequence of the 4EHP-specific interactions by the auxiliary 
sequences, the helix α3 (A3) of GYF1/2 is oriented in close structural proximity to the cap-
binding pocket of 4EHP. However, the GYF2 peptide containing all the 4EHP-binding 
elements did not increase the affinity of 4EHP for an m7GpppG cap analog (Table S2). In the 
GYF1/2 proteins, there is a long stretch of Gly/Arg-rich sequence immediately following the 
auxiliary motifs. Given that such low-complexity Gly/Arg-rich regions often confer non-
specific RNA binding properties to the proteins that contain them (Thandapani et al. 2013), it 
is tempting to speculate that the GYF1/2 proteins may play a role in stabilizing 4EHP bound 
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to capped transcripts. Furthermore, because 4EHP has a reduced affinity for the cap structure 
compared to eIF4E (Rom et al. 1998; Zuberek et al. 2007), it is possible that the auxiliary 
sequence-mediated dimerization observed in this study may have some as yet undefined 
functions, e.g., increasing local concentration of repressor complexes on the mRNA but this 
hypothesis needs to be tested in future studies. The affinity of 4EHP for capped mRNAs may 
also be stimulated by post-translational modifications such as ISG15 modification (Okumura 
et al. 2007) and mono/di-ubiquitinylation (von Stechow et al. 2015), but whether these are 
synergistic with the GYF1/2 proteins is currently not known. 
 
Mechanism of repressor complex assembly is likely to be divergent among the 4EHP 
interactors 
Our study provides mechanistic insights into the assembly of 4EHP repressor complexes and 
raises the question of whether the binding mode is conserved among other 4EHP-binding 
proteins. However, it is important to note that although the Dm Brat protein sequence 
contains a canonical 4EHP-binding motif, the motif is buried within the hydrophobic core of 
a folded domain (the NHL domain) and therefore unlikely to participate in interaction with 
4EHP (Cho et al. 2006). Furthermore, the canonical motifs in Dm Bcd and the mammalian 
Prep1 proteins contain internal proline residues and are unlikely to adopt helical 
conformations, which are crucial for stable binding to 4EHP (Cho et al. 2006; Villaescusa et 
al. 2009). Thus, the interaction with Bcd and Prep1 is either indirect or the mode of binding 
has diverged. Only 4E-T features canonical and non-canonical motifs that bind directly to 
eIF4E and are likely to bind 4EHP in a similar manner (Kubacka et al. 2013; Peter et al. 
2015a). Although the 4E-T orthologs do not contain motifs with similarity to the GYF1/2 
auxiliary motifs, our structural data indicate that the precise sequence composition of these 
motifs may not be critical for interactions because the 4EHP-specific residues principally 
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stabilize the complex via contacts with the auxiliary sequences backbone. However, it 
remains to be seen whether 4E-T may indeed contain auxiliary sequences and what is their 
mode of binding to 4EHP.  
 
4EHP–GYF1/2 complex assembly is required for post-transcriptional mRNA regulation 
Because 4EHP has a reduced affinity for the cap structure compared to eIF4E (Rom et al. 
1998; Zuberek et al. 2007), it has been proposed that it is recruited to specific mRNAs 
through interactions with proteins that are bound (directly or indirectly) to the mRNA, thus 
increasing its local concentration and competing with eIF4E in cis for binding to the 5’-cap 
(Cho et al. 2005; Cho et al. 2006; Villaescusa et al. 2009; Morita et al. 2012). According to 
this model, 4EHP should repress translation independently of GYF1/2 proteins when directly 
tethered to the 3'-UTR of an mRNA reporter. Unexpectedly, however, we observed that 
4EHP not only loses its repressive activity in GYF1/2-null cells, but also that its interaction 
with GYF1/2 proteins is in fact required for full repression. Thus, rather than merely 
facilitating 4EHP recruitment to an mRNA (e.g., by bridging the interaction between 4EHP 
and the Zn-finger proteins ZNF598 or TTP), the GYF1/2 proteins act directly in the 
repression. In agreement with this conclusion, GYF1/2 repressed target transcripts in 
tethering assays independently of 4EHP binding. However, it is also evident that regulation 
of endogenous transcripts is dependent on the 4EHP–GYF1/2 complex assembly. Indeed, the 
TTP-mediated repression of an ARE-containing reporter in the GYF1/2-null cell line was 
restored only when 4EHP was coexpressed with GYF2 that was competent for binding to the 
4EHP. Intriguingly, the cap binding by 4EHP was necessary for full repression in this 
context.  
In summary, our studies reveal the structural basis for the assembly of a translational 
repressor complex consisting of 4EHP and its specific binding partners, the GYF1/2 proteins. 
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We show that the GYF1/2 proteins directly contribute to the repressive activity of 4EHP, thus 
uncovering an unexpected facet of a mechanism that regulates mRNA expression. 
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Materials and Methods 
DNA constructs   
The DNA constructs used in this study are described in the Supplemental Material and are 
listed in Supplemental Table S1. All of the constructs and mutations were confirmed by 
sequencing.   
 
Protein expression and purification 
All of the recombinant proteins were expressed in E. coli BL21 Star (DE3) cells (Thermo 
Fisher Scientific) grown in LB medium overnight at 20°C. The cells were lysed by sonication 
in lysis buffer containing 50 mM HEPES (pH 7.2), 200 mM (4EHP–4E-BP1) or 300 mM 
(4EHP–GYF1/2) NaCl and 2 mM DTT supplemented with DNase I (5 µg/ml), lysozyme (1 
mg/ml) and protease inhibitor cocktail (Roche). To purify the complexes containing 4EHP 
bound to GYF1, GYF2 or 4E-BP1 for crystallization and SAXS, His6-tagged 4EHP (residues 
A52–F234) was coexpressed with MBP-tagged GYF1 (residues K33–M103), GYF2 (residues 
A35–T105) or 4E-BP1 (residues T50–S83). The complexes were purified from cleared cell 
lysates using an amylose resin (New England Biolabs), followed by cleavage of the MBP and 
His6 tags with HRV3C protease overnight at 4°C. After cleavage of the tags, the complexes 
were separated from the MBP and His6 tags using a heparin column (HiTrap Heparin HP 5 
ml, GE Healthcare) and further purified on a Superdex 75 column (GE Healthcare) in a buffer 
consisting of 10 mM HEPES (pH 7.2), 200 mM NaCl, and 2 mM DTT. The complexes were 
stored at -80°C or used directly for crystallization and SAXS. The 4EHP-complexes used in 
the competition assays were expressed and purified as described above with the difference 
that the C-terminal His6 tag was not removed from the 4EHP and that the copurified 4E-BP1 
peptide contained a C-terminal GB1-tag. The complexes were stored in a buffer containing 
20 mM Na-phosphate (pH 7.0), 200 mM NaCl and 5% (w/v) glycerol. 
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For the pulldown assays, eIF4E (full-length) was expressed with a C-terminal His6 tag, 
purified from cleared cell lysates using a nickel column (HisTrap HP 5 ml, GE Healthcare) 
and further purified on a heparin column (HiTrap Heparin HP 5 ml, GE Healthcare) followed 
by size exclusion chromatography (Superdex 75 column, GE Healthcare) without removing 
the C-terminal His6 tag. The purified eIF4E-His6 was stored at -80°C in a buffer consisting of 
20 mM Na-phosphate (pH 7.0) and 200 mM NaCl.  
 
Pulldowns,,competition assays, coimmunoprecipitation and western blotting  
The in vitro pulldown and competition assays were performed as previously described (Igreja 
et al. 2014; Peter et al. 2015a,b). All coimmunoprecipitation and pulldown assays in 
HEK293T cell lysates were performed in the presence of RNase A as described previously 
(Peter et al. 2015a). All of the western blots were developed using the ECL western blotting 
detection system (GE Healthcare). The antibodies used in this study are listed in 
Supplemental Table S4. A detailed description of these assays is included in the 
Supplemental Material. 
 
ITC measurements and small-angle X-ray scattering (SAXS) 
The ITC measurements and small-angle X-ray scattering (SAXS) experiments are described 
in the Supplemental Material.  
 
Crystallization, data collection and structure determination 
A detailed description of the crystallization conditions and the structure determination 
process are included in the Supplemental Material. All diffraction data sets were recorded on 
a PILATUS 6M detector at the PXII beamline of the Swiss Light Source at a temperature of 
100 K. The diffraction data and refinement statistics are summarized in Table 1. 
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Tethering and complementation assays 
A detailed description of the procedure to generate the GYF1/2-null cell line is included in 
the Supplemental Material  For the complementation assays, HEK293T cells ( wild-type or 
GYF1/2-null cells) were seeded in six-well plates ( 0.6x106 cells per well) and transfected 
using Lipofectamine 2000 (Invitrogen). The tethering reporters have been previously 
described (Kuzuoğlu-Öztürk et al. 2016). The transfection mixtures contained 0.25 µg of 
pEGFP-N3-F-Luc transfection control reporter, 0.5 µg of pCIneo-R-Luc-5BoxB-A95-
MALAT1 (or pCIneo-R-Luc-A95-MALAT1 without BoxB) and 0.3 and 0.7 µg o f  t h e  
plasmids expressing the λN-HA and λN-HA-tagged 4EHP proteins, respectively. Cells 
were also co-transfected with plasmids expressing GFP-tagged proteins (0.25 µg GFP-MBP, 
1.8 µg GFP-GYF2 wild-type and 1.2 µg GFP-GYF2 C* mutant).  
For the 4EHP tethering assays in HEK293T cells, wild-type or mutant λN-HA-4EHP 
proteins (0.3 µg for WT and cap* mutant; 0.8 µg for W-A; 1 µg for IM-AA; 1.2 µg for 
WIM-AAA and 0.4 µg RE-LL proteins) were co-transfected with the same amounts of 
reporter plasmids as described for the complementation assay. In the tethering assay with the 
GYF2 protein, the transfection mixture contained 0.25 µg of pEGFP-N3-F-Luc transfection 
control reporter, 0.5 µg of pCIneo-R-Luc-6xMS2-A95-MALAT1 or pCIneo-R-Luc-A95-
MALAT1, 0.3 µg and 1 µg o f  t he  plasmids expressing the MS2-HA and MS2-HA-tagged 
GYF2 proteins, respectively, and 0.25 µg of GFP-MBP.  
For the assay with the pCIneo-R-Luc-ARE-A90-MALAT1 reporter, wild-type and GYF1/2-null 
HEK293T cells were transfected with 1 µg of the ARE reporter and 0.25 µg of pEGFP-N3-F-
Luc transfection control reporter in the presence or absence of plasmids expressing λN-HA-
TTPΔNIM (50 ng), 0.2 µg of GFP-MBP (0.2 µg), GFP-GYF2 (1 µg, wild-type or canonical 
mutant C*) and λN-HA-4EHP (0.5 µg). 
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Firefly and Renilla luciferase activities were measured two days after transfection using the 
Dual-Luciferase Reporter Assay System (Promega).  
 
Accession numbers 
Atomic coordinates and structure factors have been deposited in the Protein Data Bank 
(PDB) under accession codes 5NVK (4EHP–GYF1 C+L+NC+A), 5NVL (4EHP–GYF2 
C+L+NC+A), 5NVM (4EHP–GYF2 C+L+NC) and 5NVN (4EHP–4E-BP1 C+L+NC). 
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Figure Legends  
Figure 1. GYF1/2 proteins use canonical, non-canonical and auxiliary sequences to bind to 
4EHP. (A) GYF1/2 proteins contain a central glycine-tyrosine-phenylalanine (GYF) domain 
and an N-terminal 4EHP-binding region (4EHP-BR). The 4EHP-binding region includes 
canonical (C), non-canonical (NC) and auxiliary motifs (A1–3) connected by linker 
sequences (nc-L and a-L1–3). The 4E-binding region (4E-BR) of 4E-BP1 contains canonical 
and non-canonical motifs. (B, C) Western blots showing the interaction between V5-SBP-
4EHP [wild-type (WT) or the indicated mutants] and GFP-4EBP1 (full-length) or 
endogenous GYF2. The proteins were pulled down using streptavidin-coated beads. V5-
SBP-MBP served as negative control. The inputs (1.5% for the V5-tagged proteins and 1% 
for the GFP-tagged proteins) and bound fractions (3–5% for the V5-tagged proteins and 20% 
for GYF2 and GFP-4E-BP1) were analyzed by western blotting using anti-V5, anti-GFP and 
anti-GYF2 antibodies. (D, E) Ni-NTA pulldown assays showing the interactions between 
GYF2 fragments (C+L+NC+A, C+L+NC and C) and 4EHP-His6 (M1–F234; D) or eIF4E-
His6 (E). 4E-BP1 and MBP served as positive and negative controls, respectively. The GYF2 
and 4E-BP1 peptides contain an N-terminal MBP tag and a C-terminal GB1 tag. The starting 
material (SM; 1.3% for MBP-proteins, 6% for 4EHP and purified eIF4E) and bound 
fractions (7–10%) were analyzed by SDS-PAGE followed by Coomassie blue staining. (F) 
The interaction between V5-SBP-eIF4E or 4EHP proteins with endogenous GYF2, 4E-T and 
4E-BP1 was analyzed in HEK293T cell lysates using streptavidin pulldowns. The input (1% 
for 4E-BP1 and 4E-T and 1.5% for V5-SBP-tagged proteins and GYF2) and bound fractions 
(20% for 4E-BP1 and 4ET, 30% for GYF2 and 5% for the V5-SBP-tagged proteins) were 
analyzed by western blotting using the indicated antibodies. (G) Ni-NTA pulldown assay 
showing the interaction between 4EHP (M1–F234, WT or the indicated mutants) and GYF2 
fragments. MBP served as a negative control. Samples were analyzed as described in (D). 
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The starting material (2% for the MBP-tagged proteins and 4–12% for the 4EHP proteins) 
and bound fractions (10%) were analyzed by SDS-PAGE followed by Coomassie blue 
staining.  
 
Figure 2. Overall structures of GYF1, GYF2 and 4E-BP1 bound to 4EHP. (A, B) Overview 
of the structures of 4EHP bound to GYF1/2 (C+L+NC+A) fragments. The 4EHP surface is 
shown in yellow and surface residues within a radius of 4 Å of the bound GYF1 or GYF2 
peptides are colored in orange. The GYF1 and GYF2 peptides are colored in purple and blue, 
respectively. Selected secondary structure elements in the GYF1/2 peptides are indicated. 
The invariant PLAL motif of GYF1/2 is circled with a dashed line. (C, D) Cartoon 
representation of the structures of 4EHP bound to GYF1/2. Selected secondary structure 
elements are labeled in black for 4EHP and in color for GYF1/2. (E) Superposition of the 
structures of 4EHP bound to GYF1 and GYF2. For clarity, the 4EHP molecule from the 
4EHP–GYF1 complex was omitted. The structures of the complexes are very similar and 
overall RMSDs do not exceed 0.32 Å over 227 Cα atoms. (F) Structure of 4EHP bound to 
4E-BP1. Selected secondary structure elements are labeled in black for 4EHP and in cyan for 
4E-BP1. (G) Structure of 4EHP bound to the GYF2 C+L+NC fragment. Selected secondary 
structure elements are labeled in black and red for 4EHP and GYF2, respectively. (H) 
Superposition of the structures of 4EHP bound to the 4EBP1 and GYF2 C+L+NC peptides. 
For clarity, the 4EHP molecule from the 4EHP–4E-BP1 complex was omitted. (I, J) 
Schematic representations of 4EHP bound to GYF1/2 and 4E-BP1. 
 
Figure 3. The interactions between the canonical and non-canonical sequences of GYF2 and 
4E-BP1 with 4EHP. (A, B) Close-up views of the interactions between the 4EHP dorsal 
surface and the GYF2 and 4E-BP1 canonical helices. 4E-BP1 residue R63 is colored in dark 
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blue after its Cγ atom and highlighted with a black dashed box. The corresponding residues 
in GYF2 (F52) are also highlighted by a black dashed box. (C, D) Close-up views of the 
interaction between the 4EHP lateral surface and the GYF2 and 4E-BP1 non-canonical 
linkers. (E, F) Close-up views of the interactions between the 4EHP lateral surface and the 
GYF2 and 4E-BP1 non-canonical loops. Selected interface residues are shown as sticks. For 
clarity reasons, all residues labeled with an asterisk are shown without their side chain. 
 
Figure 4. Interaction between the GYF1/2 auxiliary sequences and 4EHP. (A, B) Close-up 
view of the arrangement of the linker a-L1 and the PLAL motif (A1) in GYF1/2 proteins at 
the 4EHP dorsal surface. The surface of 4EHP is shown in yellow and the surface of the 
GYF1/2 canonical helices is shown in gray. The positions of the 4EHP-unique residues R103 
and E149 are highlighted in orange and selected GYF1/2 residues are shown as either purple 
(GYF1) or blue (GYF2) sticks. (C–H) Close-up views of the interactions between 4EHP and 
the GYF1/2 auxiliary sequences (A1, A2 and A3). Selected GYF1/2 residues and 4EHP 
interface residues are shown as sticks. The GYF1/2 canonical helices are colored in gray.  
 
Figure 5. The auxiliary interactions are crucial for the formation of the 4EHP-GYF complex.  
(A) Western blot showing the interaction of endogenous GYF2 or GFP-4E-BP1 with V5-
SBP-4EHP (WT or the indicated mutants). The proteins were pulled down using 
streptavidin-coated beads. The inputs (1.5% for the V5-tagged proteins and 1% for GYF2 
and GFP-4E-BP1) and bound fractions (3% for the V5-tagged proteins and 20% for GYF2 
and GFP-4E-BP1) were analyzed by western blot using the indicated antibodies. (B) 
Interaction of V5-SBP-4EHP with GFP-GYF2 (residues 1-180; either wild-type or the 
indicated mutants). The proteins were immunoprecipitated using anti-GFP antibodies. GFP-
MBP served as negative control. The inputs (1.5% for the GFP-tagged proteins and 0.5% for 
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V5-SBP-4EHP) and immunoprecipitates (7.5% for the GFP-tagged proteins and 30% for V5-
SBP-4EHP) were analyzed by western blot using anti-GFP and anti-V5 antibodies. (C–E) 
Purified 4EHP–4E-BP1 complexes containing 4EHP-His6 (wild-type or the RE-LL mutant) 
were incubated in the presence of equimolar amounts of the GYF2 C+L+NC+A peptide C-
terminally tagged with GB1 or MBP as a negative control. The proteins bound to 4EHP were 
pulled down using Ni-NTA beads at the indicated time points and analyzed by SDS-PAGE 
and Coomassie blue staining. Panel (C) shows the quantification of the amount of 4E-BP1 
still associated with 4EHP (n=3). The half-life of the 4EHP-4E-BP1 complex (t1/2) in the 
presence of the competitor protein is represented as the mean +/- SD. Panels (D) and (E) 
show representative SDS-PAGE gels. The positions of the GYF2 and 4E-BP1 peptides are 
marked by blue and black dashed boxes, respectively. The lanes labeled SM (starting 
material) show the purified complexes and peptides used in the assay. 
 
Figure 6. 4EHP requires interaction with GYF1/2 proteins to repress translation. 
(A) A complementation assay using the R-Luc-5BoxB-A95-MALAT1 reporter and λN-HA-
4EHP (either wild-type or the indicated mutants) was performed in control and GYF1/2-null 
HEK293T cells expressing GFP-MBP or GFP-GYF2 (wild-type or canonical mutant). A 
plasmid expressing F-Luc-GFP served as the transfection control. R-Luc activity was 
normalized to that of the F-Luc transfection control and set to 100% in cells expressing the 
λN-HA peptide. Bars represent the mean values and error bars represent standard deviations 
from three independent experiments. (B) Western blot analysis showing that full-length 
GYF1/2 levels were strongly reduced relative to control levels in the GYF1/2-null cell line. 
(C) Western blot analysis showing the expression of the λN-HA-4EHP and GFP-GYF2 
proteins used in the assay shown in A. (D) Tethering assay using the R-Luc-5BoxB-A95-
MALAT1 reporter and λN-HA-4EHP (wild-type or mutants) in HEK293T cells. Samples 
	 Peter	et	al.		
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were analyzed as described in A. The symbols (+), (+/-) and (-) indicate binding, reduced 
binding and no binding to the GYF1/2 proteins, respectively. (E) Western blot showing the 
equivalent expression of the λN-HA-4EHP proteins used in the assay shown in D. (F) 
Tethering assay using the R-Luc-6xMS2-A95-MALAT1 reporter and MS2-HA-GYF2 (wild-
type or canonical mutant) in HEK293T cells. The cells were also co-transfected with GFP-
MBP and F-Luc-GFP as transfection controls. R-Luc activity was normalized to that of the F-
Luc transfection control and set to 100% in cells expressing the MS2-HA Samples were 
analyzed as described in A. (G) Western blot analysis showing the equivalent expression of 
the MS2-HA-GYF2 proteins. (H) Control HEK293T cells or cells depleted of GYF1/2 (KO) were 
transfected with the R-Luc-ARE-A90-MALAT1 reporter and plasmids expressing the indicated 
proteins. F-Luc-GFP reporter served as a transfection control. R-Luc activity was normalized 
to that of the F-Luc transfection control and set to 100% in the absence of TTP for each cell 
line. (I) Western blot showing the expression of the proteins in the experiment shown in H. 
Note that TTP is stabilized in GYF1/2-null cells expressing GYF2. However, repression did 
not correlate with TTP levels but with the coexpression of wild-type GYF2 and 4EHP. 
 
 
 
 
 
Table 1. Data collection and refinement statistics  
 Hs 4EHP–GIGYF1 
complex 
(GYF1 
C+L+NC+A) 
Hs 4EHP–GIGYF2 
complex 
(GYF2 
C+L+NC+A) 
Hs 4EHP–GIGYF2 
complex 
(GYF2 C+L+NC)  
Hs 4EHP-4E-BP1 
complex 
(4E-BP1 
C+L+NC) 
     
Space group P42 P41212 C2 P21 
Unit Cell     
Dimensions (Å)     
    a, b, c  135.3, 135.3, 60.9 82.6, 82.6, 148.5 152.2, 98.6, 39.3 38.4, 83.4, 70.5 
Angles (°)     
    α, β, γ  90, 90, 90 90, 90, 90 90, 99.6, 90 90, 104.3, 90 
Data collection     
Wavelength (Å) 1.000 1.000 1.000 0.999 
Resolution (Å) 47.8-2.9 45.9-2.3 44.6-2.0 41.7-1.9 
     
Rsym  0.111 (0.647) 0.125 (1.14) 0.066 (0.611) 0.145 (1.14) 
Mean I/σI 10.9 (1.95) 13.2 (2.06) 12.0 (2.09) 8.5 (2.07) 
Completeness (%) 99.6 (99.9) 99.8 (98.3) 99.8 (99.9) 99.7 (99.6) 
Multiplicity 3.4 (3.4) 11.2 (10.6) 5.1 (4.8) 6.6 (6.7) 
Refinement     
Resolution (Å) 47.8-2.9 45.9-2.3 44.6-2.0 41.7-1.9 
No. reflections 24694 23497 38550 33898 
Rwork/ Rfree 0.204/0.254 0.205/0.242 0.195/0.231 0.226/0.251 
No. atoms 7833 3811 3536 3547 
    Protein 7833 3741 3386 3305 
    Ligand/ion / / 20 21 
    Water / 70 130 221 
B-factors (Å2) 49.4 62.0 63.9 27.8 
    Protein 49.4 62.3 64.2 27.3 
    Ligand/ion / / 88.6 33.5 
    Water / 46.3 52.7 28.7 
Ramachandran Plot    
Favored (%) 95.9 97.3 95.5 97.7 
Disallowed (%) 0 0 0 0 
Root-Mean-Square Deviation    
    Bond lengths (Å)  0.003 0.004 0.011 0.003 
    Bond angles (º) 0.494 0.540 1.002 0.529 
Values in parentheses are for highest-resolution shell.  
 
Ligands: four PO43- ions in the Hs 4EHP-GIGYF2 (C+NC) complex, seven formic acid molecules in the Hs 
4EHP-4E-BP1 (C+NC) complex 
Peter et al. Fig. 1
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target mRNA expression 
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DNA constructs   
The plasmids used for the expression of human eIF4E, 4E-BP1 and eIF4G1 (full-length or 
fragments) in Escherichia coli or in human cells have been previously described (Peter et al. 
2015a; Grüner et al. 2016). The plasmids for the expression of 4EHP fragments (M1–F234) 
and (A52–F234) in E. coli were obtained by inserting the corresponding cDNA fragments 
either into the pnYC-NpH (between the XhoI and NheI restriction sites) or the pnYC-CvH 
(between the XhoI and BamHI restriction sites) vectors that include N- and C-terminal His6 
tags (Diebold et al. 2011), respectively. DNA fragments encoding for GYF1 [residues K33–
K52 (C), K33–D71 (C+L+NC) and K33–M103 C+L+NC+A)] and GYF2 [residues K35–K54 
(C), K35–Q72 (C+L+NC) and K35–T105 (C+L+NC+A)] were inserted into the NdeI-NheI 
and NdeI-XbaI restriction sites in the pnEA-NpM vector (Diebold et al. 2011), respectively. 
These constructs express GYF fragments that are N-terminally fused to an MBP-tag, which is 
cleavable by the HRV3C protease. A DNA fragment encoding the B1 domain of 
immunoglobulin-binding protein G (GB1; Cheng and Patel 2004) was inserted C-terminally 
to the GYF fragments by site-directed mutagenesis using the QuikChange mutagenesis kit 
(Stratagene).  
The plasmids for the expression of V5-streptavidin binding protein (SBP)-tagged and λN-
hemagglutinin (HA)-tagged 4EHP in human cells were obtained by inserting the full-length 
4EHP cDNA into the XhoI and BamHI sites in the pT7-V5-SBP and pλN-HA-C1 vectors 
(Kuzuoglu-Ozturk et al. 2016), respectively. The plasmids for the expression of full-length 
GYF1 and GYF2, which are N-terminally fused to GFP or MS2-HA were obtained by 
inserting the GYF1 cDNA (XhoI-EcoRI, obtained from the Kazusa DNA Research Institute; 
sj03926) or the GYF2 cDNA (XhoI-BamHI) into the corresponding sites of the pT7-EGFP-
C1 and pT7-MS2-HA-C1 vectors. cDNA fragments encoding for GYF1 (residues M1–C177) 
and GYF2 (residues M1–P180) were introduced into the XhoI and BamHI restriction sites in 
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the pT7-EGFP-C1 vector. The cDNA encoding 4E-T (eIF4E-Transporter protein; 
EIF4ENIF1) was inserted into the HindIII and BamHI restriction sites in the pT7-EGFP-C1 
vector. The cDNA encoding TTP (Tristetraprolin, residues M1–P313; Fabian et al. 2013) was 
inserted between the XhoI and EcoRI restriction sites of the pλN-HA-C1 vector. To generate 
a reporter containing the ARE-element (pCIneo-R-Luc-ARE-A90-MALAT1), the sequence of 
the ARE element present in the 3' UTR of the TNF (Tumor Necrosis Factor)-α mRNA was 
inserted twice into the 3' UTR of the pCIneo-R-Luc parental plasmid by site-directed 
mutagenesis. A cDNA containing a stretch of 90 A and the MALAT1 sequence was then 
inserted into the XhoI and NotI restriction sites of the R-Luc-ARE vector. The DNA 
sequence of the TNF-α ARE is as follows: 
TTATTTATTATTTATTTATTATTTATTTATTT. All of the mutants used in this study 
were generated by site-directed mutagenesis using the QuikChange mutagenesis kit 
(Stratagene). All of the constructs and mutations were confirmed by sequencing and are listed 
in Supplemental Table S1.  
 
Pulldown and competition assays  
In the pulldown assays shown in Fig. 1 and Supplemental Fig. S2 and S7, bacterial lysates 
expressing recombinant 4EHP-His6 (residues M1–F234, wild-type and mutants) or purified 
eIF4E-His6 (2 µM; 50 µg) were incubated with Ni-NTA beads for 30 min. The immobilized 
4EHP and eIF4E proteins were then incubated for 30 min with bacterial lysates expressing 
GYF1, GYF2 or 4E-BP1 fragments (wild-type and mutants) that were N-terminally tagged 
with MBP and C-terminally tagged with GB1. Proteins associated with 4EHP or eIF4E were 
eluted with imidazole and analyzed by SDS-PAGE followed by Coomassie staining.  
For the competition assays, purified 4EHP–4EBP1 complexes (2 µM) containing 4EHP 
(residues A52–F234)-His6 and 4E-BP1 C+L+NC (residues R50–S83; with a  C-terminal GB1 
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tag) were incubated with Ni-NTA beads for 30 min in 50 mM Na-phosphate (pH 7.0) and 
200 mM NaCl. The immobilized complexes were then incubated with equimolar amount of 
purified, GB1-tagged competitor peptides or with MBP as a negative control. After the 
specified time points, the beads were pelleted and washed three times in the same buffer. 
Proteins bound to the Ni-NTA beads were eluted with the same buffer containing 500 mM 
imidazole and analyzed by SDS-PAGE followed by Coomassie staining. The amount of 4E-
BP1 bound to 4EHP was quantified using the ImageJ software and normalized to 4EHP 
levels present at each time point. These values were set to 100 in the presence of MBP. Data 
points from at least three independent experiments were plotted and the resulting fitting 
curves were determined using the Levenberg-Marquardt algorithm for single exponential 
decay functions. The R2 values associated with the fitting of the exponential decay curves 
were between 0.82 and 0.96. 
 
ITC analysis  
For the ITC measurements, the GB1-stabilized GYF1/2 peptides (wild-type and mutants) and 
4E-BP1 peptides were purified as previously described for the other 4E-BPs (Igreja et al. 
2014; Peter et al. 2015a,b). The 4EHP protein (residues A52–F234; wild-type and mutants) 
used in the ITC measurements was expressed with an N-terminal His6 tag and purified from 
cleared cell lysates using a nickel column (HisTrap HP 5 ml, GE Healthcare). The His6 tag 
was cleaved by HRV3C protease overnight at 4°C. The protein was further purified using a 
heparin column (HiTrap Heparin HP 5 ml, GE Healthcare) and a final purification on a 
Superdex 75 column (GE Healthcare). The 4EHP-GYF2 complex (GYF2 residues K35–
T105) used for measuring the affinity for m7GpppG cap analog was purified as described for 
the 4EHP–GYF2 complex used for crystallization. All of the proteins used in the ITC 
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measurements were stored at -80°C in a buffer consisting of 20 mM Na-phosphate (pH 7.0) 
and 200 mM NaCl. 
The ITC experiments were performed using a VP-ITC microcalorimeter (MicroCal) at 20°C 
as described previously (Igreja et al. 2014; Peter et al. 2015a,b). A solution containing either 
4EHP (residues A52–F234, wild-type, S99N mutant and dimerization mutant, 1-5 µM) or 
eIF4E (residues K36–V217, 5 µM) in a calorimetric cell was titrated with tenfold 
concentrated solutions of GB1-stabilized peptides that were dissolved in the same buffer (20 
mM Na-phosphate (pH 7.0) and 150 mM NaCl). The following peptides were used: GYF1 
(C, residues K33–K52, 50 µM; C+L+NC, residues K33–D71, 20 µM; C+L+NC+A wild type 
or dimerization mutant, residues K33–M103, 10 µM), GYF2 (C, residues K35–K54, 50 µM; 
C+L+NC, residues K35–Q72, 20 µM; C+L+NC+A wild type or dimerization mutant, 
residues K35–T105, 10 µM) and 4E-BP1 (C+L+NC, residues T50–S83, 50 µM). The affinity 
for the m7GpppG cap analog was measured in a buffer containing 20 mM HEPES (pH 7.5) 
and 200 mM NaCl by titrating a solution of m7GpppG (400 µM; New England Biolabs) into 
a solution of 4EHP (residues A52–F234, 40 µM) or 4EHP in complex with GIGYF2 
(residues K35–T105, 40 µM) diluted in the same buffer. 
The titration experiments consisted of an initial injection of 2 µl followed by 28 injections of 
10 µl at 240 s intervals. Each binding experiment was repeated three times. Correction for 
dilution heating and mixing was achieved by subtracting the final baseline, which consisted 
of small peaks of similar size. The thermodynamic parameters were estimated using a one-
site binding model (Origin version 7.0), whereby the data points for the first injection were 
removed from the analysis (Mizoue and Tellinghuisen 2004). Because the protein 
concentration used in these measurements is low (1 µM for 4EHP in the calorimetric cell), 
dimerization of the 4EHP–GYF1/2 complexes is unlikely to occur and thus it does not 
contribute to the measured binding constants. Accordingly, GYF2 and 4EHP dimerization 
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mutants still display a binding affinity similar to that observed for the complexes containing 
the wild type proteins (Supplemental Table S2 and Fig. S7). 
 
Crystallization 
Crystals of 4EHP (residues A52–F234) in complex with GYF1 (residues K33–M103) were 
obtained at 18°C using the hanging-drop vapor diffusion method two days after mixing the 
protein solution (16 mg/ml; 1 µl) with the crystallization solution (1 µl) containing 20% PEG 
3350 in 0.2 M potassium nitrate. Crystals of 4EHP (residues A52–F234) bound to GYF2 
(residues A35–T105) were obtained at 18°C using the hanging-drop vapor diffusion method 
one day after mixing the protein solution (16 mg/ml, 1 µl) with the crystallization solution (1 
µl) containing 0.1 M sodium citrate (pH 5.0), 0.1 M magnesium chloride and 12% PEG 
4000.. Crystals of 4EHP (residues A52–F234) in complex with GYF2 (residues A35–Q72) 
were obtained at 18°C using the hanging-drop vapor diffusion method. Crystals grew in one 
day after mixing the protein solution (16 mg/ml, 1 µl) with the crystallization solution (1 µl) 
containing in 0.1 M sodium acetate (pH 4.6) and 0.6 M diammonium phosphate. All of the 
crystals containing GYF peptides were soaked in mother liquor supplemented with 10–15% 
glycerol for cryoprotection before flash-freezing in liquid nitrogen.  
Crystals of 4EHP (residues A52–F234) in complex with 4E-BP1 (residues T50–S83) were 
obtained at 18°C using the sitting-drop vapor diffusion method. The crystals grew three days 
after mixing the protein solution (16.5 mg/ml; 0.1 µl) with the crystallization solution (0.1 µl) 
containing 0.1 M sodium acetate (pH 4.6) and 1.7 M sodium formate. The crystals were 
cryoprotected in mother liquor supplemented with 3.5 M sodium formate and flash-frozen in 
liquid nitrogen. 
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Data collection and structure determination 
The data for all the crystals were collected at 100K on a PILATUS 6M detector at the PXII 
beamline at the Swiss Light Source. Diffraction data were processed with XDS and scaled 
using XSCALE (Kabsch 2010). The phases were obtained by molecular replacement using 
PHASER (McCoy et al., 2007). For the 4EHP–GYF2 (residues K35–T105; C+L+NC+A) 
complex, the structure of human 4EHP (PDB 2JGB; Rosettani et al. 2007) was used as a 
search model with an asymmetric unit containing two copies of the model. To solve the 
structures of the 4EHP–GYF2 (residues K35–Q72; C+L+NC) and 4EHP–4E-BP1 (residues 
T50–S83; C+L+NC) complexes, two copies of 4EHP from the 4EHP–GYF2 (C+L+NC+A) 
complex were used as a search model. In the case of the 4EHP–GYF1 (residues K33–M103; 
C+L+NC+A) complex, four copies of the 4EHP–GYF2 (C+L+NC+A) complex were used as 
a search model. To minimize model bias, the molecular replacement solutions were used to 
rebuild the initial models using the PHENIX AutoBuild wizard (Terwilliger et al., 2008). To 
complete the structure, iterative cycles of model building and refinement were performed 
with COOT (Emsley et al. 2010) and PHENIX (Afonine et al. 2012), respectively. The GYF2 
(C+L+NC+A and C+L+NC) and 4E-BP1 (C+L+NC) peptide chains were manually built into 
the difference density in COOT and further refined with PHENIX. In the final refinement 
rounds for the 4EHP–GYF1 (C+L+NC+A) and 4EHP–GYF2 (C+L+NC+A) complexes, 
translation/libration/screw (TLS) parameters were refined for the peptide chains in addition 
to the individual B-factors; in the case of the GYF1 complex, non-crystallographic symmetry 
(NCS) torsional restraints were also used in refinement. 
The stereochemical properties for all of the structures were verified with MOLPROBITY 
(Chen et al. 2010), and structural images were prepared with PyMOL 
(http://www.pymol.org). The diffraction data and refinement statistics are summarized in 
Table 1. 
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Small-angle X-ray scattering (SAXS)  
SAXS experiments were conducted at the SWING beamline at the SOLEIL synchrotron. 
Data collection for the 4EHP–GYF2 complexes was performed in-line with size exclusion 
chromatography (Superdex 200 Increase 5/150 GL, GE Healthcare) using an Agilent HPLC 
system in a buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl, and 1 mM TCEP 
[Tris(2-carboxyethyl)phosphine]. The scattering data were collected at 1 s exposures using an 
Aviex charge-coupled device detector at a sample-detector distance of 1798 mm and a 
wavelength of 1.033 Å. Data reduction to absolute units, frame averaging and buffer 
subtraction were performed using the FOXTROT software (Xenocs, France). Theoretical 
scattering curves and fitting to the experimental SAXS data was performed using the FoXS 
software (Schneidman-Duhovny et al. 2013). To ensure protein stability during SAXS data 
collection, all the 4EHP–GYF2 complexes were measured with a 1.5x molar excess of 
m7GpppG cap analog (New England Biolabs) in the protein samples. Therefore, the 
coordinates of the structures used during the fitting procedures were adjusted such that the 
4EHP cap-binding loops were fixed in the bound conformation including the cap analog, 
which was based on the structure of the m7GTP-bound 4EHP (PDB 2JGB; Rosettani et al. 
2007). 
 
Generation of GYF1/2-null cell line 
Two sgRNAs targeting GYF1 and two sgRNAs targeting GYF2 were designed using the 
DNA 2.0 (ATUM) or CHOPCHOP (http://chopchop.cbu.uib.no) online tools and cloned into 
the pSpCas9(BB)-2A-Puro (PX459) vector [a gift from F. Zhang, Addgene plasmid 48139; 
(Ran et al., 2013)]. HEK293T cells were transfected with the sgRNA-Cas9 vectors and 
selected with puromycin (3 µg ml-1) to obtain stable GYF1/2 knockout cells. To obtain clonal 
cell lines, single cells were distributed in 96-well plates using serial dilutions. Genomic 
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DNAs from single clones were isolated using the Wizard SV Genomic DNA Purification 
System (Promega) and the targeted GYF1 and GYF2 loci were PCR amplified and sequenced 
to confirm gene editing. For GYF1 we observed two frameshift mutations in exon 7 (4 bp 
deletion and a 8 bp deletion together with a C->T mutation) targeted by sgGYF1-a and two 
indels in exon 16 (insertion of 43 bp or 93 bp) produced by sgGYF1-b. These mutations 
changed the GYF1 reading frame after the respective targeted site and introduced premature 
STOP codons. One frameshift mutation (16 bp deletion in the first exon removing the start 
codon) was detected for the GYF2 locus (targeted by sgGYF2-a and sgGYF2-b). This 
deletion was caused by sgGYF2-b. In contrast, sgGYF2-a did not target the genomic locus as 
the sequence around this target site is wild-type. The knockouts of GYF1/2 were further 
confirmed by western blotting. For the GYF2 gene we observe low levels of truncated 
protein fragments that  are consistent with translation initiation at internal AUGs (Figure 6B, 
lane 4). Taking the GYF2 sequence and the position of the mutations into account, these 
truncated forms lack the 4EHP-binding region and the expression levels are approximately 
10% of wild-type levels. The following guide sequences were used: sgGYF1-a: 5’- 
GCCAGCGGTCGCCGTCTCGC-3’; sgGYF1-b: GACAAGGACCGGCTCATCGT-3’; 
sgGYF2-a: 5’- ATTTTGAAAACTCACCATTC-3’; sgGYF2-b: 5’- 
AATACGGAAAAGAATGGCAG 
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Supplemental Table S1. Mutants and constructs used in this study. 
Protein Name of the construct Fragments / mutations Binding site / motif 
Hs 4EHP 
(isoform 1) 
O60573-1 
4EHP Full-length (1–245)  
4EHP ΔC-term 1–234 Δ235–245 
4EHP truncated 52–234 Δ1–51 & 235–245 
W-A W95A Dorsal surface 
IM-AA I85A, M101A Lateral surface 
WIM-AAA W95A, I85A, M101A Dorsal + lateral surface 
RE-LL R103L, E149L Auxiliary surface 
WRE-ALL W95A, R103L, E149L Dorsal + auxiliary surface 
S99N S99N Dorsal surface 
Cap mutant (cap*) W124A Cap-binding pocket 
D* (dimer mutant) Q159S, M161D, R202E Dimer interface 
Hs eIF4E 
(isoform 1) 
P06730-1 
4E Full-length (1–217)  
4E trunc  36–217  
Cap mutant (cap*) W102A Cap-binding pocket 
Hs GIGYF1 
O75420 
GYF1 Full-length (1–1035)  
C+L+NC+A 33–103 Complete 4EHP-binding region 
C+L+NC 33–71 Bipartite 4EHP-binding region 
C 33–52 Canonical 4EHP-binding region 
C* Y39A, Y41A, M46A, L47A Canonical 
NC* L60D, F65D, V68D Non-canonical 
A1* P76D, L77A Auxiliary site 1 
A2* E86A, N95F Auxiliary site 2 
NC+A1* L60D, F65D, V68D, P76D, L77A Non-canonical + auxiliary site 1 
NC+A2+3* L60D, F65D, V68D, E86A, N95F Non-canonical + auxiliary site 2 
1-177  N-terminus 
D* (dimer mutant) E44A, E45F, Q87A Dimer interface 
Hs GIGYF2 
(isoform 1) 
Q6Y7W6-1 
GYF2 Full-length (1–1299)  
C+L+NC+A 35–105 Complete 4EHP-binding region 
C+L+NC 35–72 Bipartite 4EHP-binding region 
C 35–54 Canonical 4EHP-binding region 
C* Y41A, Y43A, M48A, L49A Canonical motif 
NC* L62D, F67D, I70D Non-canonical 
A1* P78D, L79A Auxiliary site 1 
A2* E88A, N96F Auxiliary site 2 
NC+A1* L62D, F67D, I70D, P78D, L79A Non-canonical + auxiliary site 1 
NC+A2+3* L62D, F67D, I70D, E88A, N97F Non-canonical + auxiliary site 2 
1-180  N-terminus 
D* (dimer mutant) E46A, E47F, Q89A Dimer interface 
Hs 4E-BP1 
Q13541 
4E-BP1 Full-length (1–118)  
4E-BP1 C+L+NC 50–83 eIF4E-binding region 
C* Y54A, L59A Canonical motif 
NC* L75A, V81A Non-canonical 
C+NC* Y54A, L59A, L75A, V81A Canonical+ non-canonical 
Hs 4E-T 
Q9NRA8 4E-T Full-length (1–985)  
Hs TTP 
(1–326) 
P26651 
TTP ΔNIM 1–313 Δ314-326, deletion of the NOT1 interacting motif (NIM) 
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Supplemental Table S2. Thermodynamic parameters for the interaction of 4EHP and eIF4E 
with the indicated peptides. 
GYF peptides vs 4EHP 
GYF protein KD (nM) ΔH (kcal mol-1) -TΔS (kcal mol-1) ΔG (kcal mol-1) Molar ratio 
GYF1 C  
(33-52) 
360 ± 
120 
-23 ± 3 14.6 -8.7 1.00 ± 0.01 
GYF1 C+L+NC 
(33-71) 
12 ± 2 -30 ± 1 19.3 -10.6 1.00 ± 0.01 
GYF1 
C+L+NC+A 
(33-103) 
0.4 ± 0.2 -37 ± 4 24.4 -12.6 1.00 ± 0.02 
GYF2 C 
(35-54) 
290 ± 
160 
-22 ± 2 13.5 -8.8 1.00 ± 0.01 
GYF2 C+L+NC 
(35-72) 
14 ± 1 -23 ± 2 12.3 -10.6 1.00 ± 0.01 
GYF2 
C+L+NC+A 
(35-105) 
0.3 ± 0.1 -32 ± 1 19.1 -12.8 1.00 ± 0.01 
GYF peptides vs 4EHP dimerization mutants 
GYF protein KD (nM) ΔH (kcal mol-1) -TΔS (kcal mol-1) ΔG (kcal mol-1) Molar ratio 
GYF1 
C+L+NC+A 
(33-103) D* 
0.4 ± 0.3 -34 ± 1 21.6 -12.7 1.01 ± 0.01 
GYF2 
C+L+NC+A 
(35-105) D* 
0.5 ± 0.3 -30.8 ± 0.5 18.1 -12.7 1.01 ± 0.02 
4EBP1 C+L+NC vs eIF4E or 4EHP 
4E molecule KD (nM) ΔH (kcal mol-1) -TΔS (kcal mol-1) ΔG (kcal mol-1) Molar ratio 
eIF4E 5 ± 2 -18 ± 1 6.4 -11.2 1.00 ± 0.01 
4EHP 55 ± 14 -16.4 ± 0.8 6.6 -9.8 1.01 ± 0.01 
4EHP S99N 4 ± 1 -21 ± 2 9.7 -11.3 1.01 ± 0.01 
m7GpppG cap analog vs 4EHP or 4EHP-GIGYF2 complex 
Protein KD (µM) ΔH (kcal mol-
1) 
-TΔS (kcal mol-
1) 
ΔG (kcal mol-
1) 
Molar 
ratio 
4EHP 4 ± 1 -7.3 ± 0.4 0.1 ± 0.5 -7.2 1.01 ± 0.01 
4EHP–GYF2 
(35–105) 
complex 
6 ± 3 -9 ± 2 1 ± 3 -7.2 1.01 ± 0.01 
	
Note that the presence of the auxiliary sequences increases the entropic penalty (-T∆S) of the 
interaction between GYF1/2 and 4EHP compared to that of the peptides lacking these sequences 
[Δ(-TΔS)GYF1 = 5.1 kcal/mol-1, Δ(-TΔS)GYF2 = 6.8 kcal/mol-1]. One explanation for the increase in 
the entropic penalty is a higher disorder-to-order transition for the binding of the GYF1/2 
C+L+NC+A peptides compared to the C+L+NC peptides. This is supported by the crystal 
structures in which the auxiliary sequences fold into two α-helices in complex with 4EHP.  
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Supplemental Table S3. Experimental and theoretical SAXS parameters for different  
4EHP–GYF complexes. 
Experimental parameters 
4EHP bound to: Rg 
(Guinier) 
[Å] 
Rg (real space) 
[Å] 
Dmax  
[Å] 
Exp. 
I(0)  
[x10-2] 
Concentration 
[mg/ml] 
GYF2 C+L+NC 21.1 21.2 71.1 4 10 
GYF2 C+L+NC+A 26.1 26.2 90.3 7.9 10 
GYF2 C+L+NC+A 25.8 25.8 89.3 3.6 5 
GYF2 C+L+NC+A 24.7 24.8 83.7 1.7 2.5 
GYF2 C+L+NC+A 23.7 23.7 80.2 0.7 1.25 
4EHP D mutant 
bound to: 
Rg 
(Guinier) 
[Å] 
Rg (real space) 
[Å] 
Dmax  
[Å] 
Exp. 
I(0)  
[x10-2] 
Concentration 
[mg/ml] 
GYF2 C+L+NC+A 
D* 
(dim. mutant) 
20.6 20.6 73.7 1.3 5 
Theoretical parameters 
4EHP–GYF2 C+L+NC+A 
Single complex Symmetric dimer 
Rg (Guinier) [Å] Dmax [Å] Rg (Guinier) [Å] Dmax [Å] 
17.7 64 24.7 85 
4EHP–GYF2 C+L+NC 
Single complex Symmetric dimer 
Rg (Guinier) [Å] Dmax [Å] Rg (Guinier) [Å] Dmax [Å] 
17.1 64 26.1 90 		
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Supplemental Table S4. Antibodies used in this study. 
Antibody Source Catalog Number Dilution 
Monoclonal/ 
Polyclonal 
Anti-HA-HRP (Western 
blot) 
Roche 12 013 819 001 1:5,000 Monoclonal 
Anti-HA 
(Immunoprecipitation) 
Biolegend MMS-101P 1:1,000 Monoclonal 
Anti-Hs GYF2 Bethyl laboratories A303-731A 1:1,000 Rabbit polyclonal 
Anti-Hs GYF1 Bethyl laboratories A304-132A-M 1:1,000 Rabbit polyclonal 
Anti-Hs 4E-T Abcam ab95030 1:2,000 Rabbit polyclonal 
Anti-Hs 4EHP In house  1:200 Rabbit polyclonal 
Anti-Hs eIF4E Bethyl laboratories A301-154A 1:2,000 Rabbit polyclonal 
Anti-Hs 4E-BP1 
Cell Signaling 
Technology 
9452 1:1,000 Rabbit polyclonal 
Anti-GFP In house  IP Rabbit polyclonal 
Anti-GFP Roche  11814460001 1:2,000 Monoclonal 
Anti-rabbit-HRP GE Healthcare NA934V 1:10,000 Polyclonal 
Anti-mouse-HRP GE Healthcare RPN4201 1:10,000 Polyclonal 
Anti-V5 QED Bioscience Inc. 18870 1:5,000 Rabbit polyclonal 
Anti-V5 
LSBio LifeSpan 
BioSciences, Inc. 
LS-C57305 1:5,000 Monoclonal 
Anti-tubulin Sigma Aldrich T6199 1:10,000 Monoclonal 	
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Supplemental Figures 
 
 
Supplemental Figure S1. Sequence alignments. In all aligned sequences, residues with 
>70% similarity are shown with a light color background and conserved residues are 
highlighted with a darker background and printed in white. Secondary structure elements are 
indicated above the sequences for 4EHP and GYF1 and are based on the structures presented 
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in this study. (A) Sequence alignment of 4EHP and eIF4E orthologous proteins from Homo 
sapiens (Hs), Mus musculus (Mm), Danio rerio (Dr) and Drosophila melanogaster (Dm). 
Residues highlighted in black boxes are specific for 4EHP and are relevant for the 
interactions described in this study. The dorsal and lateral binding surfaces (BS) of 4EHP are 
indicated by a line below the sequences. Residues that were mutated in this study are 
indicated by open circles colored as follows: cyan (dorsal surface), blue (lateral surface), red 
(4EHP specific residues) and green (dimerization). (B) Sequence alignment of GYF proteins. 
The canonical (C), non-canonical (NC) and auxiliary (A1, A2, A3) sequences are boxed in 
black. The GYF1/2 sequences visible in the crystal structures are indicated with a red box. 
Only a short stretch of the Arg/Gly-rich sequence adjacent to the auxiliary motif is shown 
and underlined. The species are as in A. Open circles above the alignment indicate the 
residues mutated in this study and are colored as follows: cyan (canonical), blue (non-
canonical), red (auxiliary) and orange (dimerization).  
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Supplemental Figure S2. Interaction of GYF1, GYF2 and 4E-BP1 with 4EHP. (A) The 
interaction of HA-4EHP with V5-SBP-4E-BP1 (wild-type or the indicated mutants) was 
tested in HEK293T cell lysates. The proteins were pulled down using streptavidin-coated 
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beads. V5-SBP-MBP served as negative control. The inputs (1.5%) and bound fractions (3% 
for the V5-proteins and 5% for HA-4EHP) were analyzed by western blotting using anti-HA 
and anti-V5 antibodies. (B) The interaction of GFP-GYF1 [either full-length, canonical 
mutant (C*) or N-terminal fragment (residues 1–177)] with V5-SBP-4EHP was analyzed by 
immunoprecipitation assay in HEK293T cells using anti-GFP antibodies. GFP-MBP served 
as negative control. The input samples (1.5%) and the immunoprecipitates (10%) were 
analyzed by western blotting using anti-V5 and anti-GFP antibodies. GYF1 residues 1–177 
bound to 4EHP to a similar extent as the full-length protein, indicating that this protein 
fragment contains the principal 4EHP-binding region of the protein. (C) The interaction of 
GFP-GYF2 [either full-length, canonical mutant (C*) or N-terminal fragment (residues 1–
180)] with V5-SBP-4EHP was analyzed as described in B. GYF2 residues 1–180 bound to 
4EHP to a similar extent as the full-length protein. (D) Western blot showing the interaction 
of V5-SBP-4EHP (wild-type or the indicated mutants) with endogenous GYF1. The proteins 
were pulled down using streptavidin-coated beads. V5-SBP-MBP served as negative control. 
The inputs (1.5% for the V5-tagged proteins and 3% for GYF1) and bound fractions (3% for 
V5-tagged proteins and 35% for GYF1) were analyzed by western blotting using anti-V5 and 
anti-GYF1 antibodies. (E, F) Ni-NTA pulldown assays showing the interactions of GYF1 
fragments (C+L+NC+A, C+L+NC and C) with 4EHP-His6 (E) or eIF4E-His6 (F). The eIF4E-
binding region of 4E-BP1 (C+L+NC) binds similarly to both 4EHP and eIF4E, whereas 
GYF1 associates preferentially with 4EHP. The GYF1 and 4E-BP1 peptides contain an N-
terminal MBP-tag and a C-terminal GB1 tag. The starting material (4% for the GYF1 
fragments, 6% for 4EHP and recombinant eIF4E) and bound fractions (10% and 15% in 
panels E and F, respectively) were analyzed by SDS-PAGE followed by Coomassie blue 
staining. MBP served as a negative control. (G) The interaction of V5-SBP-tagged eIF4E or 
4EHP proteins with endogenous GYF1, 4E-T and 4E-BP1 was analyzed in HEK293T cell 
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lysates. The proteins were pulled down using streptavidin-coated beads. Inputs (1.5%) and 
bound fractions (30% for 4E-BP1, GYF1 and 4E-T and 5% for the V5-SBP-tagged proteins) 
were analyzed by western blotting using anti-V5, anti-4E-BP1, anti-4E-T and anti-GYF1 
antibodies. (H, I) Western blot analysis showing the interaction of GFP-tagged GYF1, GYF2 
and 4E-T with HA-4EHP (H) or HA-eIF4E (I) in HEK293T cells. The proteins were 
immunoprecipitated using anti-GFP antibodies. The inputs (0.75% for GFP-tagged proteins 
and 0.5% for the HA-tagged proteins) and immunoprecipitates (15% for GFP-tagged proteins 
and 25% for HA-tagged proteins) were analyzed using anti-GFP and anti-HA antibodies, 
respectively. (J) Ni-NTA pulldown assay showing the interaction of 4EHP-His6 (wild-type, 
W-A and IM-AA mutants) with GYF1 fragments with or without the auxiliary region 
(C+L+NC+A vs. C+L+NC). MBP served as a negative control. The starting material (4%) 
and bound fractions (9%) were analyzed by SDS-PAGE followed by Coomassie blue 
staining. 
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Supplemental Figure S3. Calorimetric titration data for the interaction of 4EHP with 
peptides derived from GYF1, GYF2 and 4E-BP1 or with m7GpppG cap analog. (A–F) 
Isothermal titration calorimetry (ITC) profiles for the interaction of 4EHP (residues 52–234) 
with the following peptides: (A) GYF1 C; (B) GYF2 C; (C) GYF1 C+L+NC; (D) GYF2 
C+L+NC; (E) GYF1 C+L+NC+A; (F) GYF2 C+L+NC+A. (G) ITC profile for the binding of 
4EHP (residues 52-234) to m7GpppG cap analog. (H) ITC profile for the binding of 4EHP-
GYF2 C+L+NC+A complex to m7GpppG cap analog. (I, J) ITC profiles for the interaction of 
4EHP dimerization mutant with GYF1 and GYF2 (C+L+NC+A) dimerization mutant 
peptides. (K - M) ITC profiles for the interaction of 4E-BP1 (residues 50–83, C+L+NC) with 
the following proteins: (K) wild-type 4EHP (residues 52–234); (L) wild-type eIF4E (residues 
36–217); (M) 4EHP (residues 52–234) S99N mutant. The thermodynamic parameters are 
shown in Table S2. Upper panels show raw data in (µcal sec-1) and lower panels represent the 
integration of heat changes associated with each injection (kcal mol-1 of injectant). Data was 
fit using a one-site binding model. 
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Supplemental Figure S4. Structures of 4EHP bound to GYF1, GYF2 and 4EBP1. (A) 
Cartoon representation showing the asymmetric unit (ASU) of the 4EHP–GYF1 crystal 
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form. The ASU contains four 4EHP–GYF1 complexes. In complex 1, which was used for 
representation, GYF1 is colored in purple and 4EHP is colored in yellow; in the other 
complexes of the ASU GYF1 is colored in cyan and 4EHP in grey. (B) Cartoon 
representation showing the ASU of the 4EHP–GYF2 crystal form. The ASU contains two 
4EHP–GYF2 complexes. In complex 1, GYF2 is colored in blue and 4EHP in yellow. In 
complex 2, GYF2 is colored in red and 4EHP in grey. (C) ASU of the 4EHP–4E-BP1 
(C+L+NC) crystal form. There are two 4EHP–4E-BP1complexes in the ASU. In complex 1, 
4E-BP1 is colored in cyan and 4EHP is colored in yellow. In complex 2, 4EHP is colored in 
grey. The N-terminal portion of the 4EHP molecule from complex 1 is colored in red and 
contains residues from the expression tag, which mediate contacts to complex 2. (D) Cartoon 
representation showing the ASU of the 4EHP–GYF2 (C+L+NC) crystal structure. The ASU 
contains two 4EHP–GYF2 complexes. In complex 1, GYF2 is colored in red and 4EHP 
yellow. In complex 2, GYF2 is colored in blue and 4EHP in grey. The structural arrangement 
of the two complexes that lack the GYF2 auxiliary sequences appears similar to the dimeric 
arrangement of the complexes containing the auxiliary sequences (panel B). (E) 
Superposition of the structure of 4E-BP1 (cyan) bound to 4EHP (yellow) to the structure of 
4E-BP1 (magenta) bound to eIF4E (grey; PDB: 4UED, Peter et al. 2015a). Selected 
secondary structural elements in 4EHP are label in black. The structures superpose with an 
RMSD of 0.41 Å over 194 Cα atoms. (F) Schematic representation of eIF4E and 4EHP 
bound to 4E-BP1. (G) Superposition of the structure of 4EHP bound to GYF2 C+L+NC+A 
(blue) with the structure of 4EHP bound to GYF2 C+L+NC (red) peptides. Selected 
secondary structural elements in 4EHP are label in black. The structures superpose with an 
RMSD of 0.38 Å over 207 Cα atoms. (H) Overlay of all complex structures of 4EHP bound 
to GYF1 and GYF2 peptides to illustrate the conformational flexibility of helix α2 (A2), 
which is circled with a black dashed line. The surface of 4EHP is shown in pale yellow and 
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the GYF peptides are colored in purple and blue for GYF1 and GYF2, respectively. Helical 
secondary elements (canonical helix, helices α2 and α3) are represented as cylinders. 
 
Supplemental Figure S5. Interactions of GYF1, GYF2 and 4E-BP1 with 4EHP and eIF4E. 
 (A–D) Close-up views of the interaction between the dorsal surface of 4EHP (A,C,D) or 
eIF4E (B) and the canonical helices of 4E-BP1 (A, B; Peter et al. 2015a), GYF1 C+L+NC+A 
(C) and GYF2 C+L+NC (D). Selected residues are shown as sticks. Selected secondary 
structure elements are labeled in black for 4EHP or eIF4E and in color for the interacting 
partners. Residue R634E-BP1 is colored in dark blue following the Cγ atom in A and 
highlighted by a black dashed box in A and B. (E–H) Close-up views of the interaction 
between 4EHP (E,G,H) or eIF4E (F) and the non-canonical linkers of 4E-BP1 (E, F; Peter et 
al. 2015a), GYF1 C+L+NC+A (G) and GYF2 C+L+NC (H). Selected residues are shown as 
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sticks. Residue R634E-BP1 is colored in dark blue following the Cγ atom in E and highlighted 
by a black dashed box in E and F. The corresponding residues in GYF1 (Y50) or GYF2 (F52) 
are also highlighted by a black dashed box. For visual clarity, only backbone atoms are 
shown for the residues labeled with an asterisk. The residues N77 in eIF4E and S99 in 4EHP 
are highlighted with orange dashed boxes. (I–L) Close-up views of the interaction between 
the lateral surface of 4EHP (I,K,L) or eIF4E (J) and the non-canonical loops of 4E-BP1 (I, J; 
Peter et al. 2015a), GYF1 C+L+NC+A (K) and GYF2 C+L+NC (L). 
 
 
Supplemental Figure S6. Validation of the interfaces observed in the 4EHP–GYF1/2 and 
4EHP–4E-BP1 complex structures. (A) Western blot analysis showing the interaction of 
endogenous GYF1 with V5-SBP-tagged 4EHP (WT or the indicated mutants). The proteins 
were pulled down using streptavidin-coated beads. V5-SBP-MBP served as negative control. 
The inputs (2.5%) and immunoprecipitates (3% for the V5-tagged proteins and 20% for 
GYF1) were analyzed by western blotting using anti-V5 and anti-GYF1 antibodies. (B) 
Interaction of GFP-GYF1 N-terminal fragment (residues 1–177; either wild-type or the 
indicated mutants) with V5-SBP-tagged full-length 4EHP. The proteins were 
immunoprecipitated from HEK293T cell lysates using anti-GFP antibodies. GFP-MBP 
served as negative control. The inputs (1.5% for the GFP-tagged proteins and 0.5% for V5-
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SBP-4EHP) and immunoprecipitates (7.5% for the GFP-tagged proteins and 30% for V5-
SBP-4EHP) were analyzed by western blotting using anti-GFP and anti-V5 antibodies.  
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Supplemental Figure S7. The 4EHP–GYF1/2 complexes form dimers in solution. (A) 
Representation of the dimeric arrangement of the 4EHP–GYF2 complexes in the asymmetric 
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unit of the crystal. In this dimeric arrangement, the two 4EHP–GYF2 complexes adopt a two-
fold rotational symmetry with their dorsal surfaces facing each other. The interface of this 
arrangement involves: I) the canonical helix of GYF2, which is in contact with the 
neighboring 4EHP molecule and is extended by the canonical helix of the GYF2 molecule of 
the neighboring complex, and II) the auxiliary region of GYF2, where helix α2 of one 
complex faces, in an antiparallel fashion, helix α2 of the GYF2 and loop 8 of the 4EHP 
present in the neighboring complex. The contacts between the two complexes are highlighted 
with dashed black circles. In complex 1, GYF2 is colored in blue and 4EHP in yellow. In 
complex 2, GYF2 is colored in red and 4EHP in grey. (B, C) Close-up views on the dimeric 
interface involving the canonical helices (C helix, panel B) and the auxiliary helix 2 (helix 
α2, panel C). Selected residues are shown as sticks and colored as in panel A. GYF2 residues 
E46 and E47 within the canonical motifs of interacting GYF2 molecules contact the 
guanidinium group of R2024EHP and the side chain of Q1594EHP on neighboring 4EHP 
molecules. M1614EHP contacts the aliphatic portion of E46GYF2 in the canonical helix of the 
neighboring complex. Pro residues in 4EHP loop L8 (P207 and P208) are facing residues 
proximal to the helix α2 of GYF2 from the neighboring complex (P83, F84, Q89GYF2). (D, F) 
Crystallographic models of the 4EHP–GYF2 complexes. The radius of gyration (RG) and the 
maximum particle size (Dmax) were calculated using Scatter and are summarized in Table S3. 
In the case of the dimeric assemblies, the dimer interface (B/2) was calculated using PISA 
from the CCP4 package and is indicated below the structures. 4EHP is shown in grey. The 
GYF2 (C+L+NC+A) peptide is colored in red and cyan in the single and dimeric 
arrangements, respectively. The GYF2 (C+L+NC) peptide is colored in green and purple in 
the single and dimeric arrangements, respectively. (E, G, I) Small-angle X-ray scattering 
profiles comparing single and dimeric arrangements of the 4EHP–GYF2 complexes with the 
experimental data. The data are plotted with the logarithmic scattering intensity on the y-axis 
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and the scattering angle q on the x-axis. Experimental scattering data of the complexes in 
solution are shown as open black circles and the fits for the single and dimeric arrangements 
are shown as a line colored as indicated on the right. The goodness-of-fit χ values, calculated 
using FoXS, are indicated for each fit. (H) Ni-NTA pulldown assay showing the interaction 
of 4EHP-His6 (M1–F234, wild-type and dimerization mutant) with MBP-tagged GYF1 and 
GYF2 proteins [(wild-type and dimerization mutant (D*)]. MBP served as a negative control. 
The input (07% for MBP-tagged proteins and 2% for 4EHP) and bound fractions (9%) 
samples were analyzed by SDS-PAGE followed by Coomassie blue staining. (J) Analysis of 
the interaction of V5-SBP-tagged eIF4E, 4EHP and the 4EHP S99N mutant with endogenous 
GYF2 and 4E-BP1 proteins in HEK293T cell lysates. The proteins were pulled down using 
streptavidin-coated beads. V5-SBP-MBP served as negative control. Input samples (1% for 
4E-BP1 and GYF2 and 1.5% for the V5-SBP-tagged proteins) and bound fractions (20% for 
4E-BP1 and GYF2 and 5% for V5-SBP-tagged proteins) were analyzed by western blotting 
using anti-V5, anti-GYF2 and anti-4E-BP1 antibodies. 
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Supplemental Figure S8. 4EHP requires GYF1/2 proteins to repress the expression of 
bound mRNAs (A) A complementation assay using the R-Luc-5BoxB-A95-MALAT1 
reporter and λN-HA-4EHP (either wild-type or the indicated mutants) was performed in 
control and GYF1/2-null HEK293T cells expressing GFP-MBP or GFP-GYF2 (wild-type or 
canonical mutant, C*). A plasmid expressing F-Luc-GFP served as the transfection control. 
R-Luc activity and mRNA levels were normalized to those of the F-Luc transfection control 
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and set to 100% in cells expressing the λN-HA peptide. Normalized R-Luc activities are 
shown in Figure 6A. The panel shows the corresponding normalize R-Luc-5BoxB-A95-
MALAT1 mRNA levels. Bars represent the mean values and error bars represent standard 
deviations from three independent experiments. (B) Northern blot of representative RNA 
samples corresponding to the experiment shown in A and Fig. 6A. (C) Complementation 
assay in WT and GYF1/2-null cells using the R-Luc-A95-MALAT1 reporter lacking the 
BoxB hairpins. A plasmid expressing F-Luc-GFP was used as a transfection control. R-Luc 
activity and mRNA levels were normalized to those of the F-Luc transfection control and set 
to 100% in cells expressing the λN-HA peptide. (D) Northern blot of representative RNA 
samples corresponding to the experiment shown in C. (E) Western blot analysis showing the 
equivalent expression of the λN-HA-4EHP and GYF2 proteins used in the complementation 
shown in C and D. (F) Normalized R-Luc-5BoxB-A95-MALAT1 mRNA levels 
corresponding to the experiment shown in Fig. 6D,E. (G) Northern blot of representative 
RNA samples corresponding to the experiment shown in F.  (H) Lysates from HEK293T 
cells expressing HA-tagged eIF4E or 4EHP (wild-type or cap mutant, cap*) were pulled 
down with m7GTP-sepharose beads. Endogenous eIF4E served as positive control. Inputs 
(0.75% for the HA-tagged proteins and 1% for endogenous eIF4E) and bound fractions (15% 
for the HA-tagged proteins and 5% for endogenous eIF4E) were analyzed by Western blot 
using anti-HA and anti-eIF4E antibodies. (I) Interaction of HA-tagged 4EHP (wild-type or 
cap mutant, cap*) with endogenous GYF2 in HEK293T cells. HA-tagged MBP served as a 
negative control. Inputs (0.37% for the HA-tagged proteins and 0.75% for endogenous 
GYF2) and immunoprecipitates (15% for the HA-tagged proteins and 20% for endogenous 
GYF2) were analyzed by Western blot using anti-HA and anti-GYF2 antibodies. 
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Supplemental Figure S9. 4EHP requires GYF1/2 proteins to repress translation of 
bound mRNAs (A) A complementation assay using the R-Luc-5BoxB-A95-MALAT1 
reporter and λN-HA-4EHP [either wild-type or cap mutant (cap*, W124A)] was performed in 
control and GYF1/2-null HEK293T cells expressing GFP-MBP or GFP-GYF2 (wild-type or 
canonical mutant). A plasmid expressing F-Luc-GFP served as the transfection control. For 
each cell type, R-Luc activity was normalized to that of the F-Luc transfection control and set 
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to 100% in cells expressing the λN-HA peptide. Samples were analyzed as described in Fig. 
6A. (B) Western blot showing similar expression of the proteins used in A. (C) Tethering 
assay using the R-Luc-A95-MALAT1 reporter and λN-HA-4EHP (wild-type or mutants) in 
HEK293T cells. Samples were analyzed as described in Fig. 6A.  (D) Northern blot of 
representative RNA samples corresponding to the experiment shown in C. (E) Western blot 
showing the equivalent expression of the λN-HA-4EHP proteins used in the tethering assay 
shown in D. 
(E) Tethering assay using the R-Luc-A95-MALAT1 reporter lacking MS2 binding sites and 
MS2-HA-GYF2 (wild-type or canonical mutant). Samples were analyzed as described in Fig. 
6F. The corresponding assay with the reporter containing the MS2 binding sites is shown in 
Fig. 6F. (G) Western blot analysis showing the expression of the GFP-GYF2 proteins used in 
the tethering assays shown in F.   
	 33	
Supplemental references 
Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, 
Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD. 2012. Towards automated 
crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol 
Crystallogr 68: 352–367. 
Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray 
LW, Richardson JS, Richardson DC. 2010. MolProbity: all-atom structure validation 
for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12–21. 
Cheng Y, Patel DJ. 2004. An efficient system for small protein expression and refolding. 
Biochem Biophys Res Commun 317: 401–405. 
Diebold ML, Fribourg S, Koch M, Metzger T, Romier C. 2011. Deciphering correct 
strategies for multiprotein complex assembly by co-expression: application to 
complexes as large as the histone octamer. J Struct Biol 175: 178–188. 
Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta 
Crystallogr D Biol Crystallogr 66: 486–501. 
Fabian MR, Frank F, Rouya C, Siddiqui N, Lai WS, Karetnikov A, Blackshear PJ, Nagar B, 
Sonenberg N. 2013. Structural basis for the recruitment of the human CCR4-NOT 
deadenylase complex by tristetraprolin. Nat Struct Mol Biol 20: 735-739. 
Kabsch W. 2010. Xds. Acta Crystallogr D Biol Crystallogr 66: 125–132. 
Kuzuoglu-Ozturk D, Bhandari D, Huntzinger E, Fauser M, Helms S, Izaurralde E. 2016. 
miRISC and the CCR4-NOT complex silence mRNA targets independently of 43S 
ribosomal scanning. EMBO J 35: 1186–1203. 
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. 
Phaser crystallographic software. J Appl Crystallogr 40: 658–674. 
	 34	
Mizoue LS, Tellinghuisen J. 2004. The role of backlash in the "first injection anomaly" in 
isothermal titration calorimetry. Anal Biochem 326: 125–127. 
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering 
using the CRISPR-Cas9 system. Nat Protoc 8: 2281–2308. 
Schneidman-Duhovny D, Hammel M, Tainer JA, Sali A. 2013. Accurate SAXS profile 
computation and its assessment by contrast variation experiments. Biophys J 105: 
962–974. 
Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung LW, 
Read RJ, Adams PD. 2008. Iterative model building, structure refinement and density 
modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol 
Crystallogr 64: 61–69.	
 
